0001214659-23-003850.txt : 20230315 0001214659-23-003850.hdr.sgml : 20230315 20230315163052 ACCESSION NUMBER: 0001214659-23-003850 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20230131 FILED AS OF DATE: 20230315 DATE AS OF CHANGE: 20230315 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alzamend Neuro, Inc. CENTRAL INDEX KEY: 0001677077 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811822909 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40483 FILM NUMBER: 23735662 BUSINESS ADDRESS: STREET 1: 3500 LENOX RD. NE STREET 2: SUITE 1500 CITY: ATLANTA STATE: GA ZIP: 30326 BUSINESS PHONE: 844-722-6333 MAIL ADDRESS: STREET 1: 3500 LENOX RD. NE STREET 2: SUITE 1500 CITY: ATLANTA STATE: GA ZIP: 30326 10-Q 1 z3723010q.htm
0001677077 false 2023 Q3 --04-30 0001677077 2022-05-01 2023-01-31 0001677077 2023-03-15 0001677077 2023-01-31 0001677077 2022-04-30 0001677077 us-gaap:SeriesAPreferredStockMember 2023-01-31 0001677077 us-gaap:SeriesAPreferredStockMember 2022-04-30 0001677077 2022-11-01 2023-01-31 0001677077 2021-11-01 2022-01-31 0001677077 2021-05-01 2022-01-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2022-10-31 0001677077 us-gaap:CommonStockMember 2022-10-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2022-10-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2022-10-31 0001677077 us-gaap:RetainedEarningsMember 2022-10-31 0001677077 2022-10-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2021-10-31 0001677077 us-gaap:CommonStockMember 2021-10-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2021-10-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2021-10-31 0001677077 us-gaap:RetainedEarningsMember 2021-10-31 0001677077 2021-10-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2022-04-30 0001677077 us-gaap:CommonStockMember 2022-04-30 0001677077 us-gaap:AdditionalPaidInCapitalMember 2022-04-30 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2022-04-30 0001677077 us-gaap:RetainedEarningsMember 2022-04-30 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2021-04-30 0001677077 us-gaap:CommonStockMember 2021-04-30 0001677077 us-gaap:AdditionalPaidInCapitalMember 2021-04-30 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2021-04-30 0001677077 us-gaap:RetainedEarningsMember 2021-04-30 0001677077 2021-04-30 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2022-11-01 2023-01-31 0001677077 us-gaap:CommonStockMember 2022-11-01 2023-01-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2022-11-01 2023-01-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2022-11-01 2023-01-31 0001677077 us-gaap:RetainedEarningsMember 2022-11-01 2023-01-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2021-11-01 2022-01-31 0001677077 us-gaap:CommonStockMember 2021-11-01 2022-01-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2021-11-01 2022-01-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2021-11-01 2022-01-31 0001677077 us-gaap:RetainedEarningsMember 2021-11-01 2022-01-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2022-05-01 2023-01-31 0001677077 us-gaap:CommonStockMember 2022-05-01 2023-01-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2022-05-01 2023-01-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2022-05-01 2023-01-31 0001677077 us-gaap:RetainedEarningsMember 2022-05-01 2023-01-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2021-05-01 2022-01-31 0001677077 us-gaap:CommonStockMember 2021-05-01 2022-01-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2021-05-01 2022-01-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2021-05-01 2022-01-31 0001677077 us-gaap:RetainedEarningsMember 2021-05-01 2022-01-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2023-01-31 0001677077 us-gaap:CommonStockMember 2023-01-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2023-01-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2023-01-31 0001677077 us-gaap:RetainedEarningsMember 2023-01-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2022-01-31 0001677077 us-gaap:CommonStockMember 2022-01-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2022-01-31 0001677077 us-gaap:RetainedEarningsMember 2022-01-31 0001677077 2022-01-31 0001677077 us-gaap:StockOptionMember 2022-05-01 2023-01-31 0001677077 us-gaap:StockOptionMember 2021-05-01 2022-01-31 0001677077 us-gaap:WarrantMember 2022-05-01 2023-01-31 0001677077 us-gaap:WarrantMember 2021-05-01 2022-01-31 0001677077 alzm:AultLifeSciencesFundLLCMember alzm:SecuritiesPurchaseAgreementMember 2019-04-29 2019-04-30 0001677077 us-gaap:WarrantMember alzm:AultLifeSciencesFundLLCMember alzm:SecuritiesPurchaseAgreementMember 2019-04-29 2019-04-30 0001677077 us-gaap:WarrantMember alzm:AultLifeSciencesFundLLCMember alzm:SecuritiesPurchaseAgreementMember 2019-04-30 0001677077 2023-01-29 2023-01-31 0001677077 2022-04-28 2022-04-30 0001677077 2023-01-05 0001677077 2022-06-16 0001677077 alzm:StockIncentivePlan2016Member 2016-04-30 0001677077 alzm:StockIncentivePlan2016Member 2019-02-28 2019-03-01 0001677077 srt:MinimumMember alzm:StockIncentivePlan2016Member 2016-04-29 2016-04-30 0001677077 srt:MaximumMember alzm:StockIncentivePlan2016Member 2016-04-29 2016-04-30 0001677077 alzm:EmployeesAndConsultantsMember 2022-05-01 2023-01-31 0001677077 alzm:EmployeesAndConsultantsMember 2021-05-01 2022-01-31 0001677077 alzm:PerformanceContingentStockOptionsMember alzm:KeyEmployeesAndDirectorMember 2019-11-25 2019-11-26 0001677077 alzm:PerformanceContingentStockOptionsMember alzm:KeyEmployeesAndDirectorMember 2021-03-22 2021-03-23 0001677077 alzm:PerformanceContingentStockOptionsMember alzm:TwoConsultantsMember 2021-10-01 2021-10-14 0001677077 alzm:UnamortizedStockBasedCompensationMember 2023-01-31 0001677077 alzm:StockBasedCompensationMember 2022-05-01 2023-01-31 0001677077 srt:MinimumMember alzm:EmployeesAndConsultantsMember 2021-05-01 2022-01-31 0001677077 srt:MaximumMember alzm:EmployeesAndConsultantsMember 2021-05-01 2022-01-31 0001677077 us-gaap:ResearchAndDevelopmentExpenseMember 2022-11-01 2023-01-31 0001677077 us-gaap:ResearchAndDevelopmentExpenseMember 2021-11-01 2022-01-31 0001677077 us-gaap:ResearchAndDevelopmentExpenseMember 2022-05-01 2023-01-31 0001677077 us-gaap:ResearchAndDevelopmentExpenseMember 2021-05-01 2022-01-31 0001677077 us-gaap:GeneralAndAdministrativeExpenseMember 2022-11-01 2023-01-31 0001677077 us-gaap:GeneralAndAdministrativeExpenseMember 2021-11-01 2022-01-31 0001677077 us-gaap:GeneralAndAdministrativeExpenseMember 2022-05-01 2023-01-31 0001677077 us-gaap:GeneralAndAdministrativeExpenseMember 2021-05-01 2022-01-31 0001677077 alzm:ExercisePrice1Member 2023-01-31 0001677077 alzm:ExercisePrice2Member 2023-01-31 0001677077 alzm:ExercisePrice3Member 2023-01-31 0001677077 alzm:ExercisePrice4Member 2023-01-31 0001677077 srt:MinimumMember 2023-01-31 0001677077 srt:MaximumMember 2023-01-31 0001677077 us-gaap:WarrantMember 2021-05-01 2022-01-31 0001677077 us-gaap:WarrantMember us-gaap:MeasurementInputOptionVolatilityMember 2022-01-31 0001677077 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2022-01-31 0001677077 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2022-01-31 0001677077 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-01-31 0001677077 alzm:DigitalPowerLendingMember alzm:SecuritiesPurchaseAgreementMember 2021-03-01 2021-03-31 0001677077 alzm:DigitalPowerLendingMember alzm:SecuritiesPurchaseAgreementMember 2021-03-01 2021-03-09 0001677077 alzm:BitnileMember alzm:BrandDevelopmentAgreementMember 2022-11-28 2022-11-30 0001677077 alzm:AL002LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:AL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:AdditionalAL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:PreIndMeetingMember alzm:AL001LicenseMember 2023-01-31 0001677077 alzm:PreIndMeetingMember alzm:AL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:IndApplicationFilingMember alzm:AL001LicenseMember 2023-01-31 0001677077 alzm:IndApplicationFilingMember alzm:AL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AL001LicenseMember 2023-01-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponCompletionOfFirstPatientDosingMember alzm:AL001LicenseMember 2023-01-31 0001677077 alzm:UponCompletionOfFirstPatientDosingMember alzm:AL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AL001LicenseMember 2023-01-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFdaApprovalMember alzm:AL001LicenseMember 2023-01-31 0001677077 alzm:UponFdaApprovalMember alzm:AL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:PreIndMeetingMember alzm:AL002LicenseMember 2023-01-31 0001677077 alzm:PreIndMeetingMember alzm:AL002LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:IndApplicationFilingMember alzm:AL002LicenseMember 2023-01-31 0001677077 alzm:IndApplicationFilingMember alzm:AL002LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AL002LicenseMember 2023-01-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AL002LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AL002LicenseMember 2023-01-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AL002LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFirstPatientTreatedInPhase3ClinicalTrialMember alzm:AL002LicenseMember 2023-01-31 0001677077 alzm:UponFirstPatientTreatedInPhase3ClinicalTrialMember alzm:AL002LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFdaApprovalMember alzm:AL002LicenseMember 2023-01-31 0001677077 alzm:UponFdaApprovalMember alzm:AL002LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:IndApplicationFilingMember alzm:AdditionalAL001LicenseMember 2023-01-31 0001677077 alzm:IndApplicationFilingMember alzm:AdditionalAL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AdditionalAL001LicenseMember 2023-01-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AdditionalAL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AdditionalAL001LicenseMember 2023-01-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AdditionalAL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFirstPatientTreatedInPhase3ClinicalTrialMember alzm:AdditionalAL001LicenseMember 2023-01-31 0001677077 alzm:UponFirstPatientTreatedInPhase3ClinicalTrialMember alzm:AdditionalAL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFdaApprovalMember alzm:AdditionalAL001LicenseMember 2023-01-31 0001677077 alzm:UponFdaApprovalMember alzm:AdditionalAL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:SecuritiesPurchaseAgreementsMember alzm:ALSFMember 2019-04-29 2019-04-30 0001677077 us-gaap:WarrantMember alzm:SecuritiesPurchaseAgreementsMember alzm:ALSFMember 2019-04-29 2019-04-30 0001677077 us-gaap:WarrantMember alzm:SecuritiesPurchaseAgreementsMember alzm:ALSFMember 2019-04-30 0001677077 alzm:ALSFMember 2019-04-29 2019-04-30 0001677077 alzm:ALSFMember 2019-04-30 0001677077 alzm:SecuritiesPurchaseAgreementsMember alzm:DigitalPowerLendingMember 2021-03-01 2021-03-31 0001677077 alzm:SecuritiesPurchaseAgreementsMember alzm:DigitalPowerLendingMember 2021-03-31 0001677077 alzm:SecuritiesPurchaseAgreementsMember alzm:DigitalPowerLendingMember 2021-03-01 2021-03-09 0001677077 alzm:ConvertiblePromissoryNoteMember alzm:SecuritiesPurchaseAgreementsMember alzm:AultGlobalMember 2021-03-01 2021-03-09 0001677077 alzm:SecuritiesPurchaseAgreementsMember alzm:FinalTrancheMember alzm:DigitalPowerLendingMember 2021-03-01 2021-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended January 31, 2023 

 

OR

 

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 001-40483

 

ALZAMEND NEURO, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 81-1822909
(State or other jurisdiction of incorporation or organization)  (I.R.S. Employer Identification Number)

 

 3480 Peachtree Rd NE, Suite 103, Atlanta, GA 30326 (844) 722-6303
(Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code)

 

Securities registered under Section 12(b) of the Act:

 

Title of Each Class Trading Symbol Name of each exchange on which registered
Common Stock, $0.0001 par value per share ALZN NASDAQ Capital Market

 

Securities registered under Section 12(g) of the Act:      None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer o Accelerated filer o
Non-accelerated filer x  Smaller reporting company x
Emerging growth company x  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

 

As of March 15, 2023 there were 96,440,124 shares of registrant’s common stock, $0.0001 par value per share, outstanding.

 

 

  
 

 

Table of Contents

 

 

    Page
     
PART I. FINANCIAL INFORMATION 3
Item 1. Financial Statements (unaudited) 3
  Condensed Balance Sheets 3
  Condensed Statements of Operations 4
  Condensed Statements of Stockholders’ Equity 5
  Condensed Statements of Cash Flows 9
  Notes to Condensed Financial Statements 10
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
Item 3. Quantitative and Qualitative Disclosures About Market Risk 31
Item 4. Controls and Procedures 31
     
PART II OTHER INFORMATION 33
Item 1. Legal Proceedings 33
Item 1A. Risk Factors 33
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33
Item 3. Defaults Upon Senior Securities 33
Item 4. Mine Safety Disclosures 33
Item 5. Other Information 33
Item 6. Exhibits 33
  Signatures 34

 

 2 
 

 

PART I – FINANCIAL INFORMATION 

 

 

ITEM 1.FINANCIAL STATEMENTS

 

Alzamend Neuro, Inc.

Condensed Balance Sheets

(Unaudited)

 

         
   January 31, 2023   April 30, 2022 
ASSETS        
         
CURRENT ASSETS        
         
Cash  $7,375,841   $14,063,811 
Prepaid expenses and other current assets   546,303    349,723 
Prepaid expenses - related party   494,668    - 
TOTAL CURRENT ASSETS   8,416,812    14,413,534 
Property, plant and equipment, net   85,166    102,909 
TOTAL ASSETS  $8,501,978   $14,516,443 
           
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
CURRENT LIABILITIES          
           
Accounts payable and accrued liabilities  $2,642,473   $1,162,850 
Related party payable   -    2,082 
TOTAL CURRENT LIABILITIES   2,642,473    1,164,932 
TOTAL LIABILITIES   2,642,473    1,164,932 
           
COMMITMENTS AND CONTINGENCIES          
           
STOCKHOLDERS’ EQUITY          
           
Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; Series A Convertible Preferred Stock, $0.0001 stated value per share, 1,360,000 shares designated; nil issued and outstanding as of January 31, 2023 and April 30, 2022   -    - 
Common stock, $0.0001 par value: 300,000,000 shares authorized; 96,427,624 and 95,481,790 shares issued and outstanding as of January 31, 2023 and April 30, 2022, respectively   9,642    9,548 
Additional paid-in capital   61,500,292    57,419,753 
Note receivable for common stock – related party   (14,883,295)   (14,883,295)
Accumulated deficit   (40,767,134)   (29,194,495)
TOTAL STOCKHOLDERS’ EQUITY   5,859,505    13,351,511 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $8,501,978   $14,516,443 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 3 
 

 

Alzamend Neuro, Inc.

Condensed Statements of Operations

(Unaudited)

 

 

                     
   For the Three Months Ended January 31,   For the Nine Months Ended January 31, 
   2023   2022   2023   2022 
OPERATING EXPENSES                
Research and development  $2,888,847   $873,653   $5,797,789   $3,540,111 
General and administrative   2,534,665    1,682,913    5,767,668    4,906,628 
Total operating expenses   5,423,512    2,556,566    11,565,457    8,446,739 
Loss from operations   (5,423,512)   (2,556,566)   (11,565,457)   (8,446,739)
                     
OTHER EXPENSE, NET                    
Interest expense   (2,062)   (16,299)   (7,182)   (45,922)
Total other expense, net   (2,062)   (16,299)   (7,182)   (45,922)
NET LOSS  $(5,425,574)  $(2,572,865)  $(11,572,639)  $(8,492,661)
                     
Basic and diluted net loss per common share  $(0.06)  $(0.03)  $(0.12)  $(0.09)
                     
Basic and diluted weighted average common shares outstanding   98,326,175    94,165,225    97,765,471    89,484,601 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 4 
 

 

 Alzamend Neuro, Inc.

Condensed Statements of Stockholders’ Equity

For the Three Months Ended January 31, 2023

(Unaudited)

 

 

                                         
   Series A Convertible           Additional   Note Receivable for         
   Preferred Stock   Common Stock   Paid-In   Common Stock -   Accumulated     
   Shares   Amount   Shares   Amount   Capital   Related Party   Deficit   Total 
BALANCES, October 31, 2022   -   $-    95,494,290   $9,549   $59,002,729   $(14,883,295)  $(35,341,560)  $8,787,423 
                                         
Stock-based compensation to employees and consultants   -    -    -    -    1,508,322    -    -    1,508,322 
                                         
Issuance of common stock for related party payable   -    -    933,334    93    989,241    -    -    989,334 
                                         
Net loss   -    -    -    -    -    -    (5,425,574)   (5,425,574)
                                         
BALANCES, January 31, 2023   -   $-    96,427,624   $9,642   $61,500,292   $(14,883,295)  $(40,767,134)  $5,859,505 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 5 
 

 

Alzamend Neuro, Inc.

Condensed Statements of Stockholders’ Equity

For the Three Months Ended January 31, 2022

(Unaudited)

 

 

                                         
   Series A Convertible           Additional   Note Receivable for         
   Preferred Stock   Common Stock   Paid-In   Common Stock -   Accumulated     
   Shares   Amount   Shares   Amount   Capital   Related Party   Deficit   Total 
BALANCES, October 31, 2021   -   $-    88,850,358   $8,885   $50,652,054   $(14,883,295)  $(22,752,233)  $13,025,411 
                                         
Stock-based compensation to employees and consultants   -    -    -    -    1,130,795    -    -    1,130,795 
                                         
Proceeds from stock option exercise   -    -    1,000,000    100    300    -    -    400 
                                         
Issuance of share of common stock for conversion of debt   -    -    252,265    25    378,373    -    -    378,398 
                                         
Net loss   -    -    -    -    -    -    (2,572,865)   (2,572,865)
                                         
BALANCES, January 31, 2022   -   $-    90,102,623   $9,010   $52,161,522   $(14,883,295)  $(25,325,098)  $11,962,139 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 6 
 

 

Alzamend Neuro, Inc.

Condensed Statements of Stockholders’ Equity

For the Nine Months Ended January 31, 2023

(Unaudited)

 

 

                                         
   Series A Convertible           Additional   Note Receivable for         
   Preferred Stock   Common Stock   Paid-In   Common Stock -   Accumulated     
   Shares   Amount   Shares   Amount   Capital   Related Party   Deficit   Total 
 BALANCES, April 30, 2022   -   $-    95,481,790   $9,548   $57,419,753   $(14,883,295)  $(29,194,495)  $13,351,511 
                                         
 Issuance of common stock for restricted stock awards   -    -    12,500    1    (1)   -    -    - 
                                         
 Stock-based compensation to employees and consultants   -    -    -    -    3,091,299    -    -    3,091,299 
                                         
 Issuance of common stock for related party payable   -    -    933,334    93    989,241    -    -    989,334 
                                         
 Net loss   -    -    -    -    -    -    (11,572,639)   (11,572,639)
                                         
 BALANCES, January 31, 2023   -   $-    96,427,624   $9,642   $61,500,292   $(14,883,295)  $(40,767,134)  $5,859,505 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 7 
 

 

Alzamend Neuro, Inc.

Condensed Statements of Stockholders’ Equity

For the Nine Months Ended January 31, 2022

(Unaudited)

 

 

                                         
   Series A Convertible           Additional   Note Receivable for         
   Preferred Stock   Common Stock   Paid-In   Common Stock -   Accumulated     
   Shares   Amount   Shares   Amount   Capital   Related Party   Deficit   Total 
 BALANCES, April 30, 2021   750,000   $75    67,429,525   $6,743   $33,721,859   $(14,883,295)  $(16,832,437)  $2,012,945 
                                         
 Issuance of common stock for restricted stock awards   -    -    212,500    21    (21)   -    -    - 
                                         
 Stock-based compensation to employees and consultants   -    -    -    -    3,150,801    -    -    3,150,801 
                                         
 Proceeds from sale of common stocks & warrants-related party   -    -    1,333,333    133    1,999,867    -    -    2,000,000 
                                         
 Proceeds from stock option exercise   -    -    3,000,000    300    900    -    -    1,200 
                                         
 Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million   -    -    2,875,000    288    12,911,168    -    -    12,911,456 
                                         
 Issuance of shares of common stock for conversion of debt   -    -    252,265    25    378,373              378,398 
                                         
 Conversion of Series A convertible stock   (750,000)   (75)   15,000,000    1,500    (1,425)   -    -    - 
                                         
 Net loss   -    -    -    -    -    -    (8,492,661)   (8,492,661)
                                         
 BALANCES, January 31, 2022   -   $-    90,102,623   $9,010   $52,161,522   $(14,883,295)  $(25,325,098)  $11,962,139 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 8 
 

 

Alzamend Neuro, Inc.

Condensed Statements of Cash Flows

(Unaudited)

 

           
   For the Nine Months Ended January 31, 
   2023   2022 
Cash flows from operating activities:        
Net loss  $(11,572,639)  $(8,492,661)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation expense   17,743    - 
Interest expense - debt discount   -    12,770 
Stock-based compensation to employees and consultants   3,091,299    3,150,801 
Changes in operating assets and liabilities:          
Prepaid expenses and other current assets   (196,580)   344,493 
Prepaid expenses related party   492,584    - 
Accounts payable and accrued expenses   1,479,623    (67,040)
Net cash used in operating activities   (6,687,970)   (5,051,637)
Cash flows from financing activities:          
Proceeds from the issuance of common stock and warrants - related party, net   -    2,000,000 
Proceeds from stock option exercise   -    1,200 
Proceeds from initial public offering, net of underwriters’ discounts and commissions and issuance costs   -    12,911,456 
Net cash provided by financing activities   -    14,912,656 
Net (decrease) increase in cash   (6,687,970)   9,861,019 
Cash at beginning of period   14,063,811    1,929,270 
Cash at end of period  $7,375,841   $11,790,289 
           
Supplemental disclosures of cash flow information:          
Non-cash financing activities:          
Fair value of warrants issued in connection with March 2021 securities purchase agreement, related party  $-   $4,799,742 
Fair value of warrants issued in connection with IPO  $-   $461,877 
Issuance of common stock on conversion of note  $-   $

378,373

 
Issuance of common stock for related party payable  $989,334   - 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 9 
 

 

Alzamend Neuro, Inc.

Notes to Unaudited Condensed Financial Statements

 

1.DESCRIPTION OF BUSINESS

 

Organization

 

Alzamend Neuro, Inc. (the “Company” or “Alzamend”), is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”). With the Company’s two current product candidates, Alzamend aims to bring treatments or cures to market as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates (collectively, the “Technology”): (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, for the treatment of Alzheimer’s BD, MDD and PTSD, known as AL001, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the “Licensor”); and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as ALZN002, through a royalty-bearing exclusive worldwide license from the same Licensor.

 

The Company is devoting substantially all its efforts towards research and development of its Technology. The Company has not generated any product revenue to date. The Company has financed its operations to date primarily through debt financings and through the sale of its common stock, par value $0.0001 per share (“Common Stock”). The Company expects to continue to incur net losses in the foreseeable future.

 

2.LIQUIDITY AND GOING CONCERN

 

The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern. As of January 31, 2023, the Company had cash of $7.4 million and an accumulated deficit of $40.8 million. The Company incurred losses for the three and nine months ended January 31, 2023 totaling $5.4 million and $11.6 million, respectively. Historically, the Company has financed its operations principally through issuances of equity and debt instruments.

 

 The Company expects to continue to incur losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development and commercial operations. However, based on the Company’s current business plan, management believes that the Company’s cash at January 31, 2023 is sufficient to meet the Company’s anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report.

 

3.SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Report on Form 10-K for the year ended April 30, 2022, filed with the SEC on July 19, 2022. In the opinion of management, the accompanying condensed interim financial statements include all adjustments necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Company’s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2022 has been derived from the audited balance sheet at April 30, 2022 contained in such Form 10-K.

 

 10 
 

 

Accounting Estimates

 

The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of January 31, 2023 and April 30, 2022, the Company had no cash equivalents.

 

Fair Value of Financial Instruments

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable:

 

Level 1: Quoted prices in active markets for identical assets or liabilities.

 

Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.

 

The fair values of warrants are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants’ contractual life.

 

Property and Equipment, Net

 

Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred.

 

Research and Development Expenses

 

Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company.

 

The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects.

 

Stock-Based Compensation

 

The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.

 

 11 
 

 

The Company recognizes stock-based compensation expense for restricted stocks on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock.

 

The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially different.

 

Warrants

 

The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity and ASC 815, Derivatives and Hedging, depending on the specific terms of the warrant agreement.

 

  Loss per Common Share

 

The Company utilizes FASB ASC 260, Earnings per Share. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then shared in the earnings of the entity.

 

Since the effects of outstanding options, warrants, convertible preferred stock and convertible notes are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share.

 

The following sets forth the number of shares of Common Stock underlying outstanding options and warrants that have been excluded from the computation of loss per common share:

          
   For the Nine Months Ended January 31, 
   2023   2022 
Stock options (1)   18,158,329    13,500,000 
Warrants   10,149,788    8,830,785 
    28,308,117    22,330,785 

 

(1)The Company has excluded 2,000,000 and 4,500,000 stock options for the nine months ended January 31, 2023 and 2022, respectively, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.

 

 Recent Accounting Standards

 

From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company’s financial position or results of operations upon adoption.

 

The Company has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its financial statements.

 

4.NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY

 

On April 30, 2019, the Company and Ault Life Sciences Fund, LLC (“ALSF”) entered into a securities purchase agreement for the purchase of 10,000,000 shares of Common Stock for a total purchase price of $15,000,000, or $1.50 per share with 5,000,000 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The total purchase price of $15,000,000 was in the form of a non-interest bearing note receivable with a 12-month term from ALSF, a related party. In November 2019, the term of the note receivable was extended to December 31, 2021, and in May 2021, the term of the note receivable was extended to December 31, 2023. The note is secured by a pledge of the purchased shares. As the note receivable from ALSF is related to the issuance of Common Stock, it is recorded as an offset to additional paid-in capital. At January 31, 2023 and April 30, 2022, the outstanding balance of the note receivable was $14,883,295. ALSF is wholly owned by Ault Life Sciences, Inc. (“ALSI”). ALSI is majority owned by Ault & Company, Inc. (“Ault & Co.”). Messrs. Horne and Nisser, directors of the Company, are also directors of Ault & Co.

 

 12 
 

 

5.PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets were as follows:

          
   January 31, 2023   April 30, 2022 
Prepaid clinical trial fees  $315,987   $- 
Prepaid insurance   222,742    155,880 
Other prepaid expenses   7,574    7,176 
Prepaid consulting fees   -    186,667 
Total prepaid expenses and other current assets  $546,303   $349,723 

 

 On January 5, 2023, the Company prepaid $437,466 for clinical trial fees related to AL002. Prepaid clinical trial fees at January 31, 2023, represented the unused portion of the prepaid clinical fees. On June 16, 2022, the Company purchased directors and officers (“D&O”) insurance for 12 months in the amount of $492,000. Prepaid insurance at January 31, 2023 represented the unamortized portion of the annual insurance premium.

 

6.STOCK-BASED COMPENSATION

 

2016 Stock Incentive Plan

 

On April 30, 2016, the Company’s stockholders approved the Company’s 2016 Stock Incentive Plan (the “Plan”). The Plan provides for the issuance of a maximum of 12,500,000 shares of Common Stock to be offered to the Company’s directors, officers, employees, and consultants. On March 1, 2019, the Company’s stockholders approved an additional 7,500,000 shares to be available for issuance under the Plan. Options granted under the Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant and become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and 10 years from the date of grant. Restricted stock awards granted under the Plan are subject to a vesting period determined at the date of grant.

 

2021 Stock Incentive Plan

 

In February 2021, the Company’s board of directors (the “Board”) adopted, and the stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan (the “2021 Plan”). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory), (2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation.

 

Stock Subject to the 2021 Plan. The maximum number of shares of Common Stock that may be issued under the 2021 Plan is 10,000,000 shares, which number will be increased to the extent that compensation granted under the 2021 Plan is forfeited, expires or is settled for cash (except as otherwise provided in the 2021 Plan). Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company that the Company acquires or any subsidiary of the Company or with which the Company or any subsidiary combines) will not reduce the shares authorized for grant under the 2021 Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer under the 2021 Plan.

 

All options that the Company grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the date of issuance of these options, there was not an active public market for the Company’s shares. Accordingly, the fair value of the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because the Company settles these obligations by issuing shares of Common Stock from its authorized shares instead of settling such obligations with cash payments. 

 

 13 
 

 

A summary of stock option activity for the nine months ended January 31, 2023 is presented below: 

                                       
            Outstanding Options  
      Shares
Available
for Grant
      Number of
Shares
      Weighted
Average
Exercise
Price
      Weighted
Average
Remaining
Contractual
Life (years)
     

Aggregate

Intrinsic
Value

 
Balance at April 30, 2022     8,800,000       15,700,000     $ 1.16       6.32     $ 2,219,700  
Options granted     (2,000,000)       2,000,000     $ 1.17       9.83          
Options exercised     -       -     $ -       -          
Options expired     2,391,671       (2,391,671 )   $ 1.34       -          
Balance at January 31, 2023     9,191,671       15,308,329     $ 1.18       6.32     $ 1,327,200  
Options vested and expected to vest at January 31, 2023             14,308,329     $ 1.18       6.07     $ 1,327,200  
Options exercisable at January 31, 2023             13,172,907     $ 1.11       5.91     $ 1,327,200  

 

 

The aggregate intrinsic value in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised their options.

 

Stock Options Granted to Employees and Consultants

 

The estimated fair value of stock options granted to employees and consultants during the nine months ended January 31, 2023 and 2022 were calculated using the Black-Scholes option-pricing model using the following assumptions:

       
    For the Nine Months Ended January 31,
    2023   2022
Expected term (in years)   6.25   3.506.25
Volatility   88.94%   85.53% - 87.10%
Risk-free interest rate   3.89%   1.01%-1.07%
Dividend yield   0.0%   0.0%

 

Expected Term: The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).

 

Expected Volatility: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company did not have sufficient trading history for its Common Stock at January 31, 2023 and 2022. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

 

Risk-Free Interest Rate: The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.

 

Expected Dividend: The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.

 

Stock-based compensation to employees and consultants from stock option grants for the nine months ended January 31, 2023 and 2022, was $3.1 million and $3.2 million, respectively.

 

Performance Contingent Stock Options Granted to Employee

 

On November 26, 2019, the Board granted 4,250,000 performance- and market-contingent awards to certain key employees and a director. These grants were made outside of the Plan. These awards have an exercise price of $1.50 per share. These awards have multiple separate market triggers for vesting based upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180 days after the Company’s initial public offering (“IPO”) for its Common Stock, or (ii) stepped target prices for a change in control transaction. The target prices range from $10 per share to $40 per share. In the event any of the stock price milestones are not achieved within three years, the unvested portion of the performance options will be reduced by 25%.

 

 14 
 

 

On November 22, 2022, the Compensation Committee of the Board modified the performance criteria for these awards. The target price range is now $10 per share to $20 per share. Additionally, if the stock price milestones are now not achieved by November 27, 2026, as opposed to within three years, the unvested portion of the portion of the performance options will be reduced by 25%. Due to the significant risks and uncertainties associated with achieving the market-contingent awards, as of January 31, 2023, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards.

 

On November 29, 2022, the Compensation Committee of the Board granted 2,000,000 performance-based stock option to the Chief Executive Officer at an exercise price of $1.17 per share, of which 50% vest upon the completion and announcement of topline data from the Company’s Phase II clinical trial of AL001 within three years from grant date and the remaining 50% vest upon the completion and announcement of topline data from the Company’s Phase II clinical trial of ALZN002 within four years from the grant date. As of January 31, 2023, the Company believes that it is probable that the performance condition of the completion and announcement of topline data from the Company’s Phase II clinical trial of AL001 will be achieved and has recognized the related stock-based compensation. As of January 31, 2023, the Company believes that the achievement of the second performance condition is not probable and, as a result, no compensation cost has been recognized related to Phase II of ALZN002.

 

Performance Contingent Stock Options Granted to TAMM Net

 

On March 23, 2021, the Company issued performance-based stock options to the certain team members at TAMM Net, Inc. (“TAMM Net”) to purchase an aggregate of 450,000 shares of Common Stock at a per share exercise price of $1.50 per share, of which 50% vest upon the completion of Phase I of AL001 by March 31, 2022, and the remaining 50% vest upon completion of Phase I of ALZN002 by December 31, 2022.

 

The performance goal of completing Phase I of AL001 was achieved on March 22, 2022, and the Company recognized stock-based compensation related to the completion of Phase I of AL001 over the implied service period to complete this milestone.

 

On January 19, 2023, the Board modified the performance criteria for these awards. The remaining 50% of the grant will now vest upon the completion and announcement of topline data of the first cohort from a Phase I/IIA clinical trial of ALZN002 on/or before March 31, 2024. Due to the significant risks and uncertainties associated with achieving the completion of Phase I for ALZN002, as of January 31, 2023, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards related to ALZN002.

 

Performance Contingent Stock Options Granted to Consultants

 

On October 14, 2021, the Company issued performance-based stock options to two consultants to purchase an aggregate of 200,000 shares of Common Stock with an exercise price of $2.42 per share, of which 50,000 vest upon completion of each of the Phase II clinical trials of AL001 for a Bipolar indication, AL001 for a PTSD indication, AL001 for a depression indication and ALZN002 for an Alzheimer’s indication.

 

On January 19, 2023, the Board modified the performance criteria for these awards. The revised grant will vest 25% if the Company (a) completes and announces topline data from a Phase II clinical trial of AL001 and ALZN002, as applicable, that would support a new drug application for the drug candidate and the indication listed below, and (b) obtained a “Study May Proceed” letter from the U.S. Food and Drug Administration for the additional IND on/or before December 31, 2023, as follows: (i) AL001 – bipolar disorder; (ii) AL001- major depressive disorder; (iii) AL001 – post-traumatic stress disorder; and (iv) ALZN002 – Alzheimer’s disease.

 

As of January 31, 2023, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards related to Phase II of AL001 and ALZN002.

 

 Stock-Based Compensation Expense

 

The Company’s results of operations include expenses relating to stock-based compensation for three and nine months ended January 31, 2023 and 2022, that were comprised as follows:

                    
   For the Three Months Ended January 31,   For the Nine Months Ended January 31, 
   2023   2022   2023   2022 
 Research and development  $(42,589)  $106,102   $(42,589)  $359,286 
 General and administrative   1,550,911    1,024,693    3,133,888    2,791,515 
Total  $1,508,322   $1,130,795   $3,091,299   $3,150,801 

 

 15 
 

 

As of January 31, 2023, total unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $1.5 million. The weighted-average period over which such stock-based compensation expense will be recognized is approximately 1.8 years.

 

7.WARRANTS

 

The following table summarizes information about Common Stock warrants outstanding and exercisable at January 31, 2023:

  

                                           
Outstanding     Exercisable  
            Weighted                    
            Average     Weighted           Weighted  
            Remaining     Average           Average  
Exercise     Number     Contractual     Exercise     Number     Exercise  
Price     Outstanding     Life (years)     Price     Exercisable     Price  
$ 1.00       500,000       1.1     $ 1.00       500,000     $ 1.00  
$ 1.75       161,342       1.8     $ 1.75       161,342     $ 1.75  
$ 3.00       9,427,196       2.2     $ 3.00       9,427,196     $ 3.00  
$ 6.25       61,250       3.4     $ 6.25       61,250     $ 6.25  
  $1.00 - $6.25       10,149,788       2.4     $ 2.90       10,149,788     $ 2.90  

 

The estimated fair value of warrants granted during the nine months ended January 31, 2022 were calculated using the Black-Scholes option-pricing model using the following assumptions:

     
     

For the Nine Months

Ended January 31, 2022

Expected term (in years)     5.00
Volatility     86.31%
Risk-free interest rate     0.87% - 0.90%
Dividend yield     0.0%

 

Expected Term: The expected term represents the period that the warrants granted are expected to be outstanding.

 

Expected Volatility: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company did not have sufficient trading history for its Common Stock at January 31, 2022. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

 

Risk-Free Interest Rate: The Company based the risk-free interest rate over the expected term of the warrants based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.

 

Expected Dividend: The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.

 

8.OTHER RELATED PARTY TRANSACTIONS

 

In March 2021, the Company entered into a securities purchase agreement with Ault Lending, LLC (“AL”) pursuant to which the Company sold an aggregate of 6,666,667 shares of Common Stock for an aggregate of $10 million, or $1.50 per share, which sales were made in tranches. On March 9, 2021, AL paid $4 million, less the $1.8 million in prior advances and the surrender for cancellation of a $50,000 convertible promissory note held by Ault Alliance, Inc. (formerly, BitNile Holdings, Inc.) (“Ault Alliance”), the parent company of AL, for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, AL (i) purchased an additional 1,333,333 shares of Common Stock upon approval of the IND for Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares of Common Stock upon the completion of Phase IA clinical trials for AL001 for a purchase price of $4 million. The Company issued to AL warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, AL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of the date of this Quarterly Report.

 

In November 2022, the Company entered into a marketing and brand development agreement with Ault Alliance, effective August 1, 2022, whereby Ault Alliance will provide various marketing services over twelve months valued at $1.4 million. The Company had the right to pay the fee in cash or shares of its Common Stock with a value of $1.50 per share. On November 11, 2022, the Company elected to pay the fee with 933,334 shares of its Common Stock. The Company recorded the value of the agreement using the closing price of the Company’s Common Stock on November 11, 2022, and will amortize the expense over twelve months beginning in August 2022. At January 31, 2023, the balance of related party prepaid expenses was $495,000.

 

 16 
 

 

9.COMMITMENTS AND CONTINGENCIES

 

Contractual Obligations

 

On May 1, 2016, the Company entered into a Standard Exclusive License Agreement for ALZN002 with Sublicensing Terms with Licensor, pursuant to which Licensor granted the Company a royalty bearing exclusive worldwide license limited to the field of Alzheimer’s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled “Amyloid Beta Peptides and Methods of Use,” filed April 7, 2009 and granted May 29, 2012.

 

There are certain initial license fees and milestone payments required to be paid by the Company to the Licensor pursuant to the terms of license agreements. The license agreements for ALZN002 require the Company to pay royalty payments of 4% on net sales of products developed from the licensed technology for ALZN002 while the license agreements for AL001 require that the Company pay combined royalty payments of 4.5% on net sales of products developed from the licensed technology for AL001.  The Company has already paid an initial license fee of $200,000 for ALZN002 and an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of ALZN002, the Licensor received 3,601,809 shares of common stock. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 2,227,923 shares of common stock. Minimum royalties for AL001 are $25,000 in 2023, $45,000 in 2024 and $70,000 in 2025 and every year thereafter, for the life of the agreement. Minimum royalties for ALZN002 are $20,000 in 2022, $40,000 in 2023 and $50,000 in 2024 and every year thereafter, for the life of the respective agreement. Additionally, the Company is required to pay milestone payments on the due dates to the Licensor for the license of the AL001 technologies and for the ALZN002 technology, as follows:

 

Original AL001 License:

           
Payment    Due Date    Event
$ 50,000 *  Completed September 2019    Pre-IND meeting
           
$ 65,000 *  Completed June 2021    IND application filing
           
$ 190,000 *  Completed December 2021    Upon first dosing of patient in a clinical trial
           
$ 500,000 *  Completed March 2022    Upon Completion of first clinical trial
           
$ 1,250,000    12 months from completion of the first Phase II clinical trial    Upon first patient treated in a Phase III clinical trial
           
$ 10,000,000    8 years from the effective date of the agreement    Upon U.S. Food and Drug Administration (“FDA”) approval
*Milestone met and completed

 

ALZN002 License: 

Payment   Due Date   Event
$ 50,000  * Completed September 2022    Upon IND application filing
           
$ 50,000   12 months from IND application filing date    Upon first dosing of patient in first Phase I clinical trial
           
$ 175,000   12 months from first patient dosed in Phase I    Upon completion of first Phase I clinical trial
           
$ 500,000   24 months from completion of first Phase I clinical trial    Upon completion of first Phase II clinical trial
           
$ 1,000,000   12 months from completion of the first Phase II clinical trial    Upon first patient treated in a Phase III clinical trial
           
$ 10,000,000   7 years from the effective date of the agreement    Upon FDA BLA approval
*Milestone met and completed

 

The Company has met the pre-IND meeting, IND application filing, and successfully completed the Phase I clinical trial milestones encompassing AL001 and the IND application filing milestone for ALZN002. If the Company fails to meet a milestone by its specified date, the Licensor may terminate the license agreement. 

 

 17 
 

 

Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company while Licensor remains the owner of any equity securities of the Company.

 

On June 10, 2020, the Company obtained two (2) additional royalty-bearing exclusive worldwide licenses from the Licensor to a therapy named AL001. One of the additional licenses is for the treatment of neurodegenerative diseases excluding Alzheimer’s and the other license is for the treatment of psychiatric diseases and disorders. There are certain license fees and milestone payments required to be paid pursuant to the terms of the Standard Exclusive License Agreements with Sublicensing Terms, both dated June 10, 2020 and effective as of November 1, 2019, with the Licensor and the University of South Florida (the “June AL001 License Agreements”). Under each of the June AL001 License Agreements, a royalty payment of 3% is required on net sales of products developed from the licensed technology. For the two (2) additional AL001 licenses, in the aggregate, the Company has paid initial license fees of $20,000. Additionally, under each of the June AL001 License Agreements, the Company is required to pay milestone payments on the due dates to the Licensor for the license of the technology, as follows:

 

Additional AL001 Licenses: 

Payment   Due Date   Event
$ 50,000   Upon IND application filing    IND application filing
           
$ 150,000   12 months from IND filing date    Upon first dosing of patient in a clinical trial
           
$ 400,000   12 months from first patient dosing    Upon Completion of first clinical trial
           
$ 1,000,000   36 months from completion of the first Phase II clinical trial    Upon first patient treated in a Phase III clinical trial
           
$ 8,000,000   8 years from the effective date of the agreement    First commercial sale

 

10.EQUITY TRANSACTIONS

 

The Company is authorized to issue 10,000,000 shares of Preferred Stock $0.0001 par value. The Board has designated 1,360,000 shares as the Series A Preferred Shares. The rights, preferences, privileges and restrictions on the remaining authorized 8,640,000 shares of Preferred Stock have not been determined. The Board is authorized to create a new series of preferred shares and determine the number of shares, as well as the rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred shares. 

 

Series A Preferred Shares

 

As of January 31, 2023, there were no Series A Preferred Shares or any other shares of Preferred Stock issued or outstanding.

 

Common Stock

 

On April 30, 2019, the Company and ALSF entered into a SPA for the purchase of 10,000,000 shares of Common Stock for a total purchase price of $15,000,000, or $1.50 per share with 5,000,000 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The total purchase price of $15,000,000 was in the form of a non-interest bearing note receivable with a 12-month term from ALSF, a related party. The note is secured by a pledge of the purchased shares. Pursuant to the SPA, ALSF is entitled to full ratchet anti-dilution protection, most-favored nation status, denying the Company the right to enter into a variable rate transaction absent its consent, a right to participate in any future financing the Company may consummate and to have all the shares of Common Stock to which it is entitled under the SPA registered under the Securities Act within 180 days of the final closing of the IPO. In May 2021, the term of the note receivable was extended to December 31, 2023. The note is secured by a pledge of the purchased shares.

 

In March 2021, the Company entered into a securities purchase agreement with AL pursuant to which the Company agreed to sell an aggregate of 6,666,667 shares of Common Stock for an aggregate of $10 million, or $1.50 per share, which sales were made in tranches. On March 9, 2021, AL paid $4 million, less the $1.8 million in prior advances and the surrender for cancellation of a $50,000 convertible promissory note held by Ault Alliance, for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, AL (i) purchased an additional 1,333,333 shares of Common Stock upon approval by the FDA of the Company’s IND for its Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares of Common Stock upon the completion of these Phase IA clinical trials for AL001 for a purchase price of $4 million. The Company further agreed to issue to AL warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share.

 

Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, on April 28, 2022, AL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of the date of this Quarterly Report.

 

 18 
 

 

11.SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the date the financial statements were issued. The Company has determined that there are no such events that warrant disclosure or recognition in the condensed financial statements presented herein. 

 

 19 
 

 

ITEM 2.     MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

You should read the following management’s discussion and analysis of financial condition and results of operations in conjunction with our unaudited condensed financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited financial statements and related notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission, or the SEC, on July 19, 2022.

 

NOTE ABOUT FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This section should be read in conjunction with our unaudited condensed financial statements and related notes included in Part I, Item 1 of this report. The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act.

 

These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “expects,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predict,” “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions; uncertainties and other factors may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

 

In this Quarterly Report, unless the context requires otherwise, references to the “Company,” “Alzamend,” “we,” “our company” and “us” refer to Alzamend Neuro, Inc., a Delaware corporation.

 

Overview

 

We were incorporated on February 26, 2016, as Alzamend Neuro, Inc. under the laws of the State of Delaware. We were formed to acquire and commercialize patented intellectual property and know-how to prevent, treat and potentially cure the crippling and deadly Alzheimer’s. With our two product candidates, we aim to bring treatment or cures not only for Alzheimer’s, but also, bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”). Existing Alzheimer’s treatments only temporarily relieve symptoms but do not, to our knowledge, slow or halt the underlying worsening of the disease. We have developed a novel approach in an attempt to combat Alzheimer’s through immunotherapy.

 

Critical Accounting Policies and Estimates

 

Research and Development ExpensesResearch and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of our company.

 

We have acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, product or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects.

 

Stock-Based Compensation. We maintain a stock-based compensation plan as a long-term incentive for employees, non-employee directors and consultants. The plan allows for the issuance of incentive stock options, non-qualified stock options, restricted stock units, and other forms of equity awards.

 

We recognize stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. Our stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.

 

 20 
 

 

The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. These assumptions include:

 

·Fair Value of Common Stock. See the subsection titled “Common Stock Valuations” below.

 

·Risk-Free Interest Rate. The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.

 

·Expected Volatility. Because we do not have a sufficient trading history for our common stock (“Common Stock”), the expected volatility was estimated based on the average volatility for comparable publicly traded life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on the similar size, stage in life cycle or area of specialty. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.

 

·Expected Term. The expected term represents the period that the stock-based awards are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term), as we do not have sufficient historical data to use any other method to estimate expected term.

 

·Expected Dividend Yield. We have never paid dividends on our Common Stock and have no plans to pay dividends on our Common Stock. Therefore, we used an expected dividend yield of zero.

 

Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation could be materially different.

 

Common Stock Valuations. Prior to our initial public offering (“IPO”) in June 2021, there was no public market for our Common Stock, and, as a result, the fair value of the shares of Common Stock underlying our stock-based awards was estimated on each grant date by our Board. To determine the fair value of our Common Stock underlying option grants, our Board considered, among other things, input from management, and our Board’s assessment of additional objective and subjective factors that it believed were relevant, and factors that may have changed from the date of the most recent valuation through the date of the grant. These factors included, but were not limited to:

 

·our results of operations and financial position, including our levels of available capital resources;

 

·our stage of development and material risks related to our business;

 

·progress of our research and development activities;

 

·our business conditions and projections;

 

·the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed mergers and acquisitions of peer companies;

 

·the lack of marketability of our Common Stock as a private company;

 

·the prices at which we sold shares of our Common Stock to outside investors in arms-length transactions;

 

·the likelihood of achieving a liquidity event for our security holders, such as an IPO or a sale of our company, given prevailing market conditions;

 

·trends and developments in our industry; and

 

·external market conditions affecting the life sciences and biotechnology industry sectors.

 

Following the closing of our IPO, our Board determined the fair market value of our Common Stock based on the closing price of our Common Stock as reported on the date of grant.

 

 21 
 

 

Plan of Operations

 

Our plan of operations is currently focused on the development of both our therapeutic candidates, which are at different stages of development. We submitted an Investigational New Drug (“IND”) application for AL001 to the FDA on June 30, 2021. On July 28, 2021, we announced receipt of FDA “Study May Proceed” letter for a Phase I study under our IND application for AL001, a lithium-based ionic cocrystal oral therapy for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer’s.

 

On August 17, 2021, we announced that we have contracted Altasciences Clinical Kansas (“Altasciences”) to conduct a six-month Phase I relative bioavailability study for AL001 for dementia related to Alzheimer’s beginning in September 2021. The Phase I first-in-human study was for the purpose of determining potential clinically safe and appropriate dosing for AL001 in future studies. The Phase I study investigated the pharmacokinetics (the movement of drug through the body) of lithium following a single dose of AL001 (the “study drug”) compared to a typical single dose of a marketed 300 mg immediate-release lithium carbonate capsule (the “comparator” – currently indicated to treat mood disorders) in healthy male and female subjects. The lithium and salicylate components of AL001 was given within the amounts already approved for use in patients. The purpose of the research study was to test the safety, tolerability, and bioavailability (how much and when drug gets in the body) of the study drug, AL001, compared to the currently marketed formulation of the comparator, lithium carbonate. This was expected to ascertain what AL001 doses should be given, and how often, in subsequent Phase 2 safety and efficacy trials involving Alzheimer’s patients. At least 24 healthy male and female human subjects participated in the Phase I trial.

 

On September 13, 2021, we announced that the first group of healthy participants were dosed in a six-month Phase I relative bioavailability study for AL001 for dementia related to Alzheimer’s. On March 28, 2022, we announced receipt of full data set from the Phase I clinical trial for AL001. The full data set builds upon topline data previously reported on December 17, 2021. This data affirmed that dose-adjusted relative bioavailability analysis of the rate and extent of lithium absorption in plasma indicate that AL001 as 150 mg dosage is bioavailability to the marketed 300 mg lithium carbonate product and the shapes of the lithium plasma concentration versus time curves are similar. AL001 salicylate plasma concentrations are observed to be well tolerated and consistently within safe limits and the safety profiles of both AL001 and the marketed lithium carbonate capsule were benign.

 

During Phase I first-in-human trial, participants received a single dose of AL001 containing lithium in an amount equivalent to 150 mg lithium carbonate; this is the dose proposed by the inventors as likely appropriate for Alzheimer’s treatment when given three times daily (“TID”). Currently, marketed immediate-release lithium carbonate 300 mg are given TID; for example, lithium carbonate 300 mg TID is a dose commonly used for bipolar affective disorders. It can be difficult to set the appropriate dose of lithium carbonate and other lithium products due to the small margin between effective and toxic blood levels and to avoid side effects or inadequate treatment outcomes. We see the possibility of providing the benefits from lithium at up to 50% of the currently approved lithium carbonate dosage, with the potential for better outcomes and with elimination of the need for lithium therapeutic drug monitoring. Moreover, the data confirms AL001’s potential as a replacement of the current lithium-based treatments and may provide a treatment for over 40 million Americans suffering from Alzheimer’s and other neurodegenerative diseases and psychiatric disorders.

 

Such findings may allow us to design a development program that will potentially reduce the amount of new data generated to support approval. Bioequivalence may have utility for AL001 when seeking approval for the indications of currently marketed lithium products, and for new indications as a benchmark for safety. Given the systemic pharmacokinetic similarity to marketed immediate-release lithium carbonate products, AL001 may be dosed TID in the planned Phase II study, a multiple ascending dose safety study in Alzheimer’s patients. In addition, we are pursuing investigational new drug applications with the FDA for BD, MDD, and PTSD.

 

On April 28, 2022, we announced that Ault Lending, LLC (“AL”) has made an additional investment in our company. On March 28, 2022, we announced receipt of the full data set from Phase I clinical trial for AL001. Based on the achievement of this milestone, under the March 12, 2021, securities purchase agreement, we sold an additional 2,666,667 shares of common stock to AL for $4 million, or $1.50 per share, and issued to AL warrants to acquire 1,333,333 shares of common stock with an exercise price of $3.00 per share.

 

On May 5, 2022, we announced that the first patient with mild to moderate Alzheimer’s was dosed in a 12-month Phase IIA multiple ascending dose (“MAD”) study for dementia related to Alzheimer’s. The Phase IIA study will evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions and determine the maximum tolerated dose in patients diagnosed with mild to moderate Alzheimer’s. Lithium has been well characterized for safety and is approved/marketed in multiple formulations for bipolar affective disorders. Lithium dosing for the MAD cohorts is based on a fraction of the usual dose for treatment of bipolar affective disorder (i.e., AL001 lithium content at a lithium carbonate equivalent of 300 mg TID, daily total of 900 mg), with the target dose for Alzheimer’s treatment at half of that lithium carbonate equivalent value (150 mg TID, daily total of 450 mg). In each cohort, consisting of six active and two placebo patients (as per randomization), multiple ascending doses will be administered TID for 14 days under fasted conditions (at least 1 hour before or 4 hours after meals) up to tolerability/safety limits. The lithium and salicylate components of AL001 will be given within the amounts already approved for use in patients. Up to 40 subjects will complete the Phase IIA trial. The maximum tolerated dose will then be used for further studies. On October 5, 2022, we announced the addition of a healthy adult subject cohort to the MAD study and that the first healthy patient was dosed.

 

 22 
 

 

On May 17, 2022, we announced submission of a Pre-IND meeting request for AL001 and supporting briefing documents to the FDA for the treatment of BD, MDD and PTSD. On July 18, 2022, we announced receipt of a written response from the FDA to our meeting request relating to our Pre-IND application. The FDA’s response provided a path for our planned clinical development of AL001 for the treatment of BD, MDD and PTSD. Based on the FDA’s written feedback, we anticipate filing INDs for BD, MDD and PTSD upon the completion of the current Phase IIA MAD study. This will allow us to initiate Phase II clinical trials for all three new indications.

 

We have an additional preclinical candidate for Alzheimer’s, ALZN002, which has transitioned from early-stage development to an extensive program of preclinical study and evaluation, which was completed on May 31, 2021. This was followed by a comprehensive report prepared by Charles River Laboratories, Inc., an independent preclinical service provider, received on July 23, 2021. Our preclinical program included a toxicologic evaluation, histopathology study and brain beta amyloid analysis and was expanded to include an immunoglobulin analysis and biodistribution study.

 

On July 30, 2021, we announced that we submitted a pre-IND meeting request for ALZN002 and supporting briefing documents to the Center for Biological Evaluation and Research of the FDA. On September 30, 2021, we announced that we have received a written response to our meeting request relating to our Type B Pre-IND application from the FDA providing a path for our planned clinical development of ALZN002. ALZN002 is a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Preclinical work supports ALZN002 being associated with a positive anti-inflammatory response and a decrease in brain amyloid contents. Based on ALZN002’s positive toxicology results, the biologic nature of this product and the urgent need to deliver treatments for Alzheimer’s to patients, we proposed, and the FDA agreed, to conduct a combined Phase I/II study.

 

On September 29, 2022, we announced that we submitted an IND application to the FDA for ALZN002 to conduct a Phase I/IIA clinical trial. The purpose of this trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared with that of placebo in 20-30 subjects with mild to moderate dementia of the Alzheimer’s type. Also, the trial is designed to determine the optimal dosage of ALZN002, allowing for induction of anti-Amyloid-beta antibody responses that can target Alzheimer’s-associated brain proteins while maintaining safety. The primary goal of this initial clinical trial is to determine an appropriate dose of ALZN002 for treatment of patients with Alzheimer’s in a larger Phase IIB efficacy and safety clinical trial (ALZN002-02), which we expect to initiate within three months of receiving data from the initial trial.

 

On October 31, 2022 we announced receipt of a “study may proceed” letter from the FDA for a phase I/IIA clinical trial under our IND application for ALZN002 to treat mild to moderate dementia of the Alzheimer’s type. We are advancing the process and expect that the first patient will be dosed in the first quarter of 2023.

 

The continuation of our current plan of operations with respect to completing our IND applications and conducting the series of human clinical trials for each of our therapeutics requires us to raise additional capital to fund our operations.

 

Because our working capital requirements depend upon numerous factors, including the progress of our preclinical and clinical testing, timing and cost of obtaining regulatory approvals, changes in levels of resources that we devote to the development of manufacturing and marketing capabilities, competitive and technological advances, status of competitors, and our ability to establish collaborative arrangements with other organizations, we will require additional financing to fund future operations.

 

 23 
 

 

 Results of Operations

 

Results of Operations for the Three Months Ended January 31, 2023 and 2022

 

The following table summarizes the results of our operations for the three months ended January 31, 2023 and 2022:

 

   For the Three Months Ended January 31, 
   2023   2022   $ Change   %
Change
 
 OPERATING EXPENSES                    
 Research and development  $2,888,847   $873,653   $2,015,194    231%
 General and administrative   2,534,665    1,682,913    851,752    51%
 Total operating expenses   5,423,512    2,556,566    2,866,946    112%
 Loss from operations   (5,423,512)   (2,556,566)   (2,866,946)   112%
                     
 OTHER EXPENSE, NET                    
 Interest expense   (2,062)   (16,299)   14,237    -87%
 Total other expense, net   (2,062)   (16,298)   14,237    -87%
                     
 NET LOSS  $(5,425,574)  $(2,572,865)  $(2,852,709)   111%
                     
 Basic and diluted net loss per common share  $(0.06)  $(0.03)  $(0.03)   * 
                     
 Basic and diluted weighted average common shares outstanding   98,326,175    94,165,225         * 

 

* Not meaningful

 

Revenue

 

We were formed on February 26, 2016, to acquire and commercialize patented intellectual property and know-how to prevent, treat and potentially cure the crippling and deadly Alzheimer’s. With our two product candidates, we aim to bring treatments or cures not only for Alzheimer’s, but also BD, MDD and PTSD. These product candidates are in the early clinical stage of development and will require extensive clinical study, review and evaluation, regulatory review and approval, significant marketing efforts and substantial investment before either or both of them, or any respective successors, will provide us with any revenue. We did not generate any revenues during the three months ended January 31, 2023 and 2022, and we do not anticipate that we will generate revenue for the foreseeable future.

 

General and Administrative Expenses

 

General and administrative expenses for each of the three months ended January 31, 2023 and 2022 were $2.5 million and $1.7 million, respectively. As reflected in the table below, general and administrative expenses primarily consisted of the following expense categories: stock-based compensation expense; professional fees; insurance; marketing fees; travel and entertainment; board fees; as well as salaries and benefits. For the three months ended January 31, 2023 and 2022, the remaining general and administrative expenses of $119,000 and $102,000, respectively, consisted of payments for filing fees, transfer agent fees, license fees, and other office expenses, none of which was significant individually. 

 

   For the Three Months Ended January 31, 
   2023   2022   $ Change   %
Change
 
 Stock-based compensation expense  $1,550,911   $1,024,693   $526,218    51%
 Professional fees   190,169    114,524    75,645    66%
 Insurance   130,838    214,299    (83,461)   -39%
 Salary and benefits   233,246    203,954    29,292    14%
 Travel and entertainment   25,436    23,917    1,519    6%
 Marketing fees   247,333    -    247,333    * 
 Board of director fees   37,500    -    37,500    * 
 Other general and administrative expenses   119,232    101,527    17,705    17%
 Total general and administrative expenses  $2,534,665   $1,682,914   $851,751    51%

* Not meaningful

 

 24 
 

 

Stock-Based Compensation Expense

 

During the three months ended January 31, 2023 and 2022, we incurred general and administrative stock-based compensation expense of $1.6 million and $1.0 million, respectively, related to stock option grants to executives, employees and consultants as well as shares issued for previously issued for services to Spartan Capital Securities, LLC (“Spartan Capital”). All option grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. We valued the options at their date of grant utilizing the Black-Scholes option pricing model. We valued the shares issued for services at their intrinsic value on the date of issuance. Stock-based compensation is a non-cash expense because we settle these obligations by issuing shares of Common Stock from authorized shares instead of settling such obligations with cash payments.

 

Marketing Fees 

 

During the three months ended January 31, 2023, we reported marketing fees of $247,000, which were principally comprised of the related party marketing and brand development agreement. 

 

Salaries and Benefits

 

During the three months ended January 31, 2023 and 2022, we incurred $233,000 and $204,000, respectively, in employee-related expenses. As of January 31, 2023, we had four full-time and three part-time employees.

 

Henry C.W. Nisser, our Executive Vice President and General Counsel and Kenneth S. Cragun, our Senior Vice President of Finance work for us on a part-time basis. Mr. Nisser spends no less than an average of 8 hours per week on our company’s business and Mr. Cragun spends no less than an average of 4 hours per week on our company’s business.

 

Research and Development Expenses

 

Research and development expenses for the three months ended January 31, 2023 and 2022 were $2.9 million and $874,000, respectively. As reflected in the table below, research and development expenses primarily consisted of professional fees, clinical trial fees, licenses and fees, as well as stock-based compensation expense. 

 

   For the Three Months Ended January 31, 
   2023   2022   $ Change   % Change 
 Professional fees  $860,798   $479,549   $381,249    80%
 Clinical trial fees   2,050,000    283,497    1,766,503    623%
 Licenses and fees   -    (45,000)   45,000    * 
 Stock-based compensation expense   (42,589)   106,102    (148,691)   -140%
 Other research and development expenses   20,638    49,505    (28,867)   -58%
 Total research and development expenses  $2,888,847   $873,653   $2,015,194    231%

 *Not meaningful

 

Professional Fees

 

During the three months ended January 31, 2023 and 2022, we incurred professional fees of $861,000 and $480,000, respectively, which were principally comprised of professional fees attributed to various types of scientific services, including FDA consulting services. The increase relates to professional fees incurred related to IND preparation for ALZN002.

 

Clinical Trial Fees

 

During the three months ended January 31, 2023 and 2022, we incurred clinical trial fees of $2.1 million and $283,000, respectively, which were principally comprised of clinical trial fees attributed to our Phase I and Phase IIA clinical trials for AL001.

 

Licenses and Fees

 

There are certain initial license fees and milestone payments required to be paid to the University of South Florida and the Licensor, for the licenses of the technologies, pursuant to the terms of the License Agreement with Sublicensing Terms.

 

Stock-Based Compensation Expense

 

During the three months ended January 31, 2023 and 2022, we incurred $(43,000) and $106,000, respectively, in research and development stock-based compensation expense related to stock option grants to consultants. All option grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. We valued the options at their date of grant utilizing the Black-Scholes option pricing model. Stock-based compensation is a non-cash expense because we settle these obligations by issuing shares of Common Stock from authorized shares instead of settling such obligations with cash payments.

 

 25 
 

 

Other Expense, Net

 

Interest Expense

 

Interest expense was $2,000 for the three months ended January 31, 2023, primarily related to financing of D&O insurance. 

 

Results of Operations for the Nine Months Ended January 31, 2023 and 2022

 

The following table summarizes the results of our operations for the nine months ended January 31, 2023 and 2022:

 

   For the Nine Months Ended January 31, 
   2023   2022   $ Change   %
Change
 
 OPERATING EXPENSES                    
 Research and development  $5,797,789   $3,540,111   $2,257,678    64%
 General and administrative   5,767,668    4,906,628    861,040    18%
Total operating expenses   11,565,457    8,446,739    3,118,718    37%
 Loss from operations   (11,565,457)   (8,446,739)   (3,118,718)   37%
                     
 OTHER EXPENSE, NET                    
 Interest expense   (7,182)   (45,922)   38,740    -84%
 Total other expense, net   (7,182)   (45,922)   38,740    -84%
                     
 NET LOSS  $(11,572,639)  $(8,492,661)  $(3,079,978)   36%
                     
 Basic and diluted net loss per common share  $(0.12)  $(0.09)  $(0.03)   * 
                     
 Basic and diluted weighted average common shares outstanding   97,765,471    89,484,601         * 

* Not meaningful

 

Revenue

 

We were formed on February 26, 2016, to acquire and commercialize patented intellectual property and know-how to prevent, treat and potentially cure the crippling and deadly Alzheimer’s. With our two product candidates, we aim to bring treatment or cures not only for Alzheimer’s, but also BD, MDD and PTSD. These product candidates are in the early clinical stage of development and will require extensive clinical study, review and evaluation, regulatory review and approval, significant marketing efforts and substantial investment before either or both of them, or any respective successors, will provide us with any revenue. We did not generate any revenues during the nine months ended January 31, 2023 and 2022, and we do not anticipate that we will generate revenue for the foreseeable future.

 

General and Administrative Expenses

 

General and administrative expenses for each of the nine months ended January 31, 2023 and 2022 were $5.8 million and $4.9 million, respectively. As reflected in the table below, general and administrative expenses primarily consisted of the following expense categories: stock-based compensation expense; professional fees; insurance; marketing fees; travel and entertainment; board of director fees; as well as salaries and benefits. For the nine months ended January 31, 2023 and 2022, the remaining general and administrative expenses of $191,000 and $294,000, respectively, consisted of payments for filing fees, transfer agent fees, license fees, and other office expenses, none of which is significant individually. 

 

 26 
 

 

   For the Nine Months Ended January 31, 
   2023   2022   $ Change   %
Change
 
 Stock-based compensation expense  $3,133,888   $2,791,515   $342,373    12%
 Professional fees   566,674    615,765    (49,091)   -8%
 Insurance   456,838    500,031    (43,193)   -9%
 Salary and benefits   676,155    547,244    128,911    24%
 Travel and entertainment   135,447    120,086    15,361    13%
 Marketing fees   495,267    7,154    488,113    

6,823

%
 Board of director fees   112,500    31,256    81,244    260%
 Other general and administrative expenses   190,899    293,577    (102,678)   -35%
 Total general and administrative expenses  $5,767,668   $4,906,628   $861,040    18%

 

Stock-Based Compensation Expense

 

During the nine months ended January 31, 2023 and 2022, we incurred general and administrative stock-based compensation expense of $3.1 million and $2.8 million, respectively, related to stock option grants to executives, employees and consultants as well as shares issued for services to Spartan Capital. All option grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. We valued the options at their date of grant utilizing the Black-Scholes option pricing model. We valued the shares issued for services at their intrinsic value on the date of issuance. Stock-based compensation is a non-cash expense because we settle these obligations by issuing shares of Common Stock from authorized shares instead of settling such obligations with cash payments.

 

Salaries and Benefits

 

During the nine months ended January 31, 2023 and 2022, we incurred $676,000 and $547,000, respectively, in employee-related expenses. As of January 31, 2023, we had four full-time and three part-time employees.

 

Henry C.W. Nisser, our Executive Vice President and General Counsel and Kenneth S. Cragun, our Senior Vice President of Finance work for us on a part-time basis. Mr. Nisser spends no less than an average of 8 hours per week on our company’s business and Mr. Cragun spends no less than an average of 4 hours per week on our company’s business.

 

Professional Fees 

 

During the nine months ended January 31, 2023 and 2022, we reported professional fees of $567,000 and $616,000, respectively, which were principally comprised of Spartan Capital consulting fees and audit fees.

 

Marketing Fees 

 

During the nine months ended January 31, 2023 and 2022, we reported marketing fees of $495,000 and $7,000, respectively, which were principally comprised of the related party marketing and brand development agreement. 

 

 Insurance 

 

During the nine months ended January 31, 2023 and 2022, we reported insurance expense of $457,000 and $500,000, respectively, which was principally comprised of Directors and Officers insurance.

 

Research and Development Expenses

 

Research and development expenses for the nine months ended January 31, 2023 and 2022 were $5.8 million and $3.5 million, respectively. As reflected in the table below, research and development expenses primarily consisted of professional fees, clinical trial fees, licenses and fees, as well as stock-based compensation expense.

 

 27 
 

 

   For the Nine Months Ended January 31, 
   2023   2022   $ Change   % Change 
 Professional fees  $2,969,835   $1,868,167   $1,101,668    59%
 Clinical trials fees   2,625,271    1,006,503    1,618,768    161%
 Licenses and fees   55,000    210,000    (155,000)   -74%
 Stock-based compensation expense   (42,589)   359,286    (401,875)   -112%
 Other research and development expenses   190,272    96,155    94,117    98%
 Total research and development expenses  $5,797,789   $3,540,111   $2,257,678    64%

 

Professional Fees

 

During the nine months ended January 31, 2023 and 2022, we reported professional fees of $3.0 million and $1.9 million, respectively, which were principally comprised of professional fees attributed to various types of scientific services, including FDA consulting services. The increase relates to professional fees incurred related to preparation of Phase IIA clinical trials for AL001 and IND preparation for ALZN002.

 

Clinical Trial Fees

 

During the nine months ended January 31, 2023 and 2022, we incurred clinical trial fees of $2.6 million and $1.0 million, respectively, which were principally comprised of clinical trial fees attributed to our Phase I and Phase IIA clinical trials for AL001.

 

 

Licenses and Fees

 

There are certain initial license fees and milestone payments required to be paid to the University of South Florida and the Licensor, for the licenses of the technologies, pursuant to the terms of the License Agreement with Sublicensing Terms.

 

Stock-Based Compensation Expense

 

During the nine months ended January 31, 2023 and 2022, we incurred $(43,000) and $359,000, respectively, in research and development stock-based compensation expense related to stock option grants to consultants. All option grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. We valued the options at their date of grant utilizing the Black-Scholes option pricing model. Stock-based compensation is a non-cash expense because we settle these obligations by issuing shares of Common Stock from authorized shares instead of settling such obligations with cash payments.

 

Other Expense, Net

 

Interest Expense

 

Interest expense was $7,000 for the nine months ended January 31, 2023, primarily related to financing of D&O insurance.

 

Liquidity and Capital Resources

 

The accompanying financial statements have been prepared on the basis that our company will continue as a going concern. As of January 31, 2023, we had cash of $7.4 million and an accumulated deficit of $40.8 million. We have incurred recurring losses and reported losses for the three and nine months ended January 31, 2023 totaling $5.4 million and $11.6 million, respectively. In the past, we have financed our operations principally through issuances of promissory notes and equity securities.

 

In March of 2021, we entered into a securities purchase agreement with AL, pursuant to which we sold an aggregate of 6,666,667 shares of Common Stock for an aggregate of $10 million, or $1.50 per share, which sales were made in tranches. On March 9, 2021, AL paid $4 million, less the $1.8 million in prior advances and the surrender for cancellation of the $50,000 convertible promissory note, previously issued to Ault Alliance, Inc. (formerly, BitNile Holdings, Inc.), the parent company of AL, for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, AL (i) purchased, in July 2021, an additional 1,333,333 shares of Common Stock upon FDA approval of our IND for our Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased, in April 2022, 2,666,667 shares of Common Stock upon completion of our Phase IA clinical trials for AL001 for a purchase price of $4 million. We issued AL warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share. Finally, we agreed that for a period of eighteen months following the date of the payment of the final tranche of $4 million, AL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of the date of this Quarterly Report.

 

 28 
 

 

We will need to obtain substantial additional funding in the future for our clinical development activities and continuing operations. If we are unable to raise capital when needed or on favorable terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts. Our future capital requirements will depend on many factors, including:

 

·successful enrollment in, and completion of, clinical trials;
·our ability to establish agreements with third-party manufacturers for clinical supply for our clinical trials and, if our product candidates are approved, commercial manufacturing;
·our ability to maintain our current research and development programs and establish new research and development programs;
·addition and retention of key research and development personnel;
·our efforts to enhance operational, financial, and information management systems, and hire additional personnel, including personnel to support development of our product candidates;
·negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter and performing our obligations in such collaborations;
·the timing and amount of milestone and other payments we may receive under our collaboration arrangements;
·our eventual commercialization plans for our product candidates;
·the costs involved in prosecuting, defending, and enforcing patent claims and other intellectual property claims; and
·the costs and timing of regulatory approvals.

 

A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.

 

We expect to continue to incur losses for the foreseeable future and need to raise additional capital until we are able to generate revenues from operations sufficient to fund our development and commercial operations. However, based on our current business plan, we believe that our cash at January 31, 2023, is sufficient to meet our anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report.

 

Cash Flows

 

The following table summarizes our cash flows for the nine months ended January 31, 2023 and 2022:

 

   For the Nine Months Ended January 31, 
   2023   2022 
Net cash provided by (used in):          
Operating activities  $(6,687,970)  $(5,051,637)
Financing activities   -    14,912,656 
Net (decrease) increase in cash  $(6,687,970)  $9,861,019 

 

Operating Activities

 

During the nine months ended January 31, 2023, net cash used in operating activities was $6.7 million. This consisted primarily of a net loss of $11.6 million, partially offset by an increase in our net operating assets and liabilities of $1.8 million and non-cash charges of $3.1 million. The non-cash charges primarily consisted of stock-based compensation expense. The increase in our net operating assets and liabilities was due to an increase in accounts payable and accrued liabilities and in prepaid expenses and other current assets.

 

During the nine months ended January 31, 2022, net cash used in operating activities was $5.1 million. This consisted primarily of a net loss of $8.5 million, partially offset by an increase in non-cash charges of $3.2 million and our net operating assets and liabilities of $277,000. The non-cash charges primarily consisted of stock-based compensation expense. The increase in our net operating assets and liabilities was primarily due to an increase in prepaid expenses and other current assets.

 

Investing Activities

 

There were no investing activities for the nine months ended January 31, 2023 or 2022.

 

 29 
 

 

Financing Activities

 

There were no financing activities for the nine months ended January 31, 2023. Financing activities for the nine months ended January 31, 2022 related primarily to proceeds from our initial public offering.

 

License Agreement

 

On May 1, 2016, we entered into a Standard Exclusive License Agreement for ALZN002 with Sublicensing Terms with the University of South Florida Research Foundation, Inc., as licensor (the “Licensor”), pursuant to which the Licensor granted us a royalty bearing exclusive worldwide license limited to the field of Alzheimer’s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled “Amyloid Beta Peptides and Methods of Use,” filed April 7, 2009 and granted May 29, 2012.

  

There are certain initial license fees and milestone payments required to be paid by us to the Licensor, pursuant to the terms of license agreements we have entered into with the Licensor. The license agreements for ALZN002 require us to pay royalty payments of 4% on net sales of products developed from the licensed technology for ALZN002 while the license agreements for AL001 require that we pay combined royalty payments of 4.5% on net sales of products developed from the licensed technology for AL001. We have already paid an initial license fee of $200,000 for ALZN002 and an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of ALZN002, the Licensor received 3,601,809 shares of our common stock. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 2,227,923 shares of our common stock. Minimum royalties for AL001 are $25,000 in 2023, $45,000 in 2024 and $70,000 in 2025 and every year thereafter, for the life of the agreement. Minimum royalties for ALZN002 are $20,000 in 2022, $40,000 in 2023 and $50,000 in 2024 and every year thereafter, for the life of the respective agreement. Additionally, we are required to pay milestone payments on the due dates to the Licensor for the license of the AL001 technologies and for the ALZN002 technology, as follows: 

 

Original AL001 License:

 

Payment    Due Date    Event
$ 50,000 * Completed September 2019   Pre-IND meeting
           
$ 65,000 * Completed June 2021    ND application filing
           
$ 190,000 * Completed December 2021   Upon first dosing of patient in a clinical trial
           
$ 500,000 * Completed March 2022   Upon Completion of first clinical trial
           
$ 1,250,000   12 months from completion of the first Phase II clinical trial   Upon first patient treated in a Phase III clinical trial
           
$ 10,000,000   8 years from the effective date of the agreement   Upon FDA approval

*Milestone met and completed 

 

ALZN002 License:

 

Payment   Due Date   Event
$ 50,000  * Completed September 2022    Upon IND application filing
           
$ 50,000   12 months from IND application filing date    Upon first dosing of patient in first Phase I clinical trial
           
$ 175,000   12 months from first patient dosed in Phase I    Upon completion of first Phase I clinical trial
           
$ 500,000   24 months from completion of first Phase I clinical trial    Upon completion of first Phase II clinical trial
           
$ 1,000,000   12 months from completion of the first Phase II clinical trial    Upon first patient treated in a Phase III clinical trial
           
$ 10,000,000   7 years from the effective date of the agreement    Upon FDA BLA approval

*Milestone met and completed 

 

We have met the pre-IND meeting, IND application filing, and successfully completed the Phase I clinical trial milestones encompassing AL001 and the IND application filing milestone for ALZN002. If we fail to meet a milestone by its specified date, Licensor may terminate the license agreement.

 

The Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by us while the Licensor remains the owner of any equity securities of our company.

 

 30 
 

 

On June 10, 2020, we obtained two (2) additional royalty-bearing exclusive worldwide licenses from the Licensor to a therapy named AL001. One of the additional licenses is for the treatment of neurodegenerative diseases excluding Alzheimer’s and the other license is for the treatment of psychiatric diseases and disorders. There are certain license fees and milestone payments required to be paid pursuant to the terms of the Standard Exclusive License Agreements with Sublicensing Terms, both dated June 10, 2020 and effective as of November 1, 2019, with the Licensor and the University of South Florida (the “June AL001 License Agreements”). Under each of the June AL001 License Agreements, a royalty payment of 3% is required on net sales of products developed from the licensed technology. For the two (2) additional AL001 licenses, in the aggregate, we have paid initial license fees of $20,000. Additionally, under each of the June AL001 License Agreements, we are required to pay milestone payments on the due dates to the Licensor for the license of the technology, as follows:

  

Additional AL001 Licenses:

 

Payment   Due Date   Event
$ 50,000    Upon IND application filing    IND application filing
           
$ 150,000    12 months from IND filing date    Upon first dosing of patient in a clinical trial
           
$ 400,000    12 months from first patient dosing    Upon Completion of first clinical trial
           
$ 1,000,000    36 months from completion of the first Phase II clinical trial    Upon first patient treated in a Phase III clinical trial
           
$ 8,000,000    8 years from the effective date of the agreement    First commercial sale

 

Recent Accounting Standards

 

For information about recent accounting pronouncements that may impact our financial statements, please refer to Note 3 of the Notes to Unaudited Condensed Financial Statements under the heading “Recent Accounting Standards.”

 

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Because we are a smaller reporting company, this section is not applicable.

 

ITEM 4.CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We have established disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and is accumulated and communicated to management, including the principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

 

Our principal executive officer and principal financial officer, with the assistance of other members of the Company’s management, have evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Based upon our evaluation, each of our principal executive officer and principal financial officer has concluded that the Company’s internal control over financial reporting was not effective as of the end of the period covered by this Quarterly Report on Form 10-Q because the Company has not yet completed its remediation of the material weakness previously identified and disclosed in the Company’s Annual Report on Form 10-K for the year ended April 30, 2022, the end of its most recent fiscal year.

 

Specifically, management has identified the following material weaknesses:

 

1.we do not have sufficient resources in our accounting function, which restricts our ability to perform sufficient reviews and approval of manual journal entries posted to the general ledger and to consistently execute review procedures over general ledger account reconciliations, financial statement preparation and accounting for non-routine transactions; and

 

2.our primary user access controls (i.e., provisioning, de-provisioning, privileged access and user access reviews) to ensure appropriate authorization and segregation of duties that would adequately restrict user and privileged access to the financially relevant systems and data to appropriate personnel were not designed and/or implemented effectively. We did not design and/or implement sufficient controls for program change management to certain financially relevant systems affecting our processes.

 

 31 
 

 

A material weakness is a control deficiency or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.

  

Planned Remediation

 

We are implementing measures designed to improve our internal control over financial reporting to remediate material weaknesses, including the following:

 

·Formalizing our internal control documentation and strengthening supervisory reviews by our management; and

 

·Adding additional accounting personnel and segregating duties amongst accounting personnel.

 

Management continues to work to improve its controls related to our material weaknesses, specifically relating to user access and change management surrounding our information technology systems and applications. Management will continue to implement measures to remediate material weaknesses, such that these controls are designed, implemented, and operating effectively. The remediation actions include: (i) enhancing design and documentation related to both user access and change management processes and control activities; and (ii) developing and communicating additional policies and procedures to govern the area of information technology change management. In order to achieve the timely implementation of the above, management has commenced the following actions and will continue to assess additional opportunities for remediation on an ongoing basis:

 

·Engaging a third-party specialist to assist management with improving the Company’s overall control environment, focusing on change management and access controls; and

 

·Implementing new applications and systems that are aligned with management’s focus on creating strong internal controls.

 

We are currently working to improve and simplify our internal processes and implement enhanced controls, as discussed above, to address the material weaknesses in our internal control over financial reporting and to remedy the ineffectiveness of our disclosure controls and procedures. These material weaknesses will not be considered to be remediated until the applicable remediated controls are operating for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

 

Despite the existence of these material weaknesses, we believe that the condensed financial statements included in the period covered by this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented in conformity with U.S. generally accepted accounting principles. 

 

Changes in Internal Control

 

Except as detailed above, during the three months ended January 31, 2023, there was no change in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 32 
 

 

PART II — OTHER INFORMATION

 

ITEM 1.LEGAL PROCEEDINGS

 

From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

 

ITEM 1A.RISK FACTORS

 

The risks described in Part I, Item 1A, “Risk Factors,” in our 2022 Annual Report on Form 10-K, could materially and adversely affect our business, financial condition and results of operations, and the trading price of our Common Stock could decline. These risk factors do not identify all risks that we face - our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations. Due to risks and uncertainties, known and unknown, our past financial results may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods. The Risk Factors section of our 2022 Annual Report on Form 10-K remains current in all material respects.

 

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

In November 2022, the Company entered into a marketing and brand development agreement with Ault Alliance, effective August 1, 2022, whereby Ault Alliance will provide various marketing services over twelve months valued at $1.4 million. The Company had the right to pay the fee in cash or shares of its Common Stock with a value of $1.50 per share. On November 11, 2022, the Company elected to pay the fee with 933,334 shares of its Common Stock.

 

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4.MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5.OTHER INFORMATION

 

None.

 

ITEM 6.EXHIBITS

 

Exhibit
No.
  Exhibit Description
 3.1   Certificate of Incorporation (incorporated by reference to Exhibit 2.1 of Form DOS filed with the SEC on August 19, 2016).
 3.2   Amended and Restated Bylaws.
 3.3   Certificate of Designation of Alzamend Neuro, Inc. Series A Convertible Preferred Stock, dated May 30, 2016 (incorporated by reference to Exhibit 2.3 of Form 1-A/A filed with the SEC on February 4, 2020).
31.1*   Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a)
31.2*   Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a)
32.1**   Certification of Chief Executive and Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code
101.INS*   XBRL Instance Document. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*   Inline XBRL Taxonomy Extension Schema Document.
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*Filed herewith.

** This certification will not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

 

 33 
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

  ALZAMEND NEURO, INC.
       
Date: March 15, 2023 By:  

/s/ Stephan Jackman

Stephan Jackman

Chief Executive Officer (principal executive officer)

 

 

Date: March 15, 2023 By:  

/s/ David J. Katzoff

David J. Katzoff

Chief Financial Officer (principal financial and accounting officer)

 

 

34

 

 

 

 

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

 

EXHIBIT 31.1

CERTIFICATION

 

I, Stephan Jackman , certify that:

 

1.  I have reviewed this quarterly report on Form 10-Q of Alzamend Neuro, Inc.;

 

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.  The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.  The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated:  March 15, 2023

 

/s/ Stephan Jackman  
Name: Stephan Jackman  
Title: Chief Executive Officer  
(Principal Executive Officer)  

 

 

 

 

 

 

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

 

EXHIBIT 31.2

CERTIFICATION

 

I, David J. Katzoff, certify that:

 

1.  I have reviewed this quarterly report on Form 10-Q of Alzamend Neuro, Inc.;

 

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.  The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.  The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated:  March 15, 2023

 

/s/ David J. Katzoff  
Name: David J. Katzoff  
Title: Chief Financial Officer  
(Principal Financial and Accounting Officer)  

 

 

 

 

 

 

EX-32.1 4 ex32_1.htm EXHIBIT 32.1

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of Alzamend Neuro, Inc. (the “Company”) on Form 10-Q for the period ended January 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 15, 2023

 

 

   
  By: /s/ Stephan Jackman  
  Name: Stephan Jackman
  Title: Chief Executive Officer
  (Principal Executive Officer)

 

Date: March 15, 2023

 

 

   
  By: /s/ David J. Katzoff  
  Name: David J. Katzoff
  Title: Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

 

 

 

 

EX-101.SCH 5 alzm-20230131.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - LIQUIDITY AND GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - OTHER RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - EQUITY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - STOCK-BASED COMPENSATION (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - STOCK-BASED COMPENSATION (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - WARRANTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - EQUITY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 alzm-20230131_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 alzm-20230131_def.xml XBRL DEFINITION FILE EX-101.LAB 8 alzm-20230131_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Equity Components [Axis] Series A Convertible Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Note Recievable For Common Stock Related Party [Member] Retained Earnings [Member] Antidilutive Securities [Axis] Equity Option [Member] Warrant [Member] Related Party [Axis] Ault Life Sciences Fund L L C [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Securities Purchase Agreement [Member] Plan Name [Axis] Stock Incentive Plan2016 [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Award Type [Axis] Employees and Consultants [Member] Perfromance Contingent Stock Options [Member] Key Employees and Director [Member] Two Consultants [Member] Income Statement Location [Axis] Unamortized Stock Based Compensation [Member] Stock Based Compensation [Member] Research and Development Expense [Member] General and Administrative Expense [Member] Exercise Price Range [Axis] 1.00 [Member] 1.75 [Member] 3.00 [Member] 6.25 [Member] Measurement Input Type [Axis] Measurement Input, Option Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Dividend Rate [Member] Digital Power Lending [Member] Bitnile [Member] Brand Development Agreement [Member] Product and Service [Axis] A L002 License [Member] A L001 License [Member] Additional A L001 License [Member] License Events Axis Pre Ind Meeting [Member] Ind Application Filing [Member] Upon First Dosing of Patient in Clinical Trial [Member] Upon Completion of First Patient Dosing [Member] Upon Completion of First Clinical Trial [Member] Upon Fda Approval [Member] Upon First Patient Treated in Phase3 Clinical Trial [Member] Securities Purchase Agreements [Member] Legal Entity [Axis] ALSF [Member] Debt Instrument [Axis] Convertible Promissory Note [Member] Ault Global [Member] Vesting [Axis] Final Tranche [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Prepaid expenses and other current assets Prepaid expenses - related party TOTAL CURRENT ASSETS Property, plant and equipment, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities Related party payable TOTAL CURRENT LIABILITIES TOTAL LIABILITIES COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; Series A Convertible Preferred Stock, $0.0001 stated value per share, 1,360,000 shares designated; nil 0 issued and outstanding as of January 31, 2023 and April 30, 2022 Common stock, $0.0001 par value: 300,000,000 shares authorized; 96,427,624 and 95,481,790 shares issued and outstanding as of January 31, 2023 and April 30, 2022, respectively Additional paid-in capital Note receivable for common stock – related party Accumulated deficit TOTAL STOCKHOLDERS’ EQUITY TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Statement [Table] Statement [Line Items] Preferred stock, par value (in dollars per share) Preferred stock, shares authorized Preferred stock shares designated Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] OPERATING EXPENSES Research and development General and administrative Total operating expenses Loss from operations OTHER EXPENSE, NET Interest expense Total other expense, net NET LOSS Basic and diluted net loss per common share Basic and diluted weighted average common shares outstanding Beginning balance, value Beginning balance (in shares)  Issuance of common stock for restricted stock awards Issuance of common stock for restricted stock awards (in shares)  Stock-based compensation to employees and consultants  Proceeds from sale of common stocks & warrants-related party Proceeds from sale of common stocks and warrants-related party (in shares)  Proceeds from stock option exercise Proceeds from stock option exercise (in shares)  Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million (in shares)  Issuance of shares of common stock for conversion of debt Issuance of shares of common stock for conversion of debt (in shares)  Conversion of Series A convertible stock Conversion of Series A convertible stock (in shares)  Issuance of common stock for related party payable Issuance of common stock for related party payable (in shares)  Net loss Ending balance, value Ending balance (in shares) Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Interest expense - debt discount Stock-based compensation to employees and consultants Changes in operating assets and liabilities: Prepaid expenses and other current assets Prepaid expenses related party Accounts payable and accrued expenses Net cash used in operating activities Cash flows from financing activities: Proceeds from the issuance of common stock and warrants - related party, net Proceeds from stock option exercise Proceeds from initial public offering, net of underwriters’ discounts and commissions and issuance costs Net cash provided by financing activities Net (decrease) increase in cash Cash at beginning of period Cash at end of period Supplemental disclosures of cash flow information: Non-cash financing activities: Fair value of warrants issued in connection with March 2021 securities purchase agreement, related party Fair value of warrants issued in connection with IPO Issuance of common stock on conversion of note Issuance of common stock for related party payable Accounting Policies [Abstract] DESCRIPTION OF BUSINESS Organization, Consolidation and Presentation of Financial Statements [Abstract] LIQUIDITY AND GOING CONCERN SIGNIFICANT ACCOUNTING POLICIES Note Receivable For Common Stock Related Party NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] PREPAID EXPENSES AND OTHER CURRENT ASSETS Share-Based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION Warrants WARRANTS Related Party Transactions [Abstract] OTHER RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Equity [Abstract] EQUITY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Accounting Estimates Cash and Cash Equivalents Fair Value of Financial Instruments Property and Equipment, Net Research and Development Expenses Stock-Based Compensation Warrants Loss per Common Share Recent Accounting Standards Schedule of antidilutive securities excluded from computation of earnings per share Schedule of prepaid expenses and other current assets Schedule of share-based payment arrangement, option, activity Schedule of stock options granted to employees and consultants Schedule of stock-based compensation Schedule of Common Stock warrants outstanding Schedule of assumptions used Schedule of Contractual Obligation, Fiscal Year Maturity Cash Accumulated deficit Net loss Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share, amount Number of stock excluded Exercise price (in dollars per share) Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Number of shares purchase (in shares) Number of shares purchase Number of warrants granted Warrant terms Exercise price (in dollars per share) Outstanding receivable amount Prepaid clinical trial fees Prepaid insurance Other prepaid expenses Prepaid consulting fees Total prepaid expenses and other current assets [custom:PrepaidClinicalTrialFees-0] Purchase D&O Insurance Shares available for grant begining (in shares) Number of shares begining (in shares) Weighted average exercise price begining (in dollars per share) Weighted average remaining contractual life begining (years) Aggregate intrinsic value begining Shares available for grant, Options granted Number of shares, Options granted Weighted average exercise price, Options granted Weighted average remaining contractual life, Option granted (years) Shares available for grant, Options exercised Number of shares, Options exercised Shares available for grant, Options cnacelled/forfieted Number of shares, Options cancelled/forfeited Weighted average exercise price, Options cancelled/forfeited Shares available for grant end (in shares) Number of shares end (in shares) Weighted average exercise price end (in dollars per share) Weighted average remaining contractual life end (years) Aggregate intrinsic value end Number of shares, Options vested and expected to vest at end Weighted average exercise price, Options vested and expected to vest at end Weighted average remaining contractual life, Options vested and expected to vest at end Aggregate intrinsic value, Options vested and expected to vest at end Number of shares, Options exercisable at end Weighted average exercise price, Options exercisable at end Weighted average remaining contractual life, Options exercisable at end Aggregate intrinsic value, Options exercisable at end Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Expected term (in years) Volatility Risk-free interest rate Dividend yield Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total Number of shares authorized for issuance Additional number of shares available for issuance Expiration period Stock-based compensation Options granted Terms of award Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercse price (in dollars per share) Number warrant outstanding Weighted average remaining contractual life (years) Warrant outstanding, weighted average exercise price (in dollars per share) Number of warrant exercisable Warrant exercisable, weighted average exercise price (in dollars per share) Expected term (in years) Warrants measurement input Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Number of shares sold (in shares) Value of stock issued Description of related party transaction Related party prepaid expenses Product Liability Contingency [Table] Product Liability Contingency [Line Items] License Events Axis [Axis] Payment Due date Percentage of royalty payments on net sales of product Description of licenses agreements Initial license fees Schedule of Stock by Class [Table] Class of Stock [Line Items] Number of shares purchase Shares purchase price Shares purchase price (in dollars per share) Number of shares issued Proceeds from sale of equity Shares issued price per share Proceeds from related party Advance from related parties Shares value surrender for cancellation Description of purchase agreement terms Additional right to invest The element represents ault life sciences fund l l c member. The element represents securities purchase agreement member. The element represents stock issued during period value new issues2. The element represents stock issued during period value new issues3. The element represents stock issued during period shares new issues2. The element represents long term debt average amount of outstanding. The element represents prepaid consulting fees. The element represents prepaid insurance1. The element represents share based compensation arrangement by share based payment award options exercised in period gross. The element represents share based compensation arrangement by share based payment award number of shares available for grant options cancelled or forfeited. The element represents sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term. The element represents employees and consultants member. The element represents stock incentive plan2016 member. The element represents perfromance contingent stock options member. The element represents key employees and director member. The element represents unamortized stock based compensation member. The element represents exercise price1 member. The element represents exercise price2 member. The element represents exercise price3 member. The element represents exercise price4 member. The element represents class of warrant or right weighted average exercise price of warrants or rights. The element represents class of warrant or right exercisable. The element represents class of warrant or right exercisable weighted average exercise price. The element represents digital power lending member. The element represents Bitnile. The element represents brand development agreement. The element represents license events axis. The element represents pre ind meeting member. The element represents a l001 license member. The element represents ind application filing member. The element represents upon first dosing of patient in clinical trial member. The element represents upon completion of first patient dosing member. The element represents upon completion of first clinical trial member. The element represents upon fda approval member. The element represents a l002 license member. The element represents upon first patient treated in phase3 clinical trial member. The element represents additional a l001 license member. The element represents description of licenses agreements. The element represents percentage of royalty payments on net sales of product.. Amount of initial license fees. The element represents number of shares purchase. The element represents securities purchase agreements member. The element represents a l s f member. The element represents shares purchase price. The element represents shares purchase price per shares. The element represents stock issued during period shares new issues one. The element represents description of purchase agreement terms. The element represents convertible promissory note member. The element represents ault global member. The element represents advance from related parties. The element represents shares value surrender for cancellation. The element represents additional right to invest. The element represents final tranche member. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Costs and Expenses Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Shares, Outstanding Increase (Decrease) in Prepaid Expense and Other Assets Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Commitments and Contingencies Disclosure [Text Block] WarrantsPolicyTextBlock Cash [Default Label] Retained Earnings, Appropriated Prepaid Expense and Other Assets Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period WarrantExpectedTerm EX-101.PRE 9 alzm-20230131_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover - shares
9 Months Ended
Jan. 31, 2023
Mar. 15, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jan. 31, 2023  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --04-30  
Entity File Number 001-40483  
Entity Registrant Name ALZAMEND NEURO, INC.  
Entity Central Index Key 0001677077  
Entity Tax Identification Number 81-1822909  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 3480 Peachtree Rd NE  
Entity Address, Address Line Two Suite 103  
Entity Address, City or Town Atlanta  
Entity Address, State or Province GA  
Entity Address, Postal Zip Code 30326  
City Area Code (844)  
Local Phone Number 722-6303  
Title of 12(b) Security Common Stock, $0.0001 par value per share  
Trading Symbol ALZN  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   96,440,124
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Balance Sheets (Unaudited) - USD ($)
Jan. 31, 2023
Apr. 30, 2022
CURRENT ASSETS    
Cash $ 7,375,841 $ 14,063,811
Prepaid expenses and other current assets 546,303 349,723
Prepaid expenses - related party 494,668
TOTAL CURRENT ASSETS 8,416,812 14,413,534
Property, plant and equipment, net 85,166 102,909
TOTAL ASSETS 8,501,978 14,516,443
CURRENT LIABILITIES    
Accounts payable and accrued liabilities 2,642,473 1,162,850
Related party payable 2,082
TOTAL CURRENT LIABILITIES 2,642,473 1,164,932
TOTAL LIABILITIES 2,642,473 1,164,932
STOCKHOLDERS’ EQUITY    
Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; Series A Convertible Preferred Stock, $0.0001 stated value per share, 1,360,000 shares designated; nil 0 issued and outstanding as of January 31, 2023 and April 30, 2022
Common stock, $0.0001 par value: 300,000,000 shares authorized; 96,427,624 and 95,481,790 shares issued and outstanding as of January 31, 2023 and April 30, 2022, respectively 9,642 9,548
Additional paid-in capital 61,500,292 57,419,753
Note receivable for common stock – related party (14,883,295) (14,883,295)
Accumulated deficit (40,767,134) (29,194,495)
TOTAL STOCKHOLDERS’ EQUITY 5,859,505 13,351,511
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 8,501,978 $ 14,516,443
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Jan. 31, 2023
Apr. 30, 2022
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 10,000,000 10,000,000
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares issued 96,427,624 95,481,790
Common stock, shares outstanding 96,427,624 95,481,790
Series A Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 8,640,000  
Preferred stock shares designated 1,360,000 1,360,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2023
Jan. 31, 2022
OPERATING EXPENSES        
Research and development $ 2,888,847 $ 873,653 $ 5,797,789 $ 3,540,111
General and administrative 2,534,665 1,682,913 5,767,668 4,906,628
Total operating expenses 5,423,512 2,556,566 11,565,457 8,446,739
Loss from operations (5,423,512) (2,556,566) (11,565,457) (8,446,739)
OTHER EXPENSE, NET        
Interest expense (2,062) (16,299) (7,182) (45,922)
Total other expense, net (2,062) (16,299) (7,182) (45,922)
NET LOSS $ (5,425,574) $ (2,572,865) $ (11,572,639) $ (8,492,661)
Basic and diluted net loss per common share $ (0.06) $ (0.03) $ (0.12) $ (0.09)
Basic and diluted weighted average common shares outstanding 98,326,175 94,165,225 97,765,471 89,484,601
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)
Series A Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Note Recievable For Common Stock Related Party [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Apr. 30, 2021 $ 75 $ 6,743 $ 33,721,859 $ (14,883,295) $ (16,832,437) $ 2,012,945
Beginning balance (in shares) at Apr. 30, 2021 750,000 67,429,525        
 Issuance of common stock for restricted stock awards $ 21 (21)
Issuance of common stock for restricted stock awards (in shares)   212,500        
 Stock-based compensation to employees and consultants 3,150,801 3,150,801
 Proceeds from sale of common stocks & warrants-related party $ 133 1,999,867 2,000,000
Proceeds from sale of common stocks and warrants-related party (in shares)   1,333,333        
 Proceeds from stock option exercise $ 300 900 1,200
Proceeds from stock option exercise (in shares)   3,000,000        
 Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million $ 288 12,911,168 12,911,456
Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million (in shares)   2,875,000        
 Issuance of shares of common stock for conversion of debt $ 25 378,373     378,398
Issuance of shares of common stock for conversion of debt (in shares)   252,265        
 Conversion of Series A convertible stock $ (75) $ 1,500 (1,425)
Conversion of Series A convertible stock (in shares) (750,000) 15,000,000        
 Net loss (8,492,661) (8,492,661)
Ending balance, value at Jan. 31, 2022 $ 9,010 52,161,522 (14,883,295) (25,325,098) 11,962,139
Ending balance (in shares) at Jan. 31, 2022 90,102,623        
Beginning balance, value at Oct. 31, 2021 $ 8,885 50,652,054 (14,883,295) (22,752,233) 13,025,411
Beginning balance (in shares) at Oct. 31, 2021 88,850,358        
 Stock-based compensation to employees and consultants 1,130,795 1,130,795
 Proceeds from stock option exercise $ 100 300 400
Proceeds from stock option exercise (in shares)   1,000,000        
 Issuance of shares of common stock for conversion of debt $ 25 378,373 378,398
Issuance of shares of common stock for conversion of debt (in shares)   252,265        
 Net loss (2,572,865) (2,572,865)
Ending balance, value at Jan. 31, 2022 $ 9,010 52,161,522 (14,883,295) (25,325,098) 11,962,139
Ending balance (in shares) at Jan. 31, 2022 90,102,623        
Beginning balance, value at Apr. 30, 2022 $ 9,548 57,419,753 (14,883,295) (29,194,495) 13,351,511
Beginning balance (in shares) at Apr. 30, 2022 95,481,790        
 Issuance of common stock for restricted stock awards $ 1 (1)
Issuance of common stock for restricted stock awards (in shares)   12,500        
 Stock-based compensation to employees and consultants 3,091,299 3,091,299
 Issuance of common stock for related party payable $ 93 989,241 989,334
Issuance of common stock for related party payable (in shares)   933,334        
 Net loss (11,572,639) (11,572,639)
Ending balance, value at Jan. 31, 2023 $ 9,642 61,500,292 (14,883,295) (40,767,134) 5,859,505
Ending balance (in shares) at Jan. 31, 2023 96,427,624        
Beginning balance, value at Oct. 31, 2022 $ 9,549 59,002,729 (14,883,295) (35,341,560) 8,787,423
Beginning balance (in shares) at Oct. 31, 2022 95,494,290        
 Stock-based compensation to employees and consultants 1,508,322 1,508,322
 Issuance of common stock for related party payable $ 93 989,241 989,334
Issuance of common stock for related party payable (in shares)   933,334        
 Net loss (5,425,574) (5,425,574)
Ending balance, value at Jan. 31, 2023 $ 9,642 $ 61,500,292 $ (14,883,295) $ (40,767,134) $ 5,859,505
Ending balance (in shares) at Jan. 31, 2023 96,427,624        
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Cash flows from operating activities:    
Net loss $ (11,572,639) $ (8,492,661)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 17,743
Interest expense - debt discount 12,770
Stock-based compensation to employees and consultants 3,091,299 3,150,801
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (196,580) 344,493
Prepaid expenses related party 492,584
Accounts payable and accrued expenses 1,479,623 (67,040)
Net cash used in operating activities (6,687,970) (5,051,637)
Cash flows from financing activities:    
Proceeds from the issuance of common stock and warrants - related party, net 2,000,000
Proceeds from stock option exercise 1,200
Proceeds from initial public offering, net of underwriters’ discounts and commissions and issuance costs 12,911,456
Net cash provided by financing activities 14,912,656
Net (decrease) increase in cash (6,687,970) 9,861,019
Cash at beginning of period 14,063,811 1,929,270
Cash at end of period $ 7,375,841 $ 11,790,289
Non-cash financing activities:    
Fair value of warrants issued in connection with March 2021 securities purchase agreement, related party 4,799,742
Fair value of warrants issued in connection with IPO 461,877
Issuance of common stock on conversion of note $ 378,373
Issuance of common stock for related party payable $ 989,334
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.4
DESCRIPTION OF BUSINESS
9 Months Ended
Jan. 31, 2023
Accounting Policies [Abstract]  
DESCRIPTION OF BUSINESS

 

1.DESCRIPTION OF BUSINESS

 

Organization

 

Alzamend Neuro, Inc. (the “Company” or “Alzamend”), is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”). With the Company’s two current product candidates, Alzamend aims to bring treatments or cures to market as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates (collectively, the “Technology”): (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, for the treatment of Alzheimer’s BD, MDD and PTSD, known as AL001, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the “Licensor”); and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as ALZN002, through a royalty-bearing exclusive worldwide license from the same Licensor.

 

The Company is devoting substantially all its efforts towards research and development of its Technology. The Company has not generated any product revenue to date. The Company has financed its operations to date primarily through debt financings and through the sale of its common stock, par value $0.0001 per share (“Common Stock”). The Company expects to continue to incur net losses in the foreseeable future.

XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.4
LIQUIDITY AND GOING CONCERN
9 Months Ended
Jan. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
LIQUIDITY AND GOING CONCERN

 

2.LIQUIDITY AND GOING CONCERN

 

The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern. As of January 31, 2023, the Company had cash of $7.4 million and an accumulated deficit of $40.8 million. The Company incurred losses for the three and nine months ended January 31, 2023 totaling $5.4 million and $11.6 million, respectively. Historically, the Company has financed its operations principally through issuances of equity and debt instruments.

 

 The Company expects to continue to incur losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development and commercial operations. However, based on the Company’s current business plan, management believes that the Company’s cash at January 31, 2023 is sufficient to meet the Company’s anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report.

XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.4
SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Jan. 31, 2023
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES

 

3.SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Report on Form 10-K for the year ended April 30, 2022, filed with the SEC on July 19, 2022. In the opinion of management, the accompanying condensed interim financial statements include all adjustments necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Company’s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2022 has been derived from the audited balance sheet at April 30, 2022 contained in such Form 10-K.

 

Accounting Estimates

 

The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of January 31, 2023 and April 30, 2022, the Company had no cash equivalents.

 

Fair Value of Financial Instruments

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable:

 

Level 1: Quoted prices in active markets for identical assets or liabilities.

 

Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.

 

The fair values of warrants are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants’ contractual life.

 

Property and Equipment, Net

 

Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred.

 

Research and Development Expenses

 

Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company.

 

The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects.

 

Stock-Based Compensation

 

The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.

 

The Company recognizes stock-based compensation expense for restricted stocks on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock.

 

The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially different.

 

Warrants

 

The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity and ASC 815, Derivatives and Hedging, depending on the specific terms of the warrant agreement.

 

  Loss per Common Share

 

The Company utilizes FASB ASC 260, Earnings per Share. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then shared in the earnings of the entity.

 

Since the effects of outstanding options, warrants, convertible preferred stock and convertible notes are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share.

 

The following sets forth the number of shares of Common Stock underlying outstanding options and warrants that have been excluded from the computation of loss per common share:

          
   For the Nine Months Ended January 31, 
   2023   2022 
Stock options (1)   18,158,329    13,500,000 
Warrants   10,149,788    8,830,785 
    28,308,117    22,330,785 

 

(1)The Company has excluded 2,000,000 and 4,500,000 stock options for the nine months ended January 31, 2023 and 2022, respectively, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.

 

 Recent Accounting Standards

 

From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company’s financial position or results of operations upon adoption.

 

The Company has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its financial statements.

XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.4
NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY
9 Months Ended
Jan. 31, 2023
Note Receivable For Common Stock Related Party  
NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY

 

4.NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY

 

On April 30, 2019, the Company and Ault Life Sciences Fund, LLC (“ALSF”) entered into a securities purchase agreement for the purchase of 10,000,000 shares of Common Stock for a total purchase price of $15,000,000, or $1.50 per share with 5,000,000 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The total purchase price of $15,000,000 was in the form of a non-interest bearing note receivable with a 12-month term from ALSF, a related party. In November 2019, the term of the note receivable was extended to December 31, 2021, and in May 2021, the term of the note receivable was extended to December 31, 2023. The note is secured by a pledge of the purchased shares. As the note receivable from ALSF is related to the issuance of Common Stock, it is recorded as an offset to additional paid-in capital. At January 31, 2023 and April 30, 2022, the outstanding balance of the note receivable was $14,883,295. ALSF is wholly owned by Ault Life Sciences, Inc. (“ALSI”). ALSI is majority owned by Ault & Company, Inc. (“Ault & Co.”). Messrs. Horne and Nisser, directors of the Company, are also directors of Ault & Co.

 

XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.4
PREPAID EXPENSES AND OTHER CURRENT ASSETS
9 Months Ended
Jan. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

5.PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets were as follows:

          
   January 31, 2023   April 30, 2022 
Prepaid clinical trial fees  $315,987   $- 
Prepaid insurance   222,742    155,880 
Other prepaid expenses   7,574    7,176 
Prepaid consulting fees   -    186,667 
Total prepaid expenses and other current assets  $546,303   $349,723 

 

 On January 5, 2023, the Company prepaid $437,466 for clinical trial fees related to AL002. Prepaid clinical trial fees at January 31, 2023, represented the unused portion of the prepaid clinical fees. On June 16, 2022, the Company purchased directors and officers (“D&O”) insurance for 12 months in the amount of $492,000. Prepaid insurance at January 31, 2023 represented the unamortized portion of the annual insurance premium.

XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION
9 Months Ended
Jan. 31, 2023
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION

 

6.STOCK-BASED COMPENSATION

 

2016 Stock Incentive Plan

 

On April 30, 2016, the Company’s stockholders approved the Company’s 2016 Stock Incentive Plan (the “Plan”). The Plan provides for the issuance of a maximum of 12,500,000 shares of Common Stock to be offered to the Company’s directors, officers, employees, and consultants. On March 1, 2019, the Company’s stockholders approved an additional 7,500,000 shares to be available for issuance under the Plan. Options granted under the Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant and become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and 10 years from the date of grant. Restricted stock awards granted under the Plan are subject to a vesting period determined at the date of grant.

 

2021 Stock Incentive Plan

 

In February 2021, the Company’s board of directors (the “Board”) adopted, and the stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan (the “2021 Plan”). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory), (2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation.

 

Stock Subject to the 2021 Plan. The maximum number of shares of Common Stock that may be issued under the 2021 Plan is 10,000,000 shares, which number will be increased to the extent that compensation granted under the 2021 Plan is forfeited, expires or is settled for cash (except as otherwise provided in the 2021 Plan). Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company that the Company acquires or any subsidiary of the Company or with which the Company or any subsidiary combines) will not reduce the shares authorized for grant under the 2021 Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer under the 2021 Plan.

 

All options that the Company grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the date of issuance of these options, there was not an active public market for the Company’s shares. Accordingly, the fair value of the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because the Company settles these obligations by issuing shares of Common Stock from its authorized shares instead of settling such obligations with cash payments. 

 

A summary of stock option activity for the nine months ended January 31, 2023 is presented below: 

                                       
            Outstanding Options  
      Shares
Available
for Grant
      Number of
Shares
      Weighted
Average
Exercise
Price
      Weighted
Average
Remaining
Contractual
Life (years)
     

Aggregate

Intrinsic
Value

 
Balance at April 30, 2022     8,800,000       15,700,000     $ 1.16       6.32     $ 2,219,700  
Options granted     (2,000,000)       2,000,000     $ 1.17       9.83          
Options exercised     -       -     $ -       -          
Options expired     2,391,671       (2,391,671 )   $ 1.34       -          
Balance at January 31, 2023     9,191,671       15,308,329     $ 1.18       6.32     $ 1,327,200  
Options vested and expected to vest at January 31, 2023             14,308,329     $ 1.18       6.07     $ 1,327,200  
Options exercisable at January 31, 2023             13,172,907     $ 1.11       5.91     $ 1,327,200  

 

 

The aggregate intrinsic value in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised their options.

 

Stock Options Granted to Employees and Consultants

 

The estimated fair value of stock options granted to employees and consultants during the nine months ended January 31, 2023 and 2022 were calculated using the Black-Scholes option-pricing model using the following assumptions:

       
    For the Nine Months Ended January 31,
    2023   2022
Expected term (in years)   6.25   3.506.25
Volatility   88.94%   85.53% - 87.10%
Risk-free interest rate   3.89%   1.01%-1.07%
Dividend yield   0.0%   0.0%

 

Expected Term: The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).

 

Expected Volatility: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company did not have sufficient trading history for its Common Stock at January 31, 2023 and 2022. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

 

Risk-Free Interest Rate: The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.

 

Expected Dividend: The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.

 

Stock-based compensation to employees and consultants from stock option grants for the nine months ended January 31, 2023 and 2022, was $3.1 million and $3.2 million, respectively.

 

Performance Contingent Stock Options Granted to Employee

 

On November 26, 2019, the Board granted 4,250,000 performance- and market-contingent awards to certain key employees and a director. These grants were made outside of the Plan. These awards have an exercise price of $1.50 per share. These awards have multiple separate market triggers for vesting based upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180 days after the Company’s initial public offering (“IPO”) for its Common Stock, or (ii) stepped target prices for a change in control transaction. The target prices range from $10 per share to $40 per share. In the event any of the stock price milestones are not achieved within three years, the unvested portion of the performance options will be reduced by 25%.

 

On November 22, 2022, the Compensation Committee of the Board modified the performance criteria for these awards. The target price range is now $10 per share to $20 per share. Additionally, if the stock price milestones are now not achieved by November 27, 2026, as opposed to within three years, the unvested portion of the portion of the performance options will be reduced by 25%. Due to the significant risks and uncertainties associated with achieving the market-contingent awards, as of January 31, 2023, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards.

 

On November 29, 2022, the Compensation Committee of the Board granted 2,000,000 performance-based stock option to the Chief Executive Officer at an exercise price of $1.17 per share, of which 50% vest upon the completion and announcement of topline data from the Company’s Phase II clinical trial of AL001 within three years from grant date and the remaining 50% vest upon the completion and announcement of topline data from the Company’s Phase II clinical trial of ALZN002 within four years from the grant date. As of January 31, 2023, the Company believes that it is probable that the performance condition of the completion and announcement of topline data from the Company’s Phase II clinical trial of AL001 will be achieved and has recognized the related stock-based compensation. As of January 31, 2023, the Company believes that the achievement of the second performance condition is not probable and, as a result, no compensation cost has been recognized related to Phase II of ALZN002.

 

Performance Contingent Stock Options Granted to TAMM Net

 

On March 23, 2021, the Company issued performance-based stock options to the certain team members at TAMM Net, Inc. (“TAMM Net”) to purchase an aggregate of 450,000 shares of Common Stock at a per share exercise price of $1.50 per share, of which 50% vest upon the completion of Phase I of AL001 by March 31, 2022, and the remaining 50% vest upon completion of Phase I of ALZN002 by December 31, 2022.

 

The performance goal of completing Phase I of AL001 was achieved on March 22, 2022, and the Company recognized stock-based compensation related to the completion of Phase I of AL001 over the implied service period to complete this milestone.

 

On January 19, 2023, the Board modified the performance criteria for these awards. The remaining 50% of the grant will now vest upon the completion and announcement of topline data of the first cohort from a Phase I/IIA clinical trial of ALZN002 on/or before March 31, 2024. Due to the significant risks and uncertainties associated with achieving the completion of Phase I for ALZN002, as of January 31, 2023, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards related to ALZN002.

 

Performance Contingent Stock Options Granted to Consultants

 

On October 14, 2021, the Company issued performance-based stock options to two consultants to purchase an aggregate of 200,000 shares of Common Stock with an exercise price of $2.42 per share, of which 50,000 vest upon completion of each of the Phase II clinical trials of AL001 for a Bipolar indication, AL001 for a PTSD indication, AL001 for a depression indication and ALZN002 for an Alzheimer’s indication.

 

On January 19, 2023, the Board modified the performance criteria for these awards. The revised grant will vest 25% if the Company (a) completes and announces topline data from a Phase II clinical trial of AL001 and ALZN002, as applicable, that would support a new drug application for the drug candidate and the indication listed below, and (b) obtained a “Study May Proceed” letter from the U.S. Food and Drug Administration for the additional IND on/or before December 31, 2023, as follows: (i) AL001 – bipolar disorder; (ii) AL001- major depressive disorder; (iii) AL001 – post-traumatic stress disorder; and (iv) ALZN002 – Alzheimer’s disease.

 

As of January 31, 2023, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards related to Phase II of AL001 and ALZN002.

 

 Stock-Based Compensation Expense

 

The Company’s results of operations include expenses relating to stock-based compensation for three and nine months ended January 31, 2023 and 2022, that were comprised as follows:

                    
   For the Three Months Ended January 31,   For the Nine Months Ended January 31, 
   2023   2022   2023   2022 
 Research and development  $(42,589)  $106,102   $(42,589)  $359,286 
 General and administrative   1,550,911    1,024,693    3,133,888    2,791,515 
Total  $1,508,322   $1,130,795   $3,091,299   $3,150,801 

 

 

As of January 31, 2023, total unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $1.5 million. The weighted-average period over which such stock-based compensation expense will be recognized is approximately 1.8 years.

XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.4
WARRANTS
9 Months Ended
Jan. 31, 2023
Warrants  
WARRANTS

 

7.WARRANTS

 

The following table summarizes information about Common Stock warrants outstanding and exercisable at January 31, 2023:

  

                                           
Outstanding     Exercisable  
            Weighted                    
            Average     Weighted           Weighted  
            Remaining     Average           Average  
Exercise     Number     Contractual     Exercise     Number     Exercise  
Price     Outstanding     Life (years)     Price     Exercisable     Price  
$ 1.00       500,000       1.1     $ 1.00       500,000     $ 1.00  
$ 1.75       161,342       1.8     $ 1.75       161,342     $ 1.75  
$ 3.00       9,427,196       2.2     $ 3.00       9,427,196     $ 3.00  
$ 6.25       61,250       3.4     $ 6.25       61,250     $ 6.25  
  $1.00 - $6.25       10,149,788       2.4     $ 2.90       10,149,788     $ 2.90  

 

The estimated fair value of warrants granted during the nine months ended January 31, 2022 were calculated using the Black-Scholes option-pricing model using the following assumptions:

     
     

For the Nine Months

Ended January 31, 2022

Expected term (in years)     5.00
Volatility     86.31%
Risk-free interest rate     0.87% - 0.90%
Dividend yield     0.0%

 

Expected Term: The expected term represents the period that the warrants granted are expected to be outstanding.

 

Expected Volatility: The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company did not have sufficient trading history for its Common Stock at January 31, 2022. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

 

Risk-Free Interest Rate: The Company based the risk-free interest rate over the expected term of the warrants based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.

 

Expected Dividend: The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.

XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.4
OTHER RELATED PARTY TRANSACTIONS
9 Months Ended
Jan. 31, 2023
Related Party Transactions [Abstract]  
OTHER RELATED PARTY TRANSACTIONS

 

8.OTHER RELATED PARTY TRANSACTIONS

 

In March 2021, the Company entered into a securities purchase agreement with Ault Lending, LLC (“AL”) pursuant to which the Company sold an aggregate of 6,666,667 shares of Common Stock for an aggregate of $10 million, or $1.50 per share, which sales were made in tranches. On March 9, 2021, AL paid $4 million, less the $1.8 million in prior advances and the surrender for cancellation of a $50,000 convertible promissory note held by Ault Alliance, Inc. (formerly, BitNile Holdings, Inc.) (“Ault Alliance”), the parent company of AL, for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, AL (i) purchased an additional 1,333,333 shares of Common Stock upon approval of the IND for Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares of Common Stock upon the completion of Phase IA clinical trials for AL001 for a purchase price of $4 million. The Company issued to AL warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, AL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of the date of this Quarterly Report.

 

In November 2022, the Company entered into a marketing and brand development agreement with Ault Alliance, effective August 1, 2022, whereby Ault Alliance will provide various marketing services over twelve months valued at $1.4 million. The Company had the right to pay the fee in cash or shares of its Common Stock with a value of $1.50 per share. On November 11, 2022, the Company elected to pay the fee with 933,334 shares of its Common Stock. The Company recorded the value of the agreement using the closing price of the Company’s Common Stock on November 11, 2022, and will amortize the expense over twelve months beginning in August 2022. At January 31, 2023, the balance of related party prepaid expenses was $495,000.

 

XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.4
COMMITMENTS AND CONTINGENCIES
9 Months Ended
Jan. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

 

9.COMMITMENTS AND CONTINGENCIES

 

Contractual Obligations

 

On May 1, 2016, the Company entered into a Standard Exclusive License Agreement for ALZN002 with Sublicensing Terms with Licensor, pursuant to which Licensor granted the Company a royalty bearing exclusive worldwide license limited to the field of Alzheimer’s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled “Amyloid Beta Peptides and Methods of Use,” filed April 7, 2009 and granted May 29, 2012.

 

There are certain initial license fees and milestone payments required to be paid by the Company to the Licensor pursuant to the terms of license agreements. The license agreements for ALZN002 require the Company to pay royalty payments of 4% on net sales of products developed from the licensed technology for ALZN002 while the license agreements for AL001 require that the Company pay combined royalty payments of 4.5% on net sales of products developed from the licensed technology for AL001.  The Company has already paid an initial license fee of $200,000 for ALZN002 and an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of ALZN002, the Licensor received 3,601,809 shares of common stock. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 2,227,923 shares of common stock. Minimum royalties for AL001 are $25,000 in 2023, $45,000 in 2024 and $70,000 in 2025 and every year thereafter, for the life of the agreement. Minimum royalties for ALZN002 are $20,000 in 2022, $40,000 in 2023 and $50,000 in 2024 and every year thereafter, for the life of the respective agreement. Additionally, the Company is required to pay milestone payments on the due dates to the Licensor for the license of the AL001 technologies and for the ALZN002 technology, as follows:

 

Original AL001 License:

           
Payment    Due Date    Event
$ 50,000 *  Completed September 2019    Pre-IND meeting
           
$ 65,000 *  Completed June 2021    IND application filing
           
$ 190,000 *  Completed December 2021    Upon first dosing of patient in a clinical trial
           
$ 500,000 *  Completed March 2022    Upon Completion of first clinical trial
           
$ 1,250,000    12 months from completion of the first Phase II clinical trial    Upon first patient treated in a Phase III clinical trial
           
$ 10,000,000    8 years from the effective date of the agreement    Upon U.S. Food and Drug Administration (“FDA”) approval
*Milestone met and completed

 

ALZN002 License: 

Payment   Due Date   Event
$ 50,000  * Completed September 2022    Upon IND application filing
           
$ 50,000   12 months from IND application filing date    Upon first dosing of patient in first Phase I clinical trial
           
$ 175,000   12 months from first patient dosed in Phase I    Upon completion of first Phase I clinical trial
           
$ 500,000   24 months from completion of first Phase I clinical trial    Upon completion of first Phase II clinical trial
           
$ 1,000,000   12 months from completion of the first Phase II clinical trial    Upon first patient treated in a Phase III clinical trial
           
$ 10,000,000   7 years from the effective date of the agreement    Upon FDA BLA approval
*Milestone met and completed

 

The Company has met the pre-IND meeting, IND application filing, and successfully completed the Phase I clinical trial milestones encompassing AL001 and the IND application filing milestone for ALZN002. If the Company fails to meet a milestone by its specified date, the Licensor may terminate the license agreement. 

 

Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company while Licensor remains the owner of any equity securities of the Company.

 

On June 10, 2020, the Company obtained two (2) additional royalty-bearing exclusive worldwide licenses from the Licensor to a therapy named AL001. One of the additional licenses is for the treatment of neurodegenerative diseases excluding Alzheimer’s and the other license is for the treatment of psychiatric diseases and disorders. There are certain license fees and milestone payments required to be paid pursuant to the terms of the Standard Exclusive License Agreements with Sublicensing Terms, both dated June 10, 2020 and effective as of November 1, 2019, with the Licensor and the University of South Florida (the “June AL001 License Agreements”). Under each of the June AL001 License Agreements, a royalty payment of 3% is required on net sales of products developed from the licensed technology. For the two (2) additional AL001 licenses, in the aggregate, the Company has paid initial license fees of $20,000. Additionally, under each of the June AL001 License Agreements, the Company is required to pay milestone payments on the due dates to the Licensor for the license of the technology, as follows:

 

Additional AL001 Licenses: 

Payment   Due Date   Event
$ 50,000   Upon IND application filing    IND application filing
           
$ 150,000   12 months from IND filing date    Upon first dosing of patient in a clinical trial
           
$ 400,000   12 months from first patient dosing    Upon Completion of first clinical trial
           
$ 1,000,000   36 months from completion of the first Phase II clinical trial    Upon first patient treated in a Phase III clinical trial
           
$ 8,000,000   8 years from the effective date of the agreement    First commercial sale
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.4
EQUITY TRANSACTIONS
9 Months Ended
Jan. 31, 2023
Equity [Abstract]  
EQUITY TRANSACTIONS

 

10.EQUITY TRANSACTIONS

 

The Company is authorized to issue 10,000,000 shares of Preferred Stock $0.0001 par value. The Board has designated 1,360,000 shares as the Series A Preferred Shares. The rights, preferences, privileges and restrictions on the remaining authorized 8,640,000 shares of Preferred Stock have not been determined. The Board is authorized to create a new series of preferred shares and determine the number of shares, as well as the rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred shares. 

 

Series A Preferred Shares

 

As of January 31, 2023, there were no Series A Preferred Shares or any other shares of Preferred Stock issued or outstanding.

 

Common Stock

 

On April 30, 2019, the Company and ALSF entered into a SPA for the purchase of 10,000,000 shares of Common Stock for a total purchase price of $15,000,000, or $1.50 per share with 5,000,000 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The total purchase price of $15,000,000 was in the form of a non-interest bearing note receivable with a 12-month term from ALSF, a related party. The note is secured by a pledge of the purchased shares. Pursuant to the SPA, ALSF is entitled to full ratchet anti-dilution protection, most-favored nation status, denying the Company the right to enter into a variable rate transaction absent its consent, a right to participate in any future financing the Company may consummate and to have all the shares of Common Stock to which it is entitled under the SPA registered under the Securities Act within 180 days of the final closing of the IPO. In May 2021, the term of the note receivable was extended to December 31, 2023. The note is secured by a pledge of the purchased shares.

 

In March 2021, the Company entered into a securities purchase agreement with AL pursuant to which the Company agreed to sell an aggregate of 6,666,667 shares of Common Stock for an aggregate of $10 million, or $1.50 per share, which sales were made in tranches. On March 9, 2021, AL paid $4 million, less the $1.8 million in prior advances and the surrender for cancellation of a $50,000 convertible promissory note held by Ault Alliance, for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, AL (i) purchased an additional 1,333,333 shares of Common Stock upon approval by the FDA of the Company’s IND for its Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares of Common Stock upon the completion of these Phase IA clinical trials for AL001 for a purchase price of $4 million. The Company further agreed to issue to AL warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share.

 

Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, on April 28, 2022, AL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of the date of this Quarterly Report.

 

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.4
SUBSEQUENT EVENTS
9 Months Ended
Jan. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

 

11.SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the date the financial statements were issued. The Company has determined that there are no such events that warrant disclosure or recognition in the condensed financial statements presented herein. 

XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.4
SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Jan. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Report on Form 10-K for the year ended April 30, 2022, filed with the SEC on July 19, 2022. In the opinion of management, the accompanying condensed interim financial statements include all adjustments necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Company’s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2022 has been derived from the audited balance sheet at April 30, 2022 contained in such Form 10-K.

 

Accounting Estimates

Accounting Estimates

 

The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of January 31, 2023 and April 30, 2022, the Company had no cash equivalents.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable:

 

Level 1: Quoted prices in active markets for identical assets or liabilities.

 

Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.

 

The fair values of warrants are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants’ contractual life.

 

Property and Equipment, Net

Property and Equipment, Net

 

Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred.

 

Research and Development Expenses

Research and Development Expenses

 

Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company.

 

The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects.

 

Stock-Based Compensation

Stock-Based Compensation

 

The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.

 

The Company recognizes stock-based compensation expense for restricted stocks on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock.

 

The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially different.

 

Warrants

Warrants

 

The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity and ASC 815, Derivatives and Hedging, depending on the specific terms of the warrant agreement.

 

Loss per Common Share

  Loss per Common Share

 

The Company utilizes FASB ASC 260, Earnings per Share. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then shared in the earnings of the entity.

 

Since the effects of outstanding options, warrants, convertible preferred stock and convertible notes are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share.

 

The following sets forth the number of shares of Common Stock underlying outstanding options and warrants that have been excluded from the computation of loss per common share:

          
   For the Nine Months Ended January 31, 
   2023   2022 
Stock options (1)   18,158,329    13,500,000 
Warrants   10,149,788    8,830,785 
    28,308,117    22,330,785 

 

(1)The Company has excluded 2,000,000 and 4,500,000 stock options for the nine months ended January 31, 2023 and 2022, respectively, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.

 

Recent Accounting Standards

 Recent Accounting Standards

 

From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company’s financial position or results of operations upon adoption.

 

The Company has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its financial statements.

XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.4
SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Jan. 31, 2023
Accounting Policies [Abstract]  
Schedule of antidilutive securities excluded from computation of earnings per share
          
   For the Nine Months Ended January 31, 
   2023   2022 
Stock options (1)   18,158,329    13,500,000 
Warrants   10,149,788    8,830,785 
    28,308,117    22,330,785 

 

(1)The Company has excluded 2,000,000 and 4,500,000 stock options for the nine months ended January 31, 2023 and 2022, respectively, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.4
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)
9 Months Ended
Jan. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of prepaid expenses and other current assets
          
   January 31, 2023   April 30, 2022 
Prepaid clinical trial fees  $315,987   $- 
Prepaid insurance   222,742    155,880 
Other prepaid expenses   7,574    7,176 
Prepaid consulting fees   -    186,667 
Total prepaid expenses and other current assets  $546,303   $349,723 
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Tables)
9 Months Ended
Jan. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of share-based payment arrangement, option, activity
                                       
            Outstanding Options  
      Shares
Available
for Grant
      Number of
Shares
      Weighted
Average
Exercise
Price
      Weighted
Average
Remaining
Contractual
Life (years)
     

Aggregate

Intrinsic
Value

 
Balance at April 30, 2022     8,800,000       15,700,000     $ 1.16       6.32     $ 2,219,700  
Options granted     (2,000,000)       2,000,000     $ 1.17       9.83          
Options exercised     -       -     $ -       -          
Options expired     2,391,671       (2,391,671 )   $ 1.34       -          
Balance at January 31, 2023     9,191,671       15,308,329     $ 1.18       6.32     $ 1,327,200  
Options vested and expected to vest at January 31, 2023             14,308,329     $ 1.18       6.07     $ 1,327,200  
Options exercisable at January 31, 2023             13,172,907     $ 1.11       5.91     $ 1,327,200  

 

Schedule of stock options granted to employees and consultants
       
    For the Nine Months Ended January 31,
    2023   2022
Expected term (in years)   6.25   3.506.25
Volatility   88.94%   85.53% - 87.10%
Risk-free interest rate   3.89%   1.01%-1.07%
Dividend yield   0.0%   0.0%
Schedule of stock-based compensation
                    
   For the Three Months Ended January 31,   For the Nine Months Ended January 31, 
   2023   2022   2023   2022 
 Research and development  $(42,589)  $106,102   $(42,589)  $359,286 
 General and administrative   1,550,911    1,024,693    3,133,888    2,791,515 
Total  $1,508,322   $1,130,795   $3,091,299   $3,150,801 
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.4
WARRANTS (Tables)
9 Months Ended
Jan. 31, 2023
Warrants  
Schedule of Common Stock warrants outstanding
                                           
Outstanding     Exercisable  
            Weighted                    
            Average     Weighted           Weighted  
            Remaining     Average           Average  
Exercise     Number     Contractual     Exercise     Number     Exercise  
Price     Outstanding     Life (years)     Price     Exercisable     Price  
$ 1.00       500,000       1.1     $ 1.00       500,000     $ 1.00  
$ 1.75       161,342       1.8     $ 1.75       161,342     $ 1.75  
$ 3.00       9,427,196       2.2     $ 3.00       9,427,196     $ 3.00  
$ 6.25       61,250       3.4     $ 6.25       61,250     $ 6.25  
  $1.00 - $6.25       10,149,788       2.4     $ 2.90       10,149,788     $ 2.90  
Schedule of assumptions used
     
     

For the Nine Months

Ended January 31, 2022

Expected term (in years)     5.00
Volatility     86.31%
Risk-free interest rate     0.87% - 0.90%
Dividend yield     0.0%
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.4
COMMITMENTS AND CONTINGENCIES (Tables)
9 Months Ended
Jan. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contractual Obligation, Fiscal Year Maturity
           
Payment    Due Date    Event
$ 50,000 *  Completed September 2019    Pre-IND meeting
           
$ 65,000 *  Completed June 2021    IND application filing
           
$ 190,000 *  Completed December 2021    Upon first dosing of patient in a clinical trial
           
$ 500,000 *  Completed March 2022    Upon Completion of first clinical trial
           
$ 1,250,000    12 months from completion of the first Phase II clinical trial    Upon first patient treated in a Phase III clinical trial
           
$ 10,000,000    8 years from the effective date of the agreement    Upon U.S. Food and Drug Administration (“FDA”) approval
*Milestone met and completed

 

ALZN002 License: 

Payment   Due Date   Event
$ 50,000  * Completed September 2022    Upon IND application filing
           
$ 50,000   12 months from IND application filing date    Upon first dosing of patient in first Phase I clinical trial
           
$ 175,000   12 months from first patient dosed in Phase I    Upon completion of first Phase I clinical trial
           
$ 500,000   24 months from completion of first Phase I clinical trial    Upon completion of first Phase II clinical trial
           
$ 1,000,000   12 months from completion of the first Phase II clinical trial    Upon first patient treated in a Phase III clinical trial
           
$ 10,000,000   7 years from the effective date of the agreement    Upon FDA BLA approval
*Milestone met and completed

 

The Company has met the pre-IND meeting, IND application filing, and successfully completed the Phase I clinical trial milestones encompassing AL001 and the IND application filing milestone for ALZN002. If the Company fails to meet a milestone by its specified date, the Licensor may terminate the license agreement. 

 

Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company while Licensor remains the owner of any equity securities of the Company.

 

On June 10, 2020, the Company obtained two (2) additional royalty-bearing exclusive worldwide licenses from the Licensor to a therapy named AL001. One of the additional licenses is for the treatment of neurodegenerative diseases excluding Alzheimer’s and the other license is for the treatment of psychiatric diseases and disorders. There are certain license fees and milestone payments required to be paid pursuant to the terms of the Standard Exclusive License Agreements with Sublicensing Terms, both dated June 10, 2020 and effective as of November 1, 2019, with the Licensor and the University of South Florida (the “June AL001 License Agreements”). Under each of the June AL001 License Agreements, a royalty payment of 3% is required on net sales of products developed from the licensed technology. For the two (2) additional AL001 licenses, in the aggregate, the Company has paid initial license fees of $20,000. Additionally, under each of the June AL001 License Agreements, the Company is required to pay milestone payments on the due dates to the Licensor for the license of the technology, as follows:

 

Additional AL001 Licenses: 

Payment   Due Date   Event
$ 50,000   Upon IND application filing    IND application filing
           
$ 150,000   12 months from IND filing date    Upon first dosing of patient in a clinical trial
           
$ 400,000   12 months from first patient dosing    Upon Completion of first clinical trial
           
$ 1,000,000   36 months from completion of the first Phase II clinical trial    Upon first patient treated in a Phase III clinical trial
           
$ 8,000,000   8 years from the effective date of the agreement    First commercial sale
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.4
DESCRIPTION OF BUSINESS (Details Narrative) - $ / shares
Jan. 31, 2023
Apr. 30, 2022
Accounting Policies [Abstract]    
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.4
LIQUIDITY AND GOING CONCERN (Details Narrative)
3 Months Ended 9 Months Ended
Jan. 31, 2023
USD ($)
Jan. 31, 2023
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Cash $ 7,400,000 $ 7,400,000
Accumulated deficit 40,800,000 40,800,000
Net loss $ 5,400,000 $ 11,600,000
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.4
SIGNIFICANT ACCOUNTING POLICIES (Details) - $ / shares
9 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share, amount 28,308,117 22,330,785
Exercise price (in dollars per share)  
Equity Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share, amount [1] 18,158,329 13,500,000
Number of stock excluded 2,000,000 4,500,000
Exercise price (in dollars per share) $ 0.0004  
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share, amount 10,149,788 8,830,785
[1] The Company has excluded 2,000,000 and 4,500,000 stock options for the nine months ended January 31, 2023 and 2022, respectively, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.4
NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative) - USD ($)
9 Months Ended
Jan. 31, 2023
Apr. 30, 2022
Apr. 30, 2019
Jan. 31, 2023
Jan. 31, 2022
Defined Benefit Plan Disclosure [Line Items]          
Number of shares purchase      
Warrant terms 2 years 4 months 24 days     2 years 4 months 24 days  
Outstanding receivable amount $ 14,883,295 $ 14,883,295      
Ault Life Sciences Fund L L C [Member] | Securities Purchase Agreement [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Number of shares purchase (in shares)     10,000,000    
Number of shares purchase     $ 15,000,000    
Ault Life Sciences Fund L L C [Member] | Securities Purchase Agreement [Member] | Warrant [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Number of warrants granted     5,000,000    
Warrant terms     5 years    
Exercise price (in dollars per share)     $ 3.00    
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.4
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)
Jan. 31, 2023
Jan. 05, 2023
Apr. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]      
Prepaid clinical trial fees $ 315,987 $ 437,466
Prepaid insurance 222,742   155,880
Other prepaid expenses 7,574   7,176
Prepaid consulting fees   186,667
Total prepaid expenses and other current assets $ 546,303   $ 349,723
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.4
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative) - USD ($)
Jan. 31, 2023
Jan. 05, 2023
Jun. 16, 2022
Apr. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]        
[custom:PrepaidClinicalTrialFees-0] $ 315,987 $ 437,466  
Purchase D&O Insurance     $ 492,000  
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Details)
9 Months Ended
Jan. 31, 2023
USD ($)
$ / shares
shares
Share-Based Payment Arrangement [Abstract]  
Shares available for grant begining (in shares) 8,800,000
Number of shares begining (in shares) 15,700,000
Weighted average exercise price begining (in dollars per share) | $ / shares $ 1.16
Weighted average remaining contractual life begining (years) 6 years 3 months 25 days
Aggregate intrinsic value begining | $ $ 2,219,700
Shares available for grant, Options granted (2,000,000)
Number of shares, Options granted | $ / shares $ 2,000,000
Weighted average exercise price, Options granted | $ / shares $ 1.17
Weighted average remaining contractual life, Option granted (years) 9 years 9 months 29 days
Shares available for grant, Options exercised
Number of shares, Options exercised | $ / shares
Shares available for grant, Options cnacelled/forfieted 2,391,671
Number of shares, Options cancelled/forfeited (2,391,671)
Weighted average exercise price, Options cancelled/forfeited | $ / shares $ 1.34
Shares available for grant end (in shares) 9,191,671
Number of shares end (in shares) 15,308,329
Weighted average exercise price end (in dollars per share) | $ / shares $ 1.18
Weighted average remaining contractual life end (years) 6 years 3 months 25 days
Aggregate intrinsic value end | $ $ 1,327,200
Number of shares, Options vested and expected to vest at end 14,308,329
Weighted average exercise price, Options vested and expected to vest at end | $ / shares $ 1.18
Weighted average remaining contractual life, Options vested and expected to vest at end 6 years 25 days
Aggregate intrinsic value, Options vested and expected to vest at end | $ $ 1,327,200
Number of shares, Options exercisable at end 13,172,907
Weighted average exercise price, Options exercisable at end | $ / shares $ 1.11
Weighted average remaining contractual life, Options exercisable at end 5 years 10 months 28 days
Aggregate intrinsic value, Options exercisable at end | $ $ 1,327,200
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Details 1) - Employees and Consultants [Member]
9 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Expected term (in years) 6 years 3 months  
Volatility 88.94%  
Risk-free interest rate 3.89%  
Dividend yield 0.00% 0.00%
Minimum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Expected term (in years)   3 years 6 months
Volatility   85.53%
Risk-free interest rate   1.01%
Maximum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Expected term (in years)   6 years 3 months
Volatility   87.10%
Risk-free interest rate   1.07%
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Details 2) - USD ($)
3 Months Ended 9 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2023
Jan. 31, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total $ 1,508,322 $ 1,130,795 $ 3,091,299 $ 3,150,801
Research and Development Expense [Member]        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total (42,589) 106,102 (42,589) 359,286
General and Administrative Expense [Member]        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total $ 1,550,911 $ 1,024,693 $ 3,133,888 $ 2,791,515
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Oct. 14, 2021
Mar. 23, 2021
Nov. 26, 2019
Mar. 01, 2019
Apr. 30, 2016
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2023
Jan. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Stock-based compensation           $ 1,508,322 $ 1,130,795 $ 3,091,299 $ 3,150,801
Options granted               2,000,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number           14,308,329   14,308,329  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term               6 years 25 days  
Unamortized Stock Based Compensation [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number           1,500,000   1,500,000  
Stock Based Compensation [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term               1 year 9 months 18 days  
Employees and Consultants [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Stock-based compensation               $ 3,100,000 $ 3,200,000
Perfromance Contingent Stock Options [Member] | Key Employees and Director [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Options granted   450,000 4,250,000            
Terms of award     In the event any of the stock price milestones are not achieved within three years            
Perfromance Contingent Stock Options [Member] | Two Consultants [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Options granted 200,000                
Stock Incentive Plan2016 [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Number of shares authorized for issuance         12,500,000        
Additional number of shares available for issuance       7,500,000          
Stock Incentive Plan2016 [Member] | Minimum [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Expiration period         5 years        
Stock Incentive Plan2016 [Member] | Maximum [Member]                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                  
Expiration period         10 years        
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.4
WARRANTS (Details)
Jan. 31, 2023
$ / shares
shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Number warrant outstanding | shares 10,149,788
Weighted average remaining contractual life (years) 2 years 4 months 24 days
Warrant outstanding, weighted average exercise price (in dollars per share) $ 2.90
Number of warrant exercisable | shares 10,149,788
Warrant exercisable, weighted average exercise price (in dollars per share) $ 2.90
Minimum [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercse price (in dollars per share) 1.00
Maximum [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercse price (in dollars per share) 6.25
1.00 [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercse price (in dollars per share) $ 1.00
Number warrant outstanding | shares 500,000
Weighted average remaining contractual life (years) 1 year 1 month 6 days
Warrant outstanding, weighted average exercise price (in dollars per share) $ 1.00
Number of warrant exercisable | shares 500,000
Warrant exercisable, weighted average exercise price (in dollars per share) $ 1.00
1.75 [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercse price (in dollars per share) $ 1.75
Number warrant outstanding | shares 161,342
Weighted average remaining contractual life (years) 1 year 9 months 18 days
Warrant outstanding, weighted average exercise price (in dollars per share) $ 1.75
Number of warrant exercisable | shares 161,342
Warrant exercisable, weighted average exercise price (in dollars per share) $ 1.75
3.00 [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercse price (in dollars per share) $ 3.00
Number warrant outstanding | shares 9,427,196
Weighted average remaining contractual life (years) 2 years 2 months 12 days
Warrant outstanding, weighted average exercise price (in dollars per share) $ 3.00
Number of warrant exercisable | shares 9,427,196
Warrant exercisable, weighted average exercise price (in dollars per share) $ 3.00
6.25 [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercse price (in dollars per share) $ 6.25
Number warrant outstanding | shares 61,250
Weighted average remaining contractual life (years) 3 years 4 months 24 days
Warrant outstanding, weighted average exercise price (in dollars per share) $ 6.25
Number of warrant exercisable | shares 61,250
Warrant exercisable, weighted average exercise price (in dollars per share) $ 6.25
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.4
WARRANTS (Details 1) - Warrant [Member]
9 Months Ended
Jan. 31, 2022
Expected term (in years) 5 years
Measurement Input, Option Volatility [Member]  
Warrants measurement input 0.8631
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]  
Warrants measurement input 0.0087
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]  
Warrants measurement input 0.0090
Measurement Input, Expected Dividend Rate [Member]  
Warrants measurement input 0.000
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.4
OTHER RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended
Nov. 30, 2022
Mar. 09, 2021
Mar. 31, 2021
Jan. 31, 2023
Related Party Transaction [Line Items]        
Related party prepaid expenses       $ 495,000
Digital Power Lending [Member] | Securities Purchase Agreement [Member]        
Related Party Transaction [Line Items]        
Number of shares sold (in shares)     6,666,667  
Value of stock issued   $ 4,000,000 $ 10,000,000  
Description of related party transaction   surrender for cancellation of a $50,000 convertible promissory note held by Ault Alliance, Inc. (formerly, BitNile Holdings, Inc.) (“Ault Alliance”), the parent company of AL, for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, AL (i) purchased an additional 1,333,333 shares of Common Stock upon approval of the IND for Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares of Common Stock upon the completion of Phase IA clinical trials for AL001 for a purchase price of $4 million.    
Bitnile [Member] | Brand Development Agreement [Member]        
Related Party Transaction [Line Items]        
Description of related party transaction In November 2022, the Company entered into a marketing and brand development agreement with Ault Alliance, effective August 1, 2022, whereby Ault Alliance will provide various marketing services over twelve months valued at $1.4 million. The Company had the right to pay the fee in cash or shares of its Common Stock with a value of $1.50 per share. On November 11, 2022, the Company elected to pay the fee with 933,334 shares of its Common Stock. The Company recorded the value of the agreement using the closing price of the Company’s Common Stock on November 11, 2022, and will amortize the expense over twelve months beginning in August 2022.      
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.4
COMMITMENTS AND CONTINGENCIES (Details)
9 Months Ended
Jan. 31, 2023
USD ($)
Pre Ind Meeting [Member] | A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due date  Completed September 2019 [1],[2]
Pre Ind Meeting [Member] | A L002 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due date Completed September 2022 [2]
Ind Application Filing [Member] | A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 65,000
Due date  Completed June 2021 [1],[2]
Ind Application Filing [Member] | A L002 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due date 12 months from IND application filing date
Ind Application Filing [Member] | Additional A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due date Upon IND application filing
Upon First Dosing of Patient in Clinical Trial [Member] | A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 190,000
Due date  Completed December 2021 [1],[2]
Upon First Dosing of Patient in Clinical Trial [Member] | A L002 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 175,000
Due date 12 months from first patient dosed in Phase I
Upon First Dosing of Patient in Clinical Trial [Member] | Additional A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 150,000
Due date 12 months from IND filing date
Upon Completion of First Patient Dosing [Member] | A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 500,000
Due date Completed March 2022
Upon Completion of First Clinical Trial [Member] | A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 1,250,000
Due date 12 months from completion of the first Phase II clinical trial
Upon Completion of First Clinical Trial [Member] | A L002 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 500,000
Due date 24 months from completion of first Phase I clinical trial
Upon Completion of First Clinical Trial [Member] | Additional A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 400,000
Due date 12 months from first patient dosing
Upon Fda Approval [Member] | A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 10,000,000
Due date 8 years from the effective date of the agreement
Upon Fda Approval [Member] | A L002 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 10,000,000
Due date 7 years from the effective date of the agreement
Upon Fda Approval [Member] | Additional A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 8,000,000
Due date 8 years from the effective date of the agreement
Upon First Patient Treated in Phase3 Clinical Trial [Member] | A L002 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 1,000,000
Due date 12 months from completion of the first Phase II clinical trial
Upon First Patient Treated in Phase3 Clinical Trial [Member] | Additional A L001 License [Member]  
Product Liability Contingency [Line Items]  
Payment $ 1,000,000
Due date 36 months from completion of the first Phase II clinical trial
[1] Milestone met and completed
[2] Milestone met and completed
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.4
COMMITMENTS AND CONTINGENCIES (Details Narrative)
9 Months Ended
Jan. 31, 2023
USD ($)
A L002 License [Member]  
Product Liability Contingency [Line Items]  
Percentage of royalty payments on net sales of product 4.00%
A L001 License [Member]  
Product Liability Contingency [Line Items]  
Percentage of royalty payments on net sales of product 4.50%
Additional A L001 License [Member]  
Product Liability Contingency [Line Items]  
Percentage of royalty payments on net sales of product 3.00%
Description of licenses agreements The Company has already paid an initial license fee of $200,000 for ALZN002 and an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of ALZN002, the Licensor received 3,601,809 shares of common stock. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 2,227,923 shares of common stock. Minimum royalties for AL001 are $25,000 in 2023, $45,000 in 2024 and $70,000 in 2025 and every year thereafter, for the life of the agreement. Minimum royalties for ALZN002 are $20,000 in 2022, $40,000 in 2023 and $50,000 in 2024 and every year thereafter, for the life of the respective agreement.
Initial license fees $ 20,000
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.4
EQUITY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended
Mar. 09, 2021
Apr. 30, 2019
Mar. 31, 2021
Jan. 31, 2023
Apr. 30, 2022
Class of Stock [Line Items]          
Preferred stock, shares authorized       10,000,000 10,000,000
Preferred stock, par value (in dollars per share)       $ 0.0001 $ 0.0001
Warrant terms       2 years 4 months 24 days  
ALSF [Member]          
Class of Stock [Line Items]          
Shares purchase price   $ 15,000,000      
Warrant terms   12 months      
Securities Purchase Agreements [Member] | ALSF [Member]          
Class of Stock [Line Items]          
Number of shares purchase   10,000,000      
Shares purchase price   $ 15,000,000      
Shares purchase price (in dollars per share)   $ 1.50      
Securities Purchase Agreements [Member] | ALSF [Member] | Warrant [Member]          
Class of Stock [Line Items]          
Number of shares purchase   5,000,000      
Warrant terms   5 years      
Exercise price (in dollars per share)   $ 3.00      
Securities Purchase Agreements [Member] | Digital Power Lending [Member]          
Class of Stock [Line Items]          
Number of shares issued     6,666,667    
Proceeds from sale of equity     $ 10,000,000    
Shares issued price per share     $ 1.50    
Proceeds from related party $ 4,000,000        
Advance from related parties $ 1,800,000        
Description of purchase agreement terms     AL (i) purchased an additional 1,333,333 shares of Common Stock upon approval by the FDA of the Company’s IND for its Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares of Common Stock upon the completion of these Phase IA clinical trials for AL001 for a purchase price of $4 million. The Company further agreed to issue to AL warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share.    
Securities Purchase Agreements [Member] | Digital Power Lending [Member] | Final Tranche [Member]          
Class of Stock [Line Items]          
Additional right to invest     $ 10,000,000    
Securities Purchase Agreements [Member] | Ault Global [Member] | Convertible Promissory Note [Member]          
Class of Stock [Line Items]          
Number of shares issued 2,666,667        
Shares value surrender for cancellation $ 50,000        
Series A Preferred Stock [Member]          
Class of Stock [Line Items]          
Preferred stock, shares authorized       8,640,000  
Preferred stock, par value (in dollars per share)       $ 0.0001 $ 0.0001
Preferred stock shares designated       1,360,000 1,360,000
XML 49 z3723010q_htm.xml IDEA: XBRL DOCUMENT 0001677077 2022-05-01 2023-01-31 0001677077 2023-03-15 0001677077 2023-01-31 0001677077 2022-04-30 0001677077 us-gaap:SeriesAPreferredStockMember 2023-01-31 0001677077 us-gaap:SeriesAPreferredStockMember 2022-04-30 0001677077 2022-11-01 2023-01-31 0001677077 2021-11-01 2022-01-31 0001677077 2021-05-01 2022-01-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2022-10-31 0001677077 us-gaap:CommonStockMember 2022-10-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2022-10-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2022-10-31 0001677077 us-gaap:RetainedEarningsMember 2022-10-31 0001677077 2022-10-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2021-10-31 0001677077 us-gaap:CommonStockMember 2021-10-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2021-10-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2021-10-31 0001677077 us-gaap:RetainedEarningsMember 2021-10-31 0001677077 2021-10-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2022-04-30 0001677077 us-gaap:CommonStockMember 2022-04-30 0001677077 us-gaap:AdditionalPaidInCapitalMember 2022-04-30 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2022-04-30 0001677077 us-gaap:RetainedEarningsMember 2022-04-30 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2021-04-30 0001677077 us-gaap:CommonStockMember 2021-04-30 0001677077 us-gaap:AdditionalPaidInCapitalMember 2021-04-30 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2021-04-30 0001677077 us-gaap:RetainedEarningsMember 2021-04-30 0001677077 2021-04-30 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2022-11-01 2023-01-31 0001677077 us-gaap:CommonStockMember 2022-11-01 2023-01-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2022-11-01 2023-01-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2022-11-01 2023-01-31 0001677077 us-gaap:RetainedEarningsMember 2022-11-01 2023-01-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2021-11-01 2022-01-31 0001677077 us-gaap:CommonStockMember 2021-11-01 2022-01-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2021-11-01 2022-01-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2021-11-01 2022-01-31 0001677077 us-gaap:RetainedEarningsMember 2021-11-01 2022-01-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2022-05-01 2023-01-31 0001677077 us-gaap:CommonStockMember 2022-05-01 2023-01-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2022-05-01 2023-01-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2022-05-01 2023-01-31 0001677077 us-gaap:RetainedEarningsMember 2022-05-01 2023-01-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2021-05-01 2022-01-31 0001677077 us-gaap:CommonStockMember 2021-05-01 2022-01-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2021-05-01 2022-01-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2021-05-01 2022-01-31 0001677077 us-gaap:RetainedEarningsMember 2021-05-01 2022-01-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2023-01-31 0001677077 us-gaap:CommonStockMember 2023-01-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2023-01-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2023-01-31 0001677077 us-gaap:RetainedEarningsMember 2023-01-31 0001677077 alzm:SeriesAConvertiblePreferredStockMember 2022-01-31 0001677077 us-gaap:CommonStockMember 2022-01-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001677077 alzm:NoteRecievableForCommonStockRelatedPartyMember 2022-01-31 0001677077 us-gaap:RetainedEarningsMember 2022-01-31 0001677077 2022-01-31 0001677077 us-gaap:StockOptionMember 2022-05-01 2023-01-31 0001677077 us-gaap:StockOptionMember 2021-05-01 2022-01-31 0001677077 us-gaap:WarrantMember 2022-05-01 2023-01-31 0001677077 us-gaap:WarrantMember 2021-05-01 2022-01-31 0001677077 alzm:AultLifeSciencesFundLLCMember alzm:SecuritiesPurchaseAgreementMember 2019-04-29 2019-04-30 0001677077 us-gaap:WarrantMember alzm:AultLifeSciencesFundLLCMember alzm:SecuritiesPurchaseAgreementMember 2019-04-29 2019-04-30 0001677077 us-gaap:WarrantMember alzm:AultLifeSciencesFundLLCMember alzm:SecuritiesPurchaseAgreementMember 2019-04-30 0001677077 2023-01-29 2023-01-31 0001677077 2022-04-28 2022-04-30 0001677077 2023-01-05 0001677077 2022-06-16 0001677077 alzm:StockIncentivePlan2016Member 2016-04-30 0001677077 alzm:StockIncentivePlan2016Member 2019-02-28 2019-03-01 0001677077 srt:MinimumMember alzm:StockIncentivePlan2016Member 2016-04-29 2016-04-30 0001677077 srt:MaximumMember alzm:StockIncentivePlan2016Member 2016-04-29 2016-04-30 0001677077 alzm:EmployeesAndConsultantsMember 2022-05-01 2023-01-31 0001677077 alzm:EmployeesAndConsultantsMember 2021-05-01 2022-01-31 0001677077 alzm:PerformanceContingentStockOptionsMember alzm:KeyEmployeesAndDirectorMember 2019-11-25 2019-11-26 0001677077 alzm:PerformanceContingentStockOptionsMember alzm:KeyEmployeesAndDirectorMember 2021-03-22 2021-03-23 0001677077 alzm:PerformanceContingentStockOptionsMember alzm:TwoConsultantsMember 2021-10-01 2021-10-14 0001677077 alzm:UnamortizedStockBasedCompensationMember 2023-01-31 0001677077 alzm:StockBasedCompensationMember 2022-05-01 2023-01-31 0001677077 srt:MinimumMember alzm:EmployeesAndConsultantsMember 2021-05-01 2022-01-31 0001677077 srt:MaximumMember alzm:EmployeesAndConsultantsMember 2021-05-01 2022-01-31 0001677077 us-gaap:ResearchAndDevelopmentExpenseMember 2022-11-01 2023-01-31 0001677077 us-gaap:ResearchAndDevelopmentExpenseMember 2021-11-01 2022-01-31 0001677077 us-gaap:ResearchAndDevelopmentExpenseMember 2022-05-01 2023-01-31 0001677077 us-gaap:ResearchAndDevelopmentExpenseMember 2021-05-01 2022-01-31 0001677077 us-gaap:GeneralAndAdministrativeExpenseMember 2022-11-01 2023-01-31 0001677077 us-gaap:GeneralAndAdministrativeExpenseMember 2021-11-01 2022-01-31 0001677077 us-gaap:GeneralAndAdministrativeExpenseMember 2022-05-01 2023-01-31 0001677077 us-gaap:GeneralAndAdministrativeExpenseMember 2021-05-01 2022-01-31 0001677077 alzm:ExercisePrice1Member 2023-01-31 0001677077 alzm:ExercisePrice2Member 2023-01-31 0001677077 alzm:ExercisePrice3Member 2023-01-31 0001677077 alzm:ExercisePrice4Member 2023-01-31 0001677077 srt:MinimumMember 2023-01-31 0001677077 srt:MaximumMember 2023-01-31 0001677077 us-gaap:WarrantMember 2021-05-01 2022-01-31 0001677077 us-gaap:MeasurementInputOptionVolatilityMember us-gaap:WarrantMember 2022-01-31 0001677077 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2022-01-31 0001677077 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2022-01-31 0001677077 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2022-01-31 0001677077 alzm:DigitalPowerLendingMember alzm:SecuritiesPurchaseAgreementMember 2021-03-01 2021-03-31 0001677077 alzm:DigitalPowerLendingMember alzm:SecuritiesPurchaseAgreementMember 2021-03-01 2021-03-09 0001677077 alzm:BitnileMember alzm:BrandDevelopmentAgreementMember 2022-11-28 2022-11-30 0001677077 alzm:AL002LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:AL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:AdditionalAL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:PreIndMeetingMember alzm:AL001LicenseMember 2023-01-31 0001677077 alzm:PreIndMeetingMember alzm:AL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:IndApplicationFilingMember alzm:AL001LicenseMember 2023-01-31 0001677077 alzm:IndApplicationFilingMember alzm:AL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AL001LicenseMember 2023-01-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponCompletionOfFirstPatientDosingMember alzm:AL001LicenseMember 2023-01-31 0001677077 alzm:UponCompletionOfFirstPatientDosingMember alzm:AL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AL001LicenseMember 2023-01-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFdaApprovalMember alzm:AL001LicenseMember 2023-01-31 0001677077 alzm:UponFdaApprovalMember alzm:AL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:PreIndMeetingMember alzm:AL002LicenseMember 2023-01-31 0001677077 alzm:PreIndMeetingMember alzm:AL002LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:IndApplicationFilingMember alzm:AL002LicenseMember 2023-01-31 0001677077 alzm:IndApplicationFilingMember alzm:AL002LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AL002LicenseMember 2023-01-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AL002LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AL002LicenseMember 2023-01-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AL002LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFirstPatientTreatedInPhase3ClinicalTrialMember alzm:AL002LicenseMember 2023-01-31 0001677077 alzm:UponFirstPatientTreatedInPhase3ClinicalTrialMember alzm:AL002LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFdaApprovalMember alzm:AL002LicenseMember 2023-01-31 0001677077 alzm:UponFdaApprovalMember alzm:AL002LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:IndApplicationFilingMember alzm:AdditionalAL001LicenseMember 2023-01-31 0001677077 alzm:IndApplicationFilingMember alzm:AdditionalAL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AdditionalAL001LicenseMember 2023-01-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AdditionalAL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AdditionalAL001LicenseMember 2023-01-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AdditionalAL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFirstPatientTreatedInPhase3ClinicalTrialMember alzm:AdditionalAL001LicenseMember 2023-01-31 0001677077 alzm:UponFirstPatientTreatedInPhase3ClinicalTrialMember alzm:AdditionalAL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:UponFdaApprovalMember alzm:AdditionalAL001LicenseMember 2023-01-31 0001677077 alzm:UponFdaApprovalMember alzm:AdditionalAL001LicenseMember 2022-05-01 2023-01-31 0001677077 alzm:SecuritiesPurchaseAgreementsMember alzm:ALSFMember 2019-04-29 2019-04-30 0001677077 us-gaap:WarrantMember alzm:SecuritiesPurchaseAgreementsMember alzm:ALSFMember 2019-04-29 2019-04-30 0001677077 us-gaap:WarrantMember alzm:SecuritiesPurchaseAgreementsMember alzm:ALSFMember 2019-04-30 0001677077 alzm:ALSFMember 2019-04-29 2019-04-30 0001677077 alzm:ALSFMember 2019-04-30 0001677077 alzm:SecuritiesPurchaseAgreementsMember alzm:DigitalPowerLendingMember 2021-03-01 2021-03-31 0001677077 alzm:SecuritiesPurchaseAgreementsMember alzm:DigitalPowerLendingMember 2021-03-31 0001677077 alzm:SecuritiesPurchaseAgreementsMember alzm:DigitalPowerLendingMember 2021-03-01 2021-03-09 0001677077 alzm:ConvertiblePromissoryNoteMember alzm:SecuritiesPurchaseAgreementsMember alzm:AultGlobalMember 2021-03-01 2021-03-09 0001677077 alzm:SecuritiesPurchaseAgreementsMember alzm:FinalTrancheMember alzm:DigitalPowerLendingMember 2021-03-01 2021-03-31 iso4217:USD shares iso4217:USD shares pure 0001677077 false 2023 Q3 --04-30 10-Q true 2023-01-31 false 001-40483 ALZAMEND NEURO, INC. DE 81-1822909 3480 Peachtree Rd NE Suite 103 Atlanta GA 30326 (844) 722-6303 Common Stock, $0.0001 par value per share ALZN NASDAQ Yes Yes Non-accelerated Filer true true false false 96440124 7375841 14063811 546303 349723 494668 8416812 14413534 85166 102909 8501978 14516443 2642473 1162850 2082 2642473 1164932 2642473 1164932 0.0001 0.0001 10000000 10000000 0.0001 0.0001 1360000 1360000 0 0 0 0 0.0001 0.0001 300000000 300000000 96427624 96427624 95481790 95481790 9642 9548 61500292 57419753 -14883295 -14883295 -40767134 -29194495 5859505 13351511 8501978 14516443 2888847 873653 5797789 3540111 2534665 1682913 5767668 4906628 5423512 2556566 11565457 8446739 -5423512 -2556566 -11565457 -8446739 2062 16299 7182 45922 -2062 -16299 -7182 -45922 -5425574 -2572865 -11572639 -8492661 -0.06 -0.03 -0.12 -0.09 98326175 94165225 97765471 89484601 95494290 9549 59002729 -14883295 -35341560 8787423 1508322 1508322 933334 93 989241 989334 -5425574 -5425574 96427624 9642 61500292 -14883295 -40767134 5859505 88850358 8885 50652054 -14883295 -22752233 13025411 1130795 1130795 1000000 100 300 400 252265 25 378373 378398 -2572865 -2572865 90102623 9010 52161522 -14883295 -25325098 11962139 95481790 9548 57419753 -14883295 -29194495 13351511 12500 1 -1 3091299 3091299 933334 93 989241 989334 -11572639 -11572639 96427624 9642 61500292 -14883295 -40767134 5859505 750000 75 67429525 6743 33721859 -14883295 -16832437 2012945 212500 21 -21 3150801 3150801 1333333 133 1999867 2000000 3000000 300 900 1200 2875000 288 12911168 12911456 252265 25 378373 378398 -750000 -75 15000000 1500 -1425 -8492661 -8492661 90102623 9010 52161522 -14883295 -25325098 11962139 -11572639 -8492661 17743 12770 3091299 3150801 196580 -344493 492584 1479623 -67040 -6687970 -5051637 2000000 1200 12911456 14912656 -6687970 9861019 14063811 1929270 7375841 11790289 4,799,742 461,877 378373 989334 <p id="xdx_80B_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zYW1kpEj89s6" style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"/><td style="width: 0.25in"><b>1.</b></td><td style="text-align: justify"><b><span id="xdx_829_zbUrb0KhElB9">DESCRIPTION OF BUSINESS</span></b></td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Organization</i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Alzamend Neuro, Inc. (the “Company” or “Alzamend”), is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”). With the Company’s two current product candidates, Alzamend aims to bring treatments or cures to market as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates (collectively, the “Technology”): (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, for the treatment of Alzheimer’s BD, MDD and PTSD, known as AL001, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the “Licensor”); and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as ALZN002, through a royalty-bearing exclusive worldwide license from the same Licensor.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is devoting substantially all its efforts towards research and development of its Technology. The Company has not generated any product revenue to date. The Company has financed its operations to date primarily through debt financings and through the sale of its common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230131_zRjpvsJD6XA7" title="Common stock, par value (in dollars per share)"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220430_z4rOn4ZsL4y4" title="Common stock, par value (in dollars per share)">0.0001</span></span> per share (“Common Stock”). The Company expects to continue to incur net losses in the foreseeable future.</p> 0.0001 0.0001 <p id="xdx_806_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zT8JWGgiVTQk" style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"/><td style="width: 0.25in"><b>2.</b></td><td style="text-align: justify"><b><span id="xdx_820_ztvfrl1bLPm2">LIQUIDITY AND GOING CONCERN</span></b></td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern. As of January 31, 2023, the Company had cash of $<span id="xdx_909_eus-gaap--Cash_iI_pp0n3_dm_c20230131_zbY1n6YXuj43" title="Cash">7.4</span> million and an accumulated deficit of $<span id="xdx_909_eus-gaap--RetainedEarningsAppropriated_iI_pp0n3_dm_c20230131_zTesvm7x7Eg8" title="Accumulated deficit">40.8</span> million. The Company incurred losses for the three and nine months ended January 31, 2023 totaling $<span id="xdx_90A_eus-gaap--ProfitLoss_pp0n3_dm_c20221101__20230131_zJLbfWuf0q1g" title="Net loss">5.4</span> million and $<span id="xdx_905_eus-gaap--ProfitLoss_pp0n3_dm_c20220501__20230131_zmTY6nPQqwZ6" title="Net loss">11.6</span> million, respectively. Historically, the Company has financed its operations principally through issuances of equity and debt instruments.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company expects to continue to incur losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development and commercial operations. However, based on the Company’s current business plan, management believes that the Company’s cash at January 31, 2023 is sufficient to meet the Company’s anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report.</p> 7400000 40800000 5400000 11600000 <p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zEaq0fW4qMfe" style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"/><td style="width: 0.25in"><b>3.</b></td><td style="text-align: justify"><b><span id="xdx_82D_zJ6FhOX9pjx6">SIGNIFICANT ACCOUNTING POLICIES</span></b></td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"><b><i> </i></b></p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zyf33Wz4Np67" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86F_zEhVJVtjyphi">Basis of Presentation</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Report on Form 10-K for the year ended April 30, 2022, filed with the SEC on July 19, 2022. In the opinion of management, the accompanying condensed interim financial statements include all adjustments necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Company’s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2022 has been derived from the audited balance sheet at April 30, 2022 contained in such Form 10-K.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p id="xdx_84F_eus-gaap--UseOfEstimates_zhenJSXc6jI7" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_868_zUlJ6naILEWe">Accounting Estimates</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zTjNBgCNCYBk" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86D_z7a1SxYaVDv">Cash and Cash Equivalents</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of January 31, 2023 and April 30, 2022, the Company had no cash equivalents.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zYNfKxPBqJbl" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_869_zWYB8qMViHn9">Fair Value of Financial Instruments</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, <i>Fair Value Measurement</i>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable:</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 1: Quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of warrants are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants’ contractual life.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_za74aR1OKv52" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_860_z1qJStKArcH3">Property and Equipment, Net</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zQlWVyQ7Uf79" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_860_z1Qq64KGrKh1">Research and Development Expenses</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zdBx2QQUGDF1" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_865_zY8uy4PvPSKg">Stock-Based Compensation</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes stock-based compensation expense for restricted stocks on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially different.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_ecustom--WarrantsPolicyTextBlock_zSWvryQlk5zf" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_865_zjNayIdXxHak">Warrants</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, <i>Distinguishing Liabilities from Equity </i>and ASC 815, <i>Derivatives and Hedging,</i> depending on the specific terms of the warrant agreement.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zybb3T1Bpbq4" style="font: 10pt Times New Roman; margin: 0pt 0"> <b><i> <span id="xdx_863_zIhOVtrsg0Il">Loss per Common Share</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company utilizes FASB ASC 260, <i>Earnings per Share</i>. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then shared in the earnings of the entity.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the effects of outstanding options, warrants, convertible preferred stock and convertible notes are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following sets forth the number of shares of Common Stock underlying outstanding options and warrants that have been excluded from the computation of loss per common share:</p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z08HUEajKote" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span id="xdx_8BA_zpH6FW7KeMI4" style="display: none">Schedule of antidilutive securities excluded from computation of earnings per share</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Nine Months Ended January 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options (1)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220501__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zMht4TZtP3A6" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">18,158,329</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210501__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_ztHLGj7Xyfwi" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">13,500,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220501__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">10,149,788</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210501__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">8,830,785</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220501__20230131_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">28,308,117</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210501__20220131_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">22,330,785</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.2in"/><td id="xdx_F03_zl2igBGhHWMl" style="width: 0.3in">(1)</td><td id="xdx_F12_zdT4vCDg1Ua2" style="text-align: justify">The Company has excluded <span id="xdx_900_ecustom--NumberOfStockExcluded_c20220501__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zm5WSp9ThwM8" title="Number of stock excluded">2,000,000</span> and <span id="xdx_907_ecustom--NumberOfStockExcluded_c20210501__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zoRBqG7AjbK9">4,500,000</span> stock options for the nine months ended January 31, 2023 and 2022, respectively, with an exercise price of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220501__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" title="Exercise price (in dollars per share)">0.0004</span>, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.</td></tr></table> <p id="xdx_8AA_zJS3tc48pPNi" style="font: 10pt Times New Roman; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"> </p> <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zsycDMn6C2Q7" style="font: 10pt Times New Roman; margin: 0pt 0"><i> <b><span id="xdx_860_z6yqgvqVk1e3">Recent Accounting Standards</span></b></i></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company’s financial position or results of operations upon adoption.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its financial statements.</p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zyf33Wz4Np67" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86F_zEhVJVtjyphi">Basis of Presentation</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Report on Form 10-K for the year ended April 30, 2022, filed with the SEC on July 19, 2022. In the opinion of management, the accompanying condensed interim financial statements include all adjustments necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Company’s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2022 has been derived from the audited balance sheet at April 30, 2022 contained in such Form 10-K.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p id="xdx_84F_eus-gaap--UseOfEstimates_zhenJSXc6jI7" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_868_zUlJ6naILEWe">Accounting Estimates</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zTjNBgCNCYBk" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86D_z7a1SxYaVDv">Cash and Cash Equivalents</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of January 31, 2023 and April 30, 2022, the Company had no cash equivalents.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zYNfKxPBqJbl" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_869_zWYB8qMViHn9">Fair Value of Financial Instruments</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, <i>Fair Value Measurement</i>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable:</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 1: Quoted prices in active markets for identical assets or liabilities.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of warrants are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants’ contractual life.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_za74aR1OKv52" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_860_z1qJStKArcH3">Property and Equipment, Net</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zQlWVyQ7Uf79" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_860_z1Qq64KGrKh1">Research and Development Expenses</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that there is no alternative future use of the rights in other research and development projects.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zdBx2QQUGDF1" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_865_zY8uy4PvPSKg">Stock-Based Compensation</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes stock-based compensation expense for restricted stocks on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Black-Scholes option pricing model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially different.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_ecustom--WarrantsPolicyTextBlock_zSWvryQlk5zf" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_865_zjNayIdXxHak">Warrants</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for stock warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, <i>Distinguishing Liabilities from Equity </i>and ASC 815, <i>Derivatives and Hedging,</i> depending on the specific terms of the warrant agreement.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zybb3T1Bpbq4" style="font: 10pt Times New Roman; margin: 0pt 0"> <b><i> <span id="xdx_863_zIhOVtrsg0Il">Loss per Common Share</span></i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company utilizes FASB ASC 260, <i>Earnings per Share</i>. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then shared in the earnings of the entity.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the effects of outstanding options, warrants, convertible preferred stock and convertible notes are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following sets forth the number of shares of Common Stock underlying outstanding options and warrants that have been excluded from the computation of loss per common share:</p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z08HUEajKote" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span id="xdx_8BA_zpH6FW7KeMI4" style="display: none">Schedule of antidilutive securities excluded from computation of earnings per share</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Nine Months Ended January 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options (1)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220501__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zMht4TZtP3A6" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">18,158,329</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210501__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_ztHLGj7Xyfwi" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">13,500,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220501__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">10,149,788</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210501__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">8,830,785</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220501__20230131_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">28,308,117</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210501__20220131_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">22,330,785</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.2in"/><td id="xdx_F03_zl2igBGhHWMl" style="width: 0.3in">(1)</td><td id="xdx_F12_zdT4vCDg1Ua2" style="text-align: justify">The Company has excluded <span id="xdx_900_ecustom--NumberOfStockExcluded_c20220501__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zm5WSp9ThwM8" title="Number of stock excluded">2,000,000</span> and <span id="xdx_907_ecustom--NumberOfStockExcluded_c20210501__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zoRBqG7AjbK9">4,500,000</span> stock options for the nine months ended January 31, 2023 and 2022, respectively, with an exercise price of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220501__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" title="Exercise price (in dollars per share)">0.0004</span>, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.</td></tr></table> <p id="xdx_8AA_zJS3tc48pPNi" style="font: 10pt Times New Roman; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z08HUEajKote" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span id="xdx_8BA_zpH6FW7KeMI4" style="display: none">Schedule of antidilutive securities excluded from computation of earnings per share</span></td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Nine Months Ended January 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options (1)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220501__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zMht4TZtP3A6" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">18,158,329</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210501__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_ztHLGj7Xyfwi" style="width: 15%; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">13,500,000</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220501__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">10,149,788</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210501__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">8,830,785</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220501__20230131_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">28,308,117</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210501__20220131_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive securities excluded from computation of earnings per share, amount">22,330,785</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.2in"/><td id="xdx_F03_zl2igBGhHWMl" style="width: 0.3in">(1)</td><td id="xdx_F12_zdT4vCDg1Ua2" style="text-align: justify">The Company has excluded <span id="xdx_900_ecustom--NumberOfStockExcluded_c20220501__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zm5WSp9ThwM8" title="Number of stock excluded">2,000,000</span> and <span id="xdx_907_ecustom--NumberOfStockExcluded_c20210501__20220131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zoRBqG7AjbK9">4,500,000</span> stock options for the nine months ended January 31, 2023 and 2022, respectively, with an exercise price of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220501__20230131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" title="Exercise price (in dollars per share)">0.0004</span>, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.</td></tr></table> 18158329 13500000 10149788 8830785 28308117 22330785 2000000 4500000 0.0004 <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zsycDMn6C2Q7" style="font: 10pt Times New Roman; margin: 0pt 0"><i> <b><span id="xdx_860_z6yqgvqVk1e3">Recent Accounting Standards</span></b></i></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company’s financial position or results of operations upon adoption.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its financial statements.</p> <p id="xdx_803_ecustom--MortgageNoteReceivableFromRelatedPartyTextBlock_zy10FGwpvpcl" style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"/><td style="width: 0.25in"><b>4.</b></td><td style="text-align: justify"><b><span id="xdx_822_zDATlVxvB046">NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY</span></b></td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 30, 2019, the Company and Ault Life Sciences Fund, LLC (“ALSF”) entered into a securities purchase agreement for the purchase of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190429__20190430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pdd" title="Number of shares purchase (in shares)">10,000,000</span> shares of Common Stock for a total purchase price of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20190429__20190430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pp0p0" title="Number of shares purchase">15,000,000</span>, or $1.50 per share with <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190429__20190430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pdd" title="Number of warrants granted">5,000,000</span> warrants with a <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20190430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z81Cig0jrcBb" title="Warrant terms">5</span>-year life and an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20190430__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pdd" title="Exercise price (in dollars per share)">3.00</span> per share and vesting upon issuance. The total purchase price of $15,000,000 was in the form of a non-interest bearing note receivable with a 12-month term from ALSF, a related party. In November 2019, the term of the note receivable was extended to December 31, 2021, and in May 2021, the term of the note receivable was extended to December 31, 2023. The note is secured by a pledge of the purchased shares. As the note receivable from ALSF is related to the issuance of Common Stock, it is recorded as an offset to additional paid-in capital. At January 31, 2023 and April 30, 2022, the outstanding balance of the note receivable was $<span id="xdx_900_ecustom--LongTermDebtAverageAmountOfOutstanding_c20230129__20230131_pp0p0" title="Outstanding receivable amount"><span id="xdx_902_ecustom--LongTermDebtAverageAmountOfOutstanding_c20220428__20220430_pp0p0" title="Outstanding receivable amount">14,883,295</span></span>. ALSF is wholly owned by Ault Life Sciences, Inc. (“ALSI”). ALSI is majority owned by Ault &amp; Company, Inc. (“Ault &amp; Co.”). Messrs. Horne and Nisser, directors of the Company, are also directors of Ault &amp; Co.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> 10000000 15000000 5000000 P5Y 3.00 14883295 14883295 <p id="xdx_807_eus-gaap--OtherCurrentAssetsTextBlock_zbOIylLC4ogb" style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"/><td style="width: 0.25in"><b>5.</b></td><td style="text-align: justify"><b><span id="xdx_82C_zALpUpSpaK51">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prepaid expenses and other current assets were as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_z9cAidoa7CH2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B3_zmaKB6AOgJL6" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20230131_zZnx8Tvd9aXj" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220430_zXZBC1BMvW9f" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">January 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_ecustom--PrepaidClinicalTrialFees_iI_maPEAOAzZQ6_zoJM9wnoihj9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Prepaid clinical trial fees</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">315,987</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzZQ6_zJFa1ZXLODgf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">222,742</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">155,880</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzZQ6_zeVuwDgbE2C8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,574</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,176</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PrepaidConsultingFees_iI_pp0p0_maPEAOAzZQ6_zsNIFTYqkpo" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Prepaid consulting fees</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0607">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">186,667</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_pp0p0_mtPEAOAzZQ6_ztOzrFVYhiO6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">546,303</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">349,723</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On January 5, 2023, the Company prepaid $<span id="xdx_901_ecustom--PrepaidClinicalTrialFees_iI_c20230105_zcSiYKEmdcX9">437,466</span> for clinical trial fees related to AL002. Prepaid clinical trial fees at January 31, 2023, represented the unused portion of the prepaid clinical fees. On June 16, 2022, the Company purchased directors and officers (“D&amp;O”) insurance for 12 months in the amount of $<span id="xdx_900_ecustom--PrepaidInsurance1_c20220616_pp0p0">492,000</span>. Prepaid insurance at January 31, 2023 represented the unamortized portion of the annual insurance premium.</p> <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_z9cAidoa7CH2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B3_zmaKB6AOgJL6" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20230131_zZnx8Tvd9aXj" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220430_zXZBC1BMvW9f" style="text-align: right"> </td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">January 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_ecustom--PrepaidClinicalTrialFees_iI_maPEAOAzZQ6_zoJM9wnoihj9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Prepaid clinical trial fees</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">315,987</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzZQ6_zJFa1ZXLODgf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">222,742</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">155,880</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzZQ6_zeVuwDgbE2C8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,574</td><td style="white-space: nowrap; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,176</td><td style="white-space: nowrap; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PrepaidConsultingFees_iI_pp0p0_maPEAOAzZQ6_zsNIFTYqkpo" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Prepaid consulting fees</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0607">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">186,667</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_pp0p0_mtPEAOAzZQ6_ztOzrFVYhiO6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">546,303</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">349,723</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 315987 222742 155880 7574 7176 186667 546303 349723 437466 492000 <p id="xdx_80E_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zwlCZhwQ9Ggi" style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"/><td style="width: 0.25in"><b>6.</b></td><td style="text-align: justify"><b><span id="xdx_827_zQL5uA0DEH91">STOCK-BASED COMPENSATION</span></b></td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>2016 Stock Incentive Plan</i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 30, 2016, the Company’s stockholders approved the Company’s 2016 Stock Incentive Plan (the “Plan”). The Plan provides for the issuance of a maximum of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160430__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_pdd" title="Number of shares authorized for issuance">12,500,000</span> shares of Common Stock to be offered to the Company’s directors, officers, employees, and consultants. On March 1, 2019, the Company’s stockholders approved an additional <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20190228__20190301__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_pdd" title="Additional number of shares available for issuance">7,500,000</span> shares to be available for issuance under the Plan. Options granted under the Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant and become exercisable based on a vesting schedule determined at the date of grant. The options expire between five <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20160429__20160430__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_zYmppTmahuvh" style="display: none" title="Expiration period">5</span> and <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20160429__20160430__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_zTXtxDzHJAM3" title="Expiration period">10</span> years from the date of grant. Restricted stock awards granted under the Plan are subject to a vesting period determined at the date of grant.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>2021 Stock Incentive Plan</i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, the Company’s board of directors (the “Board”) adopted, and the stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan (the “2021 Plan”). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory), (2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Stock Subject to the 2021 Plan.</i> The maximum number of shares of Common Stock that may be issued under the 2021 Plan is 10,000,000 shares, which number will be increased to the extent that compensation granted under the 2021 Plan is forfeited, expires or is settled for cash (except as otherwise provided in the 2021 Plan). Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company that the Company acquires or any subsidiary of the Company or with which the Company or any subsidiary combines) will not reduce the shares authorized for grant under the 2021 Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer under the 2021 Plan.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All options that the Company grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the date of issuance of these options, there was not an active public market for the Company’s shares. Accordingly, the fair value of the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because the Company settles these obligations by issuing shares of Common Stock from its authorized shares instead of settling such obligations with cash payments. </p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of stock option activity for the nine months ended January 31, 2023 is presented below: </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zKzBBYStETxh" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt"><span id="xdx_8B0_zlRYuTE39M62" style="display: none">Schedule of share-based payment arrangement, option, activity</span></td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td colspan="14" style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><b>Outstanding Options</b></td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><b>Shares <br/> Available <br/> for Grant</b></td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><b>Number of <br/> Shares</b></td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><b>Weighted <br/> Average <br/> Exercise <br/> Price</b></td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><b>Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Life (years)</b></td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>Aggregate </b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>Intrinsic<br/> Value</b></p></td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 25%; font-size: 10pt">Balance at April 30, 2022</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20220501__20230131_zs0VfKmDIExe" style="width: 12%; font-size: 10pt; text-align: right" title="Shares available for grant begining (in shares)">8,800,000</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220501__20230131_zePPFRxCzDT9" style="width: 12%; font-size: 10pt; text-align: right" title="Number of shares begining (in shares)">15,700,000</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt">$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220501__20230131_zdh6fsBA5Wh6" style="width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price begining (in dollars per share)">1.16</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220501__20230131_zQ1mgOZPn5kb" title="Weighted average remaining contractual life begining (years)">6.32</span></td> <td style="white-space: nowrap; width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt">$</td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220501__20230131_zXJPX4FdFWkc" style="width: 12%; font-size: 10pt; text-align: right" title="Aggregate intrinsic value begining">2,219,700</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt">Options granted</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20220501__20230131_zCfO0jZTYwe2" style="font-size: 10pt; text-align: right" title="Shares available for grant, Options granted">(2,000,000)</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220501__20230131_zwgiwxtSsSjg" style="font-size: 10pt; text-align: right" title="Number of shares, Options granted">2,000,000</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">$</td> <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageExercisePrice_c20220501__20230131_zHqq1ZQ5tAs" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, Options granted">1.17</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--WeightedAverageRemainingContractualLifeOptionGranted_dtY_c20220501__20230131_zDUJcu5p9Ou1" title="Weighted average remaining contractual life, Option granted (years)">9.83</span></td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font-size: 10pt">Options exercised</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross_c20220501__20230131_zjqOPefqPSh2" style="font-size: 10pt; text-align: right" title="Shares available for grant, Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220501__20230131_zMyIhIdI9mNb" style="font-size: 10pt; text-align: right" title="Number of shares, Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl0648">-</span></td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">$</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right">-</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt">Options expired</td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 1pt solid; font-size: 10pt"> </td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited_c20220501__20230131_zaa9ARlmyEu1" style="border-bottom: black 1pt solid; font-size: 10pt; text-align: right" title="Shares available for grant, Options cnacelled/forfieted">2,391,671</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 1pt solid; font-size: 10pt"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220501__20230131_zOFehV9xOoc7" style="border-bottom: black 1pt solid; font-size: 10pt; text-align: right" title="Number of shares, Options cancelled/forfeited">(2,391,671</td> <td style="white-space: nowrap; font-size: 10pt">)</td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 1pt solid; font-size: 10pt">$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220501__20230131_zXpkPv9LLgx7" style="border-bottom: black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average exercise price, Options cancelled/forfeited">1.34</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right">-</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font-size: 10pt">Balance at January 31, 2023</td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 2.25pt double; font-size: 10pt"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20220501__20230131_zdXy1JphE1a6" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right" title="Shares available for grant end (in shares)">9,191,671</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 2.25pt double; font-size: 10pt"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220501__20230131_znopuFfGhuVj" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right" title="Number of shares end (in shares)">15,308,329</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 2.25pt double; font-size: 10pt">$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220501__20230131_z8pWt24zT6I8" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right" title="Weighted average exercise price end (in dollars per share)">1.18</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220501__20230131_zaIaZCzKDcq1" title="Weighted average remaining contractual life end (years)">6.32</span></td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">$</td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220501__20230131_zA8e92VON1rd" style="font-size: 10pt; text-align: right" title="Aggregate intrinsic value end">1,327,200</td> <td style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt">Options vested and expected to vest at January 31, 2023</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 2.25pt double; font-size: 10pt"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20230131_z7mdO8gM8DWk" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right" title="Number of shares, Options vested and expected to vest at end">14,308,329</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 2.25pt double; font-size: 10pt">$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20230131_zNjje4eEoAV6" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right" title="Weighted average exercise price, Options vested and expected to vest at end">1.18</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220501__20230131_zIGFIRv6MTUi" title="Weighted average remaining contractual life, Options vested and expected to vest at end">6.07</span></td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">$</td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pp0p0_c20230131_zhF6gkr502Sd" style="font-size: 10pt; text-align: right" title="Aggregate intrinsic value, Options vested and expected to vest at end">1,327,200</td> <td style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font-size: 10pt">Options exercisable at January 31, 2023</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 2.25pt double; font-size: 10pt"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230131_zmJM66zPkIBj" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right" title="Number of shares, Options exercisable at end">13,172,907</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 2.25pt double; font-size: 10pt">$</td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230131_zfUWZJUCAPgh" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right" title="Weighted average exercise price, Options exercisable at end">1.11</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220501__20230131_z6vUDmgdqB04" title="Weighted average remaining contractual life, Options exercisable at end">5.91</span></td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">$</td> <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20230131_zLcjgsLud3l3" style="font-size: 10pt; text-align: right" title="Aggregate intrinsic value, Options exercisable at end">1,327,200</td> <td style="white-space: nowrap; font-size: 10pt"> </td></tr> </table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p id="xdx_8A9_zt9YtzUZ6dTe" style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate intrinsic value in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised their options.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-indent: 0.3in"><b><i>Stock Options Granted to Employees and Consultants</i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The estimated fair value of stock options granted to employees and consultants during the nine months ended January 31, 2023 and 2022 were calculated using the Black-Scholes option-pricing model using the following assumptions:</p> <table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock_zfgkLn8L4GFb" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 1)"> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt"><span id="xdx_8B6_zwn1zrWgPzHd" style="display: none">Schedule of stock options granted to employees and consultants</span></td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><b>For the Nine Months Ended January 31,</b></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><b>2023</b></td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><b>2022</b></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font-size: 10pt">Expected term (in years)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220501__20230131__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zHXJWacMd3Bd" title="Expected term (in years)">6.25</span></td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210501__20220131__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zQv7FuM9dcIa" title="Expected term (in years)">3.50</span> – <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210501__20220131__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zgWcYLVJUBs5" title="Expected term (in years)">6.25</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 62%; font-size: 10pt">Volatility</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 18%; font-size: 10pt; text-align: center"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220501__20230131__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zwoWEzBo0Qqj" title="Volatility">88.94</span>%</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 18%; font-size: 10pt; text-align: center"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210501__20220131__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zHXzuN7HMB06" title="Volatility">85.53</span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210501__20220131__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zTLsDVSVHWHf" title="Volatility">87.10</span>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font-size: 10pt">Risk-free interest rate</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220501__20230131__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zpXrJUGvW1me" title="Risk-free interest rate">3.89</span>%</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210501__20220131__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zW2JKb6SeVo" title="Risk-free interest rate">1.01</span>%-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210501__20220131__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zPc2N1NaDCLe" title="Risk-free interest rate">1.07</span>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt">Dividend yield</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220501__20230131__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zGPhAWl2Jeb4" title="Dividend yield">0.0</span>%</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210501__20220131__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_znLbq5ouDBC6" title="Dividend yield">0.0</span>%</td></tr> </table> <p id="xdx_8A9_zX8yvctzBed9" style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Term:</i> The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Volatility:</i> The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company did not have sufficient trading history for its Common Stock at January 31, 2023 and 2022. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Risk-Free Interest Rate:</i> The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Dividend:</i> The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation to employees and consultants from stock option grants for the nine months ended January 31, 2023 and 2022, was $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pp0n3_dm_c20220501__20230131__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zpGQOlbjMCU2" title="Stock-based compensation">3.1</span> million and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0n3_dm_c20210501__20220131__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zcowCu8APiEb" title="Stock-based compensation">3.2</span> million, respectively.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Performance Contingent Stock Options Granted to Employee</i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 26, 2019, the Board granted <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_pdd" title="Options granted">4,250,000</span> performance- and market-contingent awards to certain key employees and a director. These grants were made outside of the Plan. These awards have an exercise price of $1.50 per share. These awards have multiple separate market triggers for vesting based upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180 days after the Company’s initial public offering (“IPO”) for its Common Stock, or (ii) stepped target prices for a change in control transaction. The target prices range from $10 per share to $40 per share. <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember" title="Terms of award">In the event any of the stock price milestones are not achieved within three years</span>, the unvested portion of the performance options will be reduced by 25%.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 22, 2022, the Compensation Committee of the Board modified the performance criteria for these awards. The target price range is now $10 per share to $20 per share. Additionally, if the stock price milestones are now not achieved by November 27, 2026, as opposed to within three years, the unvested portion of the portion of the performance options will be reduced by 25%. Due to the significant risks and uncertainties associated with achieving the market-contingent awards, as of January 31, 2023, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 29, 2022, the Compensation Committee of the Board granted 2,000,000 performance-based stock option to the Chief Executive Officer at an exercise price of $1.17 per share, of which 50% vest upon the completion and announcement of topline data from the Company’s Phase II clinical trial of AL001 within three years from grant date and the remaining 50% vest upon the completion and announcement of topline data from the Company’s Phase II clinical trial of ALZN002 within four years from the grant date. As of January 31, 2023, the Company believes that it is probable that the performance condition of the completion and announcement of topline data from the Company’s Phase II clinical trial of AL001 will be achieved and has recognized the related stock-based compensation. As of January 31, 2023, the Company believes that the achievement of the second performance condition is not probable and, as a result, no compensation cost has been recognized related to Phase II of ALZN002.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Performance Contingent Stock Options Granted to TAMM Net</i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 23, 2021, the Company issued performance-based stock options to the certain team members at TAMM Net, Inc. (“TAMM Net”) to purchase an aggregate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210322__20210323__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_pdd" title="Options granted">450,000</span> shares of Common Stock at a per share exercise price of $1.50 per share, of which 50% vest upon the completion of Phase I of AL001 by March 31, 2022, and the remaining 50% vest upon completion of Phase I of ALZN002 by December 31, 2022.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The performance goal of completing Phase I of AL001 was achieved on March 22, 2022, and the Company recognized stock-based compensation related to the completion of Phase I of AL001 over the implied service period to complete this milestone.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 19, 2023, the Board modified the performance criteria for these awards. The remaining 50% of the grant will now vest upon the completion and announcement of topline data of the first cohort from a Phase I/IIA clinical trial of ALZN002 on/or before March 31, 2024. Due to the significant risks and uncertainties associated with achieving the completion of Phase I for ALZN002, as of January 31, 2023, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards related to ALZN002.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Performance Contingent Stock Options Granted to Consultants</i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 14, 2021, the Company issued performance-based stock options to two consultants to purchase an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20211014__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoConsultantsMember_zekcoaVGTFtb" title="Options granted">200,000</span> shares of Common Stock with an exercise price of $2.42 per share, of which 50,000 vest upon completion of each of the Phase II clinical trials of AL001 for a Bipolar indication, AL001 for a PTSD indication, AL001 for a depression indication and ALZN002 for an Alzheimer’s indication.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 19, 2023, the Board modified the performance criteria for these awards. The revised grant will vest 25% if the Company (a) completes and announces topline data from a Phase II clinical trial of AL001 and ALZN002, as applicable, that would support a new drug application for the drug candidate and the indication listed below, and (b) obtained a “Study May Proceed” letter from the U.S. Food and Drug Administration for the additional IND on/or before December 31, 2023, as follows: (i) AL001 – bipolar disorder; (ii) AL001- major depressive disorder; (iii) AL001 – post-traumatic stress disorder; and (iv) ALZN002 – Alzheimer’s disease.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of January 31, 2023, the Company believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards related to Phase II of AL001 and ALZN002.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"> <b><i>Stock-Based Compensation Expense</i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company’s results of operations include expenses relating to stock-based compensation for three and nine months ended January 31, 2023 and 2022, that were comprised as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zHPUM81byZ2d" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8B2_zs7FaWvfwwm9" style="display: none">Schedule of stock-based compensation</span> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended January 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Nine Months Ended January 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left"> Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20221101__20230131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pdp0" style="width: 9%; text-align: right" title="Total">(42,589</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20211101__20220131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 9%; text-align: right" title="Total">106,102</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20230131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pdp0" style="width: 9%; text-align: right" title="Total">(42,589</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20220131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 9%; text-align: right" title="Total">359,286</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20221101__20230131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">1,550,911</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211101__20220131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">1,024,693</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20230131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">3,133,888</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20220131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">2,791,515</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20221101__20230131_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">1,508,322</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211101__20220131_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">1,130,795</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20230131_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">3,091,299</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20220131_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">3,150,801</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_z83F8KW2IwKh" style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0"/> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of January 31, 2023, total unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pin3_dm_c20230131__us-gaap--IncomeStatementLocationAxis__custom--UnamortizedStockBasedCompensationMember_zzd2WDsZi4Zg">1.5 </span>million. The weighted-average period over which such stock-based compensation expense will be recognized is approximately <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220501__20230131__us-gaap--IncomeStatementLocationAxis__custom--StockBasedCompensationMember_z1ciB0T6F725">1.8 </span>years.</p> 12500000 7500000 P5Y P10Y <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zKzBBYStETxh" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt"><span id="xdx_8B0_zlRYuTE39M62" style="display: none">Schedule of share-based payment arrangement, option, activity</span></td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td colspan="14" style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><b>Outstanding Options</b></td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><b>Shares <br/> Available <br/> for Grant</b></td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><b>Number of <br/> Shares</b></td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><b>Weighted <br/> Average <br/> Exercise <br/> Price</b></td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><b>Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Life (years)</b></td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>Aggregate </b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>Intrinsic<br/> Value</b></p></td> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 25%; font-size: 10pt">Balance at April 30, 2022</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20220501__20230131_zs0VfKmDIExe" style="width: 12%; font-size: 10pt; text-align: right" title="Shares available for grant begining (in shares)">8,800,000</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220501__20230131_zePPFRxCzDT9" style="width: 12%; font-size: 10pt; text-align: right" title="Number of shares begining (in shares)">15,700,000</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt">$</td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220501__20230131_zdh6fsBA5Wh6" style="width: 12%; font-size: 10pt; text-align: right" title="Weighted average exercise price begining (in dollars per share)">1.16</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220501__20230131_zQ1mgOZPn5kb" title="Weighted average remaining contractual life begining (years)">6.32</span></td> <td style="white-space: nowrap; width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt">$</td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220501__20230131_zXJPX4FdFWkc" style="width: 12%; font-size: 10pt; text-align: right" title="Aggregate intrinsic value begining">2,219,700</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt">Options granted</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20220501__20230131_zCfO0jZTYwe2" style="font-size: 10pt; text-align: right" title="Shares available for grant, Options granted">(2,000,000)</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220501__20230131_zwgiwxtSsSjg" style="font-size: 10pt; text-align: right" title="Number of shares, Options granted">2,000,000</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">$</td> <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageExercisePrice_c20220501__20230131_zHqq1ZQ5tAs" style="font-size: 10pt; text-align: right" title="Weighted average exercise price, Options granted">1.17</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--WeightedAverageRemainingContractualLifeOptionGranted_dtY_c20220501__20230131_zDUJcu5p9Ou1" title="Weighted average remaining contractual life, Option granted (years)">9.83</span></td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font-size: 10pt">Options exercised</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross_c20220501__20230131_zjqOPefqPSh2" style="font-size: 10pt; text-align: right" title="Shares available for grant, Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220501__20230131_zMyIhIdI9mNb" style="font-size: 10pt; text-align: right" title="Number of shares, Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl0648">-</span></td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">$</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right">-</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt">Options expired</td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 1pt solid; font-size: 10pt"> </td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited_c20220501__20230131_zaa9ARlmyEu1" style="border-bottom: black 1pt solid; font-size: 10pt; text-align: right" title="Shares available for grant, Options cnacelled/forfieted">2,391,671</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 1pt solid; font-size: 10pt"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220501__20230131_zOFehV9xOoc7" style="border-bottom: black 1pt solid; font-size: 10pt; text-align: right" title="Number of shares, Options cancelled/forfeited">(2,391,671</td> <td style="white-space: nowrap; font-size: 10pt">)</td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 1pt solid; font-size: 10pt">$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220501__20230131_zXpkPv9LLgx7" style="border-bottom: black 1pt solid; font-size: 10pt; text-align: right" title="Weighted average exercise price, Options cancelled/forfeited">1.34</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right">-</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font-size: 10pt">Balance at January 31, 2023</td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 2.25pt double; font-size: 10pt"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20220501__20230131_zdXy1JphE1a6" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right" title="Shares available for grant end (in shares)">9,191,671</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 2.25pt double; font-size: 10pt"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220501__20230131_znopuFfGhuVj" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right" title="Number of shares end (in shares)">15,308,329</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 2.25pt double; font-size: 10pt">$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220501__20230131_z8pWt24zT6I8" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right" title="Weighted average exercise price end (in dollars per share)">1.18</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220501__20230131_zaIaZCzKDcq1" title="Weighted average remaining contractual life end (years)">6.32</span></td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">$</td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220501__20230131_zA8e92VON1rd" style="font-size: 10pt; text-align: right" title="Aggregate intrinsic value end">1,327,200</td> <td style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt">Options vested and expected to vest at January 31, 2023</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 2.25pt double; font-size: 10pt"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20230131_z7mdO8gM8DWk" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right" title="Number of shares, Options vested and expected to vest at end">14,308,329</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 2.25pt double; font-size: 10pt">$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20230131_zNjje4eEoAV6" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right" title="Weighted average exercise price, Options vested and expected to vest at end">1.18</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220501__20230131_zIGFIRv6MTUi" title="Weighted average remaining contractual life, Options vested and expected to vest at end">6.07</span></td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">$</td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pp0p0_c20230131_zhF6gkr502Sd" style="font-size: 10pt; text-align: right" title="Aggregate intrinsic value, Options vested and expected to vest at end">1,327,200</td> <td style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font-size: 10pt">Options exercisable at January 31, 2023</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 2.25pt double; font-size: 10pt"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230131_zmJM66zPkIBj" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right" title="Number of shares, Options exercisable at end">13,172,907</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 2.25pt double; font-size: 10pt">$</td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230131_zfUWZJUCAPgh" style="border-bottom: black 2.25pt double; font-size: 10pt; text-align: right" title="Weighted average exercise price, Options exercisable at end">1.11</td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220501__20230131_z6vUDmgdqB04" title="Weighted average remaining contractual life, Options exercisable at end">5.91</span></td> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">$</td> <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20230131_zLcjgsLud3l3" style="font-size: 10pt; text-align: right" title="Aggregate intrinsic value, Options exercisable at end">1,327,200</td> <td style="white-space: nowrap; font-size: 10pt"> </td></tr> </table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> 8800000 15700000 1.16 P6Y3M25D 2219700 2000000 2000000 1.17 P9Y9M29D 2391671 2391671 1.34 9191671 15308329 1.18 P6Y3M25D 1327200 14308329 1.18 P6Y25D 1327200 13172907 1.11 P5Y10M28D 1327200 <table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock_zfgkLn8L4GFb" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 1)"> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt"><span id="xdx_8B6_zwn1zrWgPzHd" style="display: none">Schedule of stock options granted to employees and consultants</span></td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"><b>For the Nine Months Ended January 31,</b></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><b>2023</b></td> <td style="font-size: 10pt"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><b>2022</b></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font-size: 10pt">Expected term (in years)</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220501__20230131__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zHXJWacMd3Bd" title="Expected term (in years)">6.25</span></td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210501__20220131__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zQv7FuM9dcIa" title="Expected term (in years)">3.50</span> – <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210501__20220131__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zgWcYLVJUBs5" title="Expected term (in years)">6.25</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 62%; font-size: 10pt">Volatility</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 18%; font-size: 10pt; text-align: center"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220501__20230131__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zwoWEzBo0Qqj" title="Volatility">88.94</span>%</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 18%; font-size: 10pt; text-align: center"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210501__20220131__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zHXzuN7HMB06" title="Volatility">85.53</span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210501__20220131__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zTLsDVSVHWHf" title="Volatility">87.10</span>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font-size: 10pt">Risk-free interest rate</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220501__20230131__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zpXrJUGvW1me" title="Risk-free interest rate">3.89</span>%</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210501__20220131__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zW2JKb6SeVo" title="Risk-free interest rate">1.01</span>%-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210501__20220131__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zPc2N1NaDCLe" title="Risk-free interest rate">1.07</span>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-size: 10pt">Dividend yield</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220501__20230131__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zGPhAWl2Jeb4" title="Dividend yield">0.0</span>%</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210501__20220131__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_znLbq5ouDBC6" title="Dividend yield">0.0</span>%</td></tr> </table> P6Y3M P3Y6M P6Y3M 0.8894 0.8553 0.8710 0.0389 0.0101 0.0107 0.000 0.000 3100000 3200000 4250000 In the event any of the stock price milestones are not achieved within three years 450000 200000 <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zHPUM81byZ2d" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8B2_zs7FaWvfwwm9" style="display: none">Schedule of stock-based compensation</span> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended January 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Nine Months Ended January 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left"> Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20221101__20230131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pdp0" style="width: 9%; text-align: right" title="Total">(42,589</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20211101__20220131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 9%; text-align: right" title="Total">106,102</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20230131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pdp0" style="width: 9%; text-align: right" title="Total">(42,589</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20220131__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="width: 9%; text-align: right" title="Total">359,286</td><td style="white-space: nowrap; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20221101__20230131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">1,550,911</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20211101__20220131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">1,024,693</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20230131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">3,133,888</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20220131__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total">2,791,515</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: 10pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20221101__20230131_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">1,508,322</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20211101__20220131_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">1,130,795</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20230131_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">3,091,299</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20220131_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">3,150,801</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -42589 106102 -42589 359286 1550911 1024693 3133888 2791515 1508322 1130795 3091299 3150801 1500000 P1Y9M18D <p id="xdx_801_ecustom--WarrantsDisclosureTextBlock_zE1P33PHQTJ7" style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"/><td style="width: 0.25in"><b>7.</b></td><td style="text-align: justify"><b><span id="xdx_829_zhOJuqGmrgDk">WARRANTS</span></b></td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes information about Common Stock warrants outstanding and exercisable at January 31, 2023:</p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">  </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_z7ziQ01NTlx8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - WARRANTS (Details)"> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"><span id="xdx_8BA_zORJPBkgThw8" style="display: none">Schedule of Common Stock warrants outstanding</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="14" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Outstanding</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="6" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Exercisable</b></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Remaining</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Number</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Contractual</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Number</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Outstanding</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Life (years)</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Exercisable</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" title="Exercse price (in dollars per share)">1.00</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Number warrant outstanding">500,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zoLefK5ocM13" title="Weighted average remaining contractual life (years)">1.1</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_98C_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">1.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_982_ecustom--ClassOfWarrantOrRightExercisable_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Number of warrant exercisable">500,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 13%; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">1.00</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pdd" title="Exercse price (in dollars per share)">1.75</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pdd" style="text-align: right" title="Number warrant outstanding">161,342</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zdNJoweLhak7" title="Weighted average remaining contractual life (years)">1.8</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98D_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pdd" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">1.75</td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisable_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pdd" style="text-align: right" title="Number of warrant exercisable">161,342</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pdd" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">1.75</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" title="Exercse price (in dollars per share)">3.00</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Number warrant outstanding">9,427,196</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_z3qIWS6IQ4If" title="Weighted average remaining contractual life (years)">2.2</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_983_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">3.00</td> <td> </td> <td> </td> <td> </td> <td id="xdx_980_ecustom--ClassOfWarrantOrRightExercisable_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Number of warrant exercisable">9,427,196</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">3.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" title="Exercse price (in dollars per share)">6.25</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Number warrant outstanding">61,250</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_zUAdN5njPxUe" title="Weighted average remaining contractual life (years)">3.4</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td id="xdx_982_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">6.25</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercisable_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Number of warrant exercisable">61,250</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td id="xdx_98D_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">6.25</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">$<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230131__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercse price (in dollars per share)">1.00</span> - $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230131__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercse price (in dollars per share)">6.25</span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230131_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number warrant outstanding">10,149,788</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230131_zfSCdWWbXFs8" title="Weighted average remaining contractual life (years)">2.4</span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_982_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20230131_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">2.90</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisable_c20230131_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number of warrant exercisable">10,149,788</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20230131_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">2.90</td> <td> </td></tr> </table> <p id="xdx_8AB_zAACZS1yak41" style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-indent: 0.5in">The estimated fair value of warrants granted during the nine months ended January 31, 2022 were calculated using the Black-Scholes option-pricing model using the following assumptions:</p> <table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock_zIY3JER6Dhm3" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse" summary="xdx: Disclosure - WARRANTS (Details 1)"> <tr style="vertical-align: bottom; background-color: white"> <td><span id="xdx_8B6_ztPs1yiDM0rf" style="display: none">Schedule of assumptions used</span></td> <td> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>For the Nine Months</b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>Ended January 31, 2022</b></p></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 73%">Expected term (in years)</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 25%; text-align: center"><span id="xdx_904_ecustom--WarrantExpectedTerm_dtY_c20210501__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4T6mwPcIPPf" title="Expected term (in years)">5.00</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Volatility</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_znKIOIg3rAJ" title="Warrants measurement input">86.31</span>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk-free interest rate</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zt7dHUxhK3la" title="Warrants measurement input">0.87</span>% - <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zGZXyFTuaGXh" title="Warrants measurement input">0.90</span>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zTTamc054b9i" title="Warrants measurement input">0.0</span>%</td></tr> </table> <p id="xdx_8A4_zr1pEMW1K088" style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Term:</i> The expected term represents the period that the warrants granted are expected to be outstanding.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Volatility:</i> The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company did not have sufficient trading history for its Common Stock at January 31, 2022. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Risk-Free Interest Rate:</i> The Company based the risk-free interest rate over the expected term of the warrants based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Dividend:</i> The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_z7ziQ01NTlx8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - WARRANTS (Details)"> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"><span id="xdx_8BA_zORJPBkgThw8" style="display: none">Schedule of Common Stock warrants outstanding</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="14" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Outstanding</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="6" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Exercisable</b></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Remaining</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Number</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Contractual</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Number</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Outstanding</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Life (years)</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Exercisable</b></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" title="Exercse price (in dollars per share)">1.00</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Number warrant outstanding">500,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zoLefK5ocM13" title="Weighted average remaining contractual life (years)">1.1</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_98C_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">1.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_982_ecustom--ClassOfWarrantOrRightExercisable_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 14%; text-align: right" title="Number of warrant exercisable">500,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pdd" style="width: 13%; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">1.00</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$</td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pdd" title="Exercse price (in dollars per share)">1.75</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pdd" style="text-align: right" title="Number warrant outstanding">161,342</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zdNJoweLhak7" title="Weighted average remaining contractual life (years)">1.8</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98D_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pdd" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">1.75</td> <td> </td> <td> </td> <td> </td> <td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisable_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pdd" style="text-align: right" title="Number of warrant exercisable">161,342</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pdd" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">1.75</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" title="Exercse price (in dollars per share)">3.00</span></td> <td> </td> <td> </td> <td> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Number warrant outstanding">9,427,196</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_z3qIWS6IQ4If" title="Weighted average remaining contractual life (years)">2.2</span></td> <td> </td> <td> </td> <td>$</td> <td id="xdx_983_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">3.00</td> <td> </td> <td> </td> <td> </td> <td id="xdx_980_ecustom--ClassOfWarrantOrRightExercisable_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Number of warrant exercisable">9,427,196</td> <td> </td> <td> </td> <td>$</td> <td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pdd" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">3.00</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" title="Exercse price (in dollars per share)">6.25</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Number warrant outstanding">61,250</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_zUAdN5njPxUe" title="Weighted average remaining contractual life (years)">3.4</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td id="xdx_982_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">6.25</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercisable_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Number of warrant exercisable">61,250</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid">$</td> <td id="xdx_98D_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20230131__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_pdd" style="border-bottom: black 1pt solid; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">6.25</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">$<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230131__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercse price (in dollars per share)">1.00</span> - $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230131__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercse price (in dollars per share)">6.25</span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230131_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number warrant outstanding">10,149,788</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230131_zfSCdWWbXFs8" title="Weighted average remaining contractual life (years)">2.4</span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_982_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20230131_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">2.90</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisable_c20230131_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number of warrant exercisable">10,149,788</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20230131_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">2.90</td> <td> </td></tr> </table> 1.00 500000 P1Y1M6D 1.00 500000 1.00 1.75 161342 P1Y9M18D 1.75 161342 1.75 3.00 9427196 P2Y2M12D 3.00 9427196 3.00 6.25 61250 P3Y4M24D 6.25 61250 6.25 1.00 6.25 10149788 P2Y4M24D 2.90 10149788 2.90 <table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock_zIY3JER6Dhm3" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse" summary="xdx: Disclosure - WARRANTS (Details 1)"> <tr style="vertical-align: bottom; background-color: white"> <td><span id="xdx_8B6_ztPs1yiDM0rf" style="display: none">Schedule of assumptions used</span></td> <td> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>For the Nine Months</b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><b>Ended January 31, 2022</b></p></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 73%">Expected term (in years)</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 25%; text-align: center"><span id="xdx_904_ecustom--WarrantExpectedTerm_dtY_c20210501__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4T6mwPcIPPf" title="Expected term (in years)">5.00</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Volatility</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_znKIOIg3rAJ" title="Warrants measurement input">86.31</span>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk-free interest rate</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zt7dHUxhK3la" title="Warrants measurement input">0.87</span>% - <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zGZXyFTuaGXh" title="Warrants measurement input">0.90</span>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: center"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zTTamc054b9i" title="Warrants measurement input">0.0</span>%</td></tr> </table> P5Y 0.8631 0.0087 0.0090 0.000 <p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zHJ5GhIqinib" style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"/><td style="width: 0.25in"><b>8.</b></td><td style="text-align: justify"><b><span id="xdx_82A_zhq8PgAkSgzi">OTHER RELATED PARTY TRANSACTIONS</span></b></td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, the Company entered into a securities purchase agreement with Ault Lending, LLC (“AL”) pursuant to which the Company sold an aggregate of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210301__20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pdd" title="Number of shares sold (in shares)">6,666,667</span> shares of Common Stock for an aggregate of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueOther_pp0n3_dm_c20210301__20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zVgyiDV9E8Ri" title="Value of stock issued">10</span> million, or $1.50 per share, which sales were made in tranches. On March 9, 2021, AL paid $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueOther_pp0n3_dm_c20210301__20210309__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zjBiFjNND09">4</span> million, less the $1.8 million in prior advances and the <span id="xdx_90A_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20210301__20210309__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zcXgEpyHeIc9" title="Description of related party transaction">surrender for cancellation of a $50,000 convertible promissory note held by Ault Alliance, Inc. (formerly, BitNile Holdings, Inc.) (“Ault Alliance”), the parent company of AL, for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, AL (i) purchased an additional 1,333,333 shares of Common Stock upon approval of the IND for Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares of Common Stock upon the completion of Phase IA clinical trials for AL001 for a purchase price of $4 million.</span> The Company issued to AL warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, AL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of the date of this Quarterly Report.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_901_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20221128__20221130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BitnileMember__us-gaap--TypeOfArrangementAxis__custom--BrandDevelopmentAgreementMember" title="Description of related party transaction">In November 2022, the Company entered into a marketing and brand development agreement with Ault Alliance, effective August 1, 2022, whereby Ault Alliance will provide various marketing services over twelve months valued at $1.4 million. The Company had the right to pay the fee in cash or shares of its Common Stock with a value of $1.50 per share. On November 11, 2022, the Company elected to pay the fee with 933,334 shares of its Common Stock. The Company recorded the value of the agreement using the closing price of the Company’s Common Stock on November 11, 2022, and will amortize the expense over twelve months beginning in August 2022.</span> At January 31, 2023, the balance of related party prepaid expenses was $<span id="xdx_905_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_c20230131_pp0p0" title="Related party prepaid expenses">495,000</span>.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0"/> 6666667 10000000 4000000 surrender for cancellation of a $50,000 convertible promissory note held by Ault Alliance, Inc. (formerly, BitNile Holdings, Inc.) (“Ault Alliance”), the parent company of AL, for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, AL (i) purchased an additional 1,333,333 shares of Common Stock upon approval of the IND for Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares of Common Stock upon the completion of Phase IA clinical trials for AL001 for a purchase price of $4 million. In November 2022, the Company entered into a marketing and brand development agreement with Ault Alliance, effective August 1, 2022, whereby Ault Alliance will provide various marketing services over twelve months valued at $1.4 million. The Company had the right to pay the fee in cash or shares of its Common Stock with a value of $1.50 per share. On November 11, 2022, the Company elected to pay the fee with 933,334 shares of its Common Stock. The Company recorded the value of the agreement using the closing price of the Company’s Common Stock on November 11, 2022, and will amortize the expense over twelve months beginning in August 2022. 495000 <p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zIDaiMz4jvq4" style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"/><td style="width: 0.25in"><b>9.</b></td><td style="text-align: justify"><b><span id="xdx_82E_zmgM7denIpZ7">COMMITMENTS AND CONTINGENCIES</span></b></td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Contractual Obligations</i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 1, 2016, the Company entered into a Standard Exclusive License Agreement for ALZN002 with Sublicensing Terms with Licensor, pursuant to which Licensor granted the Company a royalty bearing exclusive worldwide license limited to the field of Alzheimer’s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled “Amyloid Beta Peptides and Methods of Use,” filed April 7, 2009 and granted May 29, 2012.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">There are certain initial license fees and milestone payments required to be paid by the Company to the Licensor pursuant to the terms of license agreements. The license agreements for ALZN002 require the Company to pay royalty payments of<span id="xdx_90A_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._dp_c20220501__20230131__srt--ProductOrServiceAxis__custom--AL002LicenseMember_zUM92RirQJH8" title="Percentage of royalty payments on net sales of product"> 4</span>% on net sales of products developed from the licensed technology for ALZN002 while the license agreements for AL001 require that the Company pay combined royalty payments of <span id="xdx_90F_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._dp_c20220501__20230131__srt--ProductOrServiceAxis__custom--AL001LicenseMember_z10rVAHjFNNl" title="Percentage of royalty payments on net sales of product">4.5</span>% on net sales of products developed from the licensed technology for AL001.  <span id="xdx_902_ecustom--DescriptionOfLicensesAgreements_c20220501__20230131__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Description of licenses agreements">The Company has already paid an initial license fee of $200,000 for ALZN002 and an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of ALZN002, the Licensor received 3,601,809 shares of common stock. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 2,227,923 shares of common stock. Minimum royalties for AL001 are $25,000 in 2023, $45,000 in 2024 and $70,000 in 2025 and every year thereafter, for the life of the agreement. Minimum royalties for ALZN002 are $20,000 in 2022, $40,000 in 2023 and $50,000 in 2024 and every year thereafter, for the life of the respective agreement.</span> Additionally, the Company is required to pay milestone payments on the due dates to the Licensor for the license of the AL001 technologies and for the ALZN002 technology, as follows:</span></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Original AL001 License:</b></span></p> <table cellpadding="0" cellspacing="0" id="xdx_891_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zl7SSUQt9MOd" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: top; background-color: white"> <td> </td> <td> <span id="xdx_8BD_zT8gWJebgm6e" style="display: none">Schedule of Contractual Obligation, Fiscal Year Maturity</span></td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"><b> Due Date</b></td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"><b> Event</b></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right"><span id="xdx_909_eus-gaap--ContractualObligation_iI_pp0p0_c20230131__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zLc1kpIQjSf9" title="Payment">50,000</span></td> <td style="width: 1%; text-align: center"><sup>*</sup></td> <td style="width: 43%"><span id="xdx_907_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____z5BOwLhaDr95" title="Due date"> Completed September 2019</span></td> <td style="width: 1%"> </td> <td style="width: 43%"> Pre-IND meeting</td></tr> <tr style="vertical-align: top; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_905_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment">65,000</span></td> <td style="text-align: center"><sup>*</sup></td> <td><span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zQMfxW8IkCqb" title="Due date"> Completed June 2021</span></td> <td> </td> <td> IND application filing</td></tr> <tr style="vertical-align: top; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment">190,000</span></td> <td style="text-align: center"><sup>*</sup></td> <td><span id="xdx_909_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zjKIjn2esyG4" title="Due date"> Completed December 2021</span></td> <td> </td> <td> Upon first dosing of patient in a clinical trial</td></tr> <tr style="vertical-align: top; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPatientDosingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment">500,000</span></td> <td style="text-align: center"><sup>*</sup></td> <td> <span title="Due date"><span id="xdx_90D_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPatientDosingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zBW0kbZd3uj1" title="Due date">Completed March 2022</span></span></td> <td> </td> <td> Upon Completion of first clinical trial</td></tr> <tr style="vertical-align: top; background-color: white"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment">1,250,000</span></td> <td> </td> <td> <span id="xdx_90D_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember" title="Due date">12 months from completion of the first Phase II clinical trial</span></td> <td> </td> <td> Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: top; background-color: white"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment">10,000,000</span></td> <td> </td> <td> <span id="xdx_90D_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember" title="Due date">8 years from the effective date of the agreement</span></td> <td> </td> <td> Upon U.S. Food and Drug Administration (“FDA”) approval</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 27pt"/><td id="xdx_F03_zH0EjDnj0oo3" style="width: 13.45pt">*</td><td id="xdx_F1C_zDJ2OrKG3yc4" style="text-align: justify">Milestone met and completed</td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0"><span style="background-color: white"><b>ALZN002 License:</b> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember_pp0p0" title="Payment">50,000</span></td> <td style="white-space: nowrap; width: 1%; text-align: center"> *</td> <td style="width: 43%"><span id="xdx_90D_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember_fKg_____zXo9HOU1LILc" title="Due date">Completed September 2022</span></td> <td style="width: 1%"> </td> <td style="width: 43%; text-align: justify"> Upon IND application filing</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember_pp0p0" title="Payment">50,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_905_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember" title="Due date">12 months from IND application filing date</span></td> <td> </td> <td style="text-align: justify"> Upon first dosing of patient in first Phase I clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember_pp0p0" title="Payment">175,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_907_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember" title="Due date">12 months from first patient dosed in Phase I</span></td> <td> </td> <td style="text-align: justify"> Upon completion of first Phase I clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember_pp0p0" title="Payment">500,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_90C_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember" title="Due date">24 months from completion of first Phase I clinical trial</span></td> <td> </td> <td style="text-align: justify"> Upon completion of first Phase II clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember_pp0p0" title="Payment">1,000,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_90F_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember" title="Due date">12 months from completion of the first Phase II clinical trial</span></td> <td> </td> <td style="text-align: justify"> Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember_pp0p0" title="Payment">10,000,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_90C_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember" title="Due date">7 years from the effective date of the agreement</span></td> <td> </td> <td style="text-align: justify"> Upon FDA BLA approval</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 27pt"/><td id="xdx_F03_zl6cKDO0tzO4" style="width: 13.45pt">*</td><td id="xdx_F18_zN0P97lxYvUf" style="text-align: justify">Milestone met and completed</td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The Company has met the pre-IND meeting, IND application filing, and successfully completed the Phase I clinical trial milestones encompassing AL001 and the IND application filing milestone for ALZN002. If the Company fails to meet a milestone by its specified date, the Licensor may terminate the license agreement. </span></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0"/> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company while Licensor remains the owner of any equity securities of the Company.</span></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On June 10, 2020, the Company obtained two (2) additional royalty-bearing exclusive worldwide licenses from the Licensor to a therapy named AL001. One of the additional licenses is for the treatment of neurodegenerative diseases excluding Alzheimer’s and the other license is for the treatment of psychiatric diseases and disorders. There are certain license fees and milestone payments required to be paid pursuant to the terms of the Standard Exclusive License Agreements with Sublicensing Terms, both dated June 10, 2020 and effective as of November 1, 2019, with the Licensor and the University of South Florida (the “June AL001 License Agreements”). Under each of the June AL001 License Agreements, a royalty payment of <span id="xdx_90E_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._dp_c20220501__20230131__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zXtrBYn3Sdy3" title="Percentage of royalty payments on net sales of product">3</span>% is required on net sales of products developed from the licensed technology. For the two (2) additional AL001 licenses, in the aggregate, the Company has paid initial license fees of $<span id="xdx_900_ecustom--InitialLicenseFees_c20220501__20230131__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Initial license fees">20,000</span>. Additionally, under each of the June AL001 License Agreements, the Company is required to pay milestone payments on the due dates to the Licensor for the license of the technology, as follows:</span></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Additional AL001 Licenses:</b> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Payment">50,000</span></td> <td style="white-space: nowrap; width: 1%"> </td> <td style="width: 43%"><span id="xdx_909_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date">Upon IND application filing</span></td> <td style="width: 1%"> </td> <td style="width: 43%"> IND application filing</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Payment">150,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date">12 months from IND filing date</span></td> <td> </td> <td> Upon first dosing of patient in a clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Payment">400,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_900_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date">12 months from first patient dosing</span></td> <td> </td> <td> Upon Completion of first clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Payment">1,000,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_90D_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date">36 months from completion of the first Phase II clinical trial</span></td> <td> </td> <td> Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Payment">8,000,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_901_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date">8 years from the effective date of the agreement</span></td> <td> </td> <td> First commercial sale</td></tr> </table> 0.04 0.045 The Company has already paid an initial license fee of $200,000 for ALZN002 and an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of ALZN002, the Licensor received 3,601,809 shares of common stock. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 2,227,923 shares of common stock. Minimum royalties for AL001 are $25,000 in 2023, $45,000 in 2024 and $70,000 in 2025 and every year thereafter, for the life of the agreement. Minimum royalties for ALZN002 are $20,000 in 2022, $40,000 in 2023 and $50,000 in 2024 and every year thereafter, for the life of the respective agreement. <table cellpadding="0" cellspacing="0" id="xdx_891_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zl7SSUQt9MOd" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: top; background-color: white"> <td> </td> <td> <span id="xdx_8BD_zT8gWJebgm6e" style="display: none">Schedule of Contractual Obligation, Fiscal Year Maturity</span></td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"><b> Due Date</b></td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"><b> Event</b></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right"><span id="xdx_909_eus-gaap--ContractualObligation_iI_pp0p0_c20230131__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zLc1kpIQjSf9" title="Payment">50,000</span></td> <td style="width: 1%; text-align: center"><sup>*</sup></td> <td style="width: 43%"><span id="xdx_907_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____z5BOwLhaDr95" title="Due date"> Completed September 2019</span></td> <td style="width: 1%"> </td> <td style="width: 43%"> Pre-IND meeting</td></tr> <tr style="vertical-align: top; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_905_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment">65,000</span></td> <td style="text-align: center"><sup>*</sup></td> <td><span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zQMfxW8IkCqb" title="Due date"> Completed June 2021</span></td> <td> </td> <td> IND application filing</td></tr> <tr style="vertical-align: top; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment">190,000</span></td> <td style="text-align: center"><sup>*</sup></td> <td><span id="xdx_909_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zjKIjn2esyG4" title="Due date"> Completed December 2021</span></td> <td> </td> <td> Upon first dosing of patient in a clinical trial</td></tr> <tr style="vertical-align: top; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPatientDosingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment">500,000</span></td> <td style="text-align: center"><sup>*</sup></td> <td> <span title="Due date"><span id="xdx_90D_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPatientDosingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zBW0kbZd3uj1" title="Due date">Completed March 2022</span></span></td> <td> </td> <td> Upon Completion of first clinical trial</td></tr> <tr style="vertical-align: top; background-color: white"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment">1,250,000</span></td> <td> </td> <td> <span id="xdx_90D_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember" title="Due date">12 months from completion of the first Phase II clinical trial</span></td> <td> </td> <td> Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: top; background-color: white"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pp0p0" title="Payment">10,000,000</span></td> <td> </td> <td> <span id="xdx_90D_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember" title="Due date">8 years from the effective date of the agreement</span></td> <td> </td> <td> Upon U.S. Food and Drug Administration (“FDA”) approval</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 27pt"/><td id="xdx_F03_zH0EjDnj0oo3" style="width: 13.45pt">*</td><td id="xdx_F1C_zDJ2OrKG3yc4" style="text-align: justify">Milestone met and completed</td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0"><span style="background-color: white"><b>ALZN002 License:</b> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember_pp0p0" title="Payment">50,000</span></td> <td style="white-space: nowrap; width: 1%; text-align: center"> *</td> <td style="width: 43%"><span id="xdx_90D_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember_fKg_____zXo9HOU1LILc" title="Due date">Completed September 2022</span></td> <td style="width: 1%"> </td> <td style="width: 43%; text-align: justify"> Upon IND application filing</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember_pp0p0" title="Payment">50,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_905_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember" title="Due date">12 months from IND application filing date</span></td> <td> </td> <td style="text-align: justify"> Upon first dosing of patient in first Phase I clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember_pp0p0" title="Payment">175,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_907_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember" title="Due date">12 months from first patient dosed in Phase I</span></td> <td> </td> <td style="text-align: justify"> Upon completion of first Phase I clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember_pp0p0" title="Payment">500,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_90C_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember" title="Due date">24 months from completion of first Phase I clinical trial</span></td> <td> </td> <td style="text-align: justify"> Upon completion of first Phase II clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember_pp0p0" title="Payment">1,000,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_90F_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember" title="Due date">12 months from completion of the first Phase II clinical trial</span></td> <td> </td> <td style="text-align: justify"> Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember_pp0p0" title="Payment">10,000,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_90C_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AL002LicenseMember" title="Due date">7 years from the effective date of the agreement</span></td> <td> </td> <td style="text-align: justify"> Upon FDA BLA approval</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 27pt"/><td id="xdx_F03_zl6cKDO0tzO4" style="width: 13.45pt">*</td><td id="xdx_F18_zN0P97lxYvUf" style="text-align: justify">Milestone met and completed</td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The Company has met the pre-IND meeting, IND application filing, and successfully completed the Phase I clinical trial milestones encompassing AL001 and the IND application filing milestone for ALZN002. If the Company fails to meet a milestone by its specified date, the Licensor may terminate the license agreement. </span></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0"/> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company while Licensor remains the owner of any equity securities of the Company.</span></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On June 10, 2020, the Company obtained two (2) additional royalty-bearing exclusive worldwide licenses from the Licensor to a therapy named AL001. One of the additional licenses is for the treatment of neurodegenerative diseases excluding Alzheimer’s and the other license is for the treatment of psychiatric diseases and disorders. There are certain license fees and milestone payments required to be paid pursuant to the terms of the Standard Exclusive License Agreements with Sublicensing Terms, both dated June 10, 2020 and effective as of November 1, 2019, with the Licensor and the University of South Florida (the “June AL001 License Agreements”). Under each of the June AL001 License Agreements, a royalty payment of <span id="xdx_90E_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._dp_c20220501__20230131__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zXtrBYn3Sdy3" title="Percentage of royalty payments on net sales of product">3</span>% is required on net sales of products developed from the licensed technology. For the two (2) additional AL001 licenses, in the aggregate, the Company has paid initial license fees of $<span id="xdx_900_ecustom--InitialLicenseFees_c20220501__20230131__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Initial license fees">20,000</span>. Additionally, under each of the June AL001 License Agreements, the Company is required to pay milestone payments on the due dates to the Licensor for the license of the technology, as follows:</span></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Additional AL001 Licenses:</b> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Payment">50,000</span></td> <td style="white-space: nowrap; width: 1%"> </td> <td style="width: 43%"><span id="xdx_909_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date">Upon IND application filing</span></td> <td style="width: 1%"> </td> <td style="width: 43%"> IND application filing</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Payment">150,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date">12 months from IND filing date</span></td> <td> </td> <td> Upon first dosing of patient in a clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Payment">400,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_900_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date">12 months from first patient dosing</span></td> <td> </td> <td> Upon Completion of first clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Payment">1,000,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_90D_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date">36 months from completion of the first Phase II clinical trial</span></td> <td> </td> <td> Upon first patient treated in a Phase III clinical trial</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ContractualObligation_c20230131__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pp0p0" title="Payment">8,000,000</span></td> <td style="white-space: nowrap"> </td> <td><span id="xdx_901_eus-gaap--OtherCommitmentsDescription_c20220501__20230131__custom--LicenseEventsAxis__custom--UponFdaApprovalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember" title="Due date">8 years from the effective date of the agreement</span></td> <td> </td> <td> First commercial sale</td></tr> </table> 50000  Completed September 2019 65000  Completed June 2021 190000  Completed December 2021 500000 Completed March 2022 1250000 12 months from completion of the first Phase II clinical trial 10000000 8 years from the effective date of the agreement 50000 Completed September 2022 50000 12 months from IND application filing date 175000 12 months from first patient dosed in Phase I 500000 24 months from completion of first Phase I clinical trial 1000000 12 months from completion of the first Phase II clinical trial 10000000 7 years from the effective date of the agreement 0.03 20000 50000 Upon IND application filing 150000 12 months from IND filing date 400000 12 months from first patient dosing 1000000 36 months from completion of the first Phase II clinical trial 8000000 8 years from the effective date of the agreement <p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zvO7W0yTcCp1" style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"/><td style="width: 0.25in"><b>10.</b></td><td><b><span id="xdx_828_zFX2ZwDQDlB7">EQUITY TRANSACTIONS</span></b></td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company is authorized to issue <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20230131_z0fbius6yUN" title="Preferred stock, shares authorized"><span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20220430_zjD5yNUO07U6" title="Preferred stock, shares authorized">10,000,000</span></span> shares of Preferred Stock $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230131_zcxSElApIHt2" title="Preferred stock, par value (in dollars per share)"><span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220430_zOpP31hrtFIa" title="Preferred stock, par value (in dollars per share)">0.0001</span></span> par value. The Board has designated <span id="xdx_902_ecustom--PreferredStockSharesDesignated_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock shares designated"><span id="xdx_901_ecustom--PreferredStockSharesDesignated_c20220430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock shares designated">1,360,000</span></span> shares as the Series A Preferred Shares. The rights, preferences, privileges and restrictions on the remaining authorized <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_c20230131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred stock, shares authorized">8,640,000</span> shares of Preferred Stock have not been determined. The Board is authorized to create a new series of preferred shares and determine the number of shares, as well as the rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred shares. </p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Series A Preferred Shares</i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of January 31, 2023, there were no Series A Preferred Shares or any other shares of Preferred Stock issued or outstanding.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Common Stock</i></b></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 30, 2019, the Company and ALSF entered into a SPA for the purchase of <span id="xdx_909_ecustom--NumberOfSharesPurchase_c20190429__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zrwRDXDsDNkd" title="Number of shares purchase">10,000,000</span> shares of Common Stock for a total purchase price of $<span id="xdx_902_ecustom--SharesPurchasePrice_c20190429__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_pp0p0" title="Shares purchase price">15,000,000</span>, or $<span id="xdx_90E_ecustom--SharesPurchasePricePerShares_c20190429__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_pdd" title="Shares purchase price (in dollars per share)">1.50</span> per share with <span id="xdx_90B_ecustom--NumberOfSharesPurchase_c20190429__20190430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_pdd" title="Number of shares purchase">5,000,000</span> warrants with a <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20190430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zLxuh62rqDrk" title="Warrant terms">5</span>-year life and an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20190430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_pdd" title="Exercise price (in dollars per share)">3.00</span> per share and vesting upon issuance. The total purchase price of $<span id="xdx_901_ecustom--SharesPurchasePrice_c20190429__20190430__dei--LegalEntityAxis__custom--ALSFMember_pp0p0" title="Shares purchase price">15,000,000</span> was in the form of a non-interest bearing note receivable with a <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20190430__dei--LegalEntityAxis__custom--ALSFMember_zEfTkgRVZ0W1" title="Warrant terms">12</span>-month term from ALSF, a related party. The note is secured by a pledge of the purchased shares. Pursuant to the SPA, ALSF is entitled to full ratchet anti-dilution protection, most-favored nation status, denying the Company the right to enter into a variable rate transaction absent its consent, a right to participate in any future financing the Company may consummate and to have all the shares of Common Stock to which it is entitled under the SPA registered under the Securities Act within 180 days of the final closing of the IPO. In May 2021, the term of the note receivable was extended to December 31, 2023. The note is secured by a pledge of the purchased shares.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, the Company entered into a securities purchase agreement with AL pursuant to which the Company agreed to sell an aggregate of <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssuesOne_c20210301__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_pdd" title="Number of shares issued">6,666,667</span> shares of Common Stock for an aggregate of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0n3_dm_c20210301__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_zbeVfAch1zre" title="Proceeds from sale of equity">10</span> million, or $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_c20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_pdd" title="Shares issued price per share">1.50</span> per share, which sales were made in tranches. On March 9, 2021, AL paid $<span id="xdx_909_eus-gaap--ProceedsFromRelatedPartyDebt_pp0n3_dm_c20210301__20210309__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_zZoQ2ikmzyFi" title="Proceeds from related party">4</span> million, less the $<span id="xdx_90D_ecustom--AdvanceFromRelatedParties_pp0n3_dm_c20210301__20210309__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_z7yCzCI4GD6" title="Advance from related parties">1.8</span> million in prior advances and the surrender for cancellation of a $<span id="xdx_90B_ecustom--SharesValueSurrenderForCancellation_c20210301__20210309__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultGlobalMember_pp0p0" title="Shares value surrender for cancellation">50,000</span> convertible promissory note held by Ault Alliance, for an aggregate of <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesNewIssuesOne_c20210301__20210309__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultGlobalMember_pdd" title="Number of shares issued">2,666,667</span> shares of Common Stock. Under the terms of the securities purchase agreement, <span id="xdx_900_ecustom--DescriptionOfPurchaseAgreementTerms_c20210301__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember" title="Description of purchase agreement terms">AL (i) purchased an additional 1,333,333 shares of Common Stock upon approval by the FDA of the Company’s IND for its Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares of Common Stock upon the completion of these Phase IA clinical trials for AL001 for a purchase price of $4 million. The Company further agreed to issue to AL warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share.</span></p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, on April 28, 2022, AL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $<span id="xdx_90F_ecustom--AdditionalRightToInvest_pp0n3_dm_c20210301__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__us-gaap--VestingAxis__custom--FinalTrancheMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_zZqdDRgCMabe" title="Additional right to invest">10</span> million as of the date of this Quarterly Report.</p> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0"/> 10000000 10000000 0.0001 0.0001 1360000 1360000 8640000 10000000 15000000 1.50 5000000 P5Y 3.00 15000000 P12M 6666667 10000000 1.50 4000000 1800000 50000 2666667 AL (i) purchased an additional 1,333,333 shares of Common Stock upon approval by the FDA of the Company’s IND for its Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares of Common Stock upon the completion of these Phase IA clinical trials for AL001 for a purchase price of $4 million. The Company further agreed to issue to AL warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share. 10000000 <p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zVM4N7aXwAae" style="font: 10pt Times New Roman; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"/><td style="width: 0.25in"><b>11.</b></td><td style="text-align: justify"><b><span id="xdx_828_zMeYWXgLEF16">SUBSEQUENT EVENTS</span></b></td></tr></table> <p style="font: 10pt Times New Roman; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has evaluated subsequent events through the date the financial statements were issued. The Company has determined that there are no such events that warrant disclosure or recognition in the condensed financial statements presented herein. </p> The Company has excluded 2,000,000 and 4,500,000 stock options for the nine months ended January 31, 2023 and 2022, respectively, with an exercise price of $0.0004, from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14. Milestone met and completed Milestone met and completed EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end

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end XML 51 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 156 201 1 true 48 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://alzamend.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://alzamend.com/role/BalanceSheets Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://alzamend.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://alzamend.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) Sheet http://alzamend.com/role/StatementsOfStockholdersEquity Condensed Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://alzamend.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://alzamend.com/role/DescriptionOfBusiness DESCRIPTION OF BUSINESS Notes 7 false false R8.htm 00000008 - Disclosure - LIQUIDITY AND GOING CONCERN Sheet http://alzamend.com/role/LiquidityAndGoingConcern LIQUIDITY AND GOING CONCERN Notes 8 false false R9.htm 00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://alzamend.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 00000010 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY Sheet http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY Notes 10 false false R11.htm 00000011 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS Sheet http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets PREPAID EXPENSES AND OTHER CURRENT ASSETS Notes 11 false false R12.htm 00000012 - Disclosure - STOCK-BASED COMPENSATION Sheet http://alzamend.com/role/Stock-basedCompensation STOCK-BASED COMPENSATION Notes 12 false false R13.htm 00000013 - Disclosure - WARRANTS Sheet http://alzamend.com/role/Warrants WARRANTS Notes 13 false false R14.htm 00000014 - Disclosure - OTHER RELATED PARTY TRANSACTIONS Sheet http://alzamend.com/role/OtherRelatedPartyTransactions OTHER RELATED PARTY TRANSACTIONS Notes 14 false false R15.htm 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://alzamend.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 15 false false R16.htm 00000016 - Disclosure - EQUITY TRANSACTIONS Sheet http://alzamend.com/role/EquityTransactions EQUITY TRANSACTIONS Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://alzamend.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://alzamend.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://alzamend.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://alzamend.com/role/SignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Sheet http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Tables http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets 20 false false R21.htm 00000021 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://alzamend.com/role/Stock-basedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://alzamend.com/role/Stock-basedCompensation 21 false false R22.htm 00000022 - Disclosure - WARRANTS (Tables) Sheet http://alzamend.com/role/WarrantsTables WARRANTS (Tables) Tables http://alzamend.com/role/Warrants 22 false false R23.htm 00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://alzamend.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://alzamend.com/role/CommitmentsAndContingencies 23 false false R24.htm 00000024 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative) Sheet http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative DESCRIPTION OF BUSINESS (Details Narrative) Details http://alzamend.com/role/DescriptionOfBusiness 24 false false R25.htm 00000025 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative) Sheet http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative LIQUIDITY AND GOING CONCERN (Details Narrative) Details http://alzamend.com/role/LiquidityAndGoingConcern 25 false false R26.htm 00000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://alzamend.com/role/SignificantAccountingPoliciesDetails SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://alzamend.com/role/SignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative) Sheet http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative) Details http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty 27 false false R28.htm 00000028 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) Sheet http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) Details http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables 28 false false R29.htm 00000029 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative) Sheet http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative) Details http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables 29 false false R30.htm 00000030 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://alzamend.com/role/Stock-basedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://alzamend.com/role/Stock-basedCompensationTables 30 false false R31.htm 00000031 - Disclosure - STOCK-BASED COMPENSATION (Details 1) Sheet http://alzamend.com/role/Stock-basedCompensationDetails1 STOCK-BASED COMPENSATION (Details 1) Details http://alzamend.com/role/Stock-basedCompensationTables 31 false false R32.htm 00000032 - Disclosure - STOCK-BASED COMPENSATION (Details 2) Sheet http://alzamend.com/role/Stock-basedCompensationDetails2 STOCK-BASED COMPENSATION (Details 2) Details http://alzamend.com/role/Stock-basedCompensationTables 32 false false R33.htm 00000033 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://alzamend.com/role/Stock-basedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://alzamend.com/role/Stock-basedCompensationTables 33 false false R34.htm 00000034 - Disclosure - WARRANTS (Details) Sheet http://alzamend.com/role/WarrantsDetails WARRANTS (Details) Details http://alzamend.com/role/WarrantsTables 34 false false R35.htm 00000035 - Disclosure - WARRANTS (Details 1) Sheet http://alzamend.com/role/WarrantsDetails1 WARRANTS (Details 1) Details http://alzamend.com/role/WarrantsTables 35 false false R36.htm 00000036 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative OTHER RELATED PARTY TRANSACTIONS (Details Narrative) Details http://alzamend.com/role/OtherRelatedPartyTransactions 36 false false R37.htm 00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://alzamend.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://alzamend.com/role/CommitmentsAndContingenciesTables 37 false false R38.htm 00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://alzamend.com/role/CommitmentsAndContingenciesTables 38 false false R39.htm 00000039 - Disclosure - EQUITY TRANSACTIONS (Details Narrative) Sheet http://alzamend.com/role/EquityTransactionsDetailsNarrative EQUITY TRANSACTIONS (Details Narrative) Details http://alzamend.com/role/EquityTransactions 39 false false All Reports Book All Reports z3723010q.htm alzm-20230131.xsd alzm-20230131_cal.xml alzm-20230131_def.xml alzm-20230131_lab.xml alzm-20230131_pre.xml ex31_1.htm ex31_2.htm ex32_1.htm http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "z3723010q.htm": { "axisCustom": 1, "axisStandard": 15, "baseTaxonomies": { "http://fasb.org/srt/2022": 1, "http://fasb.org/us-gaap/2022": 421, "http://xbrl.sec.gov/dei/2022": 31 }, "contextCount": 156, "dts": { "calculationLink": { "local": [ "alzm-20230131_cal.xml" ] }, "definitionLink": { "local": [ "alzm-20230131_def.xml" ] }, "inline": { "local": [ "z3723010q.htm" ] }, "labelLink": { "local": [ "alzm-20230131_lab.xml" ] }, "presentationLink": { "local": [ "alzm-20230131_pre.xml" ] }, "schema": { "local": [ "alzm-20230131.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 353, "entityCount": 1, "hidden": { "http://alzamend.com/20230131": 36, "http://fasb.org/us-gaap/2022": 62, "http://xbrl.sec.gov/dei/2022": 5, "total": 103 }, "keyCustom": 46, "keyStandard": 155, "memberCustom": 33, "memberStandard": 13, "nsprefix": "alzm", "nsuri": "http://alzamend.com/20230131", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://alzamend.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "alzm:MortgageNoteReceivableFromRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY", "menuCat": "Notes", "order": "10", "role": "http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty", "shortName": "NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "alzm:MortgageNoteReceivableFromRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS", "menuCat": "Notes", "order": "11", "role": "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - STOCK-BASED COMPENSATION", "menuCat": "Notes", "order": "12", "role": "http://alzamend.com/role/Stock-basedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "alzm:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - WARRANTS", "menuCat": "Notes", "order": "13", "role": "http://alzamend.com/role/Warrants", "shortName": "WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "alzm:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - OTHER RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "14", "role": "http://alzamend.com/role/OtherRelatedPartyTransactions", "shortName": "OTHER RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "15", "role": "http://alzamend.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - EQUITY TRANSACTIONS", "menuCat": "Notes", "order": "16", "role": "http://alzamend.com/role/EquityTransactions", "shortName": "EQUITY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "17", "role": "http://alzamend.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "18", "role": "http://alzamend.com/role/SignificantAccountingPoliciesPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "19", "role": "http://alzamend.com/role/SignificantAccountingPoliciesTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://alzamend.com/role/BalanceSheets", "shortName": "Condensed Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "alzm:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "menuCat": "Tables", "order": "20", "role": "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "alzm:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "menuCat": "Tables", "order": "21", "role": "http://alzamend.com/role/Stock-basedCompensationTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "alzm:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - WARRANTS (Tables)", "menuCat": "Tables", "order": "22", "role": "http://alzamend.com/role/WarrantsTables", "shortName": "WARRANTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "alzm:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "menuCat": "Tables", "order": "23", "role": "http://alzamend.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)", "menuCat": "Details", "order": "24", "role": "http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative", "shortName": "DESCRIPTION OF BUSINESS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)", "menuCat": "Details", "order": "25", "role": "http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative", "shortName": "LIQUIDITY AND GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-11-012023-01-31", "decimals": "0", "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)", "menuCat": "Details", "order": "26", "role": "http://alzamend.com/role/SignificantAccountingPoliciesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "alzm:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative", "shortName": "NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "alzm:MortgageNoteReceivableFromRelatedPartyTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2023-01-292023-01-31", "decimals": "0", "lang": null, "name": "alzm:LongTermDebtAverageAmountOfOutstanding", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "alzm:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": "0", "first": true, "lang": null, "name": "alzm:PrepaidClinicalTrialFees", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)", "menuCat": "Details", "order": "28", "role": "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "alzm:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "alzm:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": "0", "first": true, "lang": null, "name": "alzm:PrepaidClinicalTrialFees", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2022-06-16", "decimals": "0", "lang": null, "name": "alzm:PrepaidInsurance1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://alzamend.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2022-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - STOCK-BASED COMPENSATION (Details)", "menuCat": "Details", "order": "30", "role": "http://alzamend.com/role/Stock-basedCompensationDetails", "shortName": "STOCK-BASED COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2022-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "alzm:ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-012023-01-31_custom_EmployeesAndConsultantsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - STOCK-BASED COMPENSATION (Details 1)", "menuCat": "Details", "order": "31", "role": "http://alzamend.com/role/Stock-basedCompensationDetails1", "shortName": "STOCK-BASED COMPENSATION (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "alzm:ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-012023-01-31_custom_EmployeesAndConsultantsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-11-012023-01-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - STOCK-BASED COMPENSATION (Details 2)", "menuCat": "Details", "order": "32", "role": "http://alzamend.com/role/Stock-basedCompensationDetails2", "shortName": "STOCK-BASED COMPENSATION (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-11-012023-01-31_us-gaap_ResearchAndDevelopmentExpenseMember", "decimals": "0", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-11-012023-01-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "STOCK-BASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-012023-01-31_custom_StockBasedCompensationMember", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "alzm:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - WARRANTS (Details)", "menuCat": "Details", "order": "34", "role": "http://alzamend.com/role/WarrantsDetails", "shortName": "WARRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "alzm:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "alzm:ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock", "alzm:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2021-05-012022-01-31_us-gaap_WarrantMember531509750", "decimals": null, "first": true, "lang": "en-US", "name": "alzm:WarrantExpectedTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - WARRANTS (Details 1)", "menuCat": "Details", "order": "35", "role": "http://alzamend.com/role/WarrantsDetails1", "shortName": "WARRANTS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "alzm:ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock", "alzm:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2021-05-012022-01-31_us-gaap_WarrantMember531509750", "decimals": null, "first": true, "lang": "en-US", "name": "alzm:WarrantExpectedTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative", "shortName": "OTHER RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31_custom_PreIndMeetingMember_custom_AL001LicenseMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractualObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "menuCat": "Details", "order": "37", "role": "http://alzamend.com/role/CommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31_custom_PreIndMeetingMember_custom_AL001LicenseMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractualObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-012023-01-31_custom_AL002LicenseMember", "decimals": "INF", "first": true, "lang": null, "name": "alzm:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-012023-01-31_custom_AL002LicenseMember", "decimals": "INF", "first": true, "lang": null, "name": "alzm:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2023-01-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - EQUITY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "shortName": "EQUITY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2019-04-292019-04-30_custom_ALSFMember", "decimals": "0", "lang": null, "name": "alzm:SharesPurchasePrice", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-11-012023-01-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://alzamend.com/role/StatementsOfOperations", "shortName": "Condensed Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-11-012023-01-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2021-04-30_custom_SeriesAConvertiblePreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Statements of Stockholders' Equity (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://alzamend.com/role/StatementsOfStockholdersEquity", "shortName": "Condensed Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "AsOf2021-04-30_custom_SeriesAConvertiblePreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://alzamend.com/role/StatementsOfCashFlows", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": "0", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - DESCRIPTION OF BUSINESS", "menuCat": "Notes", "order": "7", "role": "http://alzamend.com/role/DescriptionOfBusiness", "shortName": "DESCRIPTION OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - LIQUIDITY AND GOING CONCERN", "menuCat": "Notes", "order": "8", "role": "http://alzamend.com/role/LiquidityAndGoingConcern", "shortName": "LIQUIDITY AND GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "9", "role": "http://alzamend.com/role/SignificantAccountingPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "z3723010q.htm", "contextRef": "From2022-05-01to2023-01-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 48, "tag": { "alzm_AL001LicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents a l001 license member.", "label": "A L001 License [Member]" } } }, "localname": "AL001LicenseMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails", "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_AL002LicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents a l002 license member.", "label": "A L002 License [Member]" } } }, "localname": "AL002LicenseMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails", "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_ALSFMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents a l s f member.", "label": "ALSF [Member]" } } }, "localname": "ALSFMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_AdditionalAL001LicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents additional a l001 license member.", "label": "Additional A L001 License [Member]" } } }, "localname": "AdditionalAL001LicenseMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails", "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_AdditionalRightToInvest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The element represents additional right to invest.", "label": "Additional right to invest" } } }, "localname": "AdditionalRightToInvest", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "alzm_AdvanceFromRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The element represents advance from related parties.", "label": "Advance from related parties" } } }, "localname": "AdvanceFromRelatedParties", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "alzm_AultGlobalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents ault global member.", "label": "Ault Global [Member]" } } }, "localname": "AultGlobalMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_AultLifeSciencesFundLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents ault life sciences fund l l c member.", "label": "Ault Life Sciences Fund L L C [Member]" } } }, "localname": "AultLifeSciencesFundLLCMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_BitnileMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents Bitnile.", "label": "Bitnile [Member]" } } }, "localname": "BitnileMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_BrandDevelopmentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents brand development agreement.", "label": "Brand Development Agreement [Member]" } } }, "localname": "BrandDevelopmentAgreementMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_ClassOfWarrantOrRightExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents class of warrant or right exercisable.", "label": "Number of warrant exercisable" } } }, "localname": "ClassOfWarrantOrRightExercisable", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "alzm_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents class of warrant or right exercisable weighted average exercise price.", "label": "Warrant exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "alzm_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents class of warrant or right weighted average exercise price of warrants or rights.", "label": "Warrant outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "alzm_ConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents convertible promissory note member.", "label": "Convertible Promissory Note [Member]" } } }, "localname": "ConvertiblePromissoryNoteMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_DescriptionOfLicensesAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents description of licenses agreements.", "label": "Description of licenses agreements" } } }, "localname": "DescriptionOfLicensesAgreements", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "alzm_DescriptionOfPurchaseAgreementTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents description of purchase agreement terms.", "label": "Description of purchase agreement terms" } } }, "localname": "DescriptionOfPurchaseAgreementTerms", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "alzm_DigitalPowerLendingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents digital power lending member.", "label": "Digital Power Lending [Member]" } } }, "localname": "DigitalPowerLendingMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_DisclosureNoteReceivableForCommonStockRelatedPartyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Receivable For Common Stock Related Party" } } }, "localname": "DisclosureNoteReceivableForCommonStockRelatedPartyAbstract", "nsuri": "http://alzamend.com/20230131", "xbrltype": "stringItemType" }, "alzm_DisclosureWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "DisclosureWarrantsAbstract", "nsuri": "http://alzamend.com/20230131", "xbrltype": "stringItemType" }, "alzm_EmployeesAndConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents employees and consultants member.", "label": "Employees and Consultants [Member]" } } }, "localname": "EmployeesAndConsultantsMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_ExercisePrice1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents exercise price1 member.", "label": "1.00 [Member]" } } }, "localname": "ExercisePrice1Member", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "xbrltype": "domainItemType" }, "alzm_ExercisePrice2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents exercise price2 member.", "label": "1.75 [Member]" } } }, "localname": "ExercisePrice2Member", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "xbrltype": "domainItemType" }, "alzm_ExercisePrice3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents exercise price3 member.", "label": "3.00 [Member]" } } }, "localname": "ExercisePrice3Member", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "xbrltype": "domainItemType" }, "alzm_ExercisePrice4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents exercise price4 member.", "label": "6.25 [Member]" } } }, "localname": "ExercisePrice4Member", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "xbrltype": "domainItemType" }, "alzm_FairValueOfWarrantsIssuedInConnectionWithIpo": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair value of warrants issued in connection with IPO" } } }, "localname": "FairValueOfWarrantsIssuedInConnectionWithIpo", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "alzm_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair value of warrants issued in connection with March 2021 securities purchase agreement, related party" } } }, "localname": "FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "alzm_FinalTrancheMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents final tranche member.", "label": "Final Tranche [Member]" } } }, "localname": "FinalTrancheMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_IndApplicationFilingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents ind application filing member.", "label": "Ind Application Filing [Member]" } } }, "localname": "IndApplicationFilingMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "alzm_InitialLicenseFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of initial license fees.", "label": "Initial license fees" } } }, "localname": "InitialLicenseFees", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "alzm_IssuanceOfCommonStockForRelatedPartyPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for related party payable" } } }, "localname": "IssuanceOfCommonStockForRelatedPartyPayable", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "alzm_IssuanceOfCommonStockForRelatedPartyPayableInShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock for related party payable (in shares)" } } }, "localname": "IssuanceOfCommonStockForRelatedPartyPayableInShares", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "alzm_IssuanceOfCommonStockForRelatedPartyPayables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for related party payable" } } }, "localname": "IssuanceOfCommonStockForRelatedPartyPayables", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alzm_IssuanceOfCommonStockOnConversionOfNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of common stock on conversion of note" } } }, "localname": "IssuanceOfCommonStockOnConversionOfNote", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alzm_IssuanceOfShareOfCommonStockForConversionOfDebtInShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of shares of common stock for conversion of debt (in shares)" } } }, "localname": "IssuanceOfShareOfCommonStockForConversionOfDebtInShare", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "alzm_KeyEmployeesAndDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents key employees and director member.", "label": "Key Employees and Director [Member]" } } }, "localname": "KeyEmployeesAndDirectorMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_LicenseEventsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents license events axis.", "label": "License Events Axis", "verboseLabel": "License Events Axis [Axis]" } } }, "localname": "LicenseEventsAxis", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "alzm_LicenseEventsDomain": { "auth_ref": [], "localname": "LicenseEventsDomain", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "alzm_LongTermDebtAverageAmountOfOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The element represents long term debt average amount of outstanding.", "label": "Outstanding receivable amount" } } }, "localname": "LongTermDebtAverageAmountOfOutstanding", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "alzm_MortgageNoteReceivableFromRelatedPartyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY" } } }, "localname": "MortgageNoteReceivableFromRelatedPartyTextBlock", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty" ], "xbrltype": "textBlockItemType" }, "alzm_NoteReceivableForCommonStockRelatedParty": { "auth_ref": [], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Note receivable for common stock \u2013 related party" } } }, "localname": "NoteReceivableForCommonStockRelatedParty", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "alzm_NoteRecievableForCommonStockRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Recievable For Common Stock Related Party [Member]" } } }, "localname": "NoteRecievableForCommonStockRelatedPartyMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "alzm_NumberOfSharesPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents number of shares purchase.", "label": "Number of shares purchase" } } }, "localname": "NumberOfSharesPurchase", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "alzm_NumberOfStockExcluded": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of stock excluded" } } }, "localname": "NumberOfStockExcluded", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "alzm_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents percentage of royalty payments on net sales of product..", "label": "Percentage of royalty payments on net sales of product" } } }, "localname": "PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "alzm_PerformanceContingentStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents perfromance contingent stock options member.", "label": "Perfromance Contingent Stock Options [Member]" } } }, "localname": "PerformanceContingentStockOptionsMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_PreIndMeetingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents pre ind meeting member.", "label": "Pre Ind Meeting [Member]" } } }, "localname": "PreIndMeetingMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "alzm_PreferredStockSharesDesignated": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred stock shares designated" } } }, "localname": "PreferredStockSharesDesignated", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "alzm_PrepaidClinicalTrialFees": { "auth_ref": [], "calculation": { "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid clinical trial fees", "verboseLabel": "[custom:PrepaidClinicalTrialFees-0]" } } }, "localname": "PrepaidClinicalTrialFees", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails", "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "alzm_PrepaidConsultingFees": { "auth_ref": [], "calculation": { "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The element represents prepaid consulting fees.", "label": "Prepaid consulting fees" } } }, "localname": "PrepaidConsultingFees", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "alzm_PrepaidInsurance1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The element represents prepaid insurance1.", "label": "Purchase D&amp;O Insurance" } } }, "localname": "PrepaidInsurance1", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "alzm_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts": { "auth_ref": [], "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from initial public offering, net of underwriters\u2019 discounts and commissions and issuance costs" } } }, "localname": "ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alzm_ProceedsFromStockOptionExerciseInShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceeds from stock option exercise (in shares)" } } }, "localname": "ProceedsFromStockOptionExerciseInShares", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "alzm_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of assumptions used" } } }, "localname": "ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "alzm_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of prepaid expenses and other current assets" } } }, "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "alzm_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of stock options granted to employees and consultants" } } }, "localname": "ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "alzm_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents securities purchase agreement member.", "label": "Securities Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative", "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_SecuritiesPurchaseAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents securities purchase agreements member.", "label": "Securities Purchase Agreements [Member]" } } }, "localname": "SecuritiesPurchaseAgreementsMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Convertible Preferred Stock [Member]" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "alzm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents share based compensation arrangement by share based payment award number of shares available for grant options cancelled or forfeited.", "label": "Shares available for grant, Options cnacelled/forfieted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "sharesItemType" }, "alzm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents share based compensation arrangement by share based payment award options exercised in period gross.", "label": "Shares available for grant, Options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "sharesItemType" }, "alzm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Options granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageExercisePrice", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "perShareItemType" }, "alzm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term.", "label": "Weighted average remaining contractual life end (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "durationItemType" }, "alzm_SharesPurchasePrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The element represents shares purchase price.", "label": "Shares purchase price" } } }, "localname": "SharesPurchasePrice", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "alzm_SharesPurchasePricePerShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents shares purchase price per shares.", "label": "Shares purchase price (in dollars per share)" } } }, "localname": "SharesPurchasePricePerShares", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "alzm_SharesValueSurrenderForCancellation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The element represents shares value surrender for cancellation.", "label": "Shares value surrender for cancellation" } } }, "localname": "SharesValueSurrenderForCancellation", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "alzm_StockBasedCompensationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Based Compensation [Member]" } } }, "localname": "StockBasedCompensationMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_StockIncentivePlan2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents stock incentive plan2016 member.", "label": "Stock Incentive Plan2016 [Member]" } } }, "localname": "StockIncentivePlan2016Member", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_StockIssuedDuringPeriodSharesNewIssues2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents stock issued during period shares new issues2.", "label": "Proceeds from sale of common stocks and warrants-related party (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues2", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "alzm_StockIssuedDuringPeriodSharesNewIssuesOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents stock issued during period shares new issues one.", "label": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssuesOne", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "alzm_StockIssuedDuringPeriodValueNewIssues2": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The element represents stock issued during period value new issues2.", "label": "Proceeds from sale of common stocks & warrants-related party" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues2", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "alzm_StockIssuedDuringPeriodValueNewIssues3": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The element represents stock issued during period value new issues3.", "label": "Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues3", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "alzm_StockbasedCompensationToEmployeesAndConsultants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stock-based compensation to employees and consultants" } } }, "localname": "StockbasedCompensationToEmployeesAndConsultants", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "alzm_TwoConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Consultants [Member]" } } }, "localname": "TwoConsultantsMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_UnamortizedStockBasedCompensationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents unamortized stock based compensation member.", "label": "Unamortized Stock Based Compensation [Member]" } } }, "localname": "UnamortizedStockBasedCompensationMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "alzm_UponCompletionOfFirstClinicalTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents upon completion of first clinical trial member.", "label": "Upon Completion of First Clinical Trial [Member]" } } }, "localname": "UponCompletionOfFirstClinicalTrialMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "alzm_UponCompletionOfFirstPatientDosingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents upon completion of first patient dosing member.", "label": "Upon Completion of First Patient Dosing [Member]" } } }, "localname": "UponCompletionOfFirstPatientDosingMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "alzm_UponFdaApprovalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents upon fda approval member.", "label": "Upon Fda Approval [Member]" } } }, "localname": "UponFdaApprovalMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "alzm_UponFirstDosingOfPatientInClinicalTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents upon first dosing of patient in clinical trial member.", "label": "Upon First Dosing of Patient in Clinical Trial [Member]" } } }, "localname": "UponFirstDosingOfPatientInClinicalTrialMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "alzm_UponFirstPatientTreatedInPhase3ClinicalTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element represents upon first patient treated in phase3 clinical trial member.", "label": "Upon First Patient Treated in Phase3 Clinical Trial [Member]" } } }, "localname": "UponFirstPatientTreatedInPhase3ClinicalTrialMember", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "alzm_WarrantExpectedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantExpectedTerm", "verboseLabel": "Expected term (in years)" } } }, "localname": "WarrantExpectedTerm", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "durationItemType" }, "alzm_WarrantsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WARRANTS" } } }, "localname": "WarrantsDisclosureTextBlock", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "alzm_WarrantsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantsPolicyTextBlock", "verboseLabel": "Warrants" } } }, "localname": "WarrantsPolicyTextBlock", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "alzm_WeightedAverageRemainingContractualLifeOptionGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life, Option granted (years)" } } }, "localname": "WeightedAverageRemainingContractualLifeOptionGranted", "nsuri": "http://alzamend.com/20230131", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "durationItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r372", "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alzamend.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Schedule of Contractual Obligation, Fiscal Year Maturity" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "srt_MaximumMember": { "auth_ref": [ "r176", "r177", "r178", "r179", "r227", "r306", "r324", "r335", "r336", "r350", "r352", "r360", "r406", "r443", "r444", "r445", "r446", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative", "http://alzamend.com/role/WarrantsDetails", "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r176", "r177", "r178", "r179", "r227", "r306", "r324", "r335", "r336", "r350", "r352", "r360", "r406", "r443", "r444", "r445", "r446", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative", "http://alzamend.com/role/WarrantsDetails", "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r167", "r307", "r351", "r359", "r401", "r402", "r408", "r450" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails", "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r167", "r307", "r351", "r359", "r401", "r402", "r408", "r450" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services." } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails", "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r176", "r177", "r178", "r179", "r225", "r227", "r256", "r257", "r258", "r305", "r306", "r324", "r335", "r336", "r350", "r352", "r360", "r398", "r406", "r444", "r445", "r446", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative", "http://alzamend.com/role/WarrantsDetails", "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r176", "r177", "r178", "r179", "r225", "r227", "r256", "r257", "r258", "r305", "r306", "r324", "r335", "r336", "r350", "r352", "r360", "r398", "r406", "r444", "r445", "r446", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative", "http://alzamend.com/role/WarrantsDetails", "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r12", "r358" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r7", "r358" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r264", "r265", "r266", "r392", "r393", "r394", "r436" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Total", "verboseLabel": "Stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails2", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r25", "r31", "r82", "r206" ], "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Interest expense - debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive securities excluded from computation of earnings per share, amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative", "http://alzamend.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative", "http://alzamend.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative", "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r86", "r96", "r110", "r128", "r161", "r163", "r165", "r168", "r180", "r181", "r183", "r184", "r185", "r186", "r187", "r189", "r190", "r272", "r276", "r284", "r358", "r404", "r405", "r441" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r107", "r116", "r128", "r168", "r180", "r181", "r183", "r184", "r185", "r186", "r187", "r189", "r190", "r272", "r276", "r284", "r358", "r404", "r405", "r441" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r255", "r256", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r36", "r42" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "DESCRIPTION OF BUSINESS" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/DescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r330", "r331", "r358", "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash [Default Label]", "verboseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r33", "r109", "r338" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r28", "r33", "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r28", "r81" ], "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r112", "r113", "r114", "r128", "r145", "r146", "r148", "r150", "r154", "r155", "r168", "r180", "r183", "r184", "r185", "r189", "r190", "r207", "r208", "r211", "r215", "r222", "r284", "r337", "r381", "r388", "r395" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Exercse price (in dollars per share)", "verboseLabel": "Exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative", "http://alzamend.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Number warrant outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r16", "r91", "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r46", "r174", "r175", "r332", "r403" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r392", "r393", "r436" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r52" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r6", "r358" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0001 par value: 300,000,000 shares authorized; 96,427,624 and 95,481,790 shares issued and outstanding as of January 31, 2023 and April 30, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Payment" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r22" ], "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r2", "r3", "r4", "r87", "r88", "r94", "r129", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r292", "r345", "r346", "r347", "r348", "r349", "r389" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r15", "r129", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r292", "r345", "r346", "r347", "r348", "r349", "r389" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r31", "r44" ], "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r230", "r261", "r262", "r263", "r268", "r353" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r12", "r182", "r183", "r184", "r188", "r189", "r190", "r300", "r391" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Related party payable" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r123", "r135", "r136", "r137", "r138", "r139", "r143", "r145", "r148", "r149", "r150", "r152", "r280", "r281", "r320", "r323", "r341" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and diluted net loss per common share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r37", "r38" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Loss per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r52", "r105", "r119", "r120", "r121", "r130", "r131", "r132", "r134", "r140", "r142", "r153", "r169", "r224", "r264", "r265", "r266", "r269", "r270", "r279", "r285", "r286", "r287", "r288", "r289", "r290", "r296", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/StatementsOfStockholdersEquity", "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r23" ], "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r172", "r173" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails2", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails2", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r30" ], "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r30" ], "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r83", "r93", "r122", "r160", "r291" ], "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Prepaid expenses related party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r13", "r128", "r168", "r180", "r181", "r183", "r184", "r185", "r186", "r187", "r189", "r190", "r273", "r276", "r277", "r284", "r342", "r404", "r441", "r442" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r11", "r89", "r98", "r358", "r390", "r396", "r439" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r14", "r108", "r128", "r168", "r180", "r181", "r183", "r184", "r185", "r186", "r187", "r189", "r190", "r273", "r276", "r277", "r284", "r358", "r404", "r441", "r442" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputOptionVolatilityMember": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.", "label": "Measurement Input, Option Volatility [Member]" } } }, "localname": "MeasurementInputOptionVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r125" ], "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r28", "r29", "r32" ], "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r20", "r32", "r92", "r102", "r106", "r117", "r118", "r121", "r128", "r133", "r135", "r136", "r137", "r138", "r141", "r142", "r147", "r161", "r162", "r164", "r166", "r168", "r180", "r181", "r183", "r184", "r185", "r186", "r187", "r189", "r190", "r281", "r284", "r343", "r404" ], "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://alzamend.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "NET LOSS", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows", "http://alzamend.com/role/StatementsOfOperations", "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r24" ], "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER EXPENSE, NET" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r161", "r162", "r164", "r166", "r343" ], "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the nature and terms of commitment.", "label": "Due date" } } }, "localname": "OtherCommitmentsDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r385", "r397" ], "calculation": { "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r5", "r207" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r5", "r207" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r5", "r358" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; Series A Convertible Preferred Stock, $0.0001 stated value per share, 1,360,000 shares designated; nil 0 issued and outstanding as of January 31, 2023 and April 30, 2022" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r386" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r115", "r170", "r171", "r339" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses - related party" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "auth_ref": [ "r90", "r101", "r115" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.", "label": "Related party prepaid expenses" } } }, "localname": "PrepaidExpenseCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r340", "r344", "r397" ], "calculation": { "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r26" ], "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from the issuance of common stock and warrants - related party, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r26" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from sale of equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r27" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r26", "r76" ], "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from stock option exercise" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductLiabilityContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Liability Contingency [Line Items]" } } }, "localname": "ProductLiabilityContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails", "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProductLiabilityContingencyTable": { "auth_ref": [ "r178", "r399", "r400", "r401" ], "lang": { "en-us": { "role": { "documentation": "Information and financial data about the reasonably possible loss or the recognized and additional reasonably possible loss from product liability related to an individual product.", "label": "Product Liability Contingency [Table]" } } }, "localname": "ProductLiabilityContingencyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/CommitmentsAndContingenciesDetails", "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r106", "r117", "r118", "r124", "r128", "r133", "r141", "r142", "r161", "r162", "r164", "r166", "r168", "r180", "r181", "r183", "r184", "r185", "r186", "r187", "r189", "r190", "r271", "r274", "r275", "r281", "r284", "r321", "r343", "r356", "r357", "r387", "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r45", "r99", "r322", "r358" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r45", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r226", "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative", "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": { "auth_ref": [ "r104", "r111", "r293", "r294", "r295", "r298" ], "lang": { "en-us": { "role": { "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.", "label": "Description of related party transaction" } } }, "localname": "RelatedPartyTransactionDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r226", "r299", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r440" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative", "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r297", "r298", "r300", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "OTHER RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/OtherRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r78", "r103", "r449" ], "calculation": { "http://alzamend.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails2" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r8", "r59", "r97", "r328", "r329", "r358" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAppropriated": { "auth_ref": [ "r19", "r49", "r50", "r95", "r127" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies.", "label": "Retained Earnings, Appropriated", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAppropriated", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r105", "r130", "r131", "r132", "r134", "r140", "r142", "r169", "r264", "r265", "r266", "r269", "r270", "r279", "r325", "r327" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of antidilutive securities excluded from computation of earnings per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in common stock outstanding.", "label": "Schedule of Common Stock warrants outstanding" } } }, "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Schedule of stock-based compensation" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r61", "r62", "r63", "r64", "r65" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r74", "r77" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails2" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r84", "r85" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r228", "r229", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r255", "r256", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r67", "r69", "r70" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of share-based payment arrangement, option, activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r47", "r48", "r51", "r53", "r54", "r55", "r56", "r57", "r58", "r59", "r112", "r113", "r114", "r154", "r207", "r208", "r209", "r211", "r215", "r220", "r222", "r350", "r381", "r388" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r383", "r384", "r407" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r30" ], "calculation": { "http://alzamend.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation to employees and consultants" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Number of warrants granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Additional number of shares available for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Number of shares authorized for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "periodEndLabel": "Shares available for grant end (in shares)", "periodStartLabel": "Shares available for grant begining (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Number of shares, Options exercisable at end" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Weighted average exercise price, Options exercisable at end" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of shares, Options cancelled/forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options granted", "negatedLabel": "Shares available for grant, Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate intrinsic value end", "periodStartLabel": "Aggregate intrinsic value begining" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of shares end (in shares)", "periodStartLabel": "Number of shares begining (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r235", "r236" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price end (in dollars per share)", "periodStartLabel": "Weighted average exercise price begining (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r251" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Aggregate intrinsic value, Options vested and expected to vest at end" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Number of shares, Options vested and expected to vest at end", "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted average exercise price, Options vested and expected to vest at end" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of award under share-based payment arrangement.", "label": "Terms of award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r255", "r256", "r257", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercise price (in dollars per share)", "verboseLabel": "Number of shares, Options exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesDetails", "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted average exercise price, Options cancelled/forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Number of shares, Options granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r234", "r253", "r254", "r255", "r256", "r259", "r267", "r268" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Aggregate intrinsic value, Options exercisable at end" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual life, Options exercisable at end" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual life begining (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted average remaining contractual life, Options vested and expected to vest at end", "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/Stock-basedCompensationDetails", "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares issued price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r36", "r126" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r112", "r113", "r114", "r128", "r145", "r146", "r148", "r150", "r154", "r155", "r168", "r180", "r183", "r184", "r185", "r189", "r190", "r207", "r208", "r211", "r215", "r222", "r284", "r337", "r381", "r388", "r395" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r18", "r52", "r105", "r119", "r120", "r121", "r130", "r131", "r132", "r134", "r140", "r142", "r153", "r169", "r224", "r264", "r265", "r266", "r269", "r270", "r279", "r285", "r286", "r287", "r288", "r289", "r290", "r296", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/StatementsOfStockholdersEquity", "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/StatementsOfStockholdersEquity", "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r130", "r131", "r132", "r153", "r307" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheetsParenthetical", "http://alzamend.com/role/StatementsOfStockholdersEquity", "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r17", "r52", "r53", "r59", "r201" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of Series A convertible stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r5", "r6", "r52", "r59" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock for restricted stock awards (in shares)", "verboseLabel": "Number of shares purchase (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative", "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Number of shares sold (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r5", "r6", "r52", "r59", "r240" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r18", "r52", "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of Series A convertible stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.", "label": "Issuance of shares of common stock for conversion of debt" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r5", "r6", "r52", "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock for restricted stock awards", "verboseLabel": "Number of shares purchase" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative", "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Value of stock issued" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r18", "r52", "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Proceeds from stock option exercise" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r6", "r9", "r10", "r43", "r358", "r390", "r396", "r439" ], "calculation": { "http://alzamend.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets", "http://alzamend.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r60", "r127", "r208", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r221", "r224", "r278" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "EQUITY TRANSACTIONS" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "LIQUIDITY AND GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/LiquidityAndGoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative", "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r39", "r40", "r41", "r156", "r157", "r158", "r159" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Accounting Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative", "http://alzamend.com/role/SignificantAccountingPoliciesDetails", "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/WarrantsDetails1" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrant terms", "verboseLabel": "Weighted average remaining contractual life (years)" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/EquityTransactionsDetailsNarrative", "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative", "http://alzamend.com/role/WarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r144", "r150" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Basic and diluted weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://alzamend.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123395306&loc=d3e36975-112693", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(30)(a)(3)(ii))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918703-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919370-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128295416&loc=SL77919784-209982", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r36": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r361": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r362": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r363": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r364": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r365": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r366": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r367": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r368": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r369": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r371": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r372": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r373": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r374": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r375": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r376": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r377": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r378": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r379": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21332-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21346-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(23)(a)(4)(i))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 56 0001214659-23-003850-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001214659-23-003850-xbrl.zip M4$L#!!0 ( -B#;U8[3*@NHPX )J2 1 86QZ;2TR,#(S,#$S,2YX M;=J_X&KE\U6K2Q+RC'QQ#-%Z_!P1Q8UHIQDYF6*(B$9%8I4 M -!'OGX;O,1+("G;$6?I/*1LHM'H&]T-$O[P\_W&DFX1H=BQSUO=D].6A&S# M,;&]/F]=:VU9&RA*2_KYIW_\78)_'_[9;DMCC"SS3!HZ1ENQ5\Z/TE3?H#/I M$MF(Z,PA/TH?=7 M'_#LWL+VESSP[OOW[SO>: B:@;Q?$BM$W>_PX:5.48091K$ 'MN4Z;:1 M@#=9-"$._*;C#R9 <2[H6Q\4AZ F2L%19)RLG=L.# !\KQ<"NK2]UO5M!+S2 MZ=)#2@EK4W?K 7_MA^#P-!D.)"28CJ0D)N<%PAP_S.:?M MTVZ[UPUGZM:W330)?@$SLTUNSQRV?]KM R2R$#QE8X=LAFBENQ:P\-75+;S" MR&Q)3"=KQ+B!TJUNH )LH97KMNV ,X!'!D_XL^T6@[7#@[]]X&9Q1AP++8!P MB?\ ;IB/FP]V!@Z$DI:$S?.6_R/' C@]/"9:81M[BP7^UI7:W+MY-V@Q"COOR2C\1R[('P>%!#D2!M$]E H11@D7PTTJMK6W=-S)#Y[QE58H5F:B02&E57ZI;G#[!:X )[QL2:>+U7 M$SMTDK.2=@@;[Q5Q.6O,,;[<.)8)B=KHJXO90U87.3!BG;PIJ9,XXG])/NH7 M[<0D/]#IS=AR[G(<9#,U,$34('C+UU!7%R[%-J*!!O*' MQ!IXQ[,>J"$LA[H$\5]&VF"NS!:*.I74L71QK2G3D:8U4M83#%X/MO8@V^:E M U4HV*>!B.V+>^^H6.(_I"4^47Z[5H;*XG=)G@ZE2U697DH#=3H8S:>-E+J& MUS84$H9N,]DP'-=F(-N98V$#HS#6"$'$\G^?EK^F7$Z5L3*0IPM)'@S4Z^F" MJV"F3I2!,FJFY4\=AN;(0/A67UH(ZKR!L]DXMK;=2(%_T@F!/2$P^.@WL4C[:9%^DN=SV R::;->3(@' M[07(D.I&K!06@XB%_3HM;#]8).*XM #Q:_* FW$SE<#W3\R\\@?"-.25/+]! M]BX!$@&(%? FK0"^H2J+*PC5?O2&U)/G/Z-I8Y,?O];/VGW.<[&LWZ9E/8), M_\6^86-TEQ1]=8&=T2V*XG7FJ5BZF=)5N[[00,(\Z1A]'#4U@ MKHPIE5+ER MJILI9PO**>E5B+B9_1NAS!>\?BJCG !0K)JJE:[TRD?;3,64*8_B^JD +U13 M+U/VEBZJFJVP/054PH>$(&*U9&K=?956L[40%EEQL:>>B>696K_BT="+YU6H93D&%.J?1'EE!!2EO/&BF M6(N9ID)U+3;=!_=4I+Y31N]%&5DYIW:9LL!BY60Z$<7*:?@^$K;9$AM'^J%8 MZ)D>PZ[YUNB=(27%;JYLBV)_IC60$6Y38[WP#9+\(%-MBE@QF8Y T4LH+R&G MN"N=B$(EX,0JRA3\!7WI1D>K8FFGG*G*!+&>,D5].3TUW8^RKQ+E*ZH$G%@_ MF7(]YQ6D_V^M\/]X;CI'*\G["OV,?_A\WJ*8WP/0"I[=$+0Z;_%OG]OAA\E_ M FLG]QLK!.&H!5^A>WI-2R-8.$2A$R.#)?.5/"!QMH@P<,9.2'R(@&'&I\]B MRTA\'0B[G:=@V=*755F&*04S?1^IP$31ZJ M.$5\2OC+89:YNU6FFAWX2N"F<.BR!UA!=O&])A!<1^-ES'SG^U-#!+8=&0J; M6[X#+2T$&=,*$8),KUEYA39+?C<,)_J\51H:6Q8_U3YO,>+RO8S?2W0&>QQV MS(6W%9LN";[P\K?FZ!:>,]/9Z-A6&-IP2)"!NZ2P"[H<^I(X[O:\Y:/# ")B M+3A@QZC@@#W)8N59=6!5=BTVP2ND =VP!=.Q:YN3R2#)61%0'1C1D.$2S#.A MF4N,&]C)Y35!'E#:$HL!:\$0MQL%Q&WS8G%FZ7;OM/LVQ8L8I@YLC"!Q=AX0 M"IH@%$R)MW>3?!0!U8&1&2(KAVQXHAHU!*S9IBG1YX[4A>3N7I(S([4@V32]!JYN"8@7P]2!#2CX%=N\0HAEHDO^ M4!V(!K+D[=;"?A]EC*T,[4*(.K!PO>5D$6Q)'QMV2M084GXNK W-G7P)>+$_YTG*6:9_(>5X'SY1_HL'%KZ=Z*?MPR"($\-F?8'80W$=/+P-"EF[$Q)N]$) M?]F.XK7-J8]EFV*H\NS%^: >HJ?JEV4OU'#V=,D3+;1*TRI8Z??5HW^N0:F+ MS"%L'_9ZYA'E_0F6*;KS1OCG*O%3D!+0?S5^?=,LS7 .>.4X],2F#!N0@9!) MQ[ 1Q0X_PDZ88OLT[SRS+/BQ&2ME<_U*%MJOLX5R$OE"ZLI3@;J*;0[>5F$' M?U-*70W1D@6:BFKD0V^^9M"_KZZ MX8DV/]>%WT()#!S*2];O\)LYLK M'8K#WFFO*Z@7\W+6YUS@4(MD7)G?4WC*UJDL#W_.L5G,#16J'=\/>%4BC"RY MX'5UB JQ\9!X6N=8L/M"IFRA*<-*1#?8[@SR< QZ\%,HEJ.;_I5#V%I?IUF! MS2'Q 2:Z9Q<6T?K@G]_.^CFJX%P;'T7;$9)A^)HW:2B+]E>,G5A\R]7: BB3P* M5^TD,P($&QXE<_*DD+L"@1R"HB9RF+J\.QWH='1O6*ZY:XKN&SQV739Q[/4" M\;^!NV0RI'FP]\D;7A6I*]5EO W+WT4*N2@-7=M&2Q""$F=_8Q1OD>T=/[@K M_[R)7TBQ'RA _'GLI ?KS8L"U/(3']1-\9$8J"D/7LLE\ZJMS$/8VC^8O7C8 MP4!EX;U_=J<3,[D/*+;?Q?R$\/H&?@_\+?&68Q0_O^^:CPBX .41\A2Y59+( M.>('>_XEN%XRZ^H6_ZK&YS!@,$J\#IM[8+0.GWX/ZRI0=*C*2-6P.J6E[>A0 M[,?>Y@YF+-JW/4KD6QU;04WL647 ]X '%LM"IDI@9(5PS-2.LW0M!)XY+_OO?+Q \/ TBF-GS]T?-<,WA;W M_R*8?(\C1\L9^,Z=.).=F1BHI0&GI=D8>J]1Y3(2#CV>E>?YS)1_S@O6K:[F MSH-N>UR.S!=[BJYP_&]X!$JBNS=$ MH]9P(=BQ^\'!B6Y 6[S"S1VIZR%-,J4+3T@S/:+T:"V2N8B@;.69&:JK_'.H MG05;$Q5P%(>I1^U;[A4UU=[IJ<*$8YN;;-YR8TB=NN&=BD0 ]38]KZ.M>><= M)N(%6U"^!13%+; (M*Z,)C:3S$L@/"G+WW?V@AY[[]E]^^?ERPM'L6\193MC MW#=\? U]Z/@7%<&/_P-02P,$% @ V(-O5@=?.Y1P"P Q'T !4 !A M;'IM+3(P,C,P,3,Q7V-A;"YX;6SM75MOX[H1?B_0_\"Z0)$#U''L[*6;W?3 ML954J-=V;6?/.4\+1:(38F721Y1R.;^^0UE.3%U)V[H4Z#YL8H<,7K:ZIVGW8\V:K<5Y'[#U&'>[D\/3V= M4O9H/3'O!S^UV4I-X-RW_("_2CM[/HO^;;I_<0G]<2'^N[,X1F ORB^>.;EL MB>M&EWTZ/V7>?:=W=M;M_/IU-+0DM:O^^G3IT[XUVW3 M1,OG.\_=7N.\LX7S*AG^2G+:[R#AY(*'\$;,MOR0]L++H,P6XE-[VZPMOFIW M>^WS[NDS=UI;XX<6])B+9WB)Q$]@[_6JEOL'T$ =05A'_+$S8."0@#3L]N#A MY64+&JU >N_\K+N1_5>ID?^R!L?D1/A5"W7VO.Z5Y0H;S1\P]GG1]5,;EX!C M:GF8^@_8)[;E:H%*[7DQT?V=QG]H\'YCH0 M98S? ^*_Z"#,[GU\I .+/UR[[$G+A(E.Q\$UQ-SVR%IP,UE>!9Q0S MQY78Z M#JX1 1(;3N7'S-/)B,5XR&SC[#+GB7 W&C>*3HRCD.^JF'UQ9Q MC."R8>0K'NNYW8Z# M[1?+\\#M"JT6;W>6WW67!5R$6[;2=*+4^3@XA7,3/XR[X"\00,0 A3Q9 M86PK=#T.QLT,0*/I;5OH((?91(74[$SKWD0D3? MPU#+(JJ+TVK0]265&K,5[:W2^;CQ6PU8>NO28Z0:.&4!)>:Y0^Q;Q.5C82>? M/.*]\MXL(>7FP;K0=>54$,VB2Q\4SF(RJLV:=3DX5&YUT5J1FCU$5:Z#,CN' MR"QU%E(=)TJ]JT#:/0QJMTJLO<.P]JK$JNS*FF*.FYLHNFM&\U*P%#ID5OL* MUKVZW.XEK/2<3Y%T=0E5(5:V^QZBREKIZT)7EY"'V+9<.W##0#*"SU(/_.P# M9NQLY0C@JB4?G_BB<52%ZZ*V*-D%PM#P:]2R-"3I=1T)40]@O&[$AY! /F0( M#HHZHTUO=')+K0!2;.S\M*V%;1&[S)90NJ(8QV)5KVUA,RRY+2U^%];= MZ^ MMZQU!QCM=;#K\^TW@N->R&_TQ?=-CA(E+%O9KG6'W?"*WZ-VL6:=6K"*CY88CRQ^ 2[[ R K+L]DZ*':/Z[;C.7W/1LQSL'?9>@WWEF=+_I(L M@$8M.CQ8K4(Q;>![M>V_]-@JS]216=D^JNQ2 BA:Z F3^P<_1%\/A7+"O,V7 M%9U0J;,:?;U:Z=.P0G/)TZ1+DZ#S!A'48$KD8E16W&Y*4,NP]O^ X[,UAK1Y MZHH-)>J(F+L64_L8Y_I_7J]FQ*E,_R]6N$D$C8AU1USB0V)=&);2VM8T>#=; MDWQJO8C-O>(D+*-]W8,[V_KQ@9ZK<),<:AC@!=M9,:LX5EZ?ND>[,D7%BC>) MIAVUE 9\H\9*!@,Y5#7(\MGWOB4)2&M;6P:[Q&!3)X14L%Y,;5RW_^3<<-G)G;'*78, MRZ.$WG-(=8-5$&(>XB6Q24[BJ-)7C<'W]0\J=4,TB;Z=I N6NSK)37'/NE,& M5=VR\U ]QFIY-1?3ALP'M9ZMW<$Y:6S\99U35P<@ZN+,77>E?!!)#30- MRCN'>.UAFTB/A*=4K:56#8C>A[&2IG232.FOF.>3/ZS-\X!#?.$6"5393"EWK+KT<3)^R>9K$Z?S!\O!5UBD,*?7PC/9U5VD.9B_?$$VB#"*W MAP'H$&]^FC2ZY7,85P0GZ['2);.86N#5UZY7"8O#U=S3Q-\MQ=T"'(27@H M"#>>L6<3_K9GDL]I1M>&+MSVXS37/.7?EB6Y%P70ECL-[EQB3Y:0TX RH.QD M>4O!I$\>6,7CVT7*YC'?U8IP<6BM^+1US[ PDG$?5XG7:^B"4,$M2C9,\^*# ML%/L@L2'EBA[XE+_8:3D%8@6G\.Q<"? _XH!'YG]NS:&Y^ WUQT-T M,S''-V@P&0^,V;C,LI/2:;H2\D]QY'/S9FQ>FX/^>('Z@\'D=KP0X*>3D3DP MC3)-KGV;]*XBW;.X(N/)PD S8V"8W_I7(P-=3V9 P=>OX$+SQ63P[[_#'T?] MA3%$T_YL\5N)BFF=NRLIU8TK-9T9T[XY1,:O4V,\-^:A>TT6_S) M]O9S!"D MS>?&HDR>BD[GE33H)?Q+V+Y]U9^#X8$.H49?C.L2 2=.\)40GL<1_M*?S<#[ MRS2AV@&^$LQW<9@;UB4?1@L /N\/A#W+A*]RLJ\$_GTAD*Z_4>S8TC@J6U-&=0M')1EJ9RNQQ>/"N3KW$;*H\\52AG=HI MPY)"B9DT:QZJ G_&8<02X,3$N9V6J@"H?B"QA#DQE>:&^2H4T3NE6%(F,>%F M+$+0220/O0HL4R/MPXLEI1(3<26W 8>)J=YGD=_KN$6 \$H#:"D>BEMXQ'*O M<6I9<;-5G=6\[OU-%4/+F^[YBC=ISSS":E+P_NCE=?F.L].R[JU2'5XRE6@> M):$6FB<%YO6INX*U!TW%)JBBAKD9Q;!R#UR1(2C$KEC;NF]'W#=PI:K7.$VOK[*5H!7FJZOL')!4T5M-;.KKU*=%+ M5T)Y:_I-B5Y]2N2/F//$TKM8F4H&2-:K#23PB:7VVUY'!2,@\X4'$L;$RCF! ML5P7W^]=!Y(*B75R40FA8E_1>"."I%=B<5RP[52!3^WSA@1)I\0"6$VG:HC2 M>(F"I%1B6D^IJF2K$B4SXC\1).&;_P)02P,$% @ V(-O5GP/+_,A'@ M#?L! !4 !A;'IM+3(P,C,P,3,Q7V1E9BYX;6SM76USVSB2_GY5]Q]TOJJK MV:IS;-EQWF9R6[(D9U7K2%I)SNQ^0E,6W!D *)$!' M^V$VM@&PNY]& ^AN-'[[Z]/*[3PBGSC8^WS0?7-\T$'>$MN.=_?YX&I^V)OW M1Z.##@DLS[9<[*'/!QX^^.O__>=_=.C_?ONOP\/.A8-<^U-G@)>'(^\6_]H9 M6ROTJ?,%>!\$#^71T]./'CS<>?K1^8/\[>;/$*[D!YX$5K,G+:,=/ MQ_'_HNZ_N8[W_1/[SXU%4(?*RR.?GHCS^8!]-_[LC],WV+\[.CD^[A[]\^OE M?'F/5M:AXS&Y+='!IA<;I:A?]^/'CT?A7S=-=(XJ?O?</G]'KLV M-4C#/]9.\%R&0KBW>DK[%KF_\\,&PFM^=KXGB(".GB M=E)#UZ5#0; I##W/_H+I4M;'5-5]3T2:J)\B-)T[S[FE,\T+>LLE7GL!_=(4 MN\[206)493JKH7., ]IRB9Q'Z\9%%]BGZ_8*>Z&RSY!+M+,<>/CT@CR!"$9U0 ^?WUSXS=3U") QWF3%4S70JE$.V0-ILET0_&UH^ M\5SG=E-#V^^6[U.U$THMVT[-UT/))]5E03]"K*74:V1%H,9][@ % MEN.2,9-3X#RB2OM>:)!Z]\%E22\[3@/6+/[T3N8L,T:SN^:R&.PZ;G/66A*: M"D,USH,T.KN,6>LJ)#M/I'HW06EW-U*[3=)ZLANM)TW2*JW*)8=1NS>15%>@ M>2VT"!42:M_ N;6M$V?1G42W5IK-ZBLE)ON:9KIKQW/8>;CDOZ8HAL]!=1D(7M#.1M0-N(; M. %K',?KNYU#%MQ?,SM+_QFWK(N0XJANBJ 32L5+&"ZDB(Y/SP=V)^[MON''Q,L6"RQ(+L)_76K)1 MMUN+W(0ZMR:'=Y;U0/7WY.0(N0'9_(:M5R>A%L>_N'ZAFHH,C>@_7_!QK1OD MAI^]CAL7M3W22W7HPI*@.&Z7I7:K,3U_0W<\426M860=/BWI/H7JV- -OT8M M#+IC_]A0=NOCE5"4L=@PEX.D;"DA!QWLV\C_?- ]WM+B8JIYGP\"?UW .KC'OO/G=@LO@B[; MKV60%9*O>C^1]V&QWQ0",$#$N?.8!A4 P'KQ.YDK?4G:04MGTBP9$;(N.T.B M/N;B(T73F,$AU;"526?@BMM]KVXML,@?);!HG.QJ,F MRP.$W)D!R,GO%#B=VH14J3W".V,0$JU20(?V(2.Q/KTW!A6IQ8G7JWWXR"Y+ M'Q*1AJ,,6_2CWVN*0@AN=J4B$&_!",1VE Z^[6S':2:2(GGW*\7+F20OR?'^ MQWK Y-=.-&R*M7U891]6>75AE4C/6=(9]L)4&;G02G&WEH17>#P;%&+)D"GR M[ /--0=:N++&,@R8%V]1 4PKHBZ[@E=/\ 7P-<81!KK&/R(_<*@=D(RNL-YR MG:_U[$OY$P-7X<(X8Y?84HO"8+FF-W M'IS VVPP,Z$HO-/MNWU>\-]50#) MQFT 2O@.\SXWXT$HI-BX2'"H*Y&O>;#VV:U=NJ'$4?!FC'Z$?^%Z!R2ZFX^5 M-!?&A8H!TB/MJPY@IG];$2QB0W7\&#J;,HKR!2?P$XAMJA)[:DU5\ MLH?4<68"/'@^H@<3E(,E.Z)";9WJT$I9 ) MXX+$/(T*_S8)B[20X1/REP[A!?5+#V4NK#MQ)!%C5I/"B9<(V>2"LI<@9D/+ MR(L4$)AYDKW-A:@L$Q J'S4L4:>[+%&G9F-2@@=>2-8H:QBID1ISR!G+7&!W M8\D\9SI/2:,@#0DKDR4"-G.TI"T#ARWIP>2V9_][3:(B%M56Q-*?::MV[, M MJ#A5'3& T69$LSO])7Z ;H)X70&,>+7!S$5W1YY #$US MQLCI:4V3W5SXE7$'*H*V*P'J N*'49;NY4V6,G0Y-1Z M!G(ATY9/.(*YP%5A!(1(L0.I!%V"(VV%D5X-9%)'W:XV+Q/=W8V\)5ZA2TPX MAC/5S%QL0&I!P1MPO2#_ZDDJ(_^=9$8^&Z83CM/,[0+^ RDI%MZSBE<.85G< M:Q^Q'X;S_FPT78PFX\[DHG-^-1^-A_-Y?<0*GTQ)T?LA2^_EZ!]7H\%H\:]. M;SSH?)F,QE\Z_3RU%_-*Q1X*5?4TGRT3W.\C&>+(:=V; _''WKG5\..Q>3&07@ZU>J/_/% MI/_W_Z5_O.PMAH/.M#=;_*L^ODJ]M9+BJ9OE:3H;3GNC06?XS^EP/!_.0]V: M+/XVI*Q=S69#!ME\/ES4B)+H0984 R]/I-FC=3+O.22HOTL M2SN;@Z/%5ZJKD?I2H\@,S'!.-B1=\_25%8VYQG%^= MSRF=;/X/OPUK5=]RC[^DR,ZMD8*EIO/+9KPZ;SR6>!8FQ4W9A;/S2S1:C;Q4 M>"'4F16]NN=RL1@W0)__P3(KD MW +*->\-\%'N,9H4+[EE%CAS='Z)Q^N\#%@C0Z6?J$GQE%M^.>>29ODJ]8!- MBJ?<$BVTO/%PFFZ7]RAKMN.NF4"WOM/AT])=4W&Q? =FT-:!%2GM)I]_4\@E MY[HHN!BD[ N:G/?+>V2O732YW9$3T4UXQ=\QYB:]:A7+1@EJPCU-G5/6.HZVU13Z07I65B0NY EWS@S'1_\15BDFNFZRU\1 MB#SMH-4T;+64MA^]%3NAUK9KBX;7%26O^?2@3C:06BDN,W'%%? V= *) M*H5M7QN0?$:-,[G1BI_U%/>8D;J+LA_.G[=MIM8S^UWOA^7;F91W,O*B?+C? MD7-W'R"[]XA\ZPYM_C[UG27/W= H':]-Z?0)$5R]]&3^[/Q =LI[F@L>EDR4 M*/02:YGF R9A9)\CC_XCF+J6M^5+PFDJV5VW1S1/)MG22:0=GE+#&.//+ 4M MZ*PL(3KC?9%0QLCY<_(O?-=BF3$,\!26@2];&JFLL S:O:1,NL"C4]16C^^N M@LAAS,QUONT&CLD.MAH ;+0R:8\R?^G]KD%_+A]-#G# M./, EZ#<.+.VH&-/;A/[=OY:!31O];+$%8%!%9X^Q9VU_D[0-PH*E M90?2LW;Q<<&[L63>&J8+7I-7OQI5H.'ZW!L'S'3M+^\M@GIW/@HI$Y3F%O33 M%1JJ.-UP2=;,L\'[W!.3EFXMJ27:JBKL4TOVJ27[U))]:HF*5 9-ST8H264P M\_6(A@H0O],#W$ZN?WG.5*<2M*,L^.O!M( QXUQ>PM U%+FFQYRX^F5X:W7D MD@+\PZ<2L5UO;-5BI/O=(P[M2XN65(C\HSEN20? UA@?R5<-$&>[81 M?2F>C#M\]5V+D,EM3/S$#TE/):F\_)'$?R5=&-A*P[41[>J,0BJ@^'V"2QRI M':NJ&.<>1;F-DUO^BRRLMUSG5N%6DBT(I429N2:SLF0NVW.OL>;*(92X;?]R MH55K+0&YA+-M)*-EDD\8K4X@EFR,/M!1ZCUPYQUS> MV7"3764N+,O]^P2X=QG>!Y9@6[%$78_>.O4T$;D%G[?%5E&)\YY/N%C]"(;I5\1((& M];3HTWLMK20QXW)N:IF< ^?1L9%G:["ER4_O=;22Q"1RBII].HH7&#XI#@Q+ MO]VR#0R?: H,;QQC<^0_.DL$8.R&'P]3^&=HB>\\YT\*<9A,VLD?F!D0N?F"DQWF@HJM_$ITU!6GE9E>VHI$4-\;9T2_(0[[E4K)[]HH*E@11\JPD MB%+=K]^V!T=YAB HW^JK6QTM_\@NWAW$+'"R[J3Z7W>+#$X#<#:S=RXC! EO MO3EG=W[J_6GN=3;Q&5YW4==]DO<^R7N?Y&W> 7R3GL8_<:=;&7#$KB?%NT@8 M!NW_9+-JS?\BHANQO;L4W[W*;_[E-]]RJ_)*;_F):;FR /UV>R4WZ9=0R53 M?GE.FU-]?KO]I=@*EV*U%=UI_W7&_:58_:? ]FN1D1N8_:7872[%:@K4F7$K MMI:@'@#=%/FWV%]9]+1."0D.C)>W+736Y?72M ME7)/N(E)!]>WJNYD0/"+'UAVJUG4]/J#R6(&*8:D^T';3;)7F>1>S_Z@4F+[ MF6' [A/;S=PB[!/;#4QL!]:N*\]:83]@":'A*3%G:;C+F63OZX\M2'8NRP^$ MT$?%;I$*L'!I[QZW! PQ%Q $W>/V55P8KQE?\7I/>NO@'OM,#W?P7Y?]U'6W MZ2!P[7FF]8@(TCMS R/H MBHI U5\XI7JFSK1@(>,UWZOZ[7I11F^VY=E DDECGV%;X^14:S97WQ,ZKCM M!'_L]:E3;4(R+BA5F5-6R)#0]9O]NP9M2PZ_UR^.6(SS:NXZ=[XA0NUXS[-? M2F9B]JO$NU_1WK$^$R=+P5XO=Y,<&,AJW=Y>FOW?$7M@D+:)'K6;(08W_3U+ M:O&M9;"VW+H*^"JG\96JOT&RA2;(>SU%!S;/9'+?OGN;+2[P>V\VZXU3SQ,: MM"YEO0Y75!Y^(K&,I::1U'.AX26$G";)KD*[?\_,4@-2?)T_YSG;L?[ KM\U MO"B!*O4L6:A #9K&5R]0S#P_(Z.6CQF;R:%(@V2VITKP,LW#K,H25+LMLN/' M]*2@U*D=RO10A)!)"2]M5T23DVM:K:S-7GU*$M'EWW@J:&K4ZW]J3 06FQ--#W)I!"?),HA.G?"MI@H, M&N%)L@PN//OJ1CK/:/N21_N21_N21P:4/&KZ9G_)DD<-%M167?*HZ6>O2I8\ MXKTQ=:;-G=5W+4(FMW'P:.+/6 0LM::\_)'$?R6<^&>EX73=16S4J5]=,I#2 M:/,\%;*2"*.65(]$SY]7$[)",,[OO='-GF='RIF@F 7%8=!%/7\*T*6$H'I; M#IQL"Q4PD_L@L$S 05C!R*];&U0*"=P -Z M,7U =@#(9:+;3XIS5@+@7KM9 M$'GJ5Q%@WI![\(72 8\*1F27O1P!TNEE9\+TLDY75X+9RQU@B>2P@K::@KP; M2D2)6)EVYB1.@6+/!D(+.34_26E#]O"/M1,\,[."/58@19!NQ.^FSRE=C ( M%8]G@XXN&3)%N0Y %,@>ILRU4Q3 MQ@=_3A2>U0U^+/0KLM@&BZG6R'M8!^*:]7 /L]<:$:<&W0XO(E5DTGA]]"PX M0H&+\3%WP5$+DI=:>M&:)-=?5PJ3-@95P%+H(>X^60MPQ/JN/M)N00XM55F]@EPIHK3R*W;SY$ MU^8W_QHU#S_5FW^*@]:Q"^>ETD-Q@@IK6M!2VW,]PE@)CV!(M+J]@X4I+]D] M4+7LH>PHY@)7E1D)SV.34>!)<(]\Z,F2.,([9CRRAZ^+0\3OLB'BR>)OPUEG M-KSL+8:#SK0W6_RKLYCUQO->?S&:C!.AXY>1-860 <9SH$L_#W6I/;S\<@=% M[AT:Z7(@I88S)E@M"S!8KZ."%(V/>ZM#\!&2R$,G#LGL-PI_H'\2Q3OZ3BWAL'VFD+D>X ML*^'-4JUT>7SEQ-IGE30[&A;$YA7>W*;*+;(7_"!YJ]B;>>*PJ!\A.1S;?3 M.<:>M?U-DG51#*;T0'HV 'Q<\&XLF;<1T 6OR5N(&E6@T:W$'"W7/A4G(M.U MO[RW".K=^2BDC/\&EZB?IJU%U>F&2[*FV@9#^P]*L3U C\C%#Z&628$CZ*5K MCZ( &QG.0&BTK8_A#9\1(6MD#ZAJ>7?1>Q#1;:#0T\GQ= G[-EZ.8$X:5<-PV_5U0)CAQVAO4X+; 2)+WPG3V":WB=^7=C)" [4,W2K< M&7)%!4+J6W(2-!/]QX>7"=Z3OZ" MFC6!<.$.C?M]2@A90+7R,!4@[:L']G&?! -,* 63VRFE)\R3Z]/.E#IWX3N6 MRP6@U!B-WR4I@4EY1B"8*M?SY,#$;EB[*#J.AE3&U$7$"A&2Z=YXEF=)<*1Y M@'!YUP0NY6:.3/?&BSKMB@O$ X3+ASK,FFU1"^OC1QGSE6U+-Q)FBQR@&#Y! MU;5PQ%-PX2/FJ1EY4Q9 .JVP>D@/1!=(P[&IP Y\7FBT-'1\H)SX<^0_4H[A M>XG%+5MS$@8Y:,:S*P<#\P/&Q,%GNRTG1 \C!2G4QOQ$K(CX:$U*YXMN-#Z MH5I@6_MMUGV(>Q_BUAOBWI_]E9[]=;A@]F?__=E_?_;?]8QJ^GFID&+59J@& MGTK3U3L5.%6:?(!:^<'?='&+B ?-NF+!3^FF@1H]ZX[=1\7/EAL\3ZWG\ PR M\<8HF%LN(I/;F+DW4+Y.N5%TU<>LLE&MRIYJCP!TTS^9=!^K$7FY] 2E9 IZ MM0T?&78:6B-&3$26&Q-Q@1 $0;YAVZ0.<"#AB&_2J1*]ME"^.-C'K"]E^(^K MD;'UP.(WOL)[5Q(N$Z"Y[LI?(3WGSR%UTO6]"CH9XQGAP@*6[@+%8'R!KI?J M@TG&)9^?RG@6M*&#TV.CWI+0269@T"J?.TI-54)6KZY MPX]'-G*B64K_L9V<](?K2W1GN4,O<,#JR+15KE$;%L BNL$IT8RP(U+ W3QM MDF[1\-+$D1@&**QWI5$M42-7@])2;SAB/+\01#0W#1HWUI V8I ZT-HJSE96 M5V7YHWDRY1,+B?BCZH1P.MF^N/A&<"36]RM#;L).4Y ^Z(+,!6/UVOWZ^[Z,+V)!V(5P!BYG5$-GJ&^WOB1+)&[ M(M5,5^D__J0H?/PK03 D^S-M3MP!N@E&'@G\M=B#6]2V1>L-S&H!(&;@,;96 MPN?JX1YZEAJ.F'EXY%DU:8E1!XO)"\W.T#5ZG.YC[Q'Y@4-G_)1RXA""_>C5_II&=#;@D#_"11]MB\PT1EO/&7V52C5JTO!0P5U#I2;/H158K MTTS/"E(DR4)9F[M>5!&WR2M#24@:70D"BMP[NL>_\N4T@+JSOSNEWW=5TPBN332K# H28-MN4 M)GIJ^1,_]#!$#T=,D1_R(8L;U+^%^/%9 6>>\O*].94:(.+<>8PNP++Q.YD- MA2S]X"*O5O[C-6.)$AT2LW-A\>?/H!I=MQ9DNJ4]/?6<)";F@I?D2 M!HE6'=:0%^_&G$%WI7A=6BGP#/7&^?IB_S#+BIHY=__DCBOY(N#&6EX5J![PZ<0:"_ M5VPD>6_@C=&/\$]DXH$KDVQ_L_&JP H$T >-):"6"-GD@DJ T4H/SHANYBWF MP8MB=KP#C:BOV?B59 /"[J.V3)A0R2+E2RWN(>W7 ?\(-[M0(G,0,@5,HKMSRRZ9PAQ 'W\F![L^4N03H;A MXXST*Q?8[S/:7!"6;!$Y/DK(]TSSGX 'PX.#]X,__\6D3 MH1><9F$2_^6+LZ_>?H%P["=!&#_]Y8L/]Z>S^\O%X@N4Y5X<>%$2X[]\$2=? M_,>__^__A9)^CW[T MHAW]);D.(YRBRV2SC7".R8_0'[\Z^Y./3D\-[/Z(XR!)/]PM:KO/>;[- MOGOSYN/'CU_%R8OW,4E_S;[RDXV9P?OWMI[?E_PKU/T=A_.MW]%^/ M7H81*:\X^^Y3%O[E"YINF>S'BZ^2].G-^=NW9V_^Z_W-O?^,-]YI&--R\_$7 ME1:U(M([^_;;;]^PKY4H)_GI,8VJ-"[>5'!JR^1KJ)!O(,G"[S(&[R;QO9Q5 MNS89))6@?SNMQ$[I3Z=GYZ<79U]]RH(OJL)G)9@F$;[#:\2R^5W^NB54RD+* MA"_*WYY3O!:#B=+T#=5_$^,G+\A;FM#9-S2AWY4_WWB/./H"44G"#VF^ MOFW9*I7>V :[PFF8!/-X&.JNMB/XI.VD^0$9:.I;S\)#DGO1(/!-3>NP;_&P M$M_KV2]IXN?QL))N:$X".^<;E&],<;\J<61/PI)QT8#BJ0U(3" [,4 M6,=0VJZM)W[+;D2]>9+R>:<]([.Y]K)'9GB7G3YYWI8D<'[^!D=Y5OUR2G]A MA5#^\ OM&_$&Q_EEY&79KC M7G7A___G-WK0;+A&/C[/9 MBEC#:8H#!NX]WCSB5)9OE895/NFAMQ@E%X?#*2W&+JL*#31#M4[%KT(- ,.J M=C+_QR[,7^D\@\Q8XCPS\5AB'2=>2P5?Z+E$"G"89H"RR[5"%.UE1W)B7O3; MAO+FXNU9,4?Y'?VE:@R724RFPGGX&&$#+]5+TP:/!F2%LJF'FG-.]<C32 31+K>TJ!G$W/)879]%:H!MST?&))YYPS@M>E M5R6,*FDX#)K%>1B$T2X/7_ ]]G71>LLO9[LER765@ MA=/[9R_%[U[%!A23T$E3M-J93U]TK:' =,F!:573YY$;AC04T%X#S#HB[7V6 M6YI=]>HA+V=W-4<"L[V"TQ$"0SL9,LE*32$)QX?_Y*6I%^=*@G1D;))#"*]) MC)8 &%*(4'4)43[F:O7MM?E'TSGT,V!TX]LU8>S!IJ@V& M?KTA\X/.UI1ERB7EV2[*;\(UOB<3*%*3V?4N#FYN+N43:(V"M?FR$?!Z>JR4 M=DX<8XC<$(CH(*J$*BU$U= -^?\E'-?V0&POUS/J<)_8%HO"BTED;3HL)=RF M;Q(*.F>3"3I^R3@BVDGJL<%T0P=YA$[-OR_S9YRB_-F+45MIXIVO:GB_(D7T M[&5X]I1BADBUZ:55LKC?99B!QE:71L,YT7K!Y#>XZ@E;I8AJ33BN:T5 T_.W M"H_5%K'IJ$3@FOZI^=TY6Q2@NMR@(NS4\\1.A^]%%,+.*6&*D/,=;&&_UD&5TL1N(TOSALL@?]N["_*77^YH'RGP M$YUO-G@BA$,YT?K@O/Y%:/BZ)L.++ ]]+T+OL9?MTK*'F'"53U/1[\,XW.PV M0D)W5UM[];JVX1K+JZFQ]A5+< M$5?=A0R[%N7@WWD3!VBC0"'@]#%1*.R>&,41N5Z?28K9Q'+66**"69-#) 2#$PID72H0T4GZJH.'NXO83S:XO@A3 MW;Q7#'Z5&C:'P@;0FP-CA;AS.IEC[!*KT$"U"JITIAU#?XB]39+FX6_EQ99W M7H8#>MH+QYDG/?_43]6:&^J9F=HS&>HY9]< L%V:-;3+$1#31TT#4W=J?8D& MA%V]* 6?1P/(,SEA1CB(E6%2F,]T9(=?<)1LV:W03Q0JUAS3-]"T>_3*."OM M,U=:->?\ZX^5/V55:!:#\;TN*I7A,+*(4161+,Z"31B'65ZMA^NJ)J'=L2X&SK]Z^G7HFTX)S;ECIYVXK M_=RDTL_!5OJYIM+_]$>KE7YA6.D7;BO]PJ32+\!6^H6RTB]LM_2O#2O]:[>5 M_K5)I7\-MM*_5E;Z-U^=C]?2#QY'-TZW+>+M+M><.Y&+VQS1ZD WAZ4R6>>\ M,03('5=J'$=D\F.>5QF=3L5 ^,M-79< E??494]%7K@V6OEK(!O2M M;*#*R+CLE#/R>"FIY(.0P LG1)>WN1=NZ$JVY [5*DV#GY\OT'JWY#DI$=-I!*V0L'(X6X MCP'#B3BO>#4N[DX4HI*H%)VZ3Z&PSHPJO2MEM=+%$%N5?@:TTH6XA)5^9JW2 MZ]#.AM6OE+='! /8>THHA(&00X]0$9/;+F/*9.8OD@=,9$+6N"$%6!."DX#! M AFL;M57%5T((BHYU:W'%"_BX#W&N7)102AF[S:C'.3^YB(O Z/.Y<#X02!= M%0U0*3MU,R=)S;;;*"SNDUR'D9(!*FEK1-!#KOD@%X5!"RT^_B90@!H:J%"9 MFB0?MA14&[?:P,:+LO[4K!X8L,FKAO##Q425L;FI6>[R'% M-,3X(E[1R*L7?<=G/:S8'Z3USB(_4C,V 8AZ0W KQFQ5%UG:HB.VPIIE!Z8( M,*P(9F*B!2'XLRS0B5X%!O.,01/!:KQXU!6#00()*^+91(0>G M4_D19W2W3=&;M"1L=B,":,W^H_'9.0WDF+HD*"6F[2FNPYC.C;W8?U9T#B(I M:TU=#K%N[+R(\WI6X^K6-1-$I:2K">!E0CJ;V2.-MN/G@BE-Y[NMR9\05C7U M:WUT7NDR1'R_3F1(PRZE;%?T5>*S02B]LBO(0?NSK6H6@:IJN?D-1"4+ '$# M_E*$78RV7,$SDG! $[^.O"LCB$H6(>)&:I4,HD*NJOD* M9WX:LJO.JGRTQ*Q7N@ D5_<-&5@4X(')F="0=>38[_!3&30OB>N(R HW)I&W M[?J5L+M]@5 8!&E,$$I[BZ;2/IJU(Q[-XGCG17=XFZ0J^K3%;+-&!+)+EJ8, M*(X(@$FI42*!VJ=$1 \4.,38I06IQMQQA M[[ZS&QE:DO"BUJ<;$K#"=0N;SIBH!@CQB;E2B&.F+Q[DLSCP(@B MM9P;@G1@BNE1"@$D1QN9CAIS&C'$'3&NP\SWH@++-?E-=&9.(6N;(%*X79)P M@J"((D,G)4NA4'&&J3@ES-^QEYK1I2'IABP<5#%5:C& 1.EBT]&$RCLAR>4N M35NHY3V.7-3:IJP&;+T_*Y$#010-.&[7MA!O$<51#U2<&+X.(WR[$QS:$(O8 MXH8,7,6)[G<07)" XAY&*8YJ4SE4"#JI^6J7(,YOO8W(0XC%[#) #++-@K8, M("8(@4G8L)=%5-@)(RZ)9TJ]:!$'^--?\:LT7YR<74Y(8+9)T1$"Q HQ,@DM M2F'$I!$1=T*,51INO/3U/O0U704O:)<:,J!M;G2E )%# DW"CE(:W2\N7?8D M#]ZG14"(&J[+>"D:EDCE[9)% [O-&8DP(.JH$4H81)106\LED>@#W.DV:1QW MN$QVQ &^7B:!?(2BT;)+*J,LM*FE5 %$,!.<$IJU5$^*,RDH25%I %$+3A@W M"P)24%GYGYLPQF?2_ ME[;)+ ;?-*8$@(";)T4GX4TJ>5'] 5 ^1 MU7/WI#DW)F3UPCUI+DQ)#2$,JWJFON21_ M7*8/R4?1X6RII!/*\%"%A-F+P:,+ATU'%JI QS-4Q25-V,!JF:[2Y"6,??F0 M62;NA# 2T$+6=&3A44<,4,>?>D!CC"%#B)*+B;6)5WI MAH;P*EGGN[TKP )8^RO C8\@2"!"Q%\!+E9/"B';U4PYFF)/XA':GZU5L@!4 M7<>-;S"JF ?$U3!KUT3&14.^2>@9J>K\9]R'&=B]]WX9JUG[\*I._+J XC:[:+ANNGJN^7:_"D-Y%'H.*(0E+P M$B)Q\A#I) .I)56AZ));963KU[/SQX/222)/B64LD4"!<2*!P(1$%20 MX^JRX39!I2@J9%U$IVJ!%62G\]T6 82PJJIO?011Z2)$7.-OU;4CES__Y#\3 M4%AR(4$L9MOUBT!VW7]3!@0%%, D+TN\HDK6Q86$?9?UI!\$/#D;!#QI!@%/ M$ ;$+PAP'!1@:+#OV0R^JPR.*5L3U*M;88@B^)HY&'@:'S$#R+QLPM2J6 M8:VX#W5I>RF].(#Q$XZBO\;)Q_@>>UD2XZ!82Q'M%*GE[9Z8T,(0,&IQR]>UE: [M[:%LH XHP0HN\-=QOS8 MCXT++4=7+'-,WXL(7_"5EWLE-FE^9>*V+U6J0'=O4XID 5%("5!Z?[+6H:%B MO(I3SD+&I)=DJ/64*$Z)=Z3L!X[A(/*Q8VH10/00X5)$D$E1)>N$"_<;+XK> M[;(PQIF\(^I(V>6"$&*;"RT10%P0X9)P@8FB2M8)%^8;G#Z1[NV'-/F8/Y?Q M6:5YDTC;Y882/)W2&H-5*E89LV2<#AMSN,8B$6. M-]+;#GH56PPR!5_Q2"P% #.!1 MR4+D,4'$))W4_SLO_C7=;7/_=94F/L;TE%56>RO=^INAMEW.],I2FTU&JH!X MU@>OA(%[$ZAAXZ318[E[W#:YS2>P_9FG)WN9$ZK"(*$?='*IGH9:AI C_2,6&D"_4R-(&9EW/?+ MUU[VR/*YRTZ?/&];,!-'>5;]LJ=H^<,O]>F1Y;H^4K)*BH4-R8OV_51M$'1( M9B@_^^@YI^< L-R!Q4J5'G7=GR"JM-'/E;Y[7LZR#.>9AH%=(9M<$P-LLJHM M 88_0EC<:;/[^_G#/1 6E"-%(S)PLO8Y(8'+4Z,C"(PA8G1)9?>FGZ2@:!/WK1KGNMHJ>N34+URDZ38$:* M8 C7!RU'0*+DG':K%&^],)A_VN(XPR0K;'FVU8XD63?2M$FY'EEI$LY #0S= MS+$*+HY3380+U0R1J25*V%*\7YYW\Y@98(SLPT$ K#/F&6QF]>32*4IQQ*:+ M6R\=^?+9P8,ODZ&"P\&6=I!EE2)YDGO1C>D(2W8GK--EB0LX5 M@9H3STF[ZRV=4=YBN7=1J=AU,GKP;5\CEP?D<]3J)R@+55BG1BNU$Y0 MC,==E!_N>Y2MQX6WD;L9B/Y%Z5B .)2;T'L,HS /<4;(RQ;OGY,HP&E&B9R_ M:B;]YNHVR=(W4TTZF>J"<4 ] 7-A/Q>S=XN;Q<-B?H]FMU?H_F%Y^=?_7-Y< MS>_N?_^[?SL_^]/W:/ZW#XN'OT/BJMF2E$K!$1\-%J?DTA YUV^9JL$VYW0J M3P-F*^_5>XPT<"Q+Z>%4L/JCIL>>FN?32X.IC?28^1&R\OW[Q9DE\O; MA\7M#_/;2PCLZKU( &59H-]"P!%,_7M/]@%/[E;-, M!K6S5=85 \,<.3;^N:?X!9,A-)UYU5HH*T[Y_LO;K]Z^?7M&Q\WHA1KY#IV] M/2$_T7]05IP!]G;YW2/4^+VT R)S=ZWS68Y&Y4SRVB+T\+B"3H[ MN?BFE42 L_ IIL+?HSB,T%L4TCA*0;$_O#^#C+R,'KW[OUZ\HT%U+LY.$"'B M!1.;;5.B>?&6_73NO#TT#F(K#\UP8K9[:Q'(;A?=E '3!B3 ^ ; SK7+&7_Q M5DGY;[\Y^?K\3R??G'_-:/;M'T^^_K>SDS]]6PL?2M431*QL,8O3$@'8M@X" M=IK5BU9>&"SB2V\;YMPS+UIIJPMK:LBME36Q*!A2J_%Q:VNU-*)G(4[#&/F% MPJ$T\J+?-I0;%V_/+LX8/^@OO]PF.;[#/@Y?Z K+=9(V&F%CP:9[<[6GK@WN M#,H.95(O1>>\&H*6#^J?8^*C*GVT3E+D-[PJ8D/1L^^!G;^YP[D7QCB8>VE, M+\_-?'^WV3&$5WA-GU"2M$$319ONS3PC34^GUW).SMY0!7L+E2 90S))Y[3C M)W7&LS_7TVFS:32L]3TI/O$R'^ 9M.X@P,#S [".;@PYL@&+<(9HM:O,T$]K MU)?='FBG+VU];2$GMQ5; (7W$ID$F.Y."$M^U_!G)N;^2F&-Z(;TU31,CFPS M0B3HA!@<4"$Y:BEX!.E"4Y"$BK+@19E[IK17)\G48IDRI %;IUGAE$47,%K: ME"N[6S'694B^B"S3!,.\7G %-S+:R\OU(AOZ,HQ1D$21EV;[A> _ "-J$?-B M5J_]&941K^2.F+(,R G9U0!*1 E,+0&YY=R)EL5$:*_J/0W1DHQ.P]H2F!GT M>N%++>Z Z!U5(.V>7,413QU1L'8%D MECRBE[&6:XY)8GH9JH!FFSZJEXQRR401O0[<(^\Y23#2=+23WF=Z8* &AH?F M6-5;\.!G!5P,/>V40*GAB(8FDP&%.$3:&4X#VG0;?0XP/K^4HSBIM%->R<=O M$E&X?%*.W(1< C)LZQ&%U4S%*:,THS70\5=[@#0B&*1!&@W$N<'U2K/FK+A4 MVB:W-)";M)*(@F&4&E^73(4T:FP+P(E(>9ED[ )%&=Q'%YM2+F[72ZE!MSV4 M6!8,ES0 N2Y#."WSW I%,#PR@0E?V.WT&'GH8.]EG.*_8!CG'H1RS=5*6F3+ JH3;X(Q&!11@Z0 M"\%$/B%:"!5SDM@]8VZ3.&GGH(K7JAYW&^C99)-Q-IKCD=6-V:#J9D2,1B=)=T@A'B]!;GVL%01\8J M=T3P6GQI"@#CB :=REP_H!NEO?NUX2J2V/5'O0[+PM]2<8DLC9YH83;Y(=0 M$,S 186N2Q7VK5CH":,=O:M'_ >*Z*B9[OI75TFI&>=L^@F'3\\$XNR%^,@G M7#P$O%Q?%VFNZI\4.+FZPD]A3#T5>O3(!Y\,7MC9(^>.QM25.'86 M1N[ ;8,W)8UIZ^XRAAU3*UJR^[-IC/K%B96K74I0KECNV2F\6_R1?9'?RS/2 MM7X'W30[G*O2*8+I=_J@[?+Q][\[^^;M]U2$D3%9MV-OT& <=*Z?AGY>7U[P M/GIIX'X-4I+MHB4.9"NG#("ND@P9\+6C"9VP8KC<\M, KH[I9"67M%B>'KT, M!Y?)ABYDL)7ZAV2^V4;)*\9E=,]L%Y$.@GL\99@):]>X!F:NOM?54]\Y40\ M+7:PS-8I,T9)6UM#>8)P98\-^OV]Q2F9JNLNSJ4E8J!IEY?&66G34:L&B(6F M6,7D6Z6)CW%0[B)F7L3YS@S]WMMLOT?$6::4>:>CQMKJQ\-.+]"'B+RJ:R;* M,J.C8ESO837E]^E!2ZK]+V=?_1%MPB@B,E!' T4;'6$XH#0$8#Q@D%'CQ:JC'!'H MH:M=M+VVA;\SRXK'L\9,(8;D : MUG98\9B.S'LG +V-'I0K_:Y)M1AXKKYTJ4';+?EZ\?FE^VA[>X747=QYT%2 %J2Y_ M8)/_,BP9\;I>]GP=)1]U4<#4*DX>E5& %SXO(Y 'XTX-0,J?G"$='E5"3 M2 MI#GB^"FP59J\A $.WKU^R'"PB.N 'C/ZU&[Q@)O[VD% M#'\'0^?FPY3(:T;D9B 7^HQS;>*[XQBLV1T^O.#T,-DTP7L]2 M1OG'QNMDZ:6(M$IL?YN?_$K_3!&A';U(00:?O3VIE49^A;<$?\AN>$A*N2UB ML_&(P#6)WOP.AI0"4%T"-47 A"::;9(T#W]CH(I]V*OR],XJQ9MPMY$U0KV> M58=KFHV6Q]0I@6&7*5)=)"QT6NR)5R>TG-.O"I[2OL*F6@40"%L/"" %S"VL M<))@**6$Q\]Z'=P.'"-T?XH)YBM<_+?1ZU]ZVS#W(GTT?V,#E@/\]\Q8)^:_ MH388LO:&S$UPG\G?Z-,EK1%9EN'RD&JT?]7<_>B,SRWQ\ELO#*[*-\VJ()EQ ML*2!Z68L'\9%9V;,+9_[9%C-;1-+\,)<'I +P4MX5+4.YLSX7@0T]'?$6)R7 M#0$ [UO1/9N;D=*"4F@X#*TJ@JX(L]H4!^1S=1BU3!OUDO8$;G7F%_<4RJWN MA]0+Y(%[S93=NDU5AM1N4J0)B(H]X'+K-J5H??Z /8/@^^D.!W BW)LOY1^\ M%P!UD^:PS1EP(63[X1;M!V@7$J&R]CJ,O=@?8:M1:0@ BPTR:L!FA14P+G@P M=-U6X[JR &J!O'F_77A83E),!GIVGP4WS$;[87"-$AA2FB)57VXE4Z']I=3N M,<9FO!=TVA[1P@@$+PG%H+W+;:#GBJK&-[6U2B"I.OP>MJN@+(OB_O>*7?]> MEK>_V574#XV;W]6>1!%WKK[U3?Y6-4[V#E6GA*9.S$G@ETD*3!@J9M24G#<7 M*]D;+];![W_W;^=G?_J^5\0#YQV&^5#NX+$@U$'Z88/SHYAJRG%+IYK;T@1Z M?!4.RYTSE^:3_D//X+]X$3V*2YI_\:$>/C),_ ML#VB.S*^FY,V+W^9V3((JR]=.BG@UCN:5A' :LE.\B[R!E\&I?H?2&]8_(DN M05$G<=P^8(J"/Z(6.GJ#@_C0Q1@9$BY:>3EZK!_'( /! H^C4_' > #PSM@X M&9(Q =--=!,.V#E&M]MN(W8MR8NJFTR+>)VD&W9,2W?+S%3;ZD&[?EEJG;PS M4W4^V1V&ESN;U]!F$]$HR795?*1JL9UTW[4]]ZOKU;']^(6T/SI%B8-ZNL+. M\NL?:3;5M_Q>:K]L==Y/-5,&0]N^B+F19A*?%@2=8@M(LJIY[84I"ZRT7/]4 M+NL7P646\642QV1<3%K(3V'^_)Z4ZC/1/]L'DUF1TGLF8^'94XI9@U.<4)HZ M,6NKFI,76+VJ.5E*SEN,E>QUFQ=-KP@_0'N">@\K9&FRZ5R=*OI(DD4L7403 M1EF=,MJ622.O2OMDW'-=AS;4Q38YJ+B9/KSFU,A6_Q9"E(^,]'O$!_-XL5K: M#(RTC)M1R&Z3W#Q.ETC5;0 D>6;408]X/1C\ZP?6.+A1$G& MX0(:?^N@P%M ]C0'(#X\U);SB5YY]I9&;4RBT#<( Z!0L'J?5 N\=9%4*NV< M?,80)<>FZ:RLTH 4Y.;=+@MCG&57.//3D!V((?-/^C1YMERO2.G1]1#V'"+^ ME+^+Y"?VAABRR<3A&6TRM+\5,,P=#)V[?S^_O[Q;K!X6RUNTO$;O/MPO;N?W M]\ZIO$R?O+B\W$V?ZR2M+?#*;#;SMUR7RRM>5$>ATOG3D6S;)/RHQ=%L Z,8 M!M,LQLQ-MZ4T;9^@EG5VH*EIGXY&ZA30/@E(G<7][I$&#J3'NJZ2W6,^>TQV M^0\)O3U,^9AJ.XD^!NQNDO3-6'N?Q%0;#.M[0^Y2^V;QMP^+J\7#W]'L]@K] ML%S<_H NE[>7\[M;]S0-G^)P'?HD?_QP34M10V6K].R5H18UC33AT+(/7&X# M;_'#[>)Z<3F[?4"SR\OEA]L'RLK5\F9QN9@?/#Z1+"MS(1O']87O[UA'R\F3W,K]!J=O?P=^<#@2K,![NT M4 :X"7_#01E@H1WV8]^4-7/!@ZW:#0(X2A&TXP8>9-)Y@Q@W'WQTPL(J8F;) MK&]O^ 25ID_8[(]91X5YM+HS"YZW\EY-5NT.-6K548]2 "T_?9!%,*P?)1O<7)$JG+*P MC:A403-Z(N*I>)0 D \VSO^[9OYU?OI@JR#;AKH(!C4.L;S-9(>&D':R RR((UCJZHNRHQ*; MB V5^3TNY4J#4MP:'PQ UX10R,)@A!X@1XG9W=WL%L XLK6<03*1>>Q$HVZD MJ%>SV=^99J+9H>ETG#.K)] NPUKKGJBI"&FP)LN7[(H+\5K+"SF"]MQPS'=;S->$.UIP^HU[R'9 M:UWG[6, #'&'H.;?]JYML.7*EA6@ZY5&^=9YX+Y&P/%9Z8?[68#V"-P@]!RS ME^_?+Q[>S\EXE2V(7B[928'Y[1C'! [FVU.]=2Y3!D*\O8HZ7?_NP@#9XI*<( M\3]VQ!O/7PRV8^3BML]ZJD!W3W:*9.&P2@V0CW%1B:-"'I2?Z^3%Y#"Q1-XE MG[1'A87"8!FEW2KX\.Z>^":ZE3S_<0YA";"\TM(Y0/I:_%M[CK5I5X9 M:EU7,M($P[U><+M$9,KT%D7S5H5S,G[(\'(]S_)PX^720+!=(9OD$@-LDJ@M M 88L0EB*VY>UJ'-.E$'3NH$GC?R3H:[M4(K&V>F&RM,J@N%;'[3B:'=T$8W^ MH:'NG(N-P"+U[;-%3(:$N\T^>Y(2,=2UR<5>V6ERT4@1#!?[H!7&@?FQB@.S MOW+8T'?.RE5*GVG*7U<1O0D4![3%;"DT,R=IKF[Y98Y>F>H\T&&D"X:A/0$+ MGA)@ZLQIUKHGZ!; 0S%W9'A)0WR17%WA%QPE#%OYO*/281IIVMW3-R]7 MJP:&B.98^1,'A2;C8$,7S:$\=BA^>WQ9Q798D/HG8]\73!NANBL?9,G]>_%& M6=4_)J\T X;)P[&+GZ$O3C\W;4U\H$_=>:M%K1_D4W3**CDH&Z8&&*J5D66INF:A4P;L@,)Q MYV18Z*6!>W=Y[S_C8!?AY7I&H 5AM*.C@'W0X^+M&AS0V]ZTM]]5 8VZ+5F[ MX39!0E;'D),55&N(.7HJ8!K39%GC!JAE0G2%RFLDU0RHC?M9?2LJ!H.\_RG[&(XC>7,5N^\_37OD_()Z)/JP92I BHU,MO( MU@]TNHV#AV2^V4;)*\;EF>9L%]'8?+UZBT/L.N@U#B\&0>\QW*CS5C%V3I2- MHO'X>8:>"O,H3Q"N$BA?7ZZ3 -2M-%T$O=Q^G:3<]?9&((=L%C%$;!0J=C3L MBOP[ME'5LR>RBL5-Y^6@N,7]G44@SIT!A-QK'4C9J_HC;A^,ZR;J5TIV.0UU M2Q_OO4NBB!3=1R\-^C?U?O:<-=X\8!YAP,%P=G6C!*[&W+.;%'RH!RD2W+=IMR1+@C?GT: M5YZE><.-D[_M73CYRR_T.B>]BK+SHN5C%#ZQ3N4ZS'PO^COVTO=>3M?^7BO< M2IJ/8,\&ST?+-B7ZP<:<,WVL'*A=>&T?[1,X0442B*:!JD26'%>63[ M![UEY[BAG'L08!(=QG9>L7VQ0#[Y] M7E N#XTX!E@%ETQVFUT1GBC Z] /W1]27:7).LSIJ0OY =U:P/(IZ ZPSCGG M\JOSOD@*B8N*CG,4D<_.ZWR\[5G:ITZ^!UPDJCLGU$[:U='",V MML+PY]+26KE1-K/AA]E.D,=2F6BU^7:W><1IN0U=95RT*"D1M+9"K 1:K_T* MI9S330N-FVW%0(G+=-I]GF(K^5 M,FA+A="788R")(J\M-$A_,&]$ZBGB%=X31?0WN&8_"%GMQ'W8>XRL[4%(QMN ME@YZ9$^\,F!@ $X#&(!:-:\OK:#2#&)V&L&$,S S=CZ_>Y2ZZ;BAKN5W ,VS MTWGM3Z\(AJ]]T I>[N.XV8IS;3BUG=(+T8'?(LMV.+@B4X?XJ>A46!>4W>*/ M[).P<T?SF'MAW3$[=BS,PTT)9@?":=->M&B]^4?:?]RF0G.H;495OQ:*I2 M MNX)IWW%-I!HFR,>%M%;RCB 3<",)7'>(:.2@]($-2TYN""ZS6%&9P:F-YO M\BS*&V5]%K*\3^"\5=9OF<7!'9UR98T3H \XW4B*4*]FLX689J+)5E6G[]@7U;J+0(S M->>NLS]6[D&RO01*L8_#%[K<,NUV4GDG_I)(AKX7/:2A%UUC+AJV1M8:A71P M:]+(!&'01(..C[A9Q!CP2WF44P6TQ@#B');8R+!T1WRI= N(%[-[L%$,LGV\ ML2WCG"D:8#*2A)6<#E;W"O6PI[LR(Q.RW1OP +NDV$N Z@4X6%P/4.W'7?W> MVVR_I_\LT0+,\'+XBGIUL(]M5LU>O#"B$^WK)&4KZJ,OX.N2.XY]';-"&V=7 M1YV6U5:T+?:T\5-(CR2;[J+#;JOE M6;W&TEA18&-7@SR=HVB=NF(:I5G*$OFLVJ,FD]JC#Y][\YOB^/=8J1]I4QW] MP/]*A?2[3(?,65L;@ZVV#_$<.(7QJ"^]Q]ZE=XX[O.N]1MI98"NKM81CZ)PW?0AKYBX#R!. M8QR7NR!Y#>,L]-FYTNE=?#>](QT?B(MMHA%!.['/? P@S"QW+_CI*<5/7HY1 M6(FC%_9&:]56C[Z-LJ6&^A[<#ZD\--$D*1U3NU04U9@M4I",G;;X;=$68\;X M8,IV*,^B^6K7"5JV8Z7#;XJZ:ZGM8G%QV[H/ E!-=_RB'?6>M7GRL,;05O.L M6V ;O<7+HCJ/DG,<#&C(#M*W%S?:0;'N TU;3-QY$W:5XYZ+9K;:L\$4_H;, MOPLPXCM^!]BQ]T3R =GEN#BHJ\XYE4#(PFM2D>1LRTZOZ#V5/ 7D:KXOBG"P3,F7-0XE8R$G,.#W'8<7\N$=RW ,1][K')SQ(5V2 M'WN%N3?DXSK$1[$0J?&19;G0P%^5EYQH(5B8$JB%Q>%%->:>@""9SVU/0)Y% M\\[7K]HV:XRL:<-OC+H1BZ!@7&P-](8!JAE/5,BC#LU[8G#>6SO.^.#5QIY> M F+O ^E*AMTY8G%29!Y/TQ>9YK7'I0P?=_\CR:SYX6O",_C+.IKR^!%GM$W&+&R*3Q^'3^A/ MMFX[FRPO;<]#!$_T1>9%S8I'U$/7>T5PDF[B3KH (TCGF'R!M)C&;.-<(I]-VY7EK/WU#,.D/\4*!=1V?\ \2EYRMI<>!B$YIC6& XIZS,6$ 3!@^0DG M>1]E>>#S]A_MB8X%-\$E>*3>0%)P$S7Z3FJ?8]L69W' G!MB@_6?<;"+<'E. M>M#1_P>:(5DUC&??:G,39514Z[#96*GJZ)+%WI8<(H)=*?5ZNM7-=5^!(&. YL=[/M=(^V MU:J*-[G+Z$/I:43\1@D#\M MUW?83Y[B\#=2/.RZWV62Y9G9(NRH:;E9D)V@N,2+LR,F!*?Q39@[U=)2O62T M;^8GJ'QEOCB$>.EMP]R+J/T3--LD.R(-99UVG++2+=J.GHK-]CE1$35;YLA) M@&F3T^1K@M8(::&W+ \;4&BWT7 MDND6#;-X_,UN%@0A5?$B6PU0E>)1-45]T8W:*.7)?3[-4YM'[H19K8!BKLVV MPE7":K)#=D'),"!,F; ^:/DX]H]BMUU6+*-LKG>-PVIJ(^9(L'5>BJ$B@):C MD&>3SP' O0'3$SW5+GK\N?HGAV6 M'I[%Z28C0PKZY['+M6W[*$:MHN(8I04U#1]_BQ'DAEMPH2)TG.E1H2/UJT<1 M2Q!CNQU^:>TS=A9H/<8!3-@DI"F9%RCM[]]J*$G!' MB_:0*W*')@KIWMPX!=CG,MUA*<(9X]G(9N\]X\(VW3LN(UPPNX@9!G-ZXX " MXXOK9M#-N\,3T7%#JQSJCUGY-1,.4P<9 K0"=AA^?G&;*-9O^TSSKL_!/EJ8Y<8PLD]) MM=1L^DW33&BYVM"!34H>J.1PP<="#25[!4=>IFHX9*95M)Q&'KK/%IGJP)N- M&B,^Y(T@@_>!#G@43$@X53@VWBEV"F<\L]:>[1JQ$.IWN$:PZ=PKC9P1KA7P M[NH$?=0\FV?UR3S5&$&PUF"HXY;7 OAJTC84 #.21RD_@5?UDXU(48X(U"-L MZPCVP!#/-+3JP<:.@[!#PI_R% ;F.TN$S: :HK(1BEDCJ@)DS3^!#)2!J ;? MT00O40VDWV,OVZ5L=641;W=YIPB&F; Y81V2.=-Y45??N;\[ +3$Q65HLY=' M(55PSM?]/L$=CNC!NI67YJ\/!&Y&IFYT[^[=:^N+T<94+UMN]IL&9%>\C=3# M$!A.'X)>%6NQU$%,"37MG="-XO9G*/L]DB*XT>SSM M=$H_:H!=]P)P>EWBUJ]PYJ?AMHA=T/B]7^<@MP*@6]9ET:"7EID P]5AN+DH M3'MQRM^T[-*WK$O/]^K.R;Q*\=8+@_(&TN4N3>F!S3BX)20I_B(I)Q-%FY0U MSTB3I7HM,,0TABH;3Q;DVQ9FV&N(Q$X&@(%)L//SF]![9%%!Z6E9TD7@V%?. MVO5J=MEGEHDV]]0Z@)AG!+3+NU(-U7JHH0AF&JW(G&XJ;:8*A(;**;6)WC'0 M43>UUE#2<'H]U5[(3>A3ESQ_P73=]E/(GVG@). (FOU.)X*;NL,GD@03*M6H>.:<7'NUSE3V-SU,MEL MPISBR1JC?DDNE1HV66, O$]VP M2%Z]*'\MF9LMXUNYNPMG$_,'-U5]93WSG+#@#-N:_: M"EL;*.R0Z5EA""4QBG&.,FJ+"FP+:Q.1M+6P4?;*V>PIQ<4+8Z)2T*I8(Z$A M^)IT&GD8)#,#J5EQBDH]Y-6*$Q%H$8=YZ$4ET&N,A9P125FCB1QBS0Q>! 89 MI+BZ]5\*5A6/UAC VD[C.B==P7_WR@[B&=X2YC4<7?&509?2.4;E M@Y1L#^:13)FI%ICUF_)H)T.G6["1R#JX/"6&*[@QU18$0R45NBZ)"K[4#!KS M$(.D2VI'AEV1C#][7)1LI:2UKDD-M>Z>Q&+.Z:#'ICU2L"WE)Z)"&Y3T6+]0 MS!H)%"!K!@AD8%2_')CPZO:^QHLS\?;JG4R[BE\-<]&0=\D$#K:*$K4P6&YT M$1J1Q.[%">5YJ5O\D7TB$WZQ)S%7ML>JOAG:4\Q4$PC?>L+5]DY CARMTL3' M.,BN29TNRJ#7RY2N-BW7\W_LPOQ5OE>F5;2\06F8D<[VI$;+.?UZ0Q5L33)% M1 N,+?Y1&F*FXIQ_10,J&E;+B\MFFG)YZQ%^5+"Y(#TB83#YL&Z\F#X90!2[;5:QQPG&IS-@A?J M4SL80_&H7B%L;?"E!5P/MJ22SAEB!(]_QX/)\]0(#U^95L[ZV+'Q>W8F,L#I M=9)>4AQ1)#K(8:YF>0YHE(G.5%"I X-$YD EO=D+NQ.05;KL'1B_H6UCF[2: MT-:;_BX.;F\CWN!O;72_\2)+ZURB!I[6A3DO;!)E"Y5QN>,<)1T413 MO"6XV $:CY@J0K=EI3&T)M901/[OHPVS^)6+RKO'_BX-Z?B'\T^2"M1JP*I$ M4[B&%9G5YD1.V65%*BXTULN,YZ:KJ1TU8%7:![-IO3:N?P+@!=_6.HH8EH ^OXG+KQ'4;ODF* M&+!T]:J,ZU:\\+Y<2X(5]U"#5<.],!M6<$1L%F'* F*U#FCG,;MTFM0(&NJD M?LO[L)=)G)'Q'D$A/-RJ(AI557>KU:QOL_*?+>ED0)"E=ESF3U M F1]ME$_ HP2M@&0P'97?LXX+V]_@_K MB9N'50@ 6X>+_/=I'(9M0]4Q- ;T?"!K\?L8='[@I%G,-]LH>25#W%E<#9QI MI%K)*JI2&A;93* :\@)7IMCSE?[>F/N5TYC>?PU?,'T#[/SMV3>RU6^%,*QJ M,T#:;V&E,H6VI2V7E49&K:07W-!>L8Z7DC>>7) MSL/XM=6RLBL'[+"&_XI?FY[G*DRQGR>II%Z5TK!JTP2J81W^BE\[/C4HK;FL MN0^QMTG2G+ZP6-SJ[ Y4)'5HJ >K-ON!-JS7W=YHV2 %@RF'-=QZC>1,-L01 M",&J.P5"TP%-ZS&5,S!U[<$5WGA2#F0UVGL\\*BJWR G8U)#YQ><4.#@'=A'H<1EE1.ZRNL"A%!,ZR$ M4M5->9-V'%SA%QPE6[9!I#GXK9$'5B=&8 UKZ3%E2VM[:_LCWV[.$0Z(R@VJ M=F3P3 \"E@$%<1&IVR,&7)TK6\3!>XQS>:S9;FI\TRZ^2C$!9KE<$&::/\5X248(S>DA#+Y+M MW/31AE6E0Z";[N)L6=42VRA@QME5WL(\/>GHEPF@G*;@NO;IGE6$B[O*K$#* M@BC*15'Q)HKPZKP'ZC[5[==F:647E5]5>4D":/5LVL!-%(^@GL=IUJ)ZAM6> MKP./]%5I\J+VVETI>#4H@]C+"P<>[7"9$=<#U'/] /4<^ !5B*_/ /4K-A=G-_+9W\59]@50Z'RWRRAS*T=GJ]:^!+ M)J#*7PZPSXW,[AL64.ICX'LBT&NHB_20JMI'27<4%,'">QVPZK,G[ F"5)'A MN:,C: ATVN93%[W9R?3>(7G.;A8T1<4[(A_$K2U]LDEZUM:>1A MU:096-.#KGMC=#I<6D,Q,>=TS+B+\A^BY%&Z$MT5@%5%$G1]HN<^,76WJ\.' M/YL JU8T,(T7A>6O*C@<8H[_7 &HRC,'W&_H&Z*N^=N HBEQF$5M4L:.BI:M'CTG$1E 9?)'1'FI7[X&4] *<-P[ M6 W1?T6%,)KE>1H^[G)V,90,3LC4 @359W%@5CLZ'9B-0@U5T5)8^*BY]G'7 M"2OI,LERBG_^:I284#EK\?(O23?T*CY7RJY:@+%(I;D\1.IT"\78*I! MCDW\6.@):L@Z\SM^BKT,7^'BOXNX?%_B"J\QF9!4/1CIRY;Y,T[E\]QAE@"U MH@,SP#N[P@SZLC+X!WK.O;19N4#6]3-SR.G$^Q;GEU[VO$J3ES# P;O7#^Q! MB+J3G/EY^"*='IIK ZKO : Y-XIS1&V@R@B-9/[EA^+UBC^@_1!C;PM6_=)U MSM@?6K\";?CUJP+=LWYK4^[KEZ*D_]!)VXL7T47H.S+22D,_QP']0+Q6^X>& M9'&O_YI_\:$>[)O*'9QJJ_\[+\7R]QKYP4>.IC 9*K&@:<7[2J MS; Z;AE">TOH9VH+,6/_[6(GNHIYNDJBT'\5UJE*#D#-&<'KUH]$WJ%WECE9 M "4LA"-R>>AG,A%DQ\]NJ*9M0E.5') ZHA(YC=&@*ZW#'5DX+2)Q'G:1AGH<].WD_,YG9BGR=_)7FTQM@Z?<0 '"E#RU>L=Z2BJR?=I^"F M(!E LY4IMSXSB2Y_>+N/]!5Q=QT1>Q];#=K^J9 MO@U9DFL5XY(TEJIJ^[Y4T"(D_&(:[]6V_H+U^/O97_M][$VI#? M>A^(1Z@5^O1OO<^6N^._\6\P-]L71(2]H?XP[_U?GIS\/;U+ M_B_N_G?7\?[\C?_/O160'L/+"WY["IS?7_'O)I_]=O7&I^NWE^_>7;S]SX^W M\^4#V5BO'8_CMB2O]KWX*&7]+MZ_?_\V^NN^::'ETSUU]]^X>KN?SF%D]E=' MTCXUD\#Y+8BF=^LOK3!BN_(S/6$+_M/K?;/7_%>O+RY?7UV\>0KL5WOP(P2I M[Y([LNKQ_S+N';YJN7\Q-G@V9]A;_L>W Y\)))MIU.V!DM7OKUBC#1O]\NK= M13SV_\XT"I^W3# #A\O5J][;BM^]MER.T?R!D#!0?;^T<0OSF%F4>.$#"9VE MY6I-JK1G,S/D2X:P7X7!=#7=\F7.Y$@)F;Q7\S.;A_[RSP??M9F6&?UKYX3/ M.C,4]VY^I@,K>+AQ_6]:$!8Z-3.O(0F6U-ERWDQ7U[O \4B@G)>T4S/SNG48 M$VS&AKYG?_#9_C3PF:A33S4U5;^&N.FL/6?%5IH7]I=+?^>%[$LSWW66#E%S M%=*YF7E._)"U7!+GT;IWR8U/V6:\\;U(V.^(RZ3+9GI#O5)TQVEF]C-*MI9C MCYZVQ M(P#@Z90J.#G:4J[I^$ 4M\X83:UT!LIKOD':_.C#/AMI/O5:EW9K M9FY?+$J9V"E1R[=KYNL1\FEQ6;"/!-82M)V .CC:S!SC/4H'0'&/AN1^=Q^0?^T8Z:-' I Q4?L.-'0CFKH=C2W]Y()K MWWJSS@[1G9Z&35U_I%9U-A!O2.=F]3=L8N6M6]>1L,F!!VCQG#LDH>6XP83C M%#J/I-*Y5S1(N^=@W:GKCM.!-DL^74N=Y<;H]M2LRX.ZXW:GK8&LJ3!4YS2 MN5-GS%9W(>@Z ?7N8J87]:9ZT>5<+^O-];++N8)%67.89L\F0'$5-&]E+DJ! M%+7OX-ZKR]M*@[5^Y@,R'3Y"5S,&XUYAJ+9N^KI3AX\@F_&6DH!1'VF26_:+ M3!?R%+))$WL_$)\YU.<3.B%OG+CA+GJON<]NQY%F_XQ;)A/93\7UEYFON]RW MY>><2'L_8>3!"LCRS=I_?&L3YRW#YI+_@X-T&0'$?O@:?:A_'X248;0?R;7N MB1N-_Y6UR35YV\&L]D@LV(CED\JVR,\IS;0^7?9\:A/*L-Z/9=%EAE5%EU_2 MXNTV\B^]7CXX[H'+*^IO1.@D2/B"B::!8I_H!LT^ET(^AQO76I?#F6L"Q/," M ]!2:K 035V-%KYT[LG;X?/E4#LY!N5X0= $"?X6I M*:34(G&@[WD[R[TC6Y\J@,^V!.+](R;>9;0AP?S/'3O:$NH^0Y N- :"_1,F MV (*D?".#H<.QP<">+$U$/&?40\> AJ1()\_$-?EUW/+ TEY67L@[+]@PBZF MTP#@(]?CD&TM<.Q378#P_VH*_ 5JD3@P(]3Q;;:E4P#VA<9 U-]CHBZ@$!7O MD6=#T3XT!=]_\,'.D8<$]8T3+"TWGM$-^UT@A[ND.11RE#NGDDQ4V/\@%@6# MGFH,A1SE&JH@L6/ $W?8<3)2K2)N#84Z(3//)MBLMO<'PVG M6:R+K: 8HUPZ142A8+NW-'@A3Q*1X9MO"<48Y:XI(PX%YP&CAUKNV+/)TS_( MLPSH0E,HTBAW3"EY*%#/J+.QZ//<6:J51K$M%&R4FZ6<0!2T%];3V&9418%* M'"0UZ,(N4.Q1KI4@+T>>!;TM5NJ(CE!TH]TT-TE&8 MTK=M!E>0_.?6\[%=P MV%'NHDHR,6$?L'].Z<+_)O! "QM#(4>YBRI(Q 0\VFFF=$;]1R?.-E>A7N@! MA1[QBBHG%E7@XTT>(NW[EE"\$:^KY<1AXCSS@]!R_[^S59TDR]M#,4>\N,H( M[=K &/.=&RU$H42Y)E!\4>ZJI>1T#2GG,"666'RS+:" HEQ RXCI&,];G_L^ M'GQ/:H\MMH+BBG*3%!'5M>+E@<2!<.FG_@R.8$-1JWDR.H;Q"W5"-@,>M+[S M$AN-P"LF: J%%^7Z)R6O8ZCG42HBSP;XR$Z(U#E6W\GB7-8."C+*94],6,<( MSRCAG";LV!W%BCC*74]-*"[RXR#8$:J+?TDO*!=0KGU0 MHKO6,V2Y8VKO^>+R?L$S9@1:IM *BC7*E4]$5,?83OP%M7@5Q/GSYMYWQ>DA MI0VA"*-<\"2D=0QR9A[E\.::0(%%N=F5DH.D$T9/RP?+6Q-Q]$)Y2RC *#<] M&7%HNG<-TKUK3=V+O\ MO2CEA]?'I9MH'C?L'^6P"YI" <=)D921US74.]L)B1U/Z<;Q+&_)KE3'$I\" MU)6]H S R:$$$HUBWO]"7/3AQ%[&0M2_WF><:0M%&#(4M)0T% MY/G&Y[])D2]I#:Y.@ B[D$BLLAN'RI_SZ&T:*D!=UAZ*.VIBI9C0 MCI%/ZLP=ST_19,;LWB8+>E#W@G(!Y;H*)1IG;TUE\DNWUDP[*-Z(%],RPG!R MIG;WKK.\<7U+>B[/-(/BBW@++2$+!=YKR_N3[K;A\GE&_24AW'T2'%8;X$($ M' #*$L3[J184..:"8VWJ^0,C.ICNPNA=.#8_J=% V@_*&LPD3@#A2*>@X)CH M1>SKYSNR(I2'*2S(4WC-/O2G_% $Z [E#VI%(3 ,)6SZ^]L"7;?L%ZU5.BU_ M."Y3\?2R][IWL(A')4_9^%Y [%[2N1?W[OWPR;-B>_K_K5\1=64%]Q&/=L'K MM65M8]$C;ACL?W.4P>077P^SG*X.MOR9'U\3)*53D^ZPWO774Q7*XO+N:AKR M[;#JK6I!FEU( DI:4&S5&;$ON@_D1Z$Y6ME6.;AE'!"0BLX(_MX@+W3-_L/K M1S]:+M>\_7!@4?K,ML+H_50Q8X#=T>J_@GC@5R')$/YEG[/8OV:1H5?,/5!G MM!*R%7BG@89AG-/DE;:3R#SNF,8/X)JIMCJ:OX-6P%^U#MCO><=D%(GH!J_@JMOI(#A\!K7QN_=N3+DSHJRTU8?#E M2M8'K0AO508(^6?J!2SQ! 8SZYD_%Z@^?PC:XY7PA6/M@R@QA#'#'5GXJ1>X MCG2)F2/K@U?PMRJ#U B@,ZE(DXZ>PRP)7)4I8HI?QG$$Q#_,PL(-,.X%<$SR M3I[$6BCKA%?&N)FS!@ 1='59Y:#?P-&^A;+(S?#L!$[TL[UBB.:J,,>7-L:K MJ Q'N6 H%-&,SH]4W(#*-U)HB5=NN2HG1-2BLZ%OV]$%GEWE+<<>>P-KZX2E M-5GVMPU1![PZS%69HJ"]+F^*+\ORWWR%/FM?P@+>']X=KQ*S-D/T"#-DZ=SQ M5X$]8H\LZO%X-'8/WVUVT42'9,5K 8E7$:0O7B'GJ@L*C@@Z\XJTZ9S<,,L] M5V6.F.(3OCZISJW5[>Z8I:4;-]I*L6F4_:@!@[,(U0<2.LO4-IZ)'KRJ$#W8 M^R$S\#F:L"W*%GSG!]"0M%,MT()XF^86RQ.4]BT@LX*M2\(3>216J+*VAK$D M(U B\%/33Q^ID!DP<*T@F*XBM=U_A_#B3-6Q])((,RSWALD[889EBVJ[.38J6E*(ZFS(Z/7C- H10AJ=Q7W-R6/H+!+2@VP*CP,8U^ULW)JN/_TC J@S=C8! MF&4:4)C$-OC10-H).TF@"IO:.A0TSQ[5SB3L@)U"4)TMANU)FD4A1%15V8W: MSP+09@YL*^K:@7 LKCM=3;>$YA['R3@/?A0Z#XZC]/Q5[S@.?A$"7OQA0P[S M4WL*A!VPUE 0!0(FV8Z H@/B'LAF P4K"NM'3CBZ=KMCX+'/\R3O(7DDKA_E MS"73E84^2+MAVPJ4L.=#'@ @H+/J _&81G+9)/OVQO$<3A(O-JMDEK(CMGU! MDUU (- 9EB<+KNWPK0J:+!&1>L)1*AM51)Z M3YB+$]_SLX3MZV$HCR" KM@F"CT.@[% UYQ1*742J,\AA8;8U@@]C@CHU%]O M[^/UYI$U-SV9N>(JK#1\,T9#*^PE:%(20G;"7#-L2X[6.X]V;H M:RMPEF+>"9ICUSW0XZ&49O2=[0MQU@_\=:A'IB;6R;OCT]70<7?LMQH&1NV! MT&LBZ+&Q(E"&&2,E =L9H^1/0*-D>KS_8VW]X&^]>%A\&V4JA+9:9BVH^SFX MN59P'HYEB ^",&OL<5%##"N;S;*;*EG!+T2.?6]H9VR'BA8;= @SY%B> M\G.K M%+FF+[3ZHL$B'%Z+P09/2K^*+HANU0J<(C$!+M5CAPB"*37ZK>= ?! M]IAHJ[EJ**$OL7R.OVIMB=IC^S^J+"HY[>BLZ:BF 7Z:1@NY[-OHV48V QJB MFETUS'C5#76(V1[BN;\4!G+9C.-0ASO**(L?!(U"NB?D6_07Z547U-V8(PEH MJ4+A,$.#%F<;2VMU[A7Z&W-8J<@^ 2 MG2>C2=Q; ;'Y+DV\(,)IX8\V6]=_ M)B2I$QGL7*9,2FOD1]=*W5&,.:$(F52)K/99I5KNES(. 3IC!VIH, 8,1;?\ MR*U?3884>V.'6M3BB @,4W>C2(*BOTVW49+!Z(G0I1/(S6 @-S6[JJLRU=&1 ET>"^ M=&6Z$HS%IADM*!T+_;F)9L[JK2K"5G>ZV \4L(E/5RF?T)PL64M>W'!"PNFJ M;__7+HBKQE?;!2M\!OW1BT:VR,KXMJ2K^31Y(<;I*I);% #PN^J,S\ MG0F"4I]GE5/:QYD\7:94XH 1#'BE0T]S@U'!YX_BZEII) />\FB87TW?:E1WR7\O,J%4\NB,/-R>QCD->@XEMON)1 MU2??(@\Q$VL&5O!PX_K?!$5^?@;FT_!A>M$X1B70'*C3RILIZ86V5_&YS*C_ MZ##V7C]_8LB/O4.%@?XR=![C-RW46?@5QC*ELK"$D<7=KR)BZ%MDNP>3MGA4 M _ V4X;9Q>[>#PCJ9IFR$DY\;\E0BC8<_OKQDOWLN"1#\\)O;*VW_V7LV+K& MQ*XK)J&KER%A/%HZ$8?$DI-MA1U8UQES? D(AO"OO_%IZ/P532HV8 ^=('KK M?D;)QMEM).I W14[!@^)TV!0T=F_+\&0C6Q37+]*VF/'\2$Q6@X?.G<9P92P MV0U)_-\4B4FN$JA4*7@,[*!!)"G0A]E R6"::6LY_ W1Z#B\+SWFV=/P@=!^ M$!"9U[_J>-A!C158I^*]#I G74DL5QU-\:[R 2]))^QPR :D00F)@4N_OXS. M)D'B6UE0RY;6](/U-R9V$F[FT8,&G9/PVVH3]CN3@B_;L-S5-@[AUY,3$)L\ MF=J(85="8.] 2A.%=QL MG(!'B_&?]A(9U6@71/VT^#WT2,SZ0M$R0H;H!CA.36SJ!H1F-J8M])$[X3,@ MIY3_/P\1>K1<;@N[8S=2ZBS9393_@0EX]A>IEG%,:_X:-'I:NCL>K,+^\6!Y M:W+'3EDCMJZD+P1U/ _TF-3&Q!6'@]^KR+?+E94R4)YU8 MU?:CA3N2J)<3X+K;;MT(.VNV8[]BQZC^FI(("(6OBW^PQ>]! M):*]Z$QMGOJ= &.& (VW?EV9B(: LKD] VPG;$[!U67VW=1+)VWR0K$"IH%[ M0_G5GGFU#K\T0<)/E&P@0Q)^2[MLS_S9.-,4.66M_ZTWP\&?1S8Q!42H5[[\?LTOO]OQ/S^-A^/%'[W^9-C[,!U/ M/O0&T\E@=#?!68)3NK:\)-::U^!D++2MA"5I7DQ7B5JUW&..H7JU-C0\EMGA MGN>9FF0Y8T#IC("_D1D6A8*/0A=* M3YWUIZSR!+$]C_ MU/97/5P,6&?),R/$43PS4KKD+M[EE]QDNACU[D:#T?AS__IVU+N9WK$]]N-' M=N*=+Z:#?_P;^^-M?S$:]F;]N\4?E9:@X/YUG >4)LG"XR/6&;#)B^5'GX9K M_E!I=A9,5M/?EBTZ/HSV*%A+KR[TQ:MF10 -6)U)0D82DQ_L,S$&.\H1S"5D M9%;F17YESNY&L_YXV!O]YVPTF8_FT2%XNOB/$5N@G^[N1GR/G,]'"Z1M<9]S M$@4N)1D+SE_$3A#(YJ <"5/OG;4'QME@BWP&[*K23LA;:4,,SNVW )@,6,:1 MMGI=>(6A?.5>%HZQ?.-\?=V?LUV3[:5\^?:Y#0EIH1ZF%EGN#L0DJC1B;Y1; M&I$[LYZ!M]6ZXR+5$(#.^CH]:\!2KCTP]G)O1$SR90B:0=L C;#W*Y6K@*N\ M"OC2O[MCM]AJ>[/RO+R?#/@\7.S0Y'EW/_KQ>ZJSK;2'&>=8$<;IT$)Z\5-^'7+3S'CQ MD5W^XOO@8!J92$<3//NHA"B=:Y_F,'AO@RLG"5BANN,@+])*+"YY9%P?NH:K MYW6]X./:N>K]]N?\.A_]\]/8B"TVID"]?//M3*G1S$V(6DM38PCD55G.&F4E M9P4B!FR3W/])_K5CPXT>B?#.58C6F7^ZGK-UPPVCH\^CJI>O1ASAZ=E# NY% M/?!<^>GY #WW@B[8%7@5["CQO4MI-V%]R'R64I?[12'&1N%R[_VP'P^I$O;+ M\+XG\5JYB3W'_PN)= /V/S7ONQXNZ,DXGP(R78V"T-FPRZ;X[3%3 1V1Z_[ MK,M$+5C0F3BC_I;P@'^7'T(\F\O=ED\4O!CA(Z 7=M9EI2XXZ-R\8X#R!#@V MUR%Y)*X?S38)8E$M2%!G])K-NCS4@ 2=?>65H:?[9(&QMV13=QX)ET>E?JTT M&'HQ9NVPS^J0M92-MO_J#,TMLNP6;%H#A=#+ 5'8M+@<%1N?%K(:.ES*]]V(:_SPFNEW_FNR\3KFT7M2FM>;\C3R+"J3V='1XA]H(Q=4H=RO[_IG1PJ MC(AV8-!/FVL .0/TI"2A0:8Z"ZFBTI0>Y)ODR>?V!#1,T3[O!5:YBMF8-8<\Y4R?^M0;L[A+JX8. M26@Y;C#A"HJ;Q,L7>"%W5E!%M/=#,E[O,.#935135R6G@YE%IS0JMV='F\K> M(2'74,K.I^;(T4#$@"4G*A8*6W6%3%E)\5!S5MZYH*@\V%NR8*._ON BH&GR M3SH.ZHZO-8_8>^]P?[NE_I8Z7!?)HDIEO;"MHVTR'H+720O$C/HK)[SU TD& M3;H-MI6Q3687L3!@)Y:&1R5;9_DN7,AC5\9')<.=3[Y&!$CQZU@7P5'Q=U0+ MN[ @S#A6-PW#8;-ZAR5 ->E@^H9$SX=(%DUC7S!#:-I9^TCW-$)(.%A](8M+( M'*_FB*6"XB"4CV1S3ZCDW%-LBGT!AU=A0 M2BPZ"VIJB?Z&'Z-;VXSWPV,;X1L^*C>[TV9YT%+@PV3'Q38)X]M/31#2(&AK MIOJLST4)R88L\O*XM'04V_5S,+WCO_0ISU0TCL M_B.AUIKL_SZCSE)F2^AX'MA&Q);U!@Y;#;!50I^;@7D1"S4%-9]':LRS^&*? M3&K0V#DD*^XGN28>^T<856HXDA. ;9F@89#O<?[U#1C!^,9!437WZ^>,.$MM?3ICO!P6ZU"-;FC+[,<*TUI96S/8 MIB^L$IXU9 T3'!?Z.S>\=59DOG2(MR3!S^9QU_DU8!*NNE M]D!F\%8JIWD#EBZ)[6B^XQ5[MJ/+!W;I[:\IB28AU7Z ?M@:L*(T9A)PH.B@ MJ\BSV]A<==V%5_CJ[!4^>X4[Y'JK;LB.C\@H\=:Q/3J2 MN6!"OD5_DFAO:'_LNBLZQJPR-SX8HI,.%A>0&B4Q51>&?'?L,UT+PE".T&G+ M@LK))?)Q3?:EG>,7L%)E]9,D\QI^RAK?Q-XV:DE=Z[Q WX@.I0P\^X[[0H-4 MT8D%H1OE\4#2$SMPJ0[KH;B@,W#@6D%P*"@QI=%L,X[L8[6)Y*_!A9BK%8?# M?KZB#JMK(8BYUPC,0K=^+*)#V$E60*4Q%@'!JQXR(\!5X4D?\;,>R'?^\[L>C7B#]@EZD;NT_\@XFN11 M1!Z(-GQ!JB]B:_E6ZNBWS)_*^\0V=I:'%@U/TYV9I.RE;+(Q9"U(KOA3Z!N; M43*K8LE96(_(M)0PW-0$T(U7A@NV9F+P"8M[X1A9Q.M>&Z\[PB/RXO+&^U+I MW.EVJ1#]KB>#;C%L;1G@L!7=(MF@"A@S$ATO<)91D%DG.CO_271;J.%:NIQ% M+T,OUT HND$<:EQ\H-(BQ*U\##TZQ$3!E;!%7V3?QR+KD34GR&QQ595ER0*# M5&I'9Q) \?[Y98EW\VQLZ]&R1B@A=D6)C)(/.YT"4!Y_.0UY[!Z_5J41<(;F M6?SQO,6A^GRL:D,!I>/7TY&..I!BZ1Q@:3);=6P#K8Z*'P-*ROO3D91VV6+^ M=??[+G08E?$Z 4E%0M'84(2VO&H)3 /NT'==8D\I^\N*..(=%V4F4.D^$;<3 M&HZGHJ05JSJAB%>JV*_K]LPYI1^#"N3WY2Z2\.7[MN>4 (-TK-">"5323] C MA,#1TU6]QH5/?85[*R^^$W\0 +%&'$(CSW!];' (E8[8?E_>H%*HSO)Z0E%4 M.K+]PEQ!S0%H@L3+K!"=QM'(C! =3P0JV*?F4T+AY^F>@PT,B])1NR?BT^H" M,A,4+;HE*>Z9/]<^/Q7'9Z0X3. ROB)>.,ZQ^^%J%XUP3B'Y+KS M F<@G,5;F]MF"'V-HY8V#*(3F*32G4ESA"Z&$_'X&8BP20NC5?W07Z]IY$3J MZJ!>8TI0L?^^_(JU>7SR4IYL:MR:W_9YO.134*E\83[ JCQY2=*&@1Q^/J29#I[INE&= O?A$KH"?KU M6N62\=6QCC/-E,>ZT"Z/U;LX%\@RH4#6X8VWZD%NX%?4:W_"C#?1VM$MS:&$ M_PA[Y2/IK?J%]B;&-D..&E][35T,;DUZ]STFDWU \1YGMMGWP>$B/MU>G M\DB)9_/72"!O:+;S-3,DIU3J&PM+E]'?SEO+H\W6]9])5-DZJ<;.JQU(WUE6 M],$N+MBFL*?CKD#0M7.##6B86O;LI^.29S]\O>.4"M0R^WOJSV8LJM;4<9;8 M=MZBA_!"N)SV$S3DS?@L7N58-O3V>R4P/SJ>L]EM9'#FFJ 5A,S#50"SE!84 M=?'1>E*BFFV"5E]0C6H9+:=K1KRQ'!I9HOI!L-OLK56)^[0E"SC@F\@EKYN[ MQC9E2 3SR0Q1K(*=C,3/OLN&<9WP^GLAG4O2TSOG.#/ M&TJX<9\P80@[%-+R3V.7J3X-$96Q[64)Z'XQ#IU'QR:>C:!%LY_&+B!]&@(J M8YOQ'L-C[DS&8WBI[S&\/'L,C?(8[@U3Q4<3PO8K-D%/0W$69:_Q#9DA;JRLW)X2-0XCO MB!Q[;,.Y_!3#7]T&,A#8'?LMS2J<%$+&70^)CL"LWJVU??!WRS-Z+=O:-BOF0&[96(FP+O=2-OH/,8N'6S*[)#$OWGY[N)G::"M MO OV-5@=(0LA^1P@>PZ0/0?(&A\@BQ'*^?(#9)LO:'&B ;+G9#+=9+(K:%T=D]J8\A92"X-_9K MOEVQ4A-.]+TW,6_.+!H^+Q@8@;6,IGG]G/Z+?&/6&<,,W=OVKJV#2.HTB"\" MJ@VYK*T9+-479 G/VMTI_T&>TQI_Z%"R9'VEBE;1!UN]BF4HK1Q!A+>TSRV^ M^=!327E3['>D81#+R$3?;%Y^L%X[VPDD0.^G"YPU+4!/H-P^>=;&IR&/ M:HG.F@4)E.H[<&_T%\JUPK:T2&MU[ZG DV888484I)H>0_:GRK[UW*N=N_#! MIUSF6@AX$'_J1>?EM\&5TY>WOFT[O(OE=BAYLH]BNZ7-%4(UJ\P0QRH%,$9/ M6X=&C;,OQC=8EZ3XB9>=1M\D&] %R[!8]--+7*\6^Z-K:FQ+FB63]1UU/=->N5$A?3W+N3Y":5-S71R-K(Z,ED)$IQ:"I3)?/(2SII+ M3=9T[!1LES67W;/F"LZ:*_1<4T367'7/FA_AK/D1/6$5D34_=A%[]IU5(FCV MA'LN3W N3X#D[CR7)VC#8W>BY0D&KA4$TU5BS)S2.^Y_R.BPPQ^#Y*^!Q U5 M<3@CHWN;LF#F+I.U$#=37E(.+$W1R/1\45?/2F)0 B0ZQP]^#L^.A3$U2>Z+ M%'-M4&&".ULC([^HV[=0C!J#J]7[NFQ[ M$WB/A81ENKVH>[P^DTL@1.*@3-PJOY M21G7T[LX1_;D?(?[I%15)$ZNW4E&SN1H,"#2Y9 2#(A2*6EKB*&S5(9$X-\: M%I I<.@_;%-CVI! M5#!-#HQQJJ_LR7M=7LK&P+8!UN:G&B#C>%KV2KPN3V5C8!M^:O-4#= Y-*?V MH:,TE*;A(O+G4)H7$$IS?NGC_-*'MM$XN5@>,G;+/=Z\:6E+[,@6H<4R[7:0 MT'C2B?LRCWM^JZX6QE 7_ 7P*>F_,4L(AP]6._ZI[8N>JP(O?@%'2M MXW]QI34NRUY7 MP7/WG5]7$9+63GKOT%D[H>7._&^$WI+DK"9)B9.TQSZHPI[\4!+V'O20UP!H@,^A86 MA7Z/@V!'["$3)6\=5X*.P\0CJY7$:@'HBVQ)AM[5"P&+4%1,9>!GR]V1:OQ+ M=\76D78 MR;L0@QWE$,6;RS+^0?!SQM*'^9,A^GBS&DP^CR6 \JEL@N'ZRO(3* Q%JUXWF,%BK MTK=WR_#6L>ZC<,3C-%4N&W5/,^Y\E;A96*0J6O&],I(Y%G20%C=O3?/.0&46 MSL3;!ITQ@IOBK;/D"G[TF$]%R=T-2]J=)NH"8NHZ/R#P"GT:A3D9XM$08*4 MM%V?!3N8C#W[(R&AREM1VA+MXB2$J8BFA,26[$7L<_WMUG7BIVEOV$)28"OK M@';BU8!837!+2'_:\L_1(!SZ ?OF=#5C,X@"HP:L,YN/NZ".YVQ?0H]1\A*JO8%KH;HV['4CK;WB:2I;:@A%MQQMZ,.Y.N*NP5&@-! M+9#X7*F$$$K"1')-F=(YH8^,0G&^5'G+T[QL"T'_(.74%CS M#:&PMI+1IHUK.9EMX6K;#H?!GKVG9^_IV7MZOO,CW_D;SB\[W_F-N/.W?CG%OR]U?C?MP)32 M?!2I^:84I"N_ =:5#F[\HJ@-0I<)5'T18J\P8>VP)6V[R MW1M"1/B7-<1.+:@*N9AH RPJ<5UI_;I![_.&E-$_/XV-+1444ZFVC^3;897+P:^T<*KVE9PA\"*/8Y539(R$)O3Q.>DJJ\CAE;0WAB4K.) O&E*KR[*KE ML#/?;%_",IJS6I$P.R?+/V']_:Q(D7'OO'<;VQ'[[>DK7ECMCE M6E@=D;4J-#)CG6AHO#(B&JW8KT8Z_K3P.,::9%L@8UR&6 '3[(S;\AG-;Q1. MC6,#-%51 */,?Y$GI"TS+$*Q1@Q L6HT]G=N^,'U[Q4)%<5F>.&U$/$44(5^ M2'_1CV]6MSM(7^+\\?P2Y_DESLY>XOSY_!*G"/\]$AHZ3$)F;-).$/CT M>>)+WNGCW92]\$Y02AR+)RH@!N@ZZC,)N'-=KIPRCK9FXWOPL??.K\=8R(*:V$*>V''(@GC3DH5KX$0& 8IV86G=+H8A,7TYT1<< MRC%Q?^PPO>JL4V'25JAKB?P,2>"L/3X3@2)3=<*.W -Q 4)(J]!/=ER9LFE& MG]W[9 20BQJ;Y(J70BVGMB6(LQ^;46T)1#RP4!W2&)40E\YW2:+:C)T*7 M3B)DAS\&R5^#"S$7*PZ'5N.O FMK(9;B=^=/.XLTJNRUD GY%OTIF'K"'0S> M'\CF7_%UK2XFZ.MX1OTE(79PPVCFLV/79L+.]1:W$,6>!-DE1]T7K>)CI0L. M% MTML42%4M:9DN7^';%7? B%BIP24DZ.G/2@F$Z!"_\,?>(PG* M-'^V;$"N-11R? N#@F"M+.+D+_Q_[AGCV&_^&U!+ P04 " #8@V]6P")# ML&(' "B( "@ &5X,S%?,2YH=&W=6FUOXS82_F[ _X%G8(L$D..\7'"% MXQIP8N^M#VDVS;I%^Y&6*)L72=22E!WWU]\SI.3WM$F;W?:<#XY%D3/#F6>> M&4KN?!A]?]NMUSH?!KT^_C/ZZXR&H]M!M]/R_^LUC&-*JYR#K]E^M2[F>R*S-3AO= M;[*QR:\ZK?NM*2\5?<66PC#U](I9\62;/)$3#&DYF=I&=_#SA^'U<,0NSD[. MV!=2%8K,"MWH=JZ[G1^[-X.'T?#]\*8W&GZ\Z[1^A$,Q_F4T_[[64@S*+! D]/3F_E%FC>W;B ME?O/(9ORF6!:S*28BZA>LU-IV.>":T0]6>!&KK1E*F/OE4YA6?,'IF+62W[E MJ<@BV%=H%;!A%IY\X>W\I4X[WW#:-3"&(*48 8+I0Z+%-,RK(B0K!89G [A7#EY@"0P'S2DC-' M) A%A*XD6<&D#)"A;%[7#2A&DB0'-*5($&I@0R& 3I]Q!H7<3%FDPJ[##S1$_ M9GUA,!$N<_2["FB]]DQ$ ZH-(2_,[IIG00".'@L$IU3E65\5&@*0MS-I'!M@ MELB<'.I^ED12KZVSD18)=^$N>7\5L:!D*KHI02HPQJA$1MPZ2\=&1I)K23N0 MOCHQXL>,)!6&H6"X##&NO#CR4$; (@NRPJ)Z+4<[(L,BX<1ZV)BS8E5ZL,07 MLO4"C&]C01/!2U@OHL/D(0^G\3:!& M99PHCAL CGH1 A+74153P$SRL4RD75 !VJ>7,.["[R+KT;DQ=:V7<4SZ5.XH M+W0.:!D"-N-AJ'3D+'!MS41D*(0)$(8[(B?LTA3T;!Y%P+C,06:'C*/PF UF M/"ENWW]06^6_$RJ-.*][2K;+-;9>.JB7.I(+PO8- 5"3_@P$<@$._1G=#4:W1T M*4NZN[47 *^@#:HQ*@P+30%8H_,]4E-E+,;I*01Z!5@(2>7IE!T]LR8&EI#/ M6[-+R]'>"G?LHA-95BP-._9F3;E9EC]B H<]$3F2=!XI^0LM?B(?15(>PK86 M!'_:28>+-]\X7[Y1X^R>7D05LT]@"KC''B.EME,)3-! M1)WQ2?D@39=/4D2:)VHA<'<^59X>^ :,$/57ES$J/3L0.?E*\?CSS[O[U,ZU MUPGW>ZZ![K/+@)V?GE_XC;R!HJ^(SE'O^G; ;@:WMY_N>S?#NW]_USAMN.O[ M7K]?79>6S&5DIV3*Z;LK4*_&.:49JB3AN1%M5GV[8F1QTR AO=D-]_:H,WJH MY,RH$J&IJ(RS*F^4;Y@ZH_Y2VU1:T30Y#R$'YUS-\Z76L;)6I6UVG?#PD9UA MO^ZD_,R>.^\_WHW6W=F,>2J31?OW'+JSD99I5>\\O+WEBX].BU30>['^:B-+ M7^,K/A[^F!MR'M&AKIF(F&!P<7*9VRNVUSE[B:(,VOFW[][2$7<\Q?>MUS][ MO; %GG^=OVO\'1SSELX829O@XF8J1U]']R$#]K$:^5EQ0&_\9;XZRQDKUJY5/:/9I.]ER*)VN[I M;O,>19@UF]U.?_C3/FD7%-LM>6YLC98;&ZO7HT032_)TTCQSGN=/GCE7.\+Z M;OFY9F%KP\2_*#PM^G%!U_W>@'Z;\#]02P,$% @ V(-O5C!^CJ17!P M5Q\ H !E>#,Q7S(N:'1MW5EM<^(X$OY.%?]!1]5L)54FY.52MY4P5)' M[+"7S>0R[-7M1V'+H(ML>209)O/K[VG)YB60W1V$@8N^%D6FK%Q:YJR=FW$QE?L&.6[T?\HDM M+KN=.Z]J)?+2M2_9?=)I&V*@A='YV>R[S5.SD* MRL/WB,WX7# CYE(L1-)LN)FT[$/)#:*N'G&CT,8QG;,WVF2PK/TOIE/65Y]X M)O($]I5&1VR4QT??>#M_J=-.-YQVQ:U(R"?98[/QD.N%$LE41,S[KO)8HF%( MKAV+81V7.>/Y(RMS9TK!K.-.P'V.7,EA%7PMN6(ICS%DF,ZD8TX'N2V!7,3" M6FX>223C#P)Z1;.Q7-1B,($UT*F()D@))%@L35QF$,LQ'Z8DPK#%3,8S9DOZ M6LU?"".J16@'F;1*\$3F4[:0;H8=VD+$WD):MX!M.L$^YY@&!$T>UQVQSZ@X M>R$J!$ME#K=3"%=NC@ )R..V6;LO\Q2)QIW$0C*/59E@481RS:41<" I.0M$ M@E!$Z%)J!9,J0):R>5TWH)A(6CDBD5(AU,"&1@"]/NL-BKF=L53IA:V!8\14 M6F40P1JL0 MO<+H6"08MNP P4H$HA\B,OP8SW@^!5/TD;OWI8+(R1EOGYP?B&#&R7D2KL*E MI,*?!]B0 D8)OH:F$%TRYAE-;$M1NJ$H/3QL-FBG3T$&$:I*^UF%/6X.^"$; M" M!N,S3[RJ@S<8S$8VH-L2\M-MSG@4!.'HB$)Q*56!]71HL@+R=2^O9 %(B M]^M0][,DDF9CG8V,4-R'N^+]5<2BBJGHI@2IP!BKE4RX\Y9.K$PD-Y)V($-U M8L2/.:U46H:"X3/$^O+BR4-; 8L< M*(Y; (YZ$0(2-TD=4\!,\HE4TCU2 =JEES#NP^\C&]"Y(;K6RW@F_5CMJ"A- M 6A9 C;C<:Q-XBWP;E MSUQRL4A3=!)R#M]8JF1/.X*ZR+V$B\+E[B;!PP8302,VM"(37;IM$ZJ>I-GX M8WU1Z%;"&M1II3O:5;;9K;))W<3Y5!#!%S#HDA;?X\ G()#@T:W0-!MT=*E* MNK^U$P"?01M48W0=R/)R:=AA,&O&[;+\$1-X[(G$DZ3W2,5?:/&5?!"J.H0]F1!] ML9/V%V^A<3[_2HVS?WJ1U,B-5OE+?+(&GK54INB_. Y4OL(Q:DIXU= M%B0_@#4S'."=$-L'J.74B4;)H_N)A(%^D0- #.1DB?WP2XU7G1CB0REA?TB" M,H_]:>UPS_OC/HZTU%E(A)R.!73"B*5 @*B AP-1=>!="/Y U4'8.LU#4^(? MIM3'V\^*>]50AG-9G?-LE?(\P40KB ="RC\7Z+J5P1P$&@U'%$J4A9-LF<%! M\I/P *HJT,Y' ?M+!\O^M8\BDQID4 3?"Y_XVC0;_@%4%>N ;,$+4/[N,4>G9@LC1=XK'ES_O'E [=[%. MN+]P W2?G$?L]/CT+&SD*RCZCN@<]Z]NANQZ>'/S_JY_/;K]Z77KN.6O[_J# M07U=6;*0B9N1*<>O+D&]!N>4=JR5XH45%ZS^=\G(XK9%0@:S_>L=UAW?U^O, MJ1*AJ:B-<[IH5>^7NN-!+54IF&CG=';!)HK'#^P$6_.'XDNB%B?:MN Q]. < M;'BQN6O-FG%OL^.S@OWC)&5 M'T]_?+7+X%N>0?;W37X2D7^B9%RMXL4_U=Z#;^8J=O MFWMP%PZC,'%E+)60_NJ\6ME^^!+C.SZ9O@X%?(\B\KR6%[Q_71-9WOQ;NPU/ M"I5<^.>5[3N4%=9N][J#T;]9_V;TT^WKULWPS;BUN4@;L;U@9Q2Y:J#.^3,B M#S][DQ/\A"M/"*?%QYH0UFG'PV!%5ZM]8+%>];UF;F?#WB]QQJ:(%^O0._&> M?TE.+]3_!U!+ P04 " #8@V]6=R_16ZX$ "#&@ "@ &5X,S)?,2YH M=&WM66UOXD80_H[$?YA:RBF1,*]->P>.)0-.PY4#"DYU^;BQU[ ]LW;6ZR3D MUW?6+X0T*7=M(*URB1#$ZWEYYIG9F04;9\ZGH5DN&6>VU<=/4'^&,W"&MFG4 MLD]<35]&+1%WI*(.>-MJ&OF.WX91YW[6]]JL@-K(RA:[X"DMU(G 9OCDF#SA=1, M^_/9H#MPH-6L-HS:Y"\@=N(IH+YSRF$1NNX7@%K!E9_/''L_AI3N?12 MH HH'^H_P?@4G#,;9M:T:XWLF3[^/+0OP.HYZDZS7F_N%-*>BO>/));,7^6+ MC'M4&:U7CQG7S $'-^2X@B$6$%!MRMPB&*9[#?!=Y5$G9ZX3(B?/5.I%='@&9/0['$*/3?P ]%:C]" MU*$':(QZ\)%P=+?*K+0:%62VV:H B<%G =Y7J,HEI3:C;B*89,@$01SVK;L@ M?$X!?2Y9'*L0\*4D/2(I+*B@B%M!A!S=-(VF %=)91-$(6+DBGH9!I<*Q5@% MHD3$">$29 CK8BV79CE=6;4B3N*%D42DF_*%D*HC!)'")^*2)_:08.4*:!P?>D?K]-U7W[KR\APV/K1^[*B:W&^T_RFG MS8Q3QG$3+TG*$[8.21CNFW*)\0>,$X;- R)!8\5M!;6 ! $ZQZ["2(#,QQ&2 M'6<[T&><<%>MHT6/I;;5!D>I)$@)#K%CI#[C(AMYGZGNOOT6!AVK.[2A9P^' MLXG5&XQ^.='J6GH]L?K]XOH?.[UAGEPHT?I!!RY#@R3FW4E'EUPNMOX.F-%6NC$ZVI M;<6FF$YUGIN^ZGOU_CB1>S2>AHQOTQWFJK#^K\C<4-XIK'71_EP_^!N(N7)> MSY>AE.&R#=V N%^@@<3%8< \M+/%>//X8)>UVD6=6ER#F:01-FL\9KA?4._I M@E$?)SY. M?\FN*8Q]G^$)\?7'?S@1#*=RA&/Y4?1'3X=?2V?FWLZP;R/ZZUE[9.G;?E#9 M,MGA;<+_;W;WVX1_8L+WR37SX&,5?B7R+O3]K2/^.?B_HVF_C=/7&?>#<7^Z M_D;Z/8[[^^CQ6WB&R7+=,.$2#\;M,K66]C,W,C,P,3!Q+FAT;>R]:W/:RM(H_#U5^0_:WL_: M;U(E$MVX.5D^A3%V2&P@!N?VA1+28!0+"4O"-OSZ=V:$0( $DI! PG.>LU<2 M$)J>OG=/3_?G__W!__WHV_FC/4-5EAY%GSB+\!_77@V_E1<_ M<#]<^&A_N?2HY?EHWG[4<] M:\19WBGZNB>:-$#?][6%C_!;Y\&QF;L7Q='\X;YH M]O"#LR^6WCK[+&>.1R,5#(%F^?X./8-_^\@[OS8-:^,O9]^O_ J^S]!58'JN MA+]9 E&VC)PU&0'3>_OPZX_H:_0;)L>P.6Y."DD?:Y8Q\<;O[,NEI2"\GIM8 M>DA4I\/Y4_ ?(MR[_$'2A^@I'G(H>X)5 1!E^">%_M]G2[%4%8I$I%L.\M^QZ;P5M$/'PI2K>=_NB:H(PK^)=K[K0I3%^DV)* MHOH;B,8E_,3$6X\*WO([6\!0=-E^Z_=0[RRYWED=&\82F#5-OA MT+6_OFXS MSXTJ,[VI_/MOB"4*B.4NNFQWIM'ME\&/PKR#Z[8'H@$@SKK8@-DO,?%G8=YS M@6!IS=[%KX&TV\O+W=;8 %W!_981_&3VCIXN3RC3FJC@WY,^E.93BF5&%M51 MAG"9!GBF;O6AJ&%-(2M/SI.R8HY4<7)*:;H&\)?*RRD2>6 @78+_I<@RT+!F M0?^$#S8@;QB*9"N-%^L6&8I+0Q\BJ-[/SIRT#C$1%KKV,@&:"V0(G2[!5S&;?A@TM<4(I\K\G M4"PX!0D#= "%$VJL*?:S4-*@Z31/-46%]LP80] A)C-KT.6Q)CX0L0Q$4A>*C 7=C39D66!6H',$@R]+Z:E@>6LW8-@#QBK\ MT->('WYL()IC"P5,*.Y+$'R6O#4>J M/@$02 U^HYEC%6[/,D^\-1'+0AY>L/*NVXR/2@GN<<8 7?C.H:YMW$\A"_N9 MT:RA6^ 62 IX$B&]+G7#M3^7FIWX[;64A;TZM+N%T18,X.6::&A0=$V_3<6G MB?&FZJ8Y1MF59M^%7(AJ-WY;X@018"\"QW$9V=^.S,G%K%CBWV=(QN3BTRR. M/6L JZ[!B!Y#ZG(]/7.( N"++"GHEC"N@=U[7JN)(L435 M#W@^%<#'(]!\_%Y[0'\T)M:/SUJ&\T?C 5_(Q^F/AJ0 &XM++1R* O& GX^5 M K%Y7.Q 2-B1 MUXO%HT!&2#DHQB_AVR.@N/FX=(@P;A>7IQ2_X.T"<+B@N12_%=R!97:4^E+\ M2:/ ASAQL'X2AU !#W%B ;]XP*!Y=K"WVQ9XYH 4B /\Y"C@8_D:X!E_XY<= MPR?Y<:5E>#;^A&H"F]M-B_'L?AVYL)L,YY/P,1YYQK:;Y:89KQQQ M\:FY!/<8V 7CN11F8I)2#UQ\_O$>:!=02W#QZ;R8SB]C%KCXXM%D][SJ' MYH7XLTE[/(?F\TRZ CIVSF:QI SX0IIB'=_-[2A#A?TFH\-N,J1%W/,Q4LC= MK(.;R@/I>*6HF,*0P)_/MIO_&(^RDJ?9CLJAF,)TP\XZ(L;CM\6FMBD(;B^R M5DHB=1+SUG9DR1A/X.+?8DA.3.!P+JZBAYCYW4&E'GBT? M0O[XO7!I.8ERQYBWMAM?"DP2N>BXMAB.$P5FOS(65QE-K#PK,"FK)=HK-\=X M06R?FP_)YS&>A^UQE^O;.$2R.FYQB_&H9)=-!(Y6!>XP57=^ (=*5@M<_/*] M \OLJ*QB/'TZ1/V7D,2EK_W5?PE"(LGJ"S R($O@-$9$O9B/_Q"@,M0A9J88 MJF;_ O2L"\7$#;8@JH;*>!BU_D3(QU\P4X> 0&)8L_XF;DF*B-$$DL M0Y< MD$T$@^>Q;V2,%I-H-[( -GAD& 384LPWUI?0"M^K0+LP[JF*U.Q#B88* ?O4 M=QI4<,_0^8!JSF%D.U,X'"HF\E30OQRR5'5SO+WK )!O0/'A^UUM+QTGBF.7)"HK))GHU9?$,4P$2,&O)Q%SS.FFE55453 M)%'M&%#E7()5\#;W8\J78SZVRA1C3 '9>!SE(YZL'-17$ M_O=8-,\GBT<@B=%'E6?1D%=-35VS0\LK8TMQR";&+0B%))RWK9LT ^[2=';Y M$RCW \CY%2BOXCUPOF]!V8\LM875N_*M, A 'RY:%")\8&<90*DU[2=0!]Q3 M$[SG"!][H!%T['5N=G '=(G'\Z_QP:5OA-7P$&A;<"//L& M5^O?EKLIKOYXL=Q'S_5FJXTPL=>A@&&,8:%N?V>+[3AO6GRW]C-@MP@\6^Q[ ML;R\]!/G\R4 G ]G*/7'\T*'\#DVGS'&N5%\4\.9L_XK_[SQ\]%W(#^=$;RBP) M"^&#%/-!HOK KRE7QM3GBI.#-Y,B)\?O%G>6L8,HE[%?8W.%_)GS25<,N66K3C9@OG,>_-OPX.R)C' MOF^^0'XGIGW?4^A/8@KG>: M7.\]]]("E:T]'CEIILN-[[J*I8/4TGKO?KI#MQO=/K>N^3'XCKG777 M^Q#:@[C>:7*]]\$!+/$J,^I5LGOD#N)5IL>K/ 3=B5>97J]RG_Q O,JL>Y6' MT![$JTR35[E'#LAR0O< %Q^($YX-)SP;-S[6V8MX\0?VXK/.."0,2%D8D%6& M(G%$)N.(K+(;"412$XAD@X5V'9-]W!R5%=<\Q=>$@P\P/VY62J=KGD'&(:YY MFEWS##$4<N>'HCVK:S8!C8.I,1 M:/8KB,7O,*#=-,0A<-O$#=L]H#DL)&\.D3[#41ZF875O%$T9CH++Z^58]]X)QZ:-8_U[)=6&(U6? &!6-+FJ:^981:[!D121 M59Y%0T8Y#!?O;-PP.>T-=9N?,$]JF"?%9[-]$^U'&=GO-]-.\@=) M,JU7KOW5,&URR7;"M#&9;/\)JR80#6F (D/P!%1]A"\YOR #!K+-J8%,]R*: MV(J' QOQS$Q>):R5+=;*T.0PPEK98JT,A1Z$M;+%6AGTM:Z !@Q1A1BMR$,8 MZ)F6(:*"D=?'7($P0?RMZ?.]O \N M:R_ D!03M Q% NQQL)!]27CUF E_:E;&UD WT/'DG28#PW4"CVJ2S?/)$D)< M65P[K^J!K6,]R@S +QSAEQ#\PKUZ?N$)OX3@%_[5\XM ^"4$OPBOBE_6ZB"R MRB6[ES@<#SW=I^3'1,]PI__9I&>X/I-YGLTSY6+^<,U!XE+NP;J>DY:16S7! M1GZ9?WH#1'-L8(S7M='8LHWE#UV%1E557LF(A3WTN%K%\Z+"R.\);TH<4-T= M8K1#,*:]5R%+L\V57:([!>21" MDTG'.KU"@TY$) O(%\H3XE9Y010B(OL7$7]J'"OSNB]0SZZ+PK\M\GT7RCT: M&M?2GX%Q#3&B:/?+-P2.OAENZ$N:OBB+E[LSU4AV_=)T^$NCF"^3/MIW2P%3 M)E) I"!]4L"4$Y4"7#8=Y?7OG:^7T+2_GA] M"QD.7,J%&2IL1A/SWIXK!9TQ -<,PUTK4O;+ME 4UC)T>2Q93:,-C">X*7?C M^[6-DJ*_T)S"OA9.80FG[, I\W'J:? . M19Q' \3 M85:9[:3V!);GE'M@(+YL9:K575I:XA >?+T\F$FE"6E5&2'TX#*^2T5]K7SK MCXA7PKYI4:&$(PE'9EBAWHT0K0S3NM!-2+!FOP7)AX_,JI" D)AJQU!$]55R M="CQ@K)NJ,F#9M7RU_!T'+*V'M-*EDPJV$ M6U^+(B:.1E"TO!+63K4B)MQ*N/4X%/&E+%9&(T-_>L5\O(:#5\*T:5*QA ]? M+Q]F4GEN.>T]CJ*XU)[V'K84+RV*D_#@Z^7!3"K-8.>[KX!O4W"^2U0HX4C" MD1E7J)%/;E\!1Z?SY):H7<*WA&]?C7(.>W3P2O@[54<'1"43;B7<>N2*V%TI MTC$ NI%>UUJHUP%/F#P\@EX)NZ=).1,.)AS\FA3VIA/AU\+1!SL1)FJ7\"'A MPTPJSP!'&D?882/5AQLI:N^1%M5*N)1PZ9$IWFB'&J^-RU-XO)$BQD^+>B:\ M3'CYU2KQ4,<@KY'GTW,@DB)V3Y/J)AQ,./@5*>R(1R.OD?'3>$B2(A%(DQ(G M7$VX^K4K=M_#EU?)Y8)+R9'25KLS1;SC%"CBL[?UL,K=DP M!,A$R4$ZOP;VHUC#NELZ_'3P?DI4=C@G%R@YS[9F5 MO4=*OF(&/_QL22)BF10QVR4G@D4$*VN"M0@15B4DB1#!WY_*/J^GD;K94IN$ M%8Y&T/TG/PNR9G5_AT'PIY M,82<<"SAV+TJY(3GC/LR>E77GH!A*3T5M."CBFGJQJ2A6RN3QT/$YV/5NE+U MGI/#S[H87(">58>ZQQBOR, 6S+VJ2'V%YD0&$_+^+Q4-52&(&A008H;VQOD. M+#^ B9J$NB!8)P@Q?(>+1,::8DO<7?MBC>^'0#3'!CA33%W@V.(I?,9YF?/5 M\A+H;3[O;P]$ YB^2\R0@!^*O :$K^6SCJP\08%;QRWZ;0/:*4.T= ^."X&# M51B]WNI:] )HT )JVY;=CI?5=;U>['R_A(4 "(4Z FPAV0C^-2#!/BLOIP90 M\3T[@;T)]+TH65)'Y?.F$LO399[IN:= Y0)\7RB=GGS^N_#[H M2PM,_"\MY;U?6BJRE/N?Y<(N:PA[6,,;X[&N4@PS#[[%F1 MK<$IQ3+,/R=+O^[I!@3._O6Y*DH/%#>R*%-7%?D3-?O2>9/]/;OXO@^5<\Y4 MIN 4?;J 'VUS]E_7#CXN;0'NT <+]O[=7Z)UX!("7+D#;:=)-< S=:L/1W-3;[7JS\?ECSQ\<+CHX/T7(--J]I6LT M=5&E."8OE#>NQ6Q=:YE[/%Y1B@[N9?/VAOILCD0-*]@7^:5;9BZZ 'HON=R% M+N&0"3EP70G5,S%YANUV49$2PT+O=]KY^?#W>O3E<@S5,A(\3=>PG5$D:F;> MH92M%M)9^J+*Z8321.2G(F_)O=S)&A8W/BT11H 0*ZH* M7R]!ZOU[ K4I^O=(E&7GWUN7H>T/:*H-@>TO2>9GI@C?7%X>*.CFE?L+-H V9 MSD,+HG,K1/\^A@X@,-3)+1CIAN5-__L:4VW]*7:&@A29 ?JZ,12M?T^4%^NT MI^LJ$#48J@,OSEB!Z>3LQ9=#9G]8\CKJ9D3-J: /*2E\R+O4:+GLB=#>V?>[ MRFVG=GO]F[JMM9JW':IU=]N^JS0Z5*=)0773@3J%8GFJ>4NQ^7?R>ZIY276^ MU"B7)IIKH4JU@[YFR[Q@LS*$$O['F)D:S(YGR:B*[:_P5Q6Z05D#0#TZ1*!L MMYZ"7C^09^NN,%5YA:E:^!9+NN8M49D)J$QF MU4X:(@S^D>.X26=*?4;I\S]N%:47I\[LBZKIJ317H3HYT_>F-3NWE4:[CG7C M:U6;57V(,LL0_=!;AC(#<=X#QJFWOG0XRLX9H>?MQ[TYZ7%T=?OEH?8H%*-; MWP6_K*Z)DH1L3F"$TB;UEZ!?RVV/"O!_<1BTCOU/2%_HQBGU7XYG+SE;S_IY M/?;F;\&]8EJH5J\!T>*-]-KM*/_<_]H#?^)#^O*Z)V>5ZS^5FQH,7!JUN]LF M3=4;U0_)T,"7;=_57F"TC"&E]#YES"&D1),R1T!"J6*94B R+9.2!M@G>'^< M9L;7E.29=;WGB]%5UN.76*^N2;H!U3/..^"ZTJH^AH[PI*K+/IQX-?TE,G>C M86-YB4\1E?065Q" M9T=\J<\.-.Q&6IOTJ'5=N'FL:]K-?6P2[;/^R5F)S;$ECBNCDRH?%"V9-2_N M"X2?=Y@X%'3:=>BU&]3?L:&8LB(A8)!$*VY"XL>,>U%3IOC?[[V)%&AA6X3? MU3_8B-]ST6/SGCA1)#M8 H#2P# .I6AK;-1P+H MM814?LOF.._-G=]]T[_S-W]OGY/<''=RUAXK4-18QL]16M\1X[6C*OQKT^CH MSYKW?LROC:O"TWUIS.3CWL]B:>A]6"JT\V+@O;!>>\':IVFTH"F!FL;'@JFM MT5?E]\WXY3QV JVL?W)V58EJDSC&1Q@]Q+#LA8N6#LVJ^D<9^=OR^ZI1-=M_ MK]5OT;,>/IA86AT*(L-SA:BHX$O!45&;H0*Q5L4 HO_FGYICKMI\^'GQI1C# MYMWK03-8$H3W/MM=X^3S&>T0%E'2M2-;IJPBL!M"2 MYA!,\'E-?S;$T?RMODX12C0IEHH#U1KT,*BJ*IKF!F7FM8B'Q,Q7WF0!.H:( M.; ]&?9T->2B =1J8Q:!(]<)BB&,M+5[^(%&P1?"3Q;LLU$?]$3IX=Z D9J< MFV5%C/O>.XX1:(XOT5P^_SZ@>O!3F3..GK!<#]/"6V5^-?YP+P59;/;D&%3F MZIHG.-D&4=.V=.F!IOZ/^8#JW*B1:%!/HCH&Z,2"PL4KFX*O-3QXLD80Y#C9 MI1F/V"SBC9F+'\.OY?X3^/(]!L0LK8?328U0&PZR-W:%\+49:_IGSG[^^L:+ MTVFK *)[>ZOY"B00ZZD*+YA.SAJ5]D7%[TR9JHHC5)5'W8C& [".R8K<+UD1 M&YC-_VU (YMDP4+D'=3>@??![GW[1MS#-6V.=!1PM0Y0K4& MHK4*_;.X#":"D<(_GFWB/4V)FDR]X^Q=]J 0P.][?^$6T//XT3[N'^^\!Y?5 M(BC06F_?C$33HLH,)8L3\X/W@<3E4CQ3'1L&?(5]CH04# RRQJ:WM/._;EH% M8W+]-.!BBVB\US\Y^XV*$3W%VKVKC:=[T%U9,Y'89.,B ]>[&GK@=^*3MIF: MS;PP(1:#W#54+ L)$_3%)*K,U? M0HW&ACE&[X9?H HR2F#R2)R@[S^V"_"H=JZS1;#>OIE)%A55L&R YO("8YM MPN#:+-KKC#>]A<'@M7Q>>:A= #XV8?!>/VW"L,:9OF_^WW_+14'X=#P2HYB4 M2*GPM8 2)1A:H?)K)#J(QPRDN]T?4\ZG,#;0VSK [[P.<\A:S5[=@76MV]6'E4T6R- US['.1;8;7:/,!KV"S?L(EVO MPX(-(267_^?D[-J;LA$"5/2VD!8O[!K":I!M*/<#J,\JJ^!3X0$)DB(+@^;U M<*BV5KEA5"'(][HQ\38)A>JW;[\+XZ]R.7K2@@W&1 ME\()%2]NP-"N=B8$'WGPCBWG;5_%N1N,JSQ06.(!O.KYV%0T8/KXR+^>&V/^ MMVS==&(YP?I&TGG"%;'ZV1.ICCW,0-*CWM_@ZZ C 4\73>G;(>]*0(.C&*CR-!T' M(6/3=I3@NKBHF;+FM9-.0($"#;28.D&K/RMP;:1(-+@)'6F8)\7$*E03-4D1 M561\47T,>AAUOY!%0X8A"ZJP4>25$&B1>W@GOO?R>3Z$B#PWZZ;:RZ(JU"Y] M]N%REF7/]2\_'U^41&M5_: *4*MZ'&&".8#.IL/%,*2%O(F]=;O$;K,K_/X# M!6.^"%F)(%%N&P&V41/>2W7EIMX0[HO1$SW!><0-#W)=]A#JII+'*OB ]D8T MI '%YNU;"H@S#$ ]P_\$RN;APQ)\5F+?4FZ.+:RC(%ZZ2AU3FV=X-M^="L\% MM?H(BG<%= 44G;7\>V*_A%H^-.>)2YRL@(^N9?4VP'&RQ$*+$0%\ MCLTOLXTV'LJZ)0-)@7[."37[B_GO2;UQ>4*A2[_X%QDJ0996"+G2@7ZS5^O#_+#N&ZT\(?L?6/L_S MWA'^JO?I>)[.K>HU$AE ?,CU !1_B((1IJN;+ 4/LI2BDL7C8M_F.CMG+;H>H?HE4?E8JKR5V\4>A!S6X'G-HU!2H, M1^R;P/5&I5&M5ZXIZ%LU;V\JG7E#A8BYWX*/(>%C0.S,FP_&$W4+#"GV0P@N MNIR'^O-N\";U;JR)8QD^+?O4/ ;FKS@P$(JU(@@25-PRFK@C4^>B"I$!8!@ M %+D!]]Z*.+OL'$7[:$E:XZ +3F[HD#(%/67D8 #NH&N0LUAS@(FRIZ3L"-2 M\IGEBZIH#JA+57_>E2_*&> +U$C31'G-!3:\=.6.F&"9@Y@(+HR)N!$UT>Y\ M.$\<7"BF-+9OA:-3\8HFJA-3P4RR0!)"G)U\1L_< G.LQJQ?N#BP%Y*1,/[X M,/C[CC+D"N085%>$4 $_4)U_(TRJ.NKS9E*5GCZV9A6G-SI?:[>X^ MNB=_', O#>^;X_ZKME#@JL&=I>) \4@ES*:1WJ-0JT/=2,5^HU YE'F]TUS5 M[VU1!=A&VJZFNVH;*<@[$Z>:9BR1"OR$YX=0QO,"]$7L-Z#YK! =FJ(;+JRD M 0-1."24C;R!&A%R1A] AG#Y"VG8>WCJYS]0(;;>Q$?.=GRB4/O54ZIBB#U%^D2AJW,VS1HZH@2W=*SD_ H? M.)-#/W+H%_30SPY^\&T EOU$>9XHQ-(3,]G3P)VTQLKYGYN9&0]FMGLJ;FWQ ML,X]C.^!O)"?]6FL=VHW.+3JK3WJ67VT= B$6V_?U!J=]O+IWL*"I([]*NH4 MZC48#S3 V-!IZ!])'Y+JI.=_.I)0Y[X[U]E34NWX-C&^4V_&,TR795&3J:\\ M5_SQP_JCJU LQD.XR 0_;AV$ Z5B_CWA M%C@3RF57:>5 '[\\MLX;3\+]2<3E0J[.='&)I\ SD&PO["7S+%;DWD/DU6UO M,B&T;O1Q<=W9,T#.!EI%A3ZAT\)V7O8VLGP\;C=R-CFUZN^D M&_38C<>"1XNSRLA05(IG,,:XQ##F#OWF8H*:7\PF2N5R%=.$2JK20Z6ADM55 MSKO3']_UF\[@^ONC))[$P?B>4%;:[1HRN4&%/&A Z.&?1U I\:V69*'0CEM) M$$N!4;)@RMH:4\[NA"]XDV$A=PJ__K:^W+4%]660''=6[VYOH4M($2XE7+K$ MI8R+2U$]1$63T1\H7?\DJJ@BH&)51<- ]ZMP"@AR+5?O#L7J5!V7NU,P_?7X M M5RB<2XY;!AB)BEQ[&:'X#6(#GSHLV: 5*1Z] MW/?Y6FWRVY0B2/%/GY3Z^CYFD%' !LT^!+0;8DLV8)2(P=RL#7W?[\VEH9DH M *3D-^\4*!=#4;#\<\V9&0+DSL*(R^4Z2*7"":]Q>_25_R\!:[=9AKM6_-V MT"XE8S97-^$3.JX)9(["TQ;176C1F-6&NEX;//X,&',&Y;PP[XG F0E*M5 6 MZ$*A%(T7/6/DH#C+%+'TI.>(E[QB^>0:'>@;%NV;",9OY^VN]/Z^/GI8G2MBU_O8S2J6_(Q]FXZS4[E MF@H3]"5M"!(WGB5:8 O0_>*.R7PF;BBAURJP/)WGO>Y=)V0KSY=LI3Z"(C%I MH1D'T#U /OL('4 T@,MD8G'Z]?7^Z48MW5T*ZH%-I@TR38U4/( )NK# 9NF M-*=;;4;U\!:CZ4^N1(0Z3[.% C&=^R39KAJ%X6C7.*7$:18T^8JRK3,KC=6) M]?#URW>U7_K6>=BO=5[?)?,$Y!F6+A=C\K8Y>ZQF5*5QK$3:W>?(LZC?2\3X/!*5=JH9W> \[,E- M#'%J?"A/-C80=R+5JF+.VN8S **WQ>5=%O=:$7N*BB\T0(_#??/8O@:R?#K_ M]$/Z9L!*7C%\?*&*^KE?.Z]?VB.-*XX)J=YK5;U^:UQ>UV_;\NO3WNWKG M=V;HE $0B:BG&T1O42][B[IW>4/_R]//R&"!D MD;A^[TZ_JPV-CW*M\*T7):$=(P>%V M\Q@NZ/5CP'"Z390D8PQD2ETHGXBD6 NEPL=)GHA+(KCEZ(+ T4(Q'0?$>\7< MKA$GS18XNI1G]I?D=MO(BS'HZ+?VL6I+-%RVAIS^ZO22; *PR>M M?>L^]G6D+=-IT8 GBL4]G"AF%(,;Q=>?JY,088YF2A&/]F)+*F_V>UW'P$B8 MD5#_:8V[TTIQP((?Y>K+14(5DI%RSNPBX[S!-SX^KEVG6PI--=$P86@5@W,@ MT&7^T-K%)X'F4BM(G0S%ZTJ[-A7Z]>ZT79]<%AX?:\U.\=!'6"YU\MK4"-$? M6252IA4'.<1*-8C;RX31G W%PDTWT84%'4\E IIDZWP6ZO=+Y;GU\N47\[W' M[KN L-J\N:EWI-T7;S:==#+L^;Z% MF)QA$@DFI J5UFD9H ]@J&D7+:Q<>&V^]+M3K<"KC]4OW-?!WT2ORD&' +\6 MG7G,H:*RS;[PV;H.7U.J>!,82]<&5L#W5"F0 [*F/8H.$J<_W"= M$X5PBP;@0*]%0U!T==G862T*FP4":A?V6%;L"P!XSN M].;[Z.)!??G^HRK$J83]C=JV'=I2$.,.C9+RJ:.#%;/*&Z:8Z77*_X^"^(/Z7@Y=>%A]T"MGM$ M\J%@UY>&*X=T>UUXCUON=\'[-G99Q?LA8'?CW0FC9<4($Y0/PT)707K!- MCQ1JL$U !QC0G5+(-Z![7ZHW?G3O"_) QB*<.5DQ+K9ZL)LT+39-B7BBRVJ7 M5'MRFF<;T*02@T%+_$KED"5^A\IT!MU0F8EU0]L;GJ##2EWS38K^O6UV*K>3 MOY6Z'&^-VYF]L&_>D_&&,632VTK=(*[^VC+>\=76M99#HG"$V^Z![Y.- KK6.X%4+M "5Z0+G%2@=$BLRW(9U>:FX@K>/I&V8ZULF>LX:/8X'])A43+.A;04*C]: [Z]I(- MT&&9P =+20A0@:7ST&WBRD_7XH7>[K[C@"%!HG!U*$;4B-A=\QGW?G MV?(X*39ZM^&(*BAJXQ%+=&3T[TG.HS]7J<1#^CO&^+T!?D11K15#O2C6>TQYOOU?W?PO=!1S$*X8N MR_>3?/C2L1G;29.HH L,72P4:39J\]^ -YC>$PHFI5:X,LV6!5J(JE;"4=!; MUUQLO QN[XZ&C$C!E]B12K&?8FU6+'TWX]Y_9:/,GID#]?CM]^BR")?;V;K M=3K&I(@@48&71TN7\C!$9))EXV._[QJ0:N&5CP_56)[F\S"8BSKR*+:K\^D_.^D ["FFAB*;LS96I/UB_P;8Y?/MM"!V^,Z4?9V>Z'_$VNB:KH$ACZ<,2 M,CZ===#FTZX1[.D:PMX9 -153Q^.1 V-R8/[M=#YI($:[E$*?.C>P"E+PT*U M/]8 F !B=C8'_.T;:3XLO*]HHB8I\&'3*0(T/]CPQK'A_^1RU*4"5/F4:HGW M -T >1P##9&(IW(Y1Q!DY6DS#X]>'#-KKY>S]-$I54*TG'W@_*" 1"W@K/6M MVXLZ#7W#Y5((N!?_N1G9?A//_^-[EW+VA/"/-WNXT>X@_!/5F8P@Q!4#RK/T MB6I *;>)TM 1)7CWCSXZOT+?^*W.>P]\7)4D1XH^?X14]B*X <2'7 ] 50$! M&F$N<1.YX$'D4E0BE])%8_M-@3#FI@ZBFBT]>U=+-DT8#YHPJXIUSHV]LXHZ MA>RFR?!]8T.GJ;HF0273.]L?!-6YQIL7.^.RR.8(&"*R)^9^X7EWYVCC]U$7 MCL_(K+X"OR:8=#E>/0^]>I;EN]-[4+K^-6!EJ8(:2(^'<*$)?N1T@7DJ1VVG M!^5"48*J.IU]D.?!4EGH(G^*91FVVYV7]$SU:^VFQOXN\K?@Q.NE:>L6L-A/ M%>V"G>^'L__M)?]V"YX0N/@-\*UE@'P"=SF(]X7!0C!WN=M$BYU [GI M5&=@ $#=P!\-3*H&=:3L+NJ)80"+\E E^"M+FT,0-#F>#MLVEV4_7+P]R<:H7"N5M M R6"*4]/>)NMVFT%=2^D:K]:M49[6P-##_IL=3@\W95 #A59+>QJO@5JKI(7 M$XB&-(!L=P&>@*KC@: M)S_X$P5%KK,H% UBL(''I=;R GR?K!G[CX^:67TL4,+?>9KS3L5M*X;8@/;E MM/ZEH0]Q6I]EAUBW]-VY/T\7RT6Z6(HX=?F5$H"U"; []_-T7F!H-FH91&#T;[_K M< 4T8(@JQ$%%'BJ:@EPM="_'T_3]_2O^$:9#[H&+,GASIT)/3\,W ]Z>\+4$ M_O&6[&PA6-)&,\\+=*% JJ[V3<+8#"]+%TH<76;)H(C]2V&PK,=G*\3+Q*LV0=@#PM<-!Y9?;5 MTBPVBP^=MGR!SA<*A&;)RUEL)IYE($WW2,85V3]"&XUDUHUVVKCJPY"NX;=:T[-I&B6OO=/8 M&003U8>T<"PWKH6+HZC$OTYDRS4]#ZS%;5E];NCM:&+35.=LCO0OJ.!BF[V-S!//C@B^;9R!V9[ZI:2F%I& F!$0O=V? MJLO]:>B:OBSG,U=PJ:Q$^-KA!6/T6%)*^W9^FITOM5NGT(2F&K5.9K!/0'PE M(&XOVJJCTC%@+DIF&EU9P2G#ZK=1=_KRQ'^77CHOTYLH,_#B2AF>G#E@.HG! M+ >^6[R;%8HD?3#(%)+-"1YS3Y@@I(KO +! <^5D$Q2OG58QI@&+-%LB@I6L M8,5UHI>GR]Q>:+6]GM77ZW52?\@JSU-_G='TXF?]ZE?IKWCH1B9>I3X?F+SK M;,\: ,,QWS2E@6-N]^9+QCWE(HE9WQ_UXD]_$DN_5^&+/^5*C/\^Q2_N).^A M_8&2VQ\ UOKQ'[;]TM-5@_GS),L#-47=%&?]JAJU#G7=;+>W<6G*VUMM8U0W M(J7GI-M+M=)B;:&L@\O!0CIQ(O5Q\6CSCPU MMGMV9TS%SZ_5W 8G8U1_-Q@9D^[!2\BXL^\;B)!Q72 AA-PNC]'GT_/??UM6P M7KKGL^ D/\_V1XGV!I<A"2UO'[U.OC@TLTSQ5HMIAT MYC'8I31"XIW][742"S1;R-,<1TB<'A+OZ(NO$[E(%]%-GF+2B4Q"Y#!RO(.? MOD;B4ID62@)=8/9)8C*T)L81"AO&U@AD;(V+ ]VL?)"Q-0(96T/&UNRHF&:O MC7=,S<85-PRD<4]8F\\+Q)/6DH(DV.@!RF[@G0P(<4[#@:]S^"3>N3IA!^*4 MNRPK=*?"S2^S80T[+R^#* -QEOA!'.FFPPY[FX]#\GZ[#%0Y+W==\Y9GE+4I M6(6ND*XA0E=>%+,KC4V(3/@4)! P*Y A,+HAT[4,T >& >SQBS< >;C=Z9\? MI:OF]$>UW\YG8L9,!D!<4*T6E&JN_FTH6[9$H;Y^S3]JQOWBL:+"D=\&#&MN88@(GI#! M@-;5Q1FW ^;;\$89^*@IGCQ6W\N7)4:+_<90PT3FDMN@24J&I"=(S0'!W^_ M=+Y"1W_ 3C*&@CRD7^^)&_VYKG[+[T MN;3SK@15VU$U2\92.!M+$+8=81>@KT@*$<, J,+]LA)#E&>Q.E_I2JB"C649 MMMM%Q_4,R[N'$;B/DNTT?5=I=Z?7OVOZP+HL7LD)C=3UVO7LC)E#1\SGE>M* MHUIKTU13LO0>,)QZ@_5!V#',L?1)Y9=+[F%,Z]7\$%->V UZ A+Z=)4)9BH7V=@WM%0^4E-U!D& MO/3K6ZE_?<\7I: \N;' =TL);\5L]NW;%DP.;F'VJ^X:8+M5;>=IH0RU7)DY MBIF]T>BP9CX2)<1:B\\RG1>.8V3R/M&_L2XC\B2Z,LTP'%WDCIH>6ZX!AR2( M[0!TPU6'[-[R2*!+)1XJKHAWBC;B<^V>=^:)Y$B-=YW*SM3@\S0OH%$^29B1 M-% C3F)$GP-7+!71'*\]SG]]OI8 B(!D8!(0(RA1T.Q"^;)%61@>J() M9!2P LW$XRP[>FTX4O4) &@8:577S+$*0TG+[$XO]2\7EW_J;;T ;Q@\,:@82VXS:E'%5*2M<%71#Y:QL:,]BDDH! M(%$= 9& 2$ D(!XVJF,645W=-,?HM+O9=^7*+W7#G2YOB1.43^].]3_#R51_ MN1^\["VB<^!#U_6=GGFX+!N:-\J8%1FAMC83^%\,)HDO@CA.7-@2A&0WM#A; M/X_$FW7-/DU.[N2=_3T^KUX_UA:5A',7(V E9&05\_$^S],\ M'W$<3PK=]1#XWQ/>UT_S(Q[/O"IL)Y(_*)?*-"=$[$V7>IN1E11@X T=09(M M=@'9A?43TO,D;T! )" 2$ F(!\\;^ U>[8Y&S(C93U; YVI*8S:(:G7[69K\ MN\-E\Z!090D=01TYZ+6$<^1>#08)0T5CJ+#I,8+!50SR!(,[8E @&/3&8/QC MQY,N3H]Y*KD/9;?.AGM=1,T6U4B2@X!(0"0@$A /FN3@RQ$Z/=2ZTVOVX6*: M_RK?"X,]MGKP&T X[_JP/F5BLX>PIYE5B_-^;O-=^MI^.T-HD^KUHUKC7YZ+ M\U/^&@9E8UN(B+.W @8"0MASMXS,,8MIHG#@>"IL\7-&T.@K6L5$16M3L#57C)&KD'D9T*5^&>G>?P[:]AO2F:1+F<8SHS9,1O2[^S_KLJ?Q^6#C(H-Y^12;$)#_ZY7"F)0GHSAIA&;Z*#<4HDNY1F:SY>.>3)H+/7+<1'"8P!BJ93$N,_C M1G\R@W(9NI#G:"8?\49 -N@1SR4-E@S*S0Z1$KY)PW%T$O=&OMQA4J[1:?YICVL2]Z.0 M3/9K?4-D4FYB4R7R61FR>23H)B- 8?CZ( M%_+^#I*36%W U1^IP_SXHFL_A(CS=P,B(&2,%F^E $LS#(/^E['@;/O!31@N MVA,)UB,#@O>#IR?XS-$@J&W)2G8Q\(:RG;]+6$JB\K^0#/^3O 0!D8!(0"0@ M'C8O<1XP+V%7^)M0^Z/Y\/-J_S8,YPSH= &S :QFOR+_A=$=[L3HSED$#?6F MG6GYV=+;MTSM?E^Y"F?L/>H#]H.H1#Y:Z%K)U41PXW0K/NH1(E'"%) M3"1))H=2+-%\,6*5>.I-7#%5)BZ@F,90V*=I)/LH1+^.1/$N6HS("(@&1 M@'A,('KG6?*N/,O2!/KNM')1^'.EW_]I,.7])#U\.HU L"@50K2*@^!M268_ MV-:*)"B5PKPG5-;$LTM)4*BRA(Z@+E^)WW&B[=%BD#!4-(8*F_85##H&QL\AEQ0'G 0* <]H0NTMCP_?-$ M7'/>@Z*1.4XT^HI6,5'1VMAT5*L+3_*UP97E764DAF:DR=;4E!F:93BZP$6L M#\@(E\4EK'&TI$NL#J=,,VS$ZP*$C#N3,9GFJ!S-%E@ZCUP?0M=M=(VG?Z=# MV&PV60U,\:WIME=%[*0SJ'F:A_]CHI89O1JJQDG4R!=_6;I<@(J7+^]1Z<[# M^8\6TC/P[V_??!XYZZ A'J<4RT#D=90A,*D&>*9N]:&H?:*&HG&OP'>B+YG% M2T=17[$,Z7P*R0!0HH1Z#(K:!$64&M2+)H5*UF'\HL"'[@U1A7LW+%2D;@V M"2!>Q3&TBD!^^P:2"88TJ$]A7]%@**K ATW'1S<_[ #OVI;_D\M1EPI0Y5.J M)=Y#/FN#QS'0$(D*5"[G,+RL/&WFU=&+D_"WU\M9^NB4*B%:SCYP?E! (O49 M$PXB3%5G'(!Y"_T;,8CS[ZW;H^T/: J%_?U/U PX25=5<63"33A_6[079M#H MDPVI=PBX%_^Y&=E^$\__XYNBFCTA_./-(&ZT.PC_1'4F(PAQQ1![BO2):D!I MMHG2T!$E"NX??71^A;[Q6YWW[A6]*DF.%'W^"*GL17 #B ^Y'H * @(TPESB M)G+!@\BEJ$0NI8O&]IL"8H&_BZ@4G5 M('#R:MJ43PJ"=W>.?G^_XQ+X=0Z#[/BF%3X[L%9&$) CTO5(S0:$(3#M_ M;&/ZJ#MM6-\N.G?GFOJWD#%4!.8$1W[#)5RZT^<'MO\%"._RE6%WP\![5 [%5/*?1(Q\PFC"V'? M:3@TMHA4A7+9Q!C@#8&8C<-3=\-JMD&*P!,;H0P^!GMN;Q+GA(/M$5D2"IH2 MH&!3@M*!A.WW!5+@BM!]Z-E(XYT+FT__8QKO/ ].[!1"I QS:B9B[P=EMD-X M#/A:B)XGB#OQ%0PCICS2*8(CQ%>&K_F)HE7@FJMJ-JEHVE<#J6(&P[ MPBY 7Y$4(H8!4-71DQ1"[\M3!7RG@&/RLSL%?(#+4^WN5#M_N 37%MJ3AFN?M>V^ V7]MH>Z(XL1M1/_F'E[$R M8AXE>7XCZAS<*YJV[5+4EMGTP6[M\$S8RT]AD!XC.=>J-V/:?MA+2P?:OB\W M5Q/EYDUGWT*^I9O@\44RXV7<>&XD"3F>2>I&4IX62BQ=+$>\RI(1"8JISCD6 M0GC<),H+$2O57S'ZD[D!5*0%MDP7\Q$OZ&6#'K%=YL $R>;-G8WX7+O7D7DB M)7WCIDRS98$6CI8:<1(C\DT9GN;S+)UGV825$VDO1$ D(!(0"8C[ M&[D7(M MX,"J!GC&WZP,$%Z+H*?7@_OJ0VGP[;S,)9,[\]NE>_+.VL ="*5E*!+*;=L? MBL^B(9M)$^\HID[Q+)NJ"1:+9,Y:*G>=>6T.]>'>0/R>6$)H(DI,X>]S;?I7 M\!P?%92)/9-&T?S+K?CS['0)?F23W9Z-D?G,S<^./)0E7WC?#T6R!:F M@P2S,:,ZIOR07_HA+OR_3XTA$5)E2&+84-BNXJG?4-@FWR3*SW),0$ D(!(0 MCPE$[RB_N!C/B_V@GF@"&<4J0#-%Y%IT]-IPI.H3 ,R*!K_1S+$*0WK+A '] M^.K<^&G]K7U5]AO08TAS&%04"\UAI2R= @ZTE*BA;^?PDH@^B)GGPI9Q'&I# M1X+N="50PD:K>+QT2+UQF$AJ90XHS919FBM'[/J6>JX*.V4L]1O*3'BX%S&Q M](6@I%($2'1'0"0@$A )B(>-[BX6T9US?H3FL,^/ 2YUPUT=UQ(GJ'RN.WT2 ME0(_/J_7*OE4'=7:=Y!0X]D)_"\&EL09@1RHL)<3]G506XS$H77-/OE+[@CV MA_+])] EYDN#"WH$Z\&A1;YGF:YX6,!5:QX/]0Q['EB/7B MKPK;B>01RJ4RS0D9.PX/:C/XK*0" V_H"))M,0E('!D$Q/P):7J2/R @$A ) MB 3$P^8/RJXRVJ6YYMUI/S^\G;8%J7#]L)\4P<8&%A X2H5PK6(B2W/E=VA, M%Q2J+*$CL%<7MC#MU6"0,%0TAMIUBC'!8(E@<$<,E@D&O3&XI9A_R4L)F2)* MZ'HZR]+Y(D<7XIHQZ$/:K>,@7P-5H^4U4D$XDO,@(!(0"8@$Q(/F/'@^0F?( M6G?Z_.>O]*?T9U@1"GOK#.EL9]$-HPGG.X1&+I8*-)L?)412:(V3LQ&[GM*E_)E MJ 9BXT5/)W\V]#YM,^T[ T")$KK%*FH3Y+EJ4!.8%#3C%/3B%/C0O2&JN*P4 MU9U: V "B+_9,/:W;Z3YD/J^HD&75X$/F_-Q]1_B'*_^GUR.NE2 *I]2+?$> M?*+:X'$,-$2+(I7+.2PI*T\;,X'Q'< .)#K@>@(H C3"7 MN(E<\"!R*2J12^FBL?VF0!AS4P=1S9:>="FFS[VSBCJ%C*7)\)=C0Z>INB9! MA=([2V*MZER/S>,W$RD\MPGZWW]+'%O\1-FF*"E(H/.%U"S5@,X!=0-?-S"I M&@1.7LVN<$E!\.[.T>_O=UPB!NY8>\6!U7& <=[DA,0_O2*"W/)%3*&"BZL^(9++72GY^I]+7]>>/G!9XU+^-!L9AND"#RQ$K)T>.IHHDC8=C''4="D<[(6174[)M\2.P<_N9FFV7^AR+G"6)JG[?K4*O\<-H7OZMZN4LP/F;E%$! M*NK9Y9'@P;:T4Y5],<_03-2Y<]F8UAY+?6B2E%FK)BTF,04\.7KX"GXQ4<'? M5"7P\[I>-I5SXP\04BODR5R;*11I@2O3>2Y;/'1(F8[]IDV!+@H1&YJ^8O0G M,R:%IXL\=PN6;%Q&;O/LQ&?:YU%,D^DI#N^%.@2S]$"7SQ2:L1) MC*C*B:,9EJ/+0M*FFO1E(2 2$ F(!,1]@>C=BU9831QN&]G>G3X/^H/^R[!> M%.Y3-<;&M Q%0HE^^T/Q631D,I\T4-.2@I#2IB6%[>QI9QD6_)E8 L=\&"J/ M/[Z,KXUBT.$UGBRYV_B:)7=P*S8\N_JQ\UZ-7*+M4CCH2>:C)G(/)C)1L+ZL M(O>$]'7?/6,C4X)$GS'C.J:$CD^$&A\!HC:GB-\RI&O$60P;"MM%.?4;"MO4 MF 3F67;C"8@$1 +B,8'H'9BSBQ&>(6><=Y7N:,2,F/T&YQC('(8214)S,"E+ MIX #*"5JZ-LYJ"0Z#V+AB^EJ*7KTZ$Y7,B1LJ(H'&H94&8>)HE:.Q6DVS] E M)F-!;&"N"CM0*?4;RDQDN&WE5BY?.:=<9_/M@I'802];G7Q]GK)?JH/Y M.6\0?D:Y#6]NWNW$=^&I;D?C0<][69KG>?2_C$5PH;&^PHF'.N]E":8/D*=@ MZ7*Y3)<*$:N04V]3LI)L#+RA8TGGQ20=.U2&,SM:K+X4@KE14K!(3;R<%R,Z/!A7;,#TN02!(V'J\+=U\+/(?O@ER'P MXL 8T@ !MW[0- "?I*.X;_<[2#&RIS(\5%* )W@_>(J@G#D:!+0.92Y5UB&& M#64FVW$(*8F>(N-(FN U!A4$1 (B ?&80 Q6G+XM-#AF_3&G/1?GP8 MCEF#/V0V08&V#K\/T#YI2@-X>#!<$QC/!D2M8?Y_E*R8$FIB M[-2Z#X>*:2+;B_^M./>%)=VT)W'^'_LA3PT5587/D!1%()\M73?XEJH>@EU6 M]\Z>A:V X)-+<%PTB[6GW\71M9SW27"$$8K_B2/=_+239.SASOPAHWB?^_-T MJ9@_ED1*\'-,_F#WYTLE@NG]UU-P=)EE:;:0->0',U?064J5N8IA0YE) NU' M/'9D?"%?(*F2UQ=8$1 )B 3$8P+1.U7"!*RHL/OVHWBHV7?U\&\#"3YI*:C( MVVKV*_)?&"*BH,[L3MM/]>?.CY?'PJ_BX1KQV4&99_\S:;XE]+4,>E;2M#R* M!(? I.MF[2+!45ND_1P6:/9QM(IX=AZ%X;[<"VZ^@(2?)?62RU@\"8.[HFS\ M^%$O>S;G"\6F,11J1,//8=,->8[F"A$;/Z?+QP]R+AI:X1XL+4%($A-)DNE; M42S1?#%C-W%>DU_VBCA])QXN)Y* (WD( B(!D8!(0#QL'J(:5Q["?4X=,0J< MWFA_!Q?U0?Y.'.PW9YS> M\_=_N4J'OY+%>8 >E!I!X_%H#<4#(CY@K)'8G-3UGN.Q#$Q=9^+$>X_OT/<] MS53R[PL?=7AJ8K19**;S^!134KF]D2PGIC%2H# 2ZL62?VVWL-)"#X_;$)D; M@I("#;V?B1TL+<277DW+T Z!3=H0MSKN7E_:2\/E$C$?I.VGW.?NTIQ8[F MFX# 42J$:Q43&W[B38N>;LC F#]_KD+0T:\H4U<5>3NAH[PG5+&/QXZ"0Y4E M= 1V/<)6%[T:#!*&BL908>_C$0RN8C!LO$8PN()!/FR ^&HPN"65L^2EA$S- MW )+5#0@UT1#@^@P8\K)E&BAS-&%0L0Y* $I^YX0-5KE4!JH1O(=!$0"(@&1 M@'C0? ?/>![ZKIPH#W05VC?3/O?M*K7N].6I7O@A??^F& F-I0ED8K@/^86) M/Z]<5QK56INFOHK:6#0F%,_2%-K2-C]AZ34A/ 7\.TK6QST5!' 6EF[A+!", MCWN;8\NT1 V!A?"[U[J>JQ_"9,S+W]J*U[/M7S&8_\<*3 M,D.S# P$N(@W8C+"97$)Z_8ZBR7SF2A!U_O8T@P;L7*%D'%G,B9R6RW/T6R! MI?/(KR%TW4;7('50P0D[*SIMZ!:XA10"3R)<%Y?)S^7UUAX;UT)3X^(J<1+H M4HFGN7+$.J? %-^:47M5Q$XX2_54#5.HD:N &7I<@$J7KZ\ M1Z4[C]@_6DC/P+^_??-YY*S3AYL\I5@&(J^C#(%)-< S=:L/1>T3-12->P6^ M$WW)+%XZBOJ*94@EZ#-# 3CK# E2A)THT5M G<'=VO!ET ODH+QBP(?NC=0 M@TFH"E&MMS4 )H!X%\ED;/(Z!ADA4HG(YA^%EY6DSKXY>G)R^O5[.TD?P%8B6 MLP^<'Q202'W&A(,(4]49!V#>0O]&#.+\>^OV:/L#&M?+]S]1,^ D757%D0DW MX?SM$_6LR-8 O87Y!ZWOFUV'@'OQGYN1[3?Q_#^^6:C9$\(_W@SB1KN#\$]4 M9S*"$%<,L:=(GZ@&E&:;* T=4:+D_M%'YU?H&[_5^7\\U<:J)#E2]/DCI+(7 MP0T@/N1Z "H("- (B$KF4+AK;;PJ$,3=U$-5LZ4F78OK<.ZNH M4\A8F@Q_.39TFJIK$E0HO;,DUJK.]=@\PX#[U%1%TM00\9V!AGW MD+%1*OG?D\+)QIVNO<];/<&P&+E\5 /&3M0-_,W I&I0ZF7W^4PX6(-7#<2, ML8V5N'YHY#9GBEWU(;N@&0EV@$(8C_<=R>ZW'N\%V;UW,7A^N1@<&:>6H3\I MD(G/)W?0>M6UY@@8H@67J\!H\ E?CZOT3 L%AUWEO#O]P[1>+E2E>*_TMQR4 M!F59;"+[V$3B/OZZ P$ESD$XW7PJ[4&D -(1Z, [AE=[T^+2MS!?@:I]*%:G MFF)TIW]+[/>7]I_J[U]<,@?3#GXJU;Y2 MT2*HA&U^ODL/K&/"M4$8C%.&LRT\8P4I!?0I^CO:.S5&\9"B1='H*:HSR@"( MVR=G7X 1))8B(HF 7,0M#$R%^W[UE7GA;EZ$O1F8]=VXX:/ RPC%TDFC?[,2 M?+SS3+U9O>A6PD,=K9F4J5&@KFL]+J8*- ;^6+ MQ&>K%(N)CZ#U]DMP)=2Y",TQJA&#O.9A!TI_'JSA#7"4TVC"03.#3SUP/ M@8K:HL]A17X%&(Y4?0* ,ZU-,\>J)4)7Y+!\Y8W_WW]IAG8V@41N) MBGPQJY"OV3Y&19.;U@ 8%4PTR%)\HRLKW:$YLP)?2ZV6)'#M;R-E'U: *WHS MV@QXQS.RN4M'@%/2&&Y'LV9LES0)MV0ZHJ$]\7"B7*#SI>QTW]P;CN-/._&" M0 OE1$*W[6EC)X"8(^';M9]:5[>%/U^+TX?$;$9@439L,'$9U>30 MK.6+P*1E%&4K\R4A8]Y;P(BQ$.\\;&])$#::OXID3W9NB1-4^-$Q1!DL!**G MUYO@UY=[I:P>SLSY'$,ZD,-O,>C8]HF29(S!0HH"G!&FME5 6'7O1G)Y[.X8NT(52D2Y'S3F2IC6[$C5^ M#9:GF3Q+%_CBX928L%V)7=J7'WQ+B*IWOQ^^_AFUV>\)]5KP2%RMU!CU'1#) MB?0^,U;NB3^0:R0 9!,)RV)HC^OBX;P.ZLI\[$Y_Z_* ,;_^T82]G],YD-JL M@TI %=<8UZ7AKG'OE%#;V6B9,\.N"0G M6GB+4,E'A/!NFR.TN%E[ 8:D0%V\+$+?)YUV0YM\'PZWE6XF><*W+$VVV.BC M6=V'#7=:A*3$'9V0>+))P@??-+=G 7$:!BUI!PB3(JJM<4]5I&:_#]"0$#S2 M]$Z#;N.S 9 EFDY":II2.?R2*<&P04D M8>TA0.W!T86#:P_W.3'"#/H?:B?R)*JH>O\6F):A2# X15] #;O\@>M)>Y#: M:B*_]B*I8P0I_ LN"KJ%@6X-*G;[DH*M@;#FF;;^#KXI+]KEKRA31OR\(^]K M2>_D&7COH=MC_PWEHI%V.7"AR'Y)D)4<<^IJ35) IMA449DN%5B:81.I$-WN MLNR$RJ[2[DX%;GAY+I=^/ X2&LGM:?YPJEBTJ!ZX5S34'PL%22-,VN,UGSL1 MRZ\_E9#CF1WL*%/@Z1*;;//^8W>+XJL#BK2?#%/EX28E--Q=RP] M@.79L3-BL#12<0LP444,B]I_ MU36;&R$;+=5"W/TI?KL:89W)WAG[2*T)ZCK4+Y*D^>Y*]Q#8J4%Q-<2^'OSI_?WNM#;5PT-!#%G MLPHIGCD$N]06!YN7HF+\$-4Q:/9_SJI-T D)RGA6=4T#V%S]5*S!C6A( ^2U MM^%O#4RIUAA^))J@T-:29 MYJ4T"MX=SN7-]T<]PPU2>(=H*@Y+F?,]4J/9)BG1V24=R[V3-9JH_SQ0. M6UT0:"^V!]08#V&4(05,5[G. !-CU),S ;II9;HHS*<&S(#<2V5!X'W51[HM M4R#_>U#OM_(U=B\W3N(2KWJKF091.7"U6JI$!;(4Y/X"2Y>*Q;WQOLOX>-;9 M-35[+)>)FVN@>1(VVQS M!RXW"[27 )V85UL7K_1EWE R$I"U$FX(42S1?-'KXMHLW8HKU)MD[PZ(=564(>O[>F8CYP>47# M+,/.F-'?]4!]AY7^!#]M^Q]S^G#E[K1W9_28;X.:>EX^.;NHM:NW]5:GWFQ0 MS4OJ_*Y=;]3:[;DGXJSD%NK(,HO@4>8T4LYBE:K9KFU65O+&-;'KW5VLX>=8 [PTD[4.W33$MU(X9A/5=NIPO]B/[U] R.*V3?. M3V=?O:V P?_BNK2Y;%DF3B004!9T#3B)M@0D#X%(1@ B EC=GO&1.=K MN/3TW0+&Y2<6P/:4D:Z*!OH)MF_SWYQ?+!X:BG_ARC)J2&R:RA-8?_KF8O[X MVS?HCLY(-ZV<98AC=)HG0=JAGZ[_KM5ISW_X@4+9);Q!%[KQAJQG?=YW;88- M2D+SG&6HPJ&)GM-/5(98\_?0_8ZW;^:(,BD==VZS[0)DDP> .KA1CV-%>H!T M@G^%$)MHIOL'JN,!P7QU9014-( %M?]43'O($@+/)A7J_P7M "(N)1OC>Q>4 M;]^\0QX#RJ/!)RW]*O5/>4R+T>RQDV&0*2A\'&#.&/A%5:P)= M.1'#"%!!*F*CMV^>=4.5H38&$#;)[LXUO^-\IRDXZ0+#=0A$6Q];>)"5 ;%) MW4(SA\]=+E$B 6_0%EH:P6"_"V[%+<'7LP\=!'_"T+]3%,2P"S0/@37090H9 M683-X1@U>*5& !I:""4TKA @98J:PT)[AQ83\=]F'6/=R'^"H1C"L340+?A# M\##K6&]:T*'%.[1[5>+M80@4"(*#X[=OE.%PC F,]80)J0Z&Z V(J/"-:U19 M(L*?!L-P"S*(_D2@UFBP(($)A>KM&P=SL0: B:ISEP C;0P5JHX[P9CC'AH# MCVZ"(9E758AE*,&@#_D>#Q1X%@T9-8B;<1?BD)DV=H0!/;^0UB5=00T@ZF'( M3=T##37H@/R /G7TE0%?I(T!(B'2!TL_??L&_=:.NI&L([5B-_E =QYGOX!O M4B!&% BZ0U?6\3%!"QBX76Y7J7>EQ32TV[^C)_/K1>%7I7A"68J%:%SU6?J= JT= MBJ(,$Y414B9ZW_N3LY@@XAB!9[I3P6AJPA_S6I@(T2':7$.V':88J@#KC$UN$40 MM:>3[-D@:$?*3. 4#=KO^8P0NX$PD@^46X"J&0^H;*]Z]:0.SF[KG^_JU_4.[^I2N."NFK6&U=4M=FHUFX;B<6" M^PZ=UI+.F[/(R-)!IZ,'@ ;M&8":UPYZD#3V4!+#]I=<00!D#U5=2#-VN>[U MV4J(P3]0%>R%NZ8@HGH)H.^(BG65JS< DN$WJQ<$PUT)\FLC*!? QT2]!(_;'6 ^30LOA1K M]Z4YMBKK:V]#WJ:EDT6JP'PH^6&5FB%UV?Y@0X-8>F9GY@'5P !VN*6AF&!H M3^\$J],[,=_"L%6'$1[B\#625):[[_05"T_L6\(^Q[++ VJ_7O?Z/\=]YI&] MG]/!&:(7H'?+;!&?HTB6M0^]8T-ZWI^3*3MF]Q)Z4*FA.7(2#1^H+PJ*.9&1=-(.[HC%+^J $@:5 M]PB'2DY,X71>,7'B"3R.4?AJ1TDP$%$T$[HY\1\6)FJ_[+6V^Y P5,1.Y(I@ MKWN0MI3C_C4ZK3,0F*F=WURW7U M9D<-U$A%QV$0S>*]/6^\!U0%OL@VUA 2KY?,;HFM:C>TW\4N<#8. ,L3#N35 M(@Y$M@*_SD <9\R&F\MCG,C VO49J$\@A[7JVS?VA30<[./32KS(:M<\3#L/ M_P1I<'4LV\6(U@ "^QV";P&4S+T%(]VP]AHA0/Y5(*H@)F9]B^&66[J*D&?Z M10?NZ2[!7M"=UL1'IO]3>+SI Q(9>$8&_$Z1P06TPH7+0?-7>?3WI7!RUJY? M->J7]6JET:$JU6KSKM%!P4&K>5VOUFN'."E*X-C3/I-C@7)RAJ%&*L9]&#LG M: SG8_O.I(:*[F:J=>%@K 5["@Y _G_VOK4Y;659]#M5_ ?=G+5/);5=D+@S2/GIY^ M/QQ7)U),0=Y:<,)"ZK!@^8P;DJ6VW3;ZOJ#)Y!K O\B01:"N$=9J@:'H-G^= MSV;>UVJ7PDS$3:/ 6@<6>P?_"(/]Z7=1(4,)BW\%0UZ?'(=C]?N @H)K8V"5 M:_: ._7)C,S"#V'[.&S'M,@316JK!^*=9;C\209.@A,I$5X*1_*ZSL#2 8KP MGB:"Y'\.;"E*GKP)/-0A<0R221SR0J&/PN"R#>E5 JIQ]LO8'0H)IR"T F+M M?0K$GJ&AN5Q]J<&164JI0.R]F,,=P[?!L@!N.,3' 9RC6F4/Y96&S:0&='-R M[U0H7C 9-07M!+0G,6\T[8/,%;8*M@V063T40[ R/'D@R0WXRV#+2!P,3?F M!18 '9; ]#RXT@.+G;$DE2%4Q+J8],&B[G $,36:[>%R =J@6"X04(R'\B4< M,!,]\1"%>#F G1"PX0N\4*P'%9MTX]VDL$FU\!(WN4UQDVKA)7!RYP(G2:43MVWL]H5R:K%4 MNQM]M;_??CFSG(/?G>5TIO%9UZ]9WGI&LW,"DE\/9:B8$"[7[HL^>#?J&O;' MZV_M\L_&4PC;E;O1K?6Q;&N-LY.O1M"K"HE_L,9=EK69E!Q$["1QV!Q:HA ' MT)2(]C<2M5#B55#@S0DKB2<;;+BTHQ@"2,P7X'F#7I\'&:!DH%%9."Z9<":M M]5@E9HQ22>RTR@*^0HF!":$*!\]/O QM;"$LA=GIA\VC, MI@@[".=$JBN%&?"O<(S@3]R.SOM)XGA.#W0+[8_AY95:VQ_ 0H6HV";I33>Q MB+$06QQ/.MJ52A_KIT2\QDZ\EN',5H*9WK\;W?R\.+H_OCC^?K2 [WMINE6_ M&QUJZO6?[]J7^H,HH07G3Q^D9>\R[1(Z/T5& L?W2 WK@A #^H5EPB9U)%U8 M8(1=;:;[ V+W0([&"PCHB^KXD!$$])AQ1QGH%!8:HA^[:$G@>?DZ!7H:S#1L MA#!,\P<3P$F(9Y !23Z;83IKW%%L.^.C[M:MDK*Y@XR'1NB?8=.'9V8FB_;N&K7H8VK4@1%%V N MP?3729#6-+@NK4-[B9Z#.U8;8-IW6358"(" M7G)JU(OV"^"5'O(W+9 9ALIKC*K_8_ILS#?">A#X*7$ LCIH^@.P6A!]G($G M8KV%68*FHOC]<&"T2'*S$/HZ<6[N[VT9_B-:"?@@F#E)'BF2/]CTO1 H/*[S M2\#3*48;"!^ :,#I%7^<0);-,)CUX.!ABC]FSQRQR&!XFDQ,+<]P'T@I,^W^ M@$M#/2"6\2<']MBS3.Z1CJ9K&BZ&M5),K.0 !#J;S5CH0"2RR6YR"-K#MXEN@KH0P MS#():&,K'"+\VB,JA.>:4PR3GM1!1VG[<.'(>"K^RC%3&J5FR-!$T'F ]A:9 M$!, ]W?L!5/<6D]:!AIDV:'\C:^S)%=;>&\D.< M.,#EU]@R(X;5P(KK&VX/;@M34I[%V9=D!?*MH,\5N!9*@[[/ MP&N'V3BLEMN0$PCQFJ1]"<-VI(90*C2Y5H9L+Z*L,CT*OV;MB7HM0]G2.,,@^TYNF&!2AMDVS $X=*$?&02OXR%H0@%5H^=L Q? MD-A!*X<>4I4L7G7G^\-+".!E;1X6<8JDF M6R%BP9@S#7$WT@[WM2NU^>GAH/@$*E/A;J3^_GCM?ZJY[0\EZM5&ZV;^;['H M'"S WU55*;(E0VR)<1.?I67YU#H.B GO01>-B.Z#*&+2-<\K=>DO)JWV@+$9 M(D.0DJP ]]%3LTBMT4F3Z"8@EPA.:"03O9X%\#(Q'=N+D7A2L0I[]A% M%7F?<,'J8<3C"=M7HDUC/Q+#/O7MN]%GZ^N7X>?#V\YA]8FNY^??Y?U/[]U/ M7?75NRLY%5%:M,)7O;/VC*NT'$OJZ4B8R]%5I^"9 &&5*6_RO&SB^11BBM>* MOA52G\&]'\ )22JUB&_#'(\\I9>>$*:(*'_G BT&&E ..I<+4S-&PP+%"ID3 MNIK54:(Q4KLE,LJ1XUJ;'$TZISO#(%R:8I/YKUQ8 ?K($ED9<&)!RFC-L&&! MX[G]PL-ANJQV&ZI)9-@8].$73,W6ACRT)9R2)S*S1'U#D3>PJ=9_+QDD\[JL.*WN.TJ M-ABN!37A"6,BU0-:U2+=,Z8/6XP*(FB]#K>[BP??O;NKRPU>L%-+3)<7?;RQ3=H 45>V&# MC#&;B0=/I3+&Y)4&[L: 3Z:9>KE:M*/F].F,7!F@67J$>B3W.C'?*?)M'BC# M.3>R1#D\#X\L3(CA(7Z)L6EA.H P4A>^@9IU3S(Z"[-MQ2=D*3.#.P,=@-D_A 0%B G$3!AB_)PUO#;,9 M%MS&@P>#I>.H(L8M$K(S'2_;(O( 7W9YQH.89!DD2\20#6I45%!4UZX&UU_?7"'GZU?!Z,%0II7H17]O-"&#?W;GP\:+%\L\SEH09S<>I*& M([PH9-_B3G&>4B]ETNAWM+-G,"9L?04W1@XW4;!@!:/D",.+ M9>F*B).@.@)BU^:[O()YO6TJ_Q!6AHMXA%K(4QY,%G& CX7N5E:V,:@X!P(" MQ<>V6'C(HX$BG*'O:2"YH41L#WHMF"+H8\'KH'G(3#&TA.4CUDV+YIVP).'U MQD#9I.6#\&OT_;#D$@#-Z6'%4(S)(:,[M9#7>0TU%)29#2!',H(]@3@JSEUYZ1!.KCH !$I4 M(OEID%PZ%JOT$5D&>YVH%YGZ<0/TS#OO8Z%83-;@ ?L>CTUP)&DM\-C3 MFEBHLO$'[=UD_G#%4.P/,O0^8JT0)D^%V9%RU0I9-@Y.C6\G>,$(,)C36G)> M[)"?X=JTV\QO8% ^"DNWE3"'@QD +H"<\!7C^,?A6IN=N P@RPVS68@";EZ5.P:L?D%WHT+EP^V)]O,3-<,"%0T0 M9TASOP6:&R2"[2E3ZIPHK^M8W,WRWJS1B+EP7^MIW=^$$4_M!SV)@A,XJMV- M^A_*IU\//QGGC5!FTTVO;VE#;#EDP]CB;)@A/3P=N9=H%,5CZ"V(?[C0PAG%^B4XA&$$X MA98!,_*G&2Y(PGC/9/?%5>Q^9L1:L),AYTSEN,N+D83KB.O[M?HFQ66E_FFX&6!@4T*[)!8DE1H49)VHDE-^]6-7(>_-[$S3E__S\-NP\VC^6V_.6+??66].>;&&"L'-*>4."H404_>K MN<-*4EGYK=.65WB?U&?)(%_NTT(<RB.6P^)BKK1*=C 3%@<,8<'J_./]#%QFFRPD-3B8+=)I MU_HOY(L4%!B_EZ>%TMW(*IKW1^^['[Z>6W&; \FE,VDP:MJ\6ZDW^P_'-?O MU5LMM$$G-VP ;.DXCH]Q 4Q9YW^0PEY]I?SI66\M#>%FV'NWU^.ID,&UC3P=?K?O6F^W@>]NZZ"()^6%B%V'0:_:#@ MU,1=+V^,7(9,H/4DQ8+"^BAAP$'\( ]G./VZI.YX^U-3 M4&NHYK!$.N]H&#YSR1*,:]AMF$$+$('-YS7L2XH^^LIC FLL)%#\?HG+V5*: M(8LW)U'X+=96=[-0?1*:--8G-[7W78Z7J_*]6-":)#RRW!W/"$,H19B4W-7* M&;C9C"CO%,B6B?&A(AG(-7@LG!B9@A*IYQE%H4O5O*ANJBBMQ$8/TG[B.9X\ M\02#.(/DSO[ Q7A'2EWEP;E[:F%O_V!/W<\3< 2G3FN-%(_SEF*N:[6[TK_0O+\PY(JG7(::M/R =MB%U3W(=V\%L'ZF"Z^P1ZO,.=3?RANWZN5T^ M+GY>H%+\*RE2?:R=%I9)*0]_WS_\_O)+-4I8383ZC"15.HVTTC)W)V3]E.(9 MS1Z%#N-_!YZ'4;&\PAA<:!R'-7O!_"V^"B^H-AN4\\,"C$/# MEV81WP8)8[!=HEM:D*P5S)'<+B8L&]]W/)/1%E>42Z<@:*E5#]$B @>6=]H9 M;(CK&U+15"RR+FM$M><$7?NN/X]I83[QA45&T;V@$-=&53EZU)S_32R!UIG(.K/.=#= M:*@63M\_]A_Z[04*8N^\(C]+(\7]I1HI@EI?K]U87_X\'!7VRZ_>731O3I2K MD^.3QI?:T=F)WJYOMZ&BMNDA(T M[4@C*FRI%B'IF+4'A"^;.<,Z<]=8 @O+X9X.;"#89V?'8;'OL^O3H-HW1=&Q M[FH.II6',F50YC3(U L4K> G(!AQ[4BVJ)*HW""25*=&'4P89W(O@(1^\E"K M44&M*E91J\%/I8*D;T3N6UBB&U0 ^1>FI(C;BX! , @H(! !%Q?"(I(-L."(JE4O$*=T4.(IFOGI]/QCXK:/P_T MZQ?ZA>D(N"#21>&TQ3@7MDTOC+5-/YB&>)1/_9>:/RA(^B^9@^*H59G'\)-F MH;@0%(]^L:9/7$"/CY%@,.NW(9$8APDD-TS^"YM?%KX9&>\08G1 M$EM$RZ?>*"D#EE64GF1!%4& -5N_HNJ'S3 1\,9P>W=FXT[WOXM;\7(79KL+ MHXIZ;-X7?KKMHU9P*?A.6$&&5Y.4KYK7[#PA2NZ!'/I6'[A8)3ENVIJ&,("@ MXUHGX>4>]:&E,LQD&TFP]F6YH'D.%+:+JT@(@Q.?C1X[]ZZ@OJ M+D[&5^).6.C47FW3?5C$JU#*3Z#0DJ4?FQ$:5!V&V@EIJC*E.L M.CO6 !YB_W#E JNB(W,/E6"YC4)L#EH=5<_4F8VQ#C_1Z]PIJ.:85Q!V<*X- MV3=+#UIBT&-Q!1Y3JYD95E/ZEJ'?!U7/PJ9V3&C/9S,U+W'. "PXH@ +K_.9 M5BLBIY@^>QP+!+'RQ=CRJM/!QENH\H=5/+#P]1YV&&5UYG$A_H1>>E+G=UR! MG+\O6FA/ -X8F97B)G*&E@LKD9!$Q&%&(I*?E M^7GDU+OX$HH++:$(HGJ%N_Z1QL^WA'2__&Q+2'1>DIT49 MS0BBG@-*U,[+-K6&L*G1. T%Y MKI=7/CBN;3""=0&7WG!SO)\6E=^+U)=G9@43U$YM_A2.7>K*N<6 M7RKG/H/*N>N/*FBBM_$8VW& 5$^MU](\:7)>[(2W[D:M9F-HG1WO._>M%[=9 MHMOL8"FWV?'=J';6O^U?][5/!^JK=Y=7)Y>U1ETY^79YJZO3VZN=]]A=DG=D?2P63PR3>8P;S-LY/T#00TQ6,P3*V7E MK:-*%(E*844FOCC1S:=FZPG7!&&]1#$HS&X(U.XE9KX;5=LU4W>TP^,/Q8E5 MGV;&KMVL_Y1 UF/%GTIWHY[VZ:A<:]Y_/"O/4ORI/RN6QLH[+5?N2*QXOWH4 M*D^C'_:?RLV#7M6^_4R,FY^_(M*TA:QJ%\50_QI]^W%TK!Z=/WRM=C:RBZD_=CR[01!V\P8NO4,#STH_2TRY-: MLS;Z\;E\-W(^GE: M^N/;6;-^WUG@3LTN=HC+8XKUK(:?IC/+R0Z6.'16]L.